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WOORD VOORAF 
Vriendschap, collega’s, professoren, chemie, veel chemie, nog meer chemie, een leuke tijd, 
schrijven, veel schrijven, nog meer schrijven, flashen, NMR, MS, klein labo, de keuken, 
practica, I’m back … HDAC, de conference room, zijn enkele woorden die in me opkomen als 
ik terugdenk aan de voorbije zes jaar die ik heb doorgebracht in Blok B op het vierde en vijfde 
verdiep aan de SynBioC groep (Faculteit Bio-ingenieurswetenschappen, Universiteit Gent). 
Het valt me op dat ik een gelukkig gevoel krijg wanneer ik terugdenk aan deze periode, wat ik 
te danken heb aan iedereen die mijn pad de voorbije jaren heeft gekruist.  
Op de eerste plaats zou ik mijn promotor Prof. Dr. ir. Matthias D’hooghe willen bedanken. 
Zonder uw advies en steun had ik dit doctoraat niet kunnen aanvatten en zouden de voorbije 
jaren er anders hebben uitgezien. Tijdens de afgelopen zes jaar stond u altijd klaar om mijn 
vragen te beantwoorden en hebben we tezamen verschillende publicaties gerealiseerd in 
internationale toptijdschriften. Bedankt hiervoor! 
Furthermore, I would like to take the opportunity to thank the members of the jury. Prof. 
Sotomayor, Prof. Van Calenbergh, Prof. Boon, Prof. De Mey and Prof. Stevens. Your critical 
remarks and valuable input lifted this PhD thesis to a higher level for which I would like to thank 
you very much. 
Daarnaast wil ik de veertien thesisstudenten bedanken die ik tijdens mijn doctoraat mocht 
begeleiden. Jullie inzet heeft geleid tot het behalen van verschillende belangrijke resultaten 
met tal van publicaties tot gevolg. Deze artikels behandelden voornamelijk de synthese van 
selectieve HDAC6-inhibitoren, curcumineanalogen en β-lactam/DNA-base-hybriden. Eén topic 
ontbreekt echter nog, namelijk de aanmaak van bis-8-hydroxychinoline-liganden, wat 
waarschijnlijk mijn laatste wapenfeit aan de SynBioC groep zal worden. 
Ook wil ik alle co-auteurs, Karus Therapeutics, Prof. De Wever en Prof. Bracke bedanken voor 
hun bijdrage tot verschillende resultaten die geleid hebben tot vijf publicaties, drie patenten en 
dit doctoraat. 
De afgelopen zes jaar hadden niet dezelfde geweest zonder de aanwezigheid van alle 
SynBioC doctoraatstudenten. Hierbij wil ik enkele personen in het bijzonder bedanken voor de 
vele leuke momenten die we samen hebben beleefd. Eerst en vooral Yves, mijn partner in 
crime om alle mysteries te ontrafelen omtrent HDAC6. Jouw inzet, positieve ingesteldheid en 
de leuke gesprekken die we gehad hebben, zorgden er steeds voor dat ik gemotiveerd bleef 
om nieuwe resultaten te behalen. Jan en Stéphanie, mijn twee überbureaumies, het was altijd 
fijn om toe te komen op het werk wanneer jullie aanwezig waren. Jullie stonden altijd klaar 
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voor een leuke babbel en namen de tijd om mijn vragen te beantwoorden. Daarnaast hebben 
we tal van culinaire hoogtepunten beleefd samen met Iris, Stijn DB en Wouter en hopelijk 
kunnen we dit in de toekomst nog meermaals herhalen! Yoshi, Hang, Eli, Stein, Pieter N, Yves 
en Jan - mijn huidige bureaumies - bedankt om voor een aangename werkomgeving te zorgen. 
Jullie enthousiasme voor Chemie en uitstekende vorm van humor, zorgden ervoor dat ik met 
veel plezier kwam werken! Gert, Stijn DK, Koen, Pieter C, Niels, Filip, Cedric, Ewout, Tamara, 
Sara, Karen, Karel, Elisabeth, Gustavo, Elena, Klicia, Junko, Sonja, Martyna, en de andere 
ex-collega’s bedankt voor de vele toffe momenten op het werk, de Koepuur, de 
Spa/Blankenberge meetings, de SynBioC activiteiten, … Ook bedankt aan Lena, Marine, Bart, 
Thomas, Sofie, Arno, Melissa, Nicola, Sari, Tim, Benz, Reinout, Flore, Jonas en Sigrid - de 
huidige collega’s - voor de mooie momenten.  
Uiteraard wil ik hier ook de ATP-leden bedanken. Els, Ans en Pieter bedankt om alles in goede 
banen te leiden aan onze Vakgroep! Bij allerhande problemen kon ik altijd bij jullie terecht en 
jullie stonden altijd klaar om mij verder te helpen. 
Tijdens mijn doctoraat was ik ook fervent lid van twee teams die voor de nodige afwisseling 
zorgden tijdens mijn lunchpauzes. Eerst en vooral het pingpongteam, of zeg ik beter het 
tafeltennisteam, die voornamelijk bestond uit Jeroen, Pieter Z, Laurens en mezelf. Het was 
altijd fijn om een balletje te slaan met jullie. Daarnaast maakte ik ook deel uit van het frietteam, 
want als Belg mag een frietje op tijd en stond niet ontbreken. 
Hierbij wil ik ook mijn familie en vrienden in de spotlights plaatsen. Jullie zorgen en zullen in 
de toekomst blijven zorgen voor de fantastische momenten naast het werk. Ik hoop dat we een 
leuke toekomst tegemoet gaan en dat er nog vele leuke gebeurtenissen mogen volgen! 
Als laatste wil ik mijn gezinnetje bedanken! Jullie betekenen alles voor mij! 
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The hydroxamic acid functionality is an important group in different chemistry disciplines, such 
as coordination chemistry and medicinal chemistry, due to its excellent metal-chelating 
properties. In this PhD thesis, the interest in the hydroxamic acid moiety is specifically related 
to effective and selective histone deacetylase 6 (HDAC6) inhibition. HDAC6 is a member of 
the broader histone deacetylases enzyme family, which regulate the folding of DNA around 
histones and thus indirectly influence transcription. A major drawback associated with non-
selective HDAC inhibitors concerns their toxic side effects. As HDAC6 recently emerged as a 
relevant drug target, the aim of this PhD thesis is to move away from classical pan-HDAC 
inhibitors and thus to synthesize new HDAC6 inhibitors with potential applications in medicine. 
In particular, three novel classes of thiaheterocyclic benzohydroxamic acids were developed 
as potent HDAC6 inhibitors displaying excellent selectivity on both an enzymatic and a cellular 
level. The most promising inhibitors identified in this work can be considered as valuable lead 
structures for elaborate follow-up studies. 
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The pharmaceutical industry is continuously searching for new small molecules that could be 
used as drugs for the treatment of various diseases. Two main approaches ‘philosophies’ are 
used to fasten the process of drug discovery; the first one is called ‘target-based drug 
discovery’ and the second one ‘phenotype-based drug discovery’ (Figure 1).1,2 In target-based 
drug discovery, an essential protein responsible for the disease state is targeted and molecules 
are identified to bind to this protein. These identified molecules interrupt the biochemical 
pathway responsible for the illness. Target-based drug discovery has the advantage that a fast 
screen of major compound libraries can be accomplished by using a simple binding assay of 
the molecule to the targeted protein. The downside of this philosophy is that only a binding 
optimization is pursued, which does not give any information about the impact of the binding 
on the more complex disease state or, in other words, no information is obtained about the 
overall effectiveness of the molecule. This problem is more or less avoided when applying 
phenotype-based drug discovery, which starts with screening the molecules in a more realistic 
environment and evaluating them for a certain phenotype (an observable characteristic in an 
organism, tissue or cell). The downside of phenotype-based drug discovery is that the 
screening of molecules takes a lot longer due to the more complex assays used. 
 
Figure 1. Advantages and disadvantages of target- and phenotype-based screening strategies. 
 
In this PhD thesis, a target-based drug discovery approach will be applied and full attention 
will be devoted to the selective inhibition of histone deacetylase 6 (HDAC6). HDAC6 belongs 
to the histone deacetylase (HDAC) family, which controls the deacetylation of histone proteins 
in the nucleus of cells (Figure 2).3,4 Simplified, this deacetylation results in a compacted 
chromatin state which is less accessible for transcription and directs the cell to its basic 
proliferating functions. Cellular proliferation is a typical phenotype of cancer cells and therefore 
histone deacetylase inhibitors (HDACi’s) play a prominent role as anticancer drugs, as it is 
believed that these inhibitors redirect cells form a proliferating state to a differentiated state. 
Now it is known that HDACs have many more functions in cells and also deacetylate non-
target-
based
fast
efficacy less 
certain
phenotype-
based
slow
efficacy 
more certain
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histone proteins, and therefore they are more correctly referred to as lysine deacetylases 
(KDACs).5 
 
 
Figure 2. The removal and addition of acetyl groups from lysine residues of histones by respectively histone deacetylases 
(HDACs) and histone acetyl transferases (HATs). Histone acetyltransferases (HATs) regulate the reverse biological pathway, 
forming a relaxed chromatin state more accessible for gene transcription. (Green: histones, Red : DNA) 
 
The HDAC family contains eighteen isoforms, which have been subdivided into four classes 
based on their homology to yeast HDACs (HDAC classes I-IV). Class I consists of HDAC1, 2, 
3 and 8, class IIa comprises HDAC4, 5, 7 and 9, class IIb contains HDAC6 and 10, class III 
exists of Sirtuins1-7 and class IV holds only one representative, HDAC11.6 Class III, the 
Sirtuins, differ from the zinc-dependent HDACs (class I, II and IV) as they catalyze the removal 
of acetyl groups from lysine residues via an NAD+-dependent (nicotinamide adenine 
dinucleotide) mechanism. Since the focus of this PhD thesis is directed toward HDAC6, a zinc-
containing HDAC, the Sirtuin class will not be discussed here. Phylogenetically speaking, 
HDAC6 is most closely related to HDAC10, however its resemblance with other HDACs is low, 
pointing to an early evolutionary separation from the other HDACs. HDAC6 is a unique isoform, 
being the only representative containing two functional catalytic domains.7 Unlike its brothers 
in the HDAC family, HDAC6 is mainly located in the cytoplasm of cells due to the presence of 
a nuclear export signal motif and a cytoplasmic anchoring motif in its amino acid sequence.8 
Furthermore, the main substrates of HDAC6 comprise non-histone proteins, such as α-tubulin, 
cortactin and HSP90 (Figure 3). Recently, the crystal structures of the second catalytic domain 
from Homo sapiens HDAC6 and the first and second catalytic domain from Danio rerio HDAC6 
have been reported, revealing important new insights into the catalytic mechanism and 
substrate scope of both catalytic domains (Figure 3).7,9 
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Figure 3. Functions of HDAC6 and the recent published crystal structure of the second catalytic domain of hHDAC6 fused to the 
maltose binding protein, complexed with Trichostatin A (a pan-HDAC inhibitor).8,9 
 
At present, four histone deacetylase inhibitors, i.e. Vorinostat 1 (SAHA), Belinostat 2 (PXD-
101), Romidepsin 3 (FK-228), and Panobinostat 4 (LBH-589), are FDA approved for the 
treatment of cancer (Figure 4), and several other HDACi’s are currently being investigated in 
clinical trials. The majority of these inhibitors are nonselective and display pronounced toxic 
side effects due to their broad activity. Therefore, the aim of this PhD thesis is to move away 
from classical pan-HDAC inhibitors and to synthesize new HDAC6 inhibitors, which may hold 
superior therapeutic potential over their nonselective counterparts. HDAC6 inhibition 
represents an enormous therapeutic potential because of the numerous disease states in 
which this protein is implicated.10 Especially the therapeutic areas of autoimmune disorders, 
neurodegenerative diseases and cancer seem to be most prone to changes in HDAC6 activity. 
Furthermore, as mice lacking HDAC6 have been shown to develop normally, it is believed that 
no or only minor side effects are expected when HDAC6 is inhibited.11 HDAC inhibitors all 
consist of (i) a zinc-binding group complexing the zinc atom in the catalytic pocket of the 
enzyme (Figure 4, red), (ii) a linker unit filling the tubular space between the catalytic pocket 
and the outer surface of the enzyme (Figure 4, blue), and (iii) a cap-group for interaction with 
the outer protein surface (Figure 4, black).  
The first selective HDAC6 inhibitor, Tubacin 5 (tubulin acetylation inducer, Figure 4), has been 
discovered in 2003 through a multidimensional, chemical genetic screen of 7392 small 
molecules.12 However, its non-drug-like structure, high lipophilicity and tedious synthesis 
encouraged other researchers to make easy-to-synthesize, drug-like selective HDAC6 
inhibitors. In that regard, Tubastatin A 6 was developed in 2010 via a rational drug design 
approach through comparing HDAC1 and HDAC6 homology models.13 This study revealed 
that the channel toward the catalytic pocket of HDAC6 is wider and shallower, suggesting that 
INTRODUCTION AND GOALS 
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a more space-filling linker and cap-group could enhance the HDAC6 selectivity. Indeed, the 
aromatic linker in Tubastatin A 6 and the tetrahydro-γ-carboline cap-group significantly 
increased the potency and selectivity for HDAC6. Ever since, Tubastatin A is considered to be 
the reference molecule of choice for benchmarking new HDAC6 inhibitors in terms of potency 
and selectivity. 
 
Figure 4. FDA-approved HDAC inhibitors 1-4 and HDAC6 selective inhibitors Tubacin 5 and Tubastatin A 6 (Red: zinc-binding 
group, Blue: linker, Black: cap-group).  
 
Inspired by the structure of the model HDAC6 inhibitor Tubastatin A, the overall aim of this 
PhD thesis involved the design, synthesis and evaluation of new HDAC6 inhibitors bearing a 
benzohydroxamic acid scaffold attached to a large heterocyclic cap-group. In particular, novel 
benzohydroxamic acids accommodating a thiaheterocyclic cap-group were pursued, as the 
synthesis of thiaheterocyclic benzohydroxamic acids comprises an unexplored field within 
HDAC inhibitor design. In collaboration with other groups, the proposed inhibitors were docked 
in a homology model of HDAC6 to evaluate their in silico potency (via computer simulations). 
When the structures appeared to have a good in silico fit, their lab synthesis was attempted, 
followed by a preliminary assessment of their biological properties. It is essential to note that 
the main focus of this work was put on the elaboration of new synthetic routes toward novel 
INTRODUCTION AND GOALS 
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thiaheterocyclic benzohydroxamic acids and a preliminary assessment of their biological 
properties. 
The first chapter in this thesis will situate these thiaheterocyclic benzohydroxamic acids in a 
broader literature context. Therefore, an overview of the synthesis and biological activity of the 
most representative benzohydroxamic acid-based histone deacetylase inhibitors published to 
date will be given. In this manner, the reader will get a profound understanding of the state-of-
the-art concerning benzohydroxamic acid HDAC inhibitors. 
The second and third chapter will be devoted to the design, synthesis and biological evaluation 
of sulfur analogs 13 of Tubastatin A (Scheme 1). In the first chapter, a select group of 
compounds will be prepared and evaluated, giving rise to preliminary structure-activity 
relationships which will be used to design a more potent group of second-generation 
compounds, discussed in chapter III. For their synthesis, the following synthetic route will be 
deployed. In a first step, aromatic hydrazines 7 will be converted to thiaheterocyclic cap-groups 
9 employing a Fischer-indole synthesis upon treatment with cyclic ketones 8. The sulfur atom 
will further be oxidized by means of a meta-chloroperbenzoic acid (mCPBA) treatment, 
resulting in oxidized analogs 10. Both cap-groups 9 and 10 will then be reacted with methyl 
(bromomethyl)benzoates 11 to furnish esters 12. In a final step, esters 12 will be transformed 
to the desired hydroxamic acids 13 using hydroxylamine. 
 
Scheme 1 
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The fourth and fifth chapter will deal with the design, synthesis and biological evaluation of two 
other classes of thiaheterocyclic benzohydroxamic acids, more specifically benzothiophene 
benzohydroxamic acids 18 and annulated benzothiazepine benzohydroxamic acids 23 
(Scheme 2 and 3). Benzothiophenes 18 will be prepared via a reductive amination starting 
from benzothiophene-3-carbaldehydes 14 employing methyl 4-aminobenzoates 15 (Scheme 
2). The secondary amino group in esters 16 will be further functionalized through a nucleophilic 
substitution with an alkyl halide, forming tertiary amines 17. A final ester to hydroxamic acid 
interconversion should yield the premised hydroxamic acids 18 from the corresponding 
substrates 16 and 17. 
 
Scheme 2 
 
For the synthesis of benzothiazepine-containing benzohydroxamic acids 23, cyclic ketones 19 
will be transformed into annulated benzothiazepines 20 over several steps (including an aldol 
condensation with formaldehyde, a tosylation, a reaction with 2-aminothiophenol and a 
reduction, Scheme 3). A following nucleophilic substitution with methyl 4-
(bromomethyl)benzoate 21 will give rise to the formation of esters 22, which will eventually be 
converted into hydroxamic acids 23.  
 
Scheme 3 
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All synthesized thiaheterocyclic benzohydroxamic acids will be evaluated for their potency to 
inhibit HDAC6. Therefore, in a first enzyme-substrate assay the percentage inhibition of 
HDAC6 will be determined using a fixed concentration of 10 µM of inhibitor. Structures 
demonstrating more than 70% inhibition of substrate conversion with respect to the control will 
be selected for determination of their IC50 value toward HDAC6. The selectivity toward the 
other zinc-dependent HDACs (HDAC1-11) will only be assessed for representative inhibitors 
bearing high potency for HDAC6 (having low nanomolar IC50 values). This will be accomplished 
through enzyme assays (by determining the IC50 values for HDAC1-11) and cellular assays (by 
evaluating the acetylation level of a known substrate of HDAC6, α-tubulin, versus the 
acetylation level of a known substrate of class I HDACs, histones, via Western Blots). The 
obtained results will be discussed within the respective chapter. 
Given the promising antiplasmodial activity of pan-HDAC inhibitors reported in the literature,14 
the final chapter VI will discuss the antimalarial activity of the benzohydroxamic acids 
synthesized in chapters II-V. These novel selective HDAC6 inhibitors could supersede the 
therapeutic potential of pan-HDAC inhibitors, because less toxic side effects are expected 
when isoform-selective inhibitors are administered to the patient. The recurring resistance of 
the malaria parasite to many antimalarial drugs compels the discovery of new chemical entities, 
such as the selective HDAC6 inhibitors presented in this thesis. 
These six chapters will provide new insights in the evaluation of thiaheterocyclic 
benzohydroxamic acids as selective HDAC6 inhibitors and give the reader a comprehensive 
overview of the state-of-the-art of benzohydroxamic acid-based HDAC inhibitors. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LITERATURE REVIEW 
  
  
  
  
1. Synthesis and applications of 
benzohydroxamic acid-based histone 
deacetylase inhibitors 
 
 
 
 
 
 
 
 
 
Abstract: This chapter provides an overview of the synthesis and biological activity of the most 
representative benzohydroxamic acid-based histone deacetylase inhibitors published to date. 
Benzohydroxamic acids comprise an important class of HDAC inhibitors, and recently several 
of these structures have been evaluated in clinical trials for the treatment of a variety of 
cancers. In this overview, benzohydroxamic acids were divided in four different classes based 
on their reported selectivity toward zinc-dependent HDACs: a first and major class consists of 
HDAC6 selective inhibitors, a second class deals with pan-HDAC inhibitors, a third class 
comprises HDAC8 selective inhibitors and a fourth, minor class includes dual HDAC6/8 
selective inhibitors. Through this approach, structure-activity relationships were identified for 
each class, which could help future researchers in the design and development of novel 
benzohydroxamic acid-based HDAC inhibitors. 
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1.1. Introduction 
The hydroxamic acid functional group can be considered as a privileged scaffold in several 
fields of chemistry due to its excellent metal-chelating properties. Metal chelation can occur 
through a monoanionic hydroxamato form or a dianionic hydroximato form in an O,O’-bidentate 
fashion. As a consequence, hydroxamic acids are ideal ligands for binding the active site of 
nickel- or zinc-containing metalloproteins (e.g. histone deacetylases, matrix metalloproteases, 
ureases and carbonic anhydrases), and they form a class of siderophores (iron-sequestering 
molecules secreted by microorganisms) as well. Hydroxamic acids are also used in heavy 
metal extraction procedures, nuclear fuel reprocessing and as chiral ligands in asymmetric 
synthesis.15 
This review will exclusively focus on the synthesis and biological activity of benzohydroxamic 
acids as histone deacetylase inhibitors. The development of benzohydroxamic acids indeed 
involves an important and active field within HDAC inhibitor design, and many research teams 
from industry and academia are currently participating in this quest. 
Histone deacetylases (HDACs) have been discovered as a class of enzymes which regulate 
the removal of acetyl groups from lysine residues of histones, consequently playing an 
important regulatory role in epigenetics.16 In following studies, other proteins have also been 
identified as HDAC substrates, and therefore these enzymes are more correctly referred to as 
lysine deacetylases or KDACs.17 In total, four classes of HDACs can be identified (HDAC I-IV). 
HDAC classes I, II and IV employ Zn2+ as an essential cofactor while HDAC class III, also 
known as the Sirtuin class, needs NAD+ to exert activity. Since the focus of this review is 
directed toward hydroxamic acids targeting zinc-containing HDACs, the Sirtuin class will not 
be discussed here. In total, eleven zinc-containing isoforms have been discovered, which were 
subdivided via their homology to yeast HDACs (Class I: HDAC1, 2, 3 and 8, Class IIa: HDAC4, 
5, 7 and 9, Class IIb: HDAC6 and 10, Class IV: HDAC11).6 Due to the involvement of these 
isoforms in modern-day diseases such as cancer, neurodegenerative diseases and 
inflammatory disorders, a lot of effort is currently being devoted to the development of safe and 
efficient histone deacetylase inhibitors (HDACi’s).18,19 In that regard, several HDACi’s have 
reached the patient, with vorinostat, the first clinically approved anti-cancer HDACi for the 
treatment of cutaneous T cell lymphoma, as a leading example.20,21 HDAC inhibitors typically 
consist of (i) a zinc-binding group complexing the zinc atom in the catalytic pocket of the 
enzyme, (ii) a linker unit filling the tubular space between the catalytic pocket and the outer 
surface of the enzyme, and (iii) a cap-group for interaction with the outer protein surface. This 
review is oriented toward the medicinal chemistry of benzohydroxamic acids as privileged 
structures in HDAC research and will encompass the synthesis and biological activities of the 
most representative HDACi’s bearing a hydroxamic acid zinc-binding group directly connected 
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to a phenyl ring. This approach will provide insights into the selectivity that can be observed 
when designing functionalized benzohydroxamic acids and will give an overview of available 
synthetic routes to obtain this kind of structures. 
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1.2. Benzohydroxamic acid-based HDAC inhibitors 
This overview is based on a classification of benzohydroxamic acids in terms of their reported 
selectivities. As a result, four groups of inhibitors were identified: a major group of HDAC6 
selective inhibitors, a group of non-selective pan-inhibitors, and two smaller groups, one 
consisting of HDAC8 selective inhibitors and one containing dual HDAC6/8 selective inhibitors. 
When reading the appropriate literature, one will notice that the term ‘selectivity’ is interpreted 
differently by various authors, and therefore the following questions arose when writing this 
review. Can one claim an inhibitor to be selective for a specific zinc-containing HDAC isoform 
if not all IC50 values for each of the eleven HDAC isoforms have been determined? When is 
an inhibitor selective over another HDAC isoform, in other words, can a certain threshold value 
be employed? Is determination of the selectivity based on the purified HDAC isoforms an 
accurate representation of the selectivity, or should the IC50 values be determined based on 
the selectivity against the in cell existing HDAC complexes?22 Can conclusions be made by 
comparing IC50 values resulting from different assays (because they depend on the type of 
substrate and the substrate concentration used), or should dissociation constants (Ki) be used? 
These important questions should be taken into account when reading the chapters below. In 
order to avoid any ambiguity concerning the interpretation of the term ‘selectivity’, an inhibitor 
will be denoted here as selective toward another isoform if it holds at least a tenfold lower 
inhibition value (Ki or IC50) over the other isoform. The tenfold cut-off value was determined 
after evaluating the IC50 values (Ki values) of the benzohydroxamic acid HDAC inhibitors 
present in the literature which gave a general image of the acceptable cut-off value for 
selectivity used in the literature. 
 
1.2.1. Selective benzohydroxamic acid-based HDAC6 inhibitors 
The selective inhibition of HDAC6 is a ‘hot topic’ in medicinal chemistry, exemplified by the 
impressive group of benzohydroxamic acids presented in Figure 1. When overviewing 
compounds 1-17, it is noticeable that the majority accommodate a rather voluminous cap-
group, para-substituted with respect to the hydroxamic acid functionality and in close proximity 
to the phenyl linker. This voluminous cap-group is never directly attached to the phenyl linker, 
implying that at least one atom (carbon or nitrogen) resides between the cap-group and the 
phenyl unit. This distance is most likely necessary to avoid a steric clash between the large 
cap-group and the protein, suggesting that this additional atom is part of the linker unit filling 
the tubular space to the catalytic pocket. Another feature which emerges when inspecting this 
group of molecules is that several members share the following common structure: a 
heterocyclic scaffold linked through a methylene bridge to the benzohydroxamic acid unit. 
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Figure 1. Overview of selective HDAC6 inhibitors bearing the benzohydroxamic acid moiety. 
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For each inhibitor depicted in Figure 1, the biological activity and synthetic pathway will be 
discussed below. 
When presenting an overview on benzohydroxamic acids as HDAC inhibitors, the simplest 
representative, i.e. benzohydroxamic acid 1 itself, must be included in the discussion as well 
(Figure 1). The search for selective HDAC6 inhibitors able to penetrate the blood-brain barrier 
encouraged Wagner and co-workers to design the smallest possible pharmacophore still 
demonstrating effective HDAC6 selectivity and activity.23 Therefore, the concept of ligand 
efficiency was used, defined as the HDAC6 activity over the number of non-hydrogen atoms, 
which is a known valuable tool in drug design to compare differently sized molecules with 
similar activity values. Compounds possessing a high ligand efficiency have a higher 
probability to demonstrate improved pharmacokinetic properties as central nervous system 
drugs. In that regard, benzohydroxamic acid 1 (a commercially available hydroxamic acid) has 
been evaluated as HDAC inhibitor and showed good potency and selectivity for HDAC6 (Table 
1) and holds a high ligand efficiency, due to the small size of the molecule. The selectivity of 
this compound was further confirmed in a Western Blot assay in HeLa cells, measuring the 
acetylation status of α-tubulin (a substrate of HDAC6) and histone H3 (a substrate of class I 
HDACs).  
Table 1. Selective inhibition of HDAC6 by benzohydroxamic acid 1. 
HDAC 1 2 3 4 5 6 7 8 9 
IC50 (µM) 4.7 7.9 7.8 >33.3 >33.3 0.115 15.6 1.9 >33.3 
 
In the same study several other substituted benzohydroxamic acids were synthesised as well, 
with compound 2 demonstrating the most pronounced HDAC6 activity (IC50 = 0.004 µM, Table 
2, Scheme 1).23 
Table 2. Selective inhibition of HDAC6 by benzohydroxamic acid 2. 
HDAC 2 4 6 8 
IC50 (µM) 0.607 >33.3 0.004 1.15 
 
All benzohydroxamic acids reported in this article bear a carbamoyl group directly linked to the 
benzohydroxamic acid scaffold, similar as in structure 2, and were prepared via the following 
procedure (no yields reported). Amide 19 was synthesized from acid 18 using peptide coupling 
chemistry with HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-
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oxide hexafluorophosphate) as acid-activating reagent. Subsequently, without purification, 
ester 19 was treated with an excess of hydroxylamine over twelve hours to yield N-
hydroxyphtalamide 2 as a white solid. 
 
Scheme 1. (a) 2-phenylethylamine (0.84 equiv), HATU (1 equiv), diisopropylethylamine (2.5 equiv), DMF, rt, overnight. (b) NH2OH 
(30 equiv, 50% in H2O), NaOH (10 equiv), CH2Cl2/MeOH 1/2, 0°C -> rt, 12h. (no yields reported) 
 
Lee et al. have developed HPOB 3 (N-hydroxy-4-(2-[(2-hydroxyethyl)(phenyl)amino]-2-
oxoethyl)benzamide), a highly selective HDAC6 inhibitor containing a free alcohol and an N-
phenylamide in the cap-region (Scheme 2).24 The selective inhibition of HDAC6 is illustrated 
in Table 3. HPOB demonstrated low nanomolar potency for HDAC6 and micromolar potency 
for all other zinc-containing HDACs. In a cellular environment, HPOB effectively inhibited 
HDAC6 by acetylating α-tubulin and peroxiredoxin, two known substrates of HDAC6, and little 
or no acetylation of histone H3 was observed. The researchers also concluded that HPOB 
caused growth inhibition of normal and transformed cells, but that no cell death was induced. 
Besides that, HPOB was evaluated in combination therapies with other anticancer drugs and 
was shown to enhance the antitumor effects of the chemotherapeutics tested (etoposide, 
doxorubicin and SAHA).  
Table 3. Selective inhibition of HDAC6 by HPOB 3. 
HDAC 1 2 3 4 5 6 7 8 9 10 11 
IC50 (µM) 2.9 4.4 1.7 >10 >10 0.056 >10 2.8 >10 3.0 >10 
 
The detailed synthesis of HPOB 3 can be found in patent literature published in 2013 (Scheme 
2).25 Reductive amination of glycolaldehyde with aniline 20 in dichloromethane, using sodium 
triacetoxyborohydride as reductant, resulted in the formation of β-aminoalcohol 21. A following 
protection of the alcohol with a tert-butyldimethylsilyl group gave silyl ether 22 in an excellent 
yield. The secondary amine in silyl ether 22 was then coupled to 2-[4-
(methoxycarbonyl)phenyl]acetic acid, using EDC (1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide) as a coupling reagent, and produced amide 23. The ester functionality present 
in this structure 23 was finally converted to hydroxamic acid 24 and the alcohol protecting 
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group was removed using trifluoroacetic acid. This approach resulted in the synthesis of HPOB 
3 in five steps in an overall yield of 36%. 
 
Scheme 2. (a) glycolaldehyde (1 equiv), dichloroethane, rt, 0.5h, Ar(g) -> sodium triacetoxyborohydride (1.15 equiv), rt, 4h. 72%. 
(b) TBDMS-Cl (1.1 equiv), imidazole (3 equiv), CH2Cl2, rt, 3h, Ar(g). 92%. (c) 2-[4-(methoxycarbonyl)phenyl]acetic acid (1.5 equiv), 
EDC (1.5 equiv), CH2Cl2, rt, overnight, Ar(g). 90%. (d) NH2OH (58 equiv, 50% in H2O), KCN (cat.), THF/MeOH (1/1), rt, 16h, Ar(g). 
66%. (e) TFA (5% in CH2Cl2), rt, 5 min. 68%. 
 
After the discovery of HPOB 3, the same research group developed a similar selective HDAC6 
inhibitor named HPB 4 (N-hydroxy-4-([N-(2-hydroxyethyl)-2-phenylacetamido]methyl)-
benzamide, Scheme 3).26 This molecule has been reported to be as effective as paclitaxel in 
anticancer activity in tumor-bearing mice and to block the growth of normal and transformed 
cells, but not to induce cell death of normal cells. Moreover, no toxic side effects were observed 
when this inhibitor was used. A full HDAC1-11 selectivity screen was performed, and HPB 4 
revealed to be 15- to almost 400-fold selective for HDAC6 over the other HDACs (Table 4). 
Table 4. Selective inhibition of HDAC6 by HPB 4. 
HDAC 1 2 3 4 5 6 7 8 9 10 11 
IC50 (µM) 0.8 2.2 2.1 2.2 9.5 0.025 1.1 0.4 5.3 0.7 3.7 
 
The detailed synthesis of this inhibitor can again be found in the patent literature (Scheme 3).27 
First a mesylation on alcohol 25 was performed to create an appropriate leaving group. The 
resulting mesylate 26 was then treated with tert-butyldimethylsilyl-protected 2-aminoethanol to 
synthesize secondary amine 27. This amine 27 could be converted into amide 28 using 2-
phenylacetyl chloride. In a final step, amide 28 was transformed into hydroxamic acid 4 using 
a similar approach as for the synthesis of HPOB 3 (step d, Scheme 2). Overall, this selective 
HDAC6 inhibitor 4 was obtained in four steps in a combined yield of 17%. 
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Scheme 3. (a) mesyl chloride (1.2 equiv), triethylamine (TEA, 1.5 equiv), CH2Cl2, 0°C-rt 1h. (b) 2-TBDMS-ethanamine (1.2 equiv), 
TEA (1 equiv), DMF, rt, 2h. (c) 2-phenylacetyl chloride (1.2 equiv), TEA (1.8 equiv), CH2Cl2, 0°C-rt, 4h. (d) NH2OH (7.2 equiv, 50% 
in H2O), KCN (cat.), MeOH, rt, 16h, Ar(g). No individual yields reported, overall yield 17%. 
 
The hydroxamic acid of pteroic acid, structure 5, has been designed to improve the delivery of 
HDACi’s to solid tumors by targeting the folate receptor, a protein overexpressed in several 
cancer cells (Scheme 4).28 This strategy should augment the delivery of the drug to cancer 
cells while minimizing its effect on healthy cells. Pteroic hydroxamic acid 5 was shown to be 
HDAC6 selective (Table 5) but did not demonstrate any cytotoxic activity on KB and HeLa cells 
up to 100 µM. The authors further established a positive correlation between potency of 
HDAC1 inhibition and cytotoxicity, pointing to HDAC1 inhibition as the responsible factor for 
cytotoxic effects in KB and HeLa cells. 
Table 5. Selective inhibition of HDAC6 by pteroic hydroxamic acid 5. 
HDAC 1 6 8 
IC50 (µM) 2.39 0.018 0.58 
 
Pteroic hydroxamic acid 5 has been prepared from folic acid 29 in three steps, but no detailed 
reaction conditions have been reported in the article for the first two steps (Scheme 4). In the 
first step, the glutamic acid side chain in folic acid 29 was cyclized to imide 30 using 
trifluoroacetic anhydride (TFAA). During this reaction, the amino functionalities and the free 
acid were reacted with TFAA forming two amides and an anhydride, respectively. After the 
addition of ice, one of the amides was retransformed into the free amine, and the free 
carboxylic acid was regenerated. This resulted in the formation of structure 31, which could be 
converted to hydroxamic acid 5 after the addition of five equiv of hydroxylamine. Also, note 
that during this final step the secondary amine presented in structure 5 was regenerated. 
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Scheme 4. (a)* TFAA, THF, rt. (b)* THF, ice. (c) NH2OH (5 equiv, 50% in H2O), DMSO, rt, 5h. 32%. *No detailed reaction 
conditions are reported. 
 
3-Aminopyrrolidinone-based hydroxamic acids, such as structure 6, have been prepared as a 
new class of selective HDAC6 inhibitors via scaffold hopping starting from an earlier discovered 
dual HDAC6/8 selective inhibitor (Scheme 5).29,30 Thorough structure-activity relationship, drug 
metabolism and pharmacokinetic studies were performed on this class of compounds and 
revealed enantiomer 6 to display the best properties in that regard (Table 6). Molecular docking 
of the compounds revealed that the para-substituted amino group (with respect to the 
hydroxamic acid functionality) could be involved in hydrogen bonding with HDAC6, 
rationalizing the excellent potency for this HDAC isoform.  
Table 6. Selective inhibition of HDAC6 by 3-aminopyrrolidinone-based hydroxamic acid 6. 
HDAC 1 6 8 
IC50 (µM) 74.1 0.017 0.18 
 
The chiral synthesis of compound 6 started by a copper-catalyzed coupling between (S)-
methionine 32 and methyl 4-iodobenzoate (Scheme 5). The resulting acid 33 was then further 
transformed to amide 34 using a coupling reagent and 4-chloroaniline. Ring closure was 
realized by adding methyl iodide to sulfide 34, furnishing a dimethylsulfonium salt which was 
intramolecularly displaced by the amide functional group. In a final step, hydroxamic acid 6 
was formed from ester 35 using a hydroxylamine solution in water. 
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Scheme 5. (a) methyl 4-iodobenzoate (0.66 equiv), CuI (3.3 mol%), K2CO3 (1 equiv), DMSO, 150°C, 10 min, MW. 90%. (b) 4-
chloroaniline (1.2 equiv), HATU (1.2 equiv), TEA (2.5 equiv), DMF, rt, 6h. 60%. (c) MeI (4 equiv), CH3CN, rt, overnight -> NaH 
(1.2 equiv), DMF, rt, 6h. 70%. (d) NH2OH (12 equiv, 50% in H2O), KOH (cat.), MeOH, 60°C, rt. 70%. 
 
Quinazolin-4-one-based HDAC6 inhibitors have been designed and synthesized as novel drug 
candidates for the treatment of Alzheimer’s disease (Scheme 6).31 It is known that HDAC6 
levels significantly increase in the hippocampi of Alzheimer patients and correlate with 
decreased neuronal survival. Therefore, the quinazolin-4-one moiety was introduced in the 
structure of these inhibitors, because this moiety is known to exert neuroprotective activity. In 
this series, the compounds bearing an N-hydroxyacrylamide functionality possessed the best 
HDAC6 activity and ADME/Tox properties, but also the benzohydroxamic acids demonstrated 
potent activity and selectivity for HDAC6. From all benzohydroxamic acids tested, compound 
7 was judged to be the most selective over the other HDACs, except for HDAC8 (Table 7). The 
safety of this drug was tested by determining inhibition values for cytochrome P450 (CYP) and 
the human ether-a-go-go-related (hERG) channel, but similar as for the HDAC6 activity the N-
hydroxyacrylamide-substituted compound showed to have a superior and safer profile than 
benzohydroxamic acid 7. Note that compound 7 does not comply with the tenfold selectivity 
rule described in the introduction, and should therefore perhaps be better classified as a dual 
selective HDAC6/8 inhibitor. 
Table 7. Selective inhibition of HDAC6 by quinazolin-4-one 7. 
HDAC 1 2 6 8 11 
IC50 (µM) >50 >10 0.079 0.282 37.1 
 
CHAPTER I  LITERATURE REVIEW 
24 
 
The synthesis of hydroxamic acid 7 started with the formation of the quinazolin-4-one moiety 
by reacting aromatic amino acid 36 with propionyl chloride and subsequently with an 
appropriate amine under microwave irradiation. Next, chlorinated quinazolin-4-one 37 was 
subjected to a Negishi coupling using ethyl 4-(bromomethyl)benzoate and zinc, which resulted 
in the formation of ester 38. After ester hydrolysis, O-benzylhydroxamate formation and 
hydrogenation, benzohydroxamic acid 7 was obtained in pure form as white needles. 
 
Scheme 6. (a) i) P(OPh)3 (1.2 equiv), EtCOCl (1.5 equiv), pyridine, 250W, 15 min, MW. ii) Ph(CH2)2NH2 (1.5 equiv), 250 W, 10 
min, MW. 47%. (b) p-EtO2CC6H4CH2Br (1 equiv), Zn (1.1 equiv), THF, rt, 7h -> Pd2(dba)3 (2 mol%), [(tBu)3PH]BF4 (8 mol%), NMP, 
200W, 15 min, MW. No yield reported. (c) i) LiOH (2.5 M), MeOH/THF 1/5, rt, 4 h. ii) NH2OBn.HCl (1.1 equiv), EDC (1.1 equiv), 
HOBt (1.1 equiv), TEA (1.1 equiv), CH2Cl2, rt, 20h. iii) Pd (10% on carbon), H2, THF/MeOH 1/4, rt, 5h. 49% in last step. 
 
In 2009, the first selective HDAC6 inhibitor containing a 4-(aminomethyl)benzohydroxamic acid 
moiety has been reported.32 As can be seen in Figure 1, later on many other selective HDAC6 
inhibitors 8-16 containing this moiety have been synthesized and biologically evaluated. To 
gain HDAC6 selectivity, a chiral capping moiety was introduced in the structure of this inhibitor 
8. The authors envisaged that this was most rapidly and efficiently accomplished through the 
use of commercially available chiral starting materials, such as R- and S-amino acids. As such, 
R-enantiomer 8 was synthesized and exhibited a 26- and 53-fold selectivity for HDAC6 over 
HDAC2 and 8, respectively (Table 8, Scheme 7). In contrast, the S-enantiomer of compound 
8 showed only moderate activity for HDAC6 (IC50 HDAC6 = 0.22 µM) and no HDAC6 over 
HDAC8 selectivity. Therefore, introducing chirality in the capping region could be an efficient 
approach to obtain selective HDAC6 inhibitors.  
Table 8. Selective inhibition of HDAC6 by R-enantiomer 8. 
HDAC 2 6 8 
IC50 (µM) 0.26 0.01 0.53 
 
For the synthesis, first an aromatic nucleophilic substitution of R-phenylalanine across 1-fluoro-
2-nitrobenzene 39 was performed.33 Esterification of the resulting acid 40 with iodomethane 
and potassium carbonate gave methylester 41 in quantitative yield. Hydrogenation of this 
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nitrobenzene 41 and in situ cyclisation afforded 3,4-dihydroquinoxalin-2(1H)-one 42. 
Functionalisation of the cyclic amino moiety in this structure was achieved via a reductive 
amination employing 4-formylbenzoic acid, catalytic dibutyltin dichloride, and phenylsilane as 
reductant. In a final step, acid 43 was converted to hydroxamic acid 8 using hydroxylamine 
hydrochloride and (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluoro-
phosphate (BOP reagent) as a coupling reagent. 
 
Scheme 7. (a) R-phenylalanine (1 equiv), K2CO3 (0.77 equiv), EtOH/H2O 5/1, 100 °C, 16h, sealed tube. >95%. (b) MeI (3 equiv), 
K2CO3 (4 equiv), DMF, rt, 16h. >95% (c) Pd (10% on carbon), H2, MeOH/EtOAc 2/1, rt, 16h. >80%. (d) 4-formylbenzoic acid (1 
equiv), PhSiH3 (1.1 equiv), Bu2SnCl2 (0.1 equiv), THF, rt, 16h. >80%. (e) NH2OH.HCl (1.2 equiv), BOP (1.2 equiv), TEA (4 equiv), 
pyridine, rt, 8h. >50%. 
 
Tubastatin A 9 is one of the most intensively discussed selective HDAC6 inhibitors to date and 
is frequently used as a positive control for the evaluation of other selective HDAC6 inhibitors. 
This molecule has been discovered in 2010 via structure-based drug design combined with 
homology modelling.13 Comparison of two homology models of HDAC1 and HDAC6 revealed 
that the catalytic channel rim differ greatly between both isoforms and suggested that this 
channel is wider and shallower for HDAC6 than for HDAC1. Therefore, a bulky and shorter 
aromatic moiety was proposed to fit this channel to possibly enhance the selectivity of the 
inhibitor for HDAC6. Indeed, when comparing IC50 values for HDAC1 and 6 of inhibitors bearing 
an alkyl versus an aromatic linker, the aromatic ones demonstrated the best potency and 
selectivity. The outstanding selectivity profile of Tubastatin A was further established by 
determining the IC50 values for HDAC1-11 (Table 9). Furthermore, Tubastatin A 9 conferred 
dose-dependent protection in primary cortical neuron cultures against glutathione depletion-
induced oxidative stress and did not show neuronal toxicity, pointing to the potential use of 
selective HDAC6 inhibitors as drugs for the treatment of neurodegenerative diseases. 
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Table 9. Selective inhibition of HDAC6 by Tubastatin A 9. 
HDAC 1 2 3 4 5 6 7 8 9 10 11 
IC50 (µM)  16.4 >30 >30 >30 >30 0.015 >30 0.85 >30 >30 >30 
 
For the preparation, the cap-group was made via a Fisher indole synthesis employing 1-
methyl-piperidin-4-one 44 and phenylhydrazine (Scheme 8), and the corresponding 
tetrahydro-γ-carboline 45 was obtained as a beige solid in an excellent yield. Next, a 
nucleophilic substitution with methyl 4-(bromomethyl)benzoate yielded ester 46, which was 
converted to Tubastatin A 9 using hydroxylamine hydrochloride and sodium methoxide as a 
base. Final purification was done using preparative HPLC and afforded pure Tubastatin A 9 as 
its trifluoroacetic acid salt.  
 
Scheme 8. (a) phenylhydrazine (1 equiv), H2SO4 (conc.), 1,4-dioxane, 0°C to 60°C, 2h. 93%. (b) methyl 4-(bromomethyl)benzoate 
(1 equiv), KOtBu (1.05 equiv), KI (cat.), DMF, 80°C, 2h, Ar(g). 61%. (c) NH2OH.HCl (6 equiv), NaOMe (25% in MeOH, 8 equiv), 
MeOH, 0°C to rt, 24h. 31%. 
 
In the following years after the discovery of Tubastatin A, several selective HDAC6 inhibitors 
have been prepared bearing a very similar structure, with only the heterocycle in the cap-region 
slightly adapted (Figure 1, structures 10-12). The same research group of Kozikowski 
developed second generation Tubastatin A analogs, optimizing the activity, selectivity and 
physiochemical properties by fine-tuning the tetrahydrocarboline cap-group.34 They discovered 
that substitution at the 2-position of the γ-carboline group was beneficial to obtain more active 
and selective compounds. This resulted in the design of compound 10 (Scheme 9), having an 
HDAC6 IC50 value of 0.8 nM and a 5000-fold selectivity over HDAC1. In this second paper, 
also the ability of these compounds to enhance Treg suppression of Teff proliferation, both in 
vitro and in vivo, was established and warranted the further investigation of selective HDAC6 
inhibitors as immunosuppressors.  
The preparation of this compound followed a similar approach as for the synthesis of 
Tubastatin A. First, a Fisher indole synthesis with phenylhydrazine and piperidinone 47 
resulted in the formation of the γ-carboline structure, in which the benzyl group was removed 
by hydrogenation. The obtained product 48 was then alkylated twice, first on the secondary 
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amino group with 2-bromoacetamide and then on the indole nitrogen atom with methyl 4-
(bromomethyl)benzoate. A final conversion of this ester 49, similar as with Tubastatin A, 
yielded the final inhibitor 10 as its trifluoroacetic acid salt after preparatory HPLC. 
 
Scheme 9. (a) i) phenylhydrazine (1 equiv), H2SO4 (conc.), 1,4-dioxane, 0°C to 60°C, 2h. 93%. ii) Pd (10% on carbon), H2, 
EtOH/H2O 7/3, 70°C, 24h. 93%. (b) i) 2-bromoacetamide (1 equiv), TEA (2 equiv), MeCN, 60°C, 2h, Ar(g). ii) methyl 4-
(bromomethyl)benzoate (1 equiv), KOtBu (1 equiv), DMF, 80°C, 2h, Ar(g). 50%. (c) NH2OH.HCl (6 equiv), NaOMe (25% in MeOH, 
8 equiv), MeOH, 0°C to rt, 16h. 15%. 
 
Another compound structurally related to Tubastatin A is the patented molecule Marb1 11 
(Scheme 10).35 In a large series of analogs, Marb1 11 showed to have improved anti-
proliferative effects on 42 solid tumor cell lines over the other compounds tested. The 
selectivity was assayed by determining the IC50 values against a panel of HDACs and showed 
that Marb1 is a potent and selective HDAC6 inhibitor (Table 10).  
Table 10. Selective inhibition of HDAC6 by Marb1 11. 
HDAC 1 2 4 5 6 8 11 
IC50 (µM)  3.62 7.45 3.82 1.57 0.004 0.25 10.5 
 
For the synthesis, first the nitro group in compound 50 was reduced to the amine using an 
acidic hydrochloric acid solution and zinc dust (Scheme 10). This was followed by a Pictet-
Spengler reaction on indole 51, resulting in tetrahydro-β-carboline 52. Urea 53 was then made 
using N-succinimidyl N-methylcarbamate and could be cyclised employing cesium carbonate 
in dioxane under reflux. As such, cap-group 54 was obtained and then N-alkylated with tert-
butyl 4-(bromomethyl)benzoate. Subsequent deprotection of the tert-butyl group produced the 
free carboxylic acid 55. Coupling of this carboxylic acid 55 with O-(tetrahydro-2H-pyran-2-
yl)hydroxylamine and THP deprotection resulted in the formation of hydroxamic acid 11 in 46% 
yield.  
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Scheme 10. (a) Zn, CuSO4, HCl (3N), THF/MeOH 1/1, , 2h. 83%. (b) formaldehyde (35% in H2O, 1.2 equiv), MeOH, 60°C, 1h. 
86%. (c) N-succinimidyl N-methylcarbamate (1.2 equiv), DIPEA, CH3CN, rt, 16h. 92%. (d) Cs2CO3 (1.2 equiv), dioxane, , 4h, 
N2(g). 72%. (e) i) tert-butyl 4-(bromomethyl)benzoate (1.1 equiv), NaH (1.1 equiv), DMF, 0°C to rt, till completion, N2(g). 73%. ii) 
TFA, rt, 15 min. 99%. (f) i) O-(tetrahydro-2H-pyran-2yl)hydroxylamine (4 equiv), BOP (1 equiv), TEA (3 equiv), rt, till completion. 
65%. ii) HCl (0.6M in H2O), MeOH, rt, till precipitation. 46%. 
 
Bicyclic-capped HDAC6 inhibitor 12 substituted with a fluorine atom in the linker has been 
developed as novel drug for the treatment of the Charcot-Marie-Tooth disease (Scheme 11).36 
The rationale behind using selective HDAC6 inhibitors was the recent discovery that HDAC6 
can serve as a druggable target for the treatment of this neurological disorder.37 Several 
classes of bicyclic-capped benzohydroxamic acids were evaluated, whereof benzimidazole 12 
showed best-in-class activity. Not only the potency and selectivity was assessed (Table 11), 
but also the ADME/Tox and pharmacokinetic properties were determined and compared with 
those of Tubastatin A. From the obtained data it was concluded that the studied compound 
showed an improved profile over Tubastatin A for certain parameters. 
Table 11. Selective inhibition of HDAC6 by benzimidazole 12. 
HDAC 1 2 3 4 5 6 7 8 9 10 11 
IC50 (µM)  9.0 20.3 12.5 0.5 0.2 0.0008 0.03 0.2 0.07 20.4 12.9 
 
Benzimidazole 12 has efficiently been synthesized in two steps from 2-methylbenzimidazole 
56 (Scheme 11). First, a nucleophilic substitution was performed at nitrogen with methyl 4-
(bromomethyl)-3-fluorobenzoate, and secondly, ester 57 to hydroxamic acid 12 conversion 
was achieved through the use of an excess of hydroxylamine. 
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Scheme 11. (a) methyl 4-(bromomethyl)-3-fluorobenzoate (1 equiv), K2CO3 (2 equiv), DMF, 80°C, 2h. 71%. (b) NH2OH (50% in 
H2O, 50 equiv), NaOH (4 equiv), THF/MeOH 1/1, 0°C to rt, 30 min. 50%. 
 
A screen of different hydroxamic acid structures revealed tetrahydroisoquinoline 13 to have 
unexpected selectivity for HDAC6 over the other HDAC isoforms (Scheme 12).38 The 
selectivity was attributed to the aromatic linker which more effectively accesses the broad 
tubular channel to the catalytic pocket, as explained previously for Tubastatin A. Furthermore, 
the hydrophobic capping group can also interact with the protein surface, further improving the 
potency and selectivity. Tetrahydroisoquinoline 13 showed to have an excellent selectivity 
profile (Table 12) and displayed negligible inhibition of matrix metalloproteases (MMP2, 4 and 
9 IC50 > 100 µM). Also the aqueous solubility was assessed and shown to be high (2 mM at 
pH 7.5), and the compound demonstrated a high Caco-2 permeability and a low efflux ratio (A-
B = 22 x 10-6 cm s-1 B-A = 1.5 x 10-6 cm s-1). 
Table 12. Selective inhibition of HDAC6 by tetrahydroisoquinoline 13. 
HDAC 1 2 3 4 5 6 7 8 10 11 
IC50 (µM)  45.0 >50 46.0 >50 >50 0.036 >50 2.1 >50 >50 
 
The synthesis of compound 13 has been performed in a polypropylene deep-well plate without 
purification of the intermediate ester 59 (Scheme 12). Tetrahydroisoquinoline 58 was used as 
starting material and connected to N-methylpyrrole-2-carboxylic acid employing N,N,N′,N′-
tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU) as a coupling 
agent. The resulting ester 59 was used for hydroxamic acid formation by means of 
hydroxylamine hydrochloride and potassium hydroxide treatment. Purification of hydroxamic 
acid 13 was accomplished by preparative HPLC and yielded 32% of compound 13 over the 
two steps. 
 
Scheme 12. (a) N-methylpyrrole-2-carboxylic acid (1.15 equiv), HBTU (1.4 equiv), N-methylmorpholine (1.5 equiv), 1,2-
dichloroethane, rt, 16h. (b) NH2OH.HCl (2.2 equiv), KOH (4.35 equiv), MeOH, 70°C, 4h. 32% over step a and b. 
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Another selective HDAC6 inhibitor which has been developed by the group of Kozikowski, 
besides Tubastatin A and analogs, is Nexturastat A 14 (Scheme 13).39 The design of this 
inhibitor was based on the knowledge that the same structure without a butyl substituent on 
the urea moiety is a modest inhibitor of HDAC6 that has no selectivity relative to HDAC1 (IC50 
HDAC1 = 265 nM, IC50 HDAC6 = 139 nM). The fact that HDAC6 accommodates a broader 
tubular channel with respect to other HDACs stimulated the researchers to add substituents 
on both nitrogen atoms of the urea functionality. After evaluation of this class of substituted 
ureas, it became clear that the presence of a butyl substituent on the nitrogen atom proximal 
to the hydroxamic acid moiety afforded the compound with the best properties, and as such 
Nexturastat A 14 was discovered. This molecule displayed high selectivity toward HDAC6 
(Table 13) and demonstrated potent inhibition of melanoma cell growth.  
Table 13. Selective inhibition of HDAC6 by Nexturastat A 14. 
HDAC 1 2 3 4 5 6 7 8 9 10 11 
IC50 (µM)  3.02 6.92 6.68 9.39 11.7 0.005 4.46 0.95 6.72 7.57 5.14 
 
Nexturastat A 14 has been prepared in three steps from methyl 4-formylbenzoate 60 (Scheme 
13). The first step comprised a reductive amination employing methyl 4-formylbenzoate 60, n-
butylamine and sodium cyanoborohydride mixed in a 5% solution of acetic acid in 
dichloromethane. In the second step, secondary amine 61 was treated with phenylisocyanate 
to obtain urea 62. The third and final step consisted of an hydroxamic acid synthesis by adding 
an excess of hydroxylamine to ester 62 in a basic environment. Nexturastat A 14 was finally 
obtained via preparative HPLC purification in 68% yield.  
 
Scheme 13. (a) n-butylamine (1 equiv), AcOH (5% in CH2Cl2), NaCNBH3 (1 equiv), rt, overnight, Ar(g). 68%. (b) phenylisocyanate 
(1 equiv), CH2Cl2, rt, overnight, Ar(g). 98%. (c) NH2OH (50% in H2O, 42 equiv), NaOH (8 equiv), THF/MeOH 1/1.6, 0°C to rt, 30 
min. 68%. 
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In a recent publication, benzohydroxamic acids having a structure similar to compound 15 have 
been patented as selective HDAC6 inhibitors (Scheme 14).40 Structure 15 is one of the 
compounds which showed a promising activity and selectivity for HDAC6 as compared to 
HDAC1 (IC50 values ≤ 500 nM and ≥ 10 µM, respectively). 
The synthesis started with a regioselective Buchwald-Hartwig amination of 2,4-
dibromopyridine 63 with pyrazine-2-amine, resulting in the formation of structure 64. Then a 
straightforward nucleophilic substitution of secondary amine 64 with methyl 4-
(bromomethyl)benzoate in the presence of sodium hydride gave ester 65. The 4-
bromosubstituent in structure 65 was replaced by a 1,2-oxazole moiety through a Suzuki-
Miyaura reaction using an organoboron species and tetrakis(triphenylphosphine)palladium as 
the catalyst. A final conversion of ester 66 to hydroxamic acid 15 was established by the 
addition of an excess of hydroxylamine and two equiv of sodium hydroxide. 
 
Scheme 14. (a) pyrazine-2-amine (1.1 equiv), Cs2CO3 (2.2 equiv), xantphos (5 mol%), Pd2(dba)3 (2 mol%), dioxane, 90°C, 
overnight, N2(g). 49%. (b) i) NaH (1.2 equiv), DMF, 0°C, 30 min, N2(g) ii) methyl 4-(bromomethyl)benzoate (1.1 equiv), DMF, 50°C, 
1.5h, N2(g). 53%. (c) 3,5-dimethyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-oxazole (1 equiv), Pd(PPh3)4 (10 mol%), Cs2CO3 (2 
equiv), DMF/H2O 4/1, 90°C, 2h, N2(g). 18%. (d) NH2OH (50% in H2O, 20 equiv), NaOH (6N, 2 equiv), rt, 1h. 16%.  
 
In another patent, trisubstituted pyrroles such as compound 16 (Figure 1) have been described 
as HDAC inhibitors with preferential inhibition of HDAC6 (Table 14).41 This compound showed 
superior anticancer activity across a panel of 42 different cancer cell lines. No detailed 
synthesis of this structure was disclosed. 
Table 14. Selective inhibition of HDAC6 by trisubstituted pyrrole 16. 
HDAC 1 2 3 4 5 6 7 8 9 10 11 
IC50 (nM)  71 157 75 1083 222 2 290 148 163 294 341 
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Inspired by the novel HDAC6 selective inhibitor 2-phenylamidonaphthoquinone (NQN-1), 
benzohydroxamic acid 17 was designed, also bearing the amidoquinone functionality.42 This 
inhibitor proved to be a strong HDAC6 inhibitor (IC50 = 6 nM) and showed promising toxicity 
toward acute myeloid leukemia cells, but unfortunately no selectivity data have been reported. 
Nonetheless, this compound is mentioned here, as the only reported HDAC inhibition value is 
the one for HDAC6. 
The synthesis of amidoquinone 17 started with the selective esterification of one of the 
carboxylic acid functionalities in bis-acid 67 by using a catalytic amount of thionyl chloride in 
methanol (Scheme 15). In this manner, mono-ester 68 was obtained, in which the remaining 
carboxylic acid group was converted to a tetrahydropyranyl-protected hydroxamate in structure 
69. Then, hydroxamic acid 70 was formed from ester 69 employing an excess of 
hydroxylamine. The next step (step d) comprised the key step of this synthetic pathway, 
producing amidonaphthoquinone 71 from hydroxamic acid 70 and 1,4-naphthoquinone. The 
final step encompassed the deprotection of the tetrahydropyranyl-protected hydroxamate 
moiety with a catalytic amount of para-toluenesulfonic acid, and delivered the pure hydroxamic 
acid 17 in 31% yield after preparative reversed-phase HPLC. 
 
Scheme 15. (a) SOCl2 (cat.), MeOH, rt, 5h. No purification. (b) i) SOCl2 (1.45 equiv), DMF (cat.), CH2Cl2, rt, overnight. ii) NH2OTHP 
(1 equiv), TEA (1.1 equiv), CH2Cl2, rt, 2h. No yield reported. (c) NH2OH (50% in H2O, 30 equiv), KOH (10 equiv), CH2Cl2/MeOH 
1/2, 0°C to rt, overnight. No purification. (d) 1,4-naphthoquinone (1.1 equiv), DIPEA (2 equiv), CH3CN, 70°C, overnight. 35%. (e) 
TsOH.H2O (0.2 equiv), MeOH, rt, overnight. 31%. 
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1.2.2. Benzohydroxamic acid-based pan-HDAC inhibitors 
A second important group of benzohydroxamic acids 72-78 is presented in Figure 2. All these 
structures inhibit multiple zinc-dependent HDAC isozymes simultaneously and display potent 
anti-cancer activity. Several of them are currently studied in clinical trials as anticancer drugs. 
In contrast to HDAC6 selective benzohydroxamic acids, these compounds mostly contain a 
heterocyclic group in the cap-region which is located further away from the benzohydroxamic 
acid scaffold and which is less space filling then the heterocyclic cap-groups present in HDAC6 
selective inhibitors. For each inhibitor presented in Figure 2 the biological activity and synthetic 
pathway will be discussed. 
 
Figure 2. Overview of pan-HDAC inhibitors bearing the benzohydroxamic acid moiety. 
 
Abexinostat 72 is one of the benzohydroxamic acids which is currently in phase 2 clinical trials 
as an anticancer agent and which demonstrated nanomolar dissociation constants for HDAC1, 
2, 3, 6, 8 and 10 (Ki = 7 - 280 nM, Table 15), explaining its classification as a pan-HDAC 
inhibitor. During the design of this molecule, careful optimization of the cap-group appeared to 
be essential to obtain a drug with excellent in vivo efficacy and pharmacokinetics.43 
Table 15. Pan-inhibition of several HDACs by Abexinostat 72. 
HDAC 1 2 3 6 8 10 
Ki (µM)  0.007 0.019 0.008 0.017 0.28 0.024 
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The synthesis of Abexinostat 72 has been disclosed in a patent published in 2004 and started 
with the formation of the 3-substituted (dimethylaminomethyl)benzofuran cap-group 83 
(Scheme 16).44 In a first step carboxylic acid 79 was converted to methyl ester 80 using oxalyl 
chloride and several drops of DMF to form the corresponding acid chloride via the in situ 
generated Vilsmeier reagent. Subsequently, triethylamine and methanol were used to convert 
the acid chloride into methyl ester 80. A radical bromination at the benzylic position generated 
alkylbromide 81, which was transformed to tertiairy amine 82 using dimethylamine. Finally, 
saponification and acidification generated benzofuran-2-carboxylic acid 83, which was coupled 
to methyl 4-(2-aminoethoxy)benzoate using the coupling reagents 1-ethyl-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl) and 1-hydroxybenzotriazole 
hydrate (HOBt.H2O) to obtain methyl ester 84. In a final stage, this methyl ester 84 was treated 
with an excess of hydroxylamine to generate Abexinostat 72.  
 
Scheme 16. (a) oxalyl chloride (1.1 equiv), DMF (5 drops), THF, rt, 1h -> MeOH, TEA (9 equiv), rt, overnight. 94%. (b) NBS (1 
equiv), AIBN (0.1 equiv), CCl4, , 3h. 99%. (c) dimethylamine (3 equiv in THF, 2M), DMF, rt, 1-2h. 56%. (d) NaOH (1N till pH 13), 
MeOH, rt, 1-1.5h -> HCl (aq. till pH 3). 99%. (e) EDC.HCl (1.4 equiv), HOBt.H2O (1.5 equiv), DMF, rt, 0.5-1h -> methyl 4-(2-
aminoethoxy)benzoate hydrochloride (1 equiv), TEA (1.2 equiv), DMF, rt, overnight. (f) NH2OH (excess), NaOH (aq. till pH 10-
11), rt, overnight -> HCl (aq. till pH 7-8). 48% over two steps. 
 
Givinostat 73 (also known as ITF2357) represents another benzohydroxamic acid which is 
currently in phase 2 clinical trials as an anticancer agent. This molecule reduces the production 
of pro-inflammatory cytokines in vitro (TNF, IL-1, IL-1 and IFN) and has anti-inflammatory 
effects in vivo.45 Several studies confirmed the anticancer activity of this molecule in multiple 
tumor cell lines and in patients with hematologic cancers.46 Data of hHDAC inhibition could not 
be found in the literature, but the compound has been tested against three maize HDACs 
(HD2, HD-1B and HD-1A) and exhibited low nanomolar potency (IC50’s = 7.5-16 nM) against 
these isoforms.  
The synthesis of Givinostat 73 started with the amidification of 2,6-naphthalenedicarboxylic 
acid 85 utilising 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 
hydroxybenzotriazole (HOBt, Scheme 17).47 Lithium aluminium hydride reduction of acid 86 
CHAPTER I  LITERATURE REVIEW 
35 
 
was performed to give access to amino alcohol 87 in an excellent yield of 79%. Nucleophilic 
addition of the alcohol group of molecule 87 across N,N’-disuccinimidyl carbonate and 
consecutive addition of 4-aminobenzoic acid resulted in the formation of carbamate 88 in 64% 
yield. Final conversion of acid 88 to hydroxamic acid 73 was accomplished through acid 
chloride formation with thionyl chloride and subsequent hydroxylamine addition in a basic 
environment (NaHCO3, NaOH).  
 
Scheme 17. (a) EDC.HCl (1 equiv), HOBt (1 equiv), DMF, rt, 2h -> diethylamine (3 equiv), rt, overnight. 60%. (b) LiAlH4 (3 equiv), 
THF, , 1h 79%. (c) N,N’-disuccinimidyl carbonate (1 equiv), CH3CN, rt, 3h -> 4-aminobenzoic acid (1 equiv), Na2CO3 (1 equiv), 
H2O/THF (2/1), rt, overnight. 64%. (d) thionyl chloride (3 equiv), CHCl3, , 4h -> NH2OH.HCl (1.2 equiv), NaHCO3 (2 equiv), NaOH 
(1.2 equiv 1N, H2O), H2O/THF (3/1), rt, overnight -> HCl (1.5 N, ether), THF. 41%. 
 
Starting from short chain fatty acids, Lu et al. have synthesized a group of hydroxamic acids, 
of which the benzohydroxamic acids showed the most pronounced HDAC inhibition.48 
Aromatic linkers were chosen to increase the structural rigidity and to increase van der Waals 
contacts with the tube-like hydrophobic region of HDACs. Hydroxamate-tethered 
phenylbutyrate 74 (HTPB, Scheme 18) was identified as the most promising HDAC inhibitor, 
exhibiting an IC50 of 44 nM in a HDAC assay using a nuclear extract (derived from DU-145 
prostate cancer cells) rich in histone deacetylases. The pan-inhibitory effect of this inhibitor 
was further proven through Western Blot analysis of acetylated histones H3 and H4 (substrates 
of class I HDACs), showing a pronounced effect at 1 µM of HTPB. HTPB also reduced cell 
proliferation of several cancer cell lines (DU-145, AN3CA, SW-48 and HCT-15) at 
submicromolar concentrations.  
The first step toward the synthesis of HTPB 74 enclosed a carbodiimide coupling of methyl 4-
aminobenzoate to 4-phenylbutyric acid 89, yielding ester 90 (Scheme 18). Saponification of 
this ester employing potassium hydroxide afforded acid 91, which was converted to O-
benzylhydroxamate 92 by means of bis(2-oxo-3-oxazolidinyl)phosphordiamidic chloride as 
coupling reagent and O-benzylhydroxylamine hydrochloride as nucleophile. In a final step, 
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hydroxamate 92 was O-deprotected using hydrogen gas and palladium on carbon, which 
resulted in the formation of HTPB 74.  
 
Scheme 18. (a) methyl 4-aminobenzoate (1 equiv), EDC (1.3 equiv), THF, rt, overnight, N2. (b) KOH/MeOH (2M), 80°C, 1h -> HCl 
(2N to pH 3), 0°C. (c) TEA (1 equiv), THF, rt, 10 min, N2 -> O-benzylhydroxylamine hydrochloride (1 equiv), bis(2-oxo-3-
oxazolidinyl)phosphordiamidic chloride (1.1 equiv), TEA (3 equiv), THF, rt, overnight, N2. (d) Pd (10% on carbon), H2 (1 atm), 
MeOH/THF (1/1), rt, 2h. No yields reported. 
 
In a consecutive study, Lu et al. have further optimized the structure of HTPB 74 by conducting 
docking studies on the crystal structure of histone deacetylase-like protein (HDLP).49 They 
observed that HDLP contains a hydrophobic microdomain nearby amino acids Phe-198 and 
Phe-200 that could be exploited by introducing an extra alkyl group in α-position with respect 
to the amide present in HTPB 74. As a result, they developed AR-42 75 as another promising 
pan-HDAC inhibitor (currently in phase 1 and 2 clinical trials) against several cancer cell 
lines.50-55 In this study, also the R-enantiomer of AR-42 was made and showed considerably 
less HDAC inhibition than AR-42 itself (AR-42 IC50 HDAC nuclear extract = 16 nM, R-
enantiomer IC50 HDAC nuclear extract = 84 nM). 
Although HTPB 74 and AR-42 75 show a lot of structural similarities, AR-42 was made through 
a different synthetic pathway (Scheme 19). First, 4-aminobenzoic acid 93 was Boc-protected 
to give molecule 94, which was subsequently coupled with O-benzylhydroxylamine using the 
same procedure as for the synthesis of HTPB 74 (Scheme 18, step c). Deprotection of 
compound 95 lead to the free amine 96, which was treated with (S)-3-methyl-2-phenylbutanoic 
acid (obtained through chiral resolution). Final deprotection of benzyl-protected hydroxamate 
97 formed AR-42 75. 
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Scheme 19. (a) Boc2O (1.5 equiv), TEA (1.5 equiv), dioxane/H2O (1/1), rt, overnight. (b) TEA (1 equiv), THF, rt, 10 min, N2 -> O-
benzylhydroxylamine hydrochloride (1 equiv), bis(2-oxo-3-oxazolidinyl)phosphordiamidic chloride (1.1 equiv), TEA (3 equiv), THF, 
rt, overnight, N2. (c) CH2Cl2/TFA (6/1), rt, 2h. (d) (S)-3-methyl-2-phenylbutanoic acid (1 equiv), EDC (1.3 equiv), THF, rt, overnight, 
N2. (e) Pd (10% on carbon), H2 (1 atm), MeOH/THF (1/1), rt, 2h. No yields reported. 
 
Meta-carboxycinnamic acid bishydroxamide 76 (CBHA, Scheme 20) has a quite peculiar 
structure as it contains both a benzohydroxamic acid and a cinnamoylhydroxamic acid group, 
two prevalent scaffolds in HDAC inhibitor design.56 CBHA is denoted as a polar hybrid 
compound, typically consisting of two polar groups separated by an organic spacer. This polar 
hybrid structure inhibited HDAC1 and 3 with submicromolar potency and increased the 
acetylation status of histone H4, which points to the pan-inhibitory activity of this molecule.  
The synthesis of CBHA 76 has been described in a patent, utilizing bis-acid chloride 98 as a 
starting point (Scheme 20).57 Four equiv of O-trimethylsilyl hydroxylamine, one equiv of acid 
chloride 98, methanol, and an acid workup were necessary to obtain CBHA 76 in 91% yield.  
 
Scheme 20. (a) Me3SiONH2 (4 equiv), CH2Cl2, -78°C, Ar(g) -> 2h, rt -> 0.5h,  -> MeOH, -78°C -> MeOH, , 0.5h -> HCl (0.2 N), 
2h, rt. 91%. 
 
PAT-1102 77 is a recently discovered orally active pan-HDAC inhibitor with encouraging 
antitumor activity in mice (Scheme 21).58 The inhibitory activity of this hydroxamic acid has 
been tested against HDAC1, 2, 3, 6, 8 and a HeLa nuclear extract (Table 16). PAT-1102 was 
shown to be active in the low nanomolar range against all enzymes (IC50 = 2-29 nM), only 
against HDAC8 a higher inhibition value was observed (IC50 = 280 nM). Clear dose-dependent 
acetylation of histones H3 and H4 was detected, comparable with vorinostat, proving the pan-
HDAC activity of the inhibitor. The compound was active at low micromolar concentrations 
against 26 different cancer cell lines, and showed comparable activity in human tumor 
CHAPTER I  LITERATURE REVIEW 
38 
 
xenograft models with other inhibitors such as vorinostat and pracinostat (a promising HDAC 
inhibitor in clinical trials).  
Table 16. Pan-inhibition of several HDACs by PAT-1102 77. 
HDAC 1 2 3 6 8 nuclear extract 
IC50 (µM)  0.025 0.029 0.002 0.011 0.28 0.003 
 
PAT-1102 77 has been prepared in seven steps from 4-bromobenzaldehyde 99 (Scheme 21). 
First, a Sonogashira coupling produced alkyn 100 in 80% yield. Removal of the trimethylsilyl 
group resulted in the synthesis of aldehyde 101 (61%), which was reduced to alcohol 102 using 
sodium borohydride. Alcohol 102 was subsequently converted into a good leaving group by 
mesylation (91%). Nucleophilic substitution of mesylate 103 with pyrrolidine gave structure 
104, but no yields of this reaction were documented in the literature. A yield of 91% was 
reported for a structurally related compound bearing a dimethylamino group instead of a 
pyrrolidinyl group. Triazole 105 was then formed using ‘click chemistry’ between methyl 4-
(azidomethyl)benzoate and alkyne 104. For the synthesis of the hydroxamic acid functional 
group an excess of hydroxylamine hydrochloride and sodium methoxide was used and 
generated PAT-1102 77 (25% yield for the synthesis of a structurally related compound). 
 
Scheme 21. (a) trimethylsilylacetylene (1.5 equiv), bis(triphenylphosphine)palladium(II)dichloride (1 mol%), CuI (2 mol%), 
diisopropylamine (solvent), 0°C, 0.5h -> , 3h. 80%. (b) K2CO3 (0.1 equiv), MeOH, rt, 1h. 72%. (c) NaBH4 (2 equiv), MeOH, 0°C, 
5 min -> rt, 1h. 61%. (d) mesyl chloride (no equiv reported), TEA (3 equiv), CH2Cl2, 0°C -> rt, 12h. 91%. (e) pyrrolidine (2.5 equiv), 
TEA (2 equiv), 0°C -> rt, 12h. 91%*. (f) methyl 4-(azidomethyl)benzoate (0.9 equiv), CuI (0.45 equiv), sodium ascorbate (cat.), N-
ethyldiisopropylamine (1.85 equiv), DMF, rt, 12h. 92%*. (g) NH2OH.HCl (100 equiv), NaOMe (150 equiv), MeOH, 0°C, 0.5h -> rt, 
3h. 25%*. *yields reported for closely related derivatives. 
 
Another pan-HDAC inhibitor with a benzohydroxamic acid moiety, which has been evaluated 
as an anticancer agent, is CRA-026440 78 (Figure 2).59 Determination of the dissociation 
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constants against HDAC1, 2, 3, 6, 8 and 10 revealed CRA-026440 78 to be a pan-HDAC 
inhibitor (Table 17). Moreover, CRA-026440 78 inhibited ex vivo angiogenesis and reduced 
the tumor growth in HCT116 or U937 tumor xenograft mice significantly. The synthesis of CRA-
026440 78 was described in a patent (compound 29 in the patent), but no exact details were 
given.60 
Table 17. Pan-inhibition profile of CRA-026440 78. 
HDAC 1 2 3 6 8 10 
Ki (µM) 0.004 0.014 0.011 0.015 0.007 0.020 
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1.2.3. Selective benzohydroxamic acid-based HDAC8 inhibitors 
Looking at the HDAC8 selective benzohydroxamic acids 106-112 presented in Figure 3, the 
meta-substitution pattern of the cap-group with respect to the hydroxamic acid functionality in 
four out of seven compounds (106, 107, 111 and 112) is remarkable. Also in PCI-34051 108, 
a similar meta-substitution-like arrangement can be perceived. Only compounds 109 and 110 
do not comply with this meta-orientation condition. Besides that, none of the HDAC6 selective 
or pan-HDAC inhibitors described above (Figures 1 and 2) contain such a meta-substituted 
structure (except for the peculiar hybrid polar inhibitor CBHA 76, Figure 2). From each inhibitor 
presented in Figure 3, the biological activity and synthetic pathway will be discussed. 
 
Figure 3. Overview of selective HDAC8 inhibitors bearing the benzohydroxamic acid moiety. 
 
Miniaturized high-throughput synthesis and screening has been performed in 96-well plates to 
discover new selective histone deacetylase 8 inhibitors, such as representative example 106 
(Figure 3).61 This high-throughput screening revealed that the hydrazones meta-substituted 
with respect to the hydroxamic acid functionality showed the best selectivity for HDAC8. As a 
representative example, compound 106 is highlighted, which demonstrated micromolar 
inhibition of HDAC2 and 3, and nanomolar inhibition of HDAC8 (Table 18). However, it should 
be noted that no HDAC6 inhibition data were provided, making this HDAC8 selectivity claim 
rather premature. 
Table 18. Selective inhibition of HDAC8 by hydrazone 106. 
HDAC 2 3 8 
IC50 (µM) 20 18 0.052 
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A two-step high-throughput synthesis process has been developed converting a first pool of 
primary alcohols into aldehydes (aldehyde 113 as an example, Scheme 22), which were further 
condensed with a second pool of hydrazides (hydrazide 114 as an example) to the 
corresponding hydrazones (hydrazone 106 as an example). All compounds, hydrazone 106 
inclusive, were formed from 18 hydrazides and 15 aldehydes and obtained in a purity of 90%. 
 
Scheme 22. High-throughput synthesis of representative example 120.  
 
Another class of novel benzohydroxamic acids has been developed to obtain a drug with a 
new mode of action against schistosomiasis.62 This is a major neglected parasitic disease 
affecting more than 265 million people worldwide. The main goal was to obtain inhibitors for 
the HDAC8 isoform of Schistosoma mansoni, but from the results it appeared that these 
inhibitors also potently and selectively inhibited human HDAC8. The most potent inhibitor was 
structure 107 (Scheme 23, Table 19), having low nanomolar IC50 values for smHDAC8 and 
hHDAC8 (75 nM and 26 nM, respectively) and low micromolar IC50 values for hHDAC1 and 
hHDAC6 (6.3 µM and 0.4 µM, respectively). This compound was effective in killing 
schistosomula in vitro, clearly demonstrating the potential of smHDAC8 inhibitors to address 
this parasitic infection. 
Table 19. Selective inhibition of HDAC8 by compound 107. 
HDAC h1 h6 h8 sm8 
IC50 (µM) 6.3 0.4 0.026 0.075 
 
The synthesis of inhibitor 107 started with an esterification of acid 115. The resulting methyl 
ester 116 was then treated with an acid chloride to give amide 117. Hydrolysis of the ester 
group in compound 117 and subsequent treatment of the obtained acid 118 with O-(tetrahydro-
2H-pyran-2-yl)hydroxylamine and the coupling reagent benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) resulted in the protected 
hydroxamate, which was liberated using a catalytic amount of hydrogen chloride. This 
approach produced the target structure 107 in 3.5% overall yield. 
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Scheme 23. (a) SOCl2 (3 equiv), MeOH, 0°C to , 1h (b) 4-phenylbenzoyl chloride, DIPEA, THF, rt, till completion. (c) NaOH (1M 
aq.), MeOH, 50°C, 2h. (d) i) NH2OTHP (1.5 equiv), PyBOP (1.2 equiv), DIPEA (2.5 equiv), THF, rt, overnight. ii) HCl (cat.), THF, 
rt, till completion. 3.5% for last step, no other yields reported. For step b, no equiv reported. 
 
From a patented series of indole hydroxamic acids, PCI-34051 108 (Scheme 24) demonstrated 
potent inhibition of HDAC8 and showed to be more than 200 fold selective over five other 
HDAC isoforms (Table 20).63,64 This inhibitor was tested against an array of tumor cell lines 
and induced caspase-dependent apoptosis in T-cell lymphomas or leukaemia’s, but not in 
other hematopoietic or solid tumors. Further prove for the HDAC8 selectivity was provided by 
determining histone and tubulin acetylation via Western Blots. Detectable increases of 
acetylation of histones and tubulin will appear when a broad-spectrum HDAC inhibitor is 
administered to a cell. In contrast to this, PCI-34051 did not increase the acetylation level of 
histones and tubulin up to a concentration of 25 µM in Jurkat cells. Due to this HDAC8 
selectivity and the discovered selectivity for T-cell-derived tumors, it could be expected that 
PCI-34051 108 will be much less toxic than pan-HDAC inhibitors and should thus be further 
explored in this context. 
Table 20. Selective inhibition of HDAC8 by PCI-34051 108. 
HDAC 1 2 3 6 8 10 
IC50 (µM)  4 >50 >50 2.9 0.01 13 
 
The synthesis of PCI-34051 108 has been realized in only two steps (Scheme 24). First, a 
nucleophilic substitution was performed on 4-(methoxybenzyl)bromide by deprotonating 
methyl 1H-indole-6-carboxylate 119. In this way, N-substituted indole derivative 120 was 
obtained in 54% yield after column chromatography. The second step comprised an ester to 
hydroxamic acid interconversion by adding an excess of hydroxylamine and five equiv of 
sodium hydroxide to ester 120. Hydroxamic acid 108 was thus obtained in an excellent yield 
(84%) as a white powder. 
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Scheme 24. (a) 4-(methoxybenzyl)bromide (1.1 equiv), NaH (1.15 equiv), DMF, rt, 3.5h. 54%. (b) NH2OH (50% in H2O, 33 equiv), 
NaOH (5 equiv), THF/MeOH 1/1, rt, 1h. 84%. 
 
Compound 109 has been reported as a selective HDAC8 inhibitor with a rather low potency 
(Scheme 25).65 This para-aminobenzoic acid derivative was the most potent HDAC8 inhibitor 
described in a series of twelve similar compounds and holds an IC50 value of 15.7 µM for 
HDAC8. The percentage inhibition at 100 µM for two other isoforms, HDAC1 and 6, was also 
determined to evaluate the selectivity. Less than 10% of HDAC1 was inhibited at this high 
concentration, and HDAC6 was inhibited for 41%, demonstrating the HDAC8 selectivity. The 
HDAC8 selectivity and moderate potency could potentially be improved by synthesizing the 
meta-substituted analogs in future follow-up studies. 
Hydrazine 121 was treated with ice cold carbon disulfide in the presence of potassium 
hydroxide and subsequently with methyl iodide to generate methyl hydrazinecarbodithioate 
122. After heating carbodithioate 122 under reflux together with isatin and a drop of 
concentrated sulfuric acid, structure 123 was generated. In the following step, compound 123 
was treated for 3-4 days with one equiv of 4-aminobenzoic acid, which yielded 
thiosemicarbazone 124. Final conversion to hydroxamic acid 109 was achieved through the 
formation of an intermediate anhydride by treatment of carboxylic acid 124 with phenyl 
chloroformate in the presence of a base. This intermediate anhydride was then added to a 
solution of hydroxylamine, producing inhibitor 109. 
 
Scheme 25. (a) i) CS2 (1 equiv), KOH (1 equiv), iPrOH, <10°C, 2.5h. ii) MeI (1 equiv), <10°C, 3.5h. (b) isatin (1.2 equiv), MeOH, 
H2SO4 (cat.), , 6-7h; (c) 4-aminobenzoic acid (1 equiv), EtOH, , 3-4 days. (d) i) phenyl chloroformate (1 equiv), TEA (1 equiv), 
THF, rt, 1h. ii) NH2OH, rt, 3h. No yields reported. 
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By means of careful inspection of HDAC8 crystal structures bound to several types of HDAC 
inhibitors, a unique sub-pocket has been discovered in the HDAC8 active site.66 This sub-
pocket could be exploited for the design of isoform selective HDAC8 inhibitors. In this work, 
six hydroxamic acids were designed which specifically target this sub-pocket. From these six 
new hydroxamic acids, naphthalene-containing derivative 110 showed the highest potency and 
selectivity for HDAC8 (Table 21, Scheme 26). 
Table 21. Selective inhibition of HDAC8 by hydroxamic acid 110. 
HDAC 1 6 8 
IC50 (µM)  >100 55 0.3 
 
Deployment of a Suzuki coupling between 4-bromobenzoic acid 125 and naphthalen-1-
ylboronic acid provided structure 126 (Scheme 26). In a following step, this acid 126 was 
converted to acid chloride 127 using thionyl chloride and a catalytic amount of DMF. Without 
purification, the crude acid chloride was treated with hydroxylamine in water/THF and yielded 
hydroxamic acid 110 in more than 80% yield over steps b and c. 
 
Scheme 26. (a) No reaction details given. (b) SOCl2, DMF (cat.). (c) NH2OH (in H2O/THF), TEA, H2O. Yield >80% for steps b and 
c. No detailed reaction conditions given. 
 
In another study, a library of potential HDAC8-selective inhibitors has been prepared by using 
‘click chemistry’.67 To that end, eight alkynes and fifteen azides were made and reacted with 
each other to give a collection of 120 triazoles. These structures were then evaluated for their 
HDAC8 inhibitory properties and their inhibition of HeLa nuclear extract rich in HDAC1 and 2. 
This assay revealed two meta-substituted benzohydroxamic acids as lead structures for further 
optimization. Therefore, a second library was designed containing 31 new triazoles bearing 
this meta-substituted benzohydroxamic acid structure and revealed NCC149 111 as the most 
potent and selective HDAC8 inhibitor (Table 22, Scheme 27). Molecular docking further 
revealed that the orientation of the phenylthiomethyl group in structure 111 is important to fit 
the unique hydrophobic sub-pocket of HDAC8 to confer selectivity. This is the same sub-pocket 
also observed by Krennhrubec et al., who designed hydroxamic acid 110 (Scheme 26).66  
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Table 22. Selective inhibition of HDAC8 by NCC149 111. 
HDAC 1 2 4 6 8 nuclear extract 
IC50 (µM)  38 >100 44 2.4 0.07 54 
 
Esterification of acid 128 employing concentrated sulfuric acid and methanol yielded methyl 
ester 129. A subsequent Sonogashira coupling with trimethylsilylacetylene gave compound 
130, which was hydrolysed to afford acid 131. Next, an EDC/HOBt-mediated coupling was 
performed with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine, resulting in hydroxamate 132. The 
tetrahydropyranyl group was removed employing para-toluenesulfonic acid, and the free 
hydroxamic acid 133 was thus obtained. In a final step through ‘click chemistry’, selective 
HDAC8 inhibitor 111 was obtained via a cupper-catalyzed coupling between alkyne 133 and 
azidomethyl phenyl sulfide. 
 
Scheme 27. (a) H2SO4 (conc.), MeOH, , 30h. (b) trimethylsilylacetylene (1.5 equiv), PdCl2(PPh3)2 (1 mol%), CuI (1.5 mol%), rt, 
18h. (c) NaOH (2N, 2 equiv), MeOH, rt, 5h. (d) NH2OTHP (1.5 equiv), EDC (1.2 equiv), HOBt.H2O (1.2 equiv), rt, 24h. (e) 
TsOH.H2O (0.1 equiv), MeOH, rt, 12h. 68%. (f) azidomethyl phenyl sulfide (1.2 equiv), TBTA (0.1 equiv), CuSO4.5H2O (0.1 equiv), 
sodium ascorbate (0.5 equiv), DMSO, rt, 1-3 days. 92%. 
In an attempt to improve the HDAC8 potency and selectivity of NCC149 111, derivatives in 
which the triazole moiety is replaced by another aromatic ring (benzene, thiazole, oxadiazole, 
reversed triazole, thiophene), have been made.68 Evaluation of the potency and selectivity for 
HDAC8 with enzyme and cellular assays revealed that thiazole 112 (Scheme 28) displayed an 
improved profile over NCC149 111 (Table 23). 
Table 23. Selective inhibition of HDAC8 by thiazole 112. 
HDAC  1 2 3 4 6 8 nuclear extract 
IC50 (µM) >100 >100 12 >100 14 0.15 >100 
 
For the synthesis of thiazole 112, α-bromoketone 136 and thioamide 139 were made as 
precursors (Scheme 28). α-Bromoketone 136 was formed from acid 134 by an esterification 
toward methyl ester 135 and a subsequent α-bromination. For the thioamide synthesis, acid 
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137 was converted to amide 138 by means of oxalyl chloride, dimethylformamide and 
ammonia, and further into thioamide 139 using Lawesson’s reagent. Cyclisation was 
performed via a Hantzsch thiazole synthesis and gave thiazole 140 in 78% yield. Final 
conversion toward hydroxamic acid 112 was accomplished in three steps from ester 140 in 
48% overall yield. The three steps involved hydrolysis, O-(tetrahydro-2H-pyran-2-
yl)hydroxylamine coupling and tetrahydropyranyl deprotection. 
 
Scheme 28. (a) H2SO4 (conc.), MeOH, , 26.5h. 97%. (b) Br2 (0.93 equiv), 25% HBr-AcOH (cat.), CHCl3, 0°C to rt, 2h. quant. (c) 
i) (COCl)2 (2.6 equiv), DMF (cat.), THF, 0°C, 0.5h. ii) NH3 (aq. 25%), THF, 0°C, 1.5h. 83%. (d) Lawesson’s reagent (0.47 equiv), 
toluene, 80°C, 3.5h. 21%. (e) MS (3Å), EtOH/CHCl3 1/1, 70°C, 3h, N2(g). 78%. (f) i) NaOH (2N aq., 4 equiv), MeOH/THF/CHCl3 
2/1/1, rt, 5h. 68%. ii) NH2OTHP (2.85 equiv), EDC.HCl (2.95 equiv), HOBt.H2O (3.04 equiv), DMF, rt, 30h. 96%. iii) TsOH.H2O 
(0.1 equiv), MeOH, rt, 5.5h. 73%. 
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1.2.4. Dual selective benzohydroxamic acid-based HDAC6/8 inhibitors 
The last group of benzohydroxamic acid-based HDAC inhibitors comprises three structures 
141, 142 and 143, all of them being nanomolar inhibitors of HDAC6 and 8 (Figure 4). Structures 
141 and 143 are meta-(like) substituted compounds typically resulting in excellent HDAC8 
inhibitory activity. In contrast to what can be expected, para-substituted compound 142 also 
demonstrated potent activity toward HDAC8. This proves that para versus meta substitution is 
not an absolute requirement to deliver HDAC6 or HDAC8 selective inhibitors, respectively. For 
each inhibitor presented in Figure 4, the biological activity and synthetic pathway will be 
discussed. 
 
Figure 4. Overview of dual selective HDAC6/8 inhibitors bearing the benzohydroxamic acid moiety. 
 
Benzohydroxamic acid 141 (Scheme 29) represents the first discovered, potent and selective 
dual HDAC6/8 inhibitor.69 Selective inhibition of these two isoforms is expected to improve the 
therapeutic window by increasing the biological activity through beneficial additive or 
synergistic effects, while still keeping possible side effects to a minimum. As can be seen from 
Table 24, dual selective inhibitor 141 has low nanomolar potency for HDAC6 and 8, and low 
micromolar potency for the other HDACs tested (HDAC1-5, 7 and 9), clearly demonstrating its 
dual selectivity and potency. Meta-substitution with a hydrophobic cap-group again proved to 
be a necessary requirement in this case to obtain potent HDAC8 inhibition. This assumption 
was also supported by docking studies with HDAC8, were these structures filled the secondary 
hydrophobic pocket of HDAC8 with their cap-group. 
Table 24. Selective dual inhibition of HDAC6 and 8 by compound 141. 
HDAC 1 2 3 4 5 6 7 8 9 
IC50 (µM)  6.1 4.8 18 14 26 0.021 8.4 0.037 12 
 
The synthesis of inhibitor 141 has been realized in two steps (Scheme 29). First, the acid 
functionality in structure 144 was converted to an amide by using 1-[bis(dimethylamino)-
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methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexa-fluorophosphate (HATU) as a 
coupling reagent. Secondly, hydroxamic acid 141 was formed from ester 145 by employing an 
excess of hydroxylamine and sodium hydroxide.  
 
Scheme 29. (a) aniline (0.91 equiv), HATU (1.4 equiv), DIPEA (2.7 equiv), DMF, rt, till completion. (b) NH2OH (50% in H2O, 30 
equiv), NaOH (1M, 10 equiv), CH2Cl2/MeOH 1/2, 0°C to rt, till completion. No yields reported. 
 
From the structure of trichostatin A, a new class of N-acylhydrazones has been designed (e.g. 
structure 142, (Scheme 30) with pronounced HDAC6/8 inhibitory activity.70 As it is known from 
the literature that meta-substitution within benzohydroxamic acids is usually favourable with 
respect to HDAC8 inhibition, it was surprising to see that the para-substituted 
benzohydroxamic acids in this case showed more potent dual HDAC6/8 inhibition. From the 
derivatives tested, N-acylhydrazone 142 is a representative example demonstrating potent and 
selective inhibition of both HDAC6 and 8 (Table 25). It was also shown that this class of 
compounds exhibited pronounced antitumor activity against melanoma and hepatocellular 
carcinoma cells. 
Table 25. Selective dual inhibition of HDAC6 and 8 by N-acylhydrazone 142. 
HDAC 1 2 6 8 
IC50 (µM)  >3 >3 0.015 0.23 
 
A convergent synthetic approach has been applied for the synthesis of N-acylhydrazone 142 
(Scheme 30). To that end, ester 147 was prepared by oxidizing aldehyde 146 using iodine and 
potassium hydroxide in methanol. This ester 147 was further converted to the proposed 
hydrazide 148 by means of hydrazine. In a second parallel pathway, aldehyde 149 was 
protected using 2,2-dimethoxypropane in an acidic environment. After treatment of the formed 
acetal-ester 150 with hydroxylamine, hydroxamic acid 151 was obtained in 90% yield. 
Hydrolysis of the acetal group in structure 151 with aqueous sulfuric acid resulted in the 
formation of aldehyde 152. In the final step, condensation of aldehyde 152 with hydrazide 148 
took place under acidic catalysis and yielded 84% of N-acylhydrazone 142. 
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Scheme 30. (a) I2 (3 equiv), KOH (6 equiv), MeOH, 0°C, 10h. 57%. (b) NH2NH2.H2O (10 equiv), MeOH, 70°C, 18h. 95%. (c) 2,2-
dimethoxypropane (1.5 equiv), TsOH (0.1 equiv), MeOH, rt, 2h. 82%. (d) NH2OH.HCl (8 equiv), KOH (12 equiv), MeOH, rt, 4h. 
90%. (e) H2SO4 (15% w/v aq.), acetone, rt, 2h. 91%. (f) HCl (cat.), EtOH, rt, 2h. 84%. 
 
R-Aminotetralin 143 has been discovered through the generation of a focused library 
containing hydroxamic acids directly attached to fused bicyclic linkers and various capping 
groups.29 In this way, a tetrahydroisoquinoline was identified as a novel lead compound. 
However, metabolic instability issues of the tetrahydroisoquinoline group urged the 
researchers to replace this system by an aminotetralin scaffold. As such, a second library was 
designed and R-aminotetralin 143 was discovered as the most potent and selective inhibitor 
of HDAC6 and 8 (Table 26). The selectivity was further proven by cellular assays determining 
the acetylation status of α-tubulin and the induction of p21. 
Table 26. Selective dual inhibition of HDAC6 and 8 by R-aminotetralin 143. 
HDAC 1 2 3 4 5 6 7 8 9 10 11 
IC50 (µM)  6.31 >100 >100 >100 >100 0.05 30.8 0.08 35.0 >100 >100 
 
The synthesis of R-aminotetralin 143 started with the separation of racemate 153 through chiral 
supercritical fluid chromatography (Scheme 31). This generated R-enantiomer 154, which was 
converted to amino ester 155 through a palladium-catalyzed carboxylation and Boc-
deprotection. Nucleophilic aromatic substitution gained access toward 2-aminopyrimidin 156, 
which was converted to hydroxamic acid 143 in a final step employing hydroxylamine. 
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Scheme 31. (a) chiral supercritical fluid chromatography. (b) i) Pd(OAc)2 (cat.), 1,3-bis(diphenylphosphino)propane (cat.), TEA (4 
equiv), DMF/MeOH 3/10, CO (g), 80°C, 12h. ii) HCl/MeOH (1M), rt, 2h. (c) aryl chloride, DIPEA, DMF, 150°C, 1h, MW. (d) NH2OH 
(50% in H2O), NaOH, MeOH, rt, 1h. No reaction details reported. 
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1.3. Conclusions 
Benzohydroxamic acids have been amply shown to be privileged building blocks in medicinal 
chemistry, especially when introduced as a zinc-binding moiety in the chemical architecture of 
HDAC inhibitors. This literature review shows that careful optimization of the part following the 
benzohydroxamic acid, i.e., the linker region and the cap-group, can give rise to HDAC6 
selective, non-selective, HDAC8 selective or dual HDAC6/8 selective inhibitors. When 
overviewing these four classes, general structure-activity relationships can be proposed for 
each class, although exceptions are present. The HDAC6 selective class mainly consists of 
inhibitors having a bulky cap-group in close proximity to the benzohydroxamic acid moiety. The 
non-selective pan-inhibitors have a rather elongated shape, and the HDAC8 selective 
inhibitors are mainly meta-(like) substituted with respect to the hydroxamic acid moiety. The 
last group of selective benzohydroxamic acid-based dual HDAC6/8 inhibitors is small and no 
class-specific structural properties can be defined at this point. The fact that exceptions on 
these structure-activity relationships can occur, and the fact that the selectivity data obtained 
through enzymatic screens (HDAC1-11) always confirmed the selectivity data obtained 
through more complex cellular screens (histone and α-tubulin acetylation, p21 induction), 
prove the importance of a HDAC1-11 screen as a preliminary tool for lead molecule selection. 
Finally, the synthetic pathways presented here could inspire future medicinal chemists to 
develop new syntheses to obtain an effective HDAC inhibitor eventually reaching the patient.
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Abstract: Eight N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes were 
efficiently prepared as sulfur analogs of Tubastatin A and thus evaluated as new HDAC6 
inhibitors. All compounds exhibited potency against HDAC6, and four of them were active in 
the nanomolar range (IC50 = 1.9-22 nM). Further analysis revealed that the sulfone derivatives 
(designated as Tubathians) are superior to their non-oxidized sulfide analogs, and the two 
most active sulfones showed good to excellent HDAC6 selectivity compared to all other HDAC 
isoform classes. 
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2.1. Introduction 
The enzymatic addition and removal of acetyl groups at specific lysine residues comprise 
important biochemical reactions with a significant impact on many cellular processes.3,71 The 
addition of acetyl groups within histone proteins, the chief protein components of chromatin, is 
catalyzed by histone acetyltransferases (HAT), and histone deacetylases (HDAC) mediate the 
corresponding deacetylation reactions. The inhibition of the latter group of deacetylases has 
become a hot topic in medicinal chemistry, and the use of HDAC inhibitors (HDACi’s) has 
found many applications with regard to cancer and CNS disorder therapies (central nervous 
system).19,72-74 In general, HDACi’s act on 11 zinc-dependent HDAC isozymes, which are 
divided into four groups: class I (HDACs 1, 2, 3, 8), class IIa (HDACs 4, 5, 7, 9), class IIb 
(HDACs 6, 10), and class IV (HDAC11).6 The majority of known HDACi’s primarily inhibit the 
class I enzymes, making them excellent candidates for cancer therapy applications, but other 
than class I HDACi’s are normally required for the pursuit of non-oncological applications.75 
Another important issue relates to the potential toxicity of compounds inhibiting multiple 
isozymes, as acetylation is involved in the control of many cellular processes and inhibition of 
some isozymes may cause undesirable side effects. Thus, the design and development of 
isozyme-selective inhibitors has emerged as an important challenge within the search for novel 
HDACi’s.76 In recent years, HDAC6 has been acknowledged as an attractive target for drug 
development,77-81 and an increasing number of research teams are currently involved in the 
quest for new compounds endowed with HDAC6 inhibitory activity.32,82-88 In addition to the 
potential of HDAC6-selective inhibitors for applications in the treatment of CNS disorders and 
neurodegenerative diseases, these compounds seem to provoke fewer side effects, hence the 
growing interest in their preparation.89 An important milestone in that respect concerns the 
identification of Tubacin as a selective HDAC6 inhibitor, although the application of this 
compound is hampered by its poor druglikeness and cumbrous synthesis.90 Since then, 
considerable advances have been made with regard to the preparation of new HDAC6 
inhibitors, leading to an array of different molecular entities with improved chemical and 
pharmacological properties. From a chemical viewpoint, many of these molecules comprise 
the typical HDACi basic structure accommodating an aromatic cap group (surface recognition 
domain), a linker and a zinc-binding hydroxamic acid unit. A major breakthrough was 
accomplished recently, involving the rational design and synthesis of Tubastatin A as a novel 
and selective HDAC6 inhibitor.13 Elaborate studies in this direction showed that the HDAC6 
isozyme tolerates modifications of the Tubastatin A chemical structure at the level of the cap 
group and, more specifically, that the introduction of structural diversity at the 2- and 8-position 
of the tetrahydropyrido[4,3-b]indole scaffold can be beneficial with regard to the overall 
bioactivity.34 
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Inspired by these recent SAR findings, and intrigued by the fact that several new HDAC6 
inhibitors contain a sulfur atom in their molecular structure,32,84,85 efforts were made toward the 
preparation of a number of sulfur analogs (sulfides and sulfones) of Tubastatin A in the present 
study, supported by HDAC6 ligand docking. Furthermore, the replacement of a methylene 
group with a sulfone moiety in medicinally relevant compounds has been shown to induce a 
significant beneficial increase in stability,91 suggesting this modification as a preferred change 
during compound optimization and thus providing an additional rationale for the work 
undertaken in this study. The results obtained point to the potential of sulfur analogs of 
Tubastatin A as new HDAC6 inhibitors, especially those containing a sulfone moiety in their 
structure. 
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2.2. Synthesis and biological evaluation of N-(4-hydroxy-
carbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes 
The 1,2,4,9-tetrahydro-3-thia-9-azafluorene scaffold was prepared via a bismuth nitrate-
promoted Fisher indole synthesis employing a phenylhydrazine hydrochloride 1 and 
tetrahydrothiopyran-4-one 2, providing a convenient access to tetrahydro-3-thia-9-
azafluorenes 3 in good yields (Scheme 1).92 Subsequently, N-benzylation of compounds 3 was 
accomplished using a methyl 4-(bromomethyl)benzoate in DMF in the presence of sodium 
hydride and potassium iodide, furnishing the corresponding N-(4-methoxycarbonylbenzyl)-
1,2,4,9-tetrahydro-3-thia-9-azafluorenes 4. The final step of the process comprised an ester to 
hydroxamic acid interconversion, which was realized utilizing an excess of hydroxylamine 
hydrochloride in the presence of methanolic sodium methoxide in DMF. In this way, the 
premised N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes 5 were 
obtained in an efficient and straightforward approach (Scheme 1, Table 1). 
Considering the presence of a (cyclic) sulfone moiety in several drugs and bioactive 
compounds,91 the sulfide in systems 3 was oxidized to the corresponding sulfones 6 by means 
of meta-chloroperbenzoic acid treatment in tetrahydrofuran. The thus obtained sulfones 6 were 
taken further in the synthesis toward the contemplated hydroxamic acids 8 via esters 7 
applying a similar strategy to that discussed above for the preparation of hydroxamic acids 5 
(Scheme 1, Table 1). 
 
Scheme 1. Synthesis of N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes 5 and their oxidized analogs 8. 
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Table 1. Synthesis of tetrahydro-3-thia-9-azafluorenes 3-5 and their oxidized analogs 6-8. 
R1 R2 Compound (yield)a 
H - 3a (85%) 
F - 3b (90%) 
H H 4a (52%) 
H MeO 4b (57%) 
F H 4c (69%) 
F MeO 4d (78%) 
H H 5a (38%) 
H MeO 5b (65%) 
F H 5c (70%) 
F MeO 5d (66%) 
H - 6a (77%) 
F - 6b (80%) 
H H 7a (48%) 
H MeO 7b (60%) 
F H 7c (47%) 
F MeO 7d (40%) 
H H 8a (51%) 
H MeO 8b (30%) 
F H 8c (69%) 
F MeO 8d (72%) 
a Yields after purification by column chromatography (SiO2) or recrystallization 
 
The binding of the various ligands 5a-d and 8a-d in the enzyme’s active site was evaluated by 
means of automated docking. Since the crystal structure of HDAC6 is not available, a 
homology model was first generated following the example of Kozikowski using the structure 
of HDAC isozymes as a template (more information on the building of the homology model can 
be found in the experimental details).13 Compounds that do not carry a methoxy group on their 
linker (5a, 5c, 8a and 8c) were found to fit perfectly in the active site of HDAC6 (Figure 1). In 
that case, the p-tolyl linker is positioned in the tubular access channel, with the carbonyl group 
of the hydroxamate moiety within chelating distance from the zinc ion at the bottom of the 
pocket. As the linker fills the access channel almost completely, very little space is left to 
accommodate a (bulky) substituent such as a methoxy group (Figure 1A), which is in line with 
previous studies in that respect. In contrast, modifications of the tricyclic cap group do not 
seem to influence the binding mode very much, since the conformation and orientation of 
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compounds 5a, 5c, 8a and 8c is nearly identical. However, oxidation of the sulfur atom might 
generate additional interactions with the enzyme in the form of hydrogen bonds between the 
introduced oxygen atoms and the backbone nitrogen of residues Asp567 and Gly619 (Figure 
1B and Figure 2 in the Experimental Details). The latter observation provided an interesting 
motive to experimentally assess the HDAC6 inhibitory activity of Tubastatin A analogs in which 
the NMe moiety is replaced by a sulfone unit. 
 
Figure 1. Docking of compound 8a in the active site of HDAC6. (A) view of the tubular access channel, and (B) additional 
interactions generated by the oxidation of the sulfur atom (green: carbon; blue: nitrogen; red: oxygen; yellow: sulfur; magenta: 
zinc ion). 
 
In vitro pharmacology studies of novel hydroxamic acids 5a-d and 8a-d with regard to their 
HDAC1 and HDAC6 inhibitory activity revealed an interesting potency of these compounds as 
HDAC6 inhibitors (Table 2). In particular, hydroxamic acids 5a, 5c, 8a and 8c showed complete 
inhibition at a test concentration of 10 µM, and also compounds 8b and 8d exhibited a good 
profile with an inhibition of 73% and 75%, respectively. In addition, these results pointed to a 
selectivity of the test compounds toward HDAC6 inhibition, with HDAC1 inhibition percentages 
ranging from 0% to a maximum of 53%. Furthermore, these data also indicate a detrimental 
effect of the introduction of a methoxy group in the linker moiety on the bioactivity (compounds 
5b,d and 8b,d), as indicated by homology modeling. HDAC1 and HDAC6 were chosen for 
activity comparison in this preliminary test, as these two enzymes have a diverse phylogeny 
and are members of separate deacetylase classes. 
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Table 2. % inhibition of control values with regard to HDAC1 and HDAC6 inhibitory activitya,b 
Compound % inhibition 
HDAC1 
% inhibition 
HDAC6 
Compound % inhibition 
HDAC1 
% inhibition 
HDAC6 
5a 26 99 8a 51 99 
5b 0 38 8b 2 73 
5c 17 99 8c 53 99 
5d 0 51 8d 8 75 
a Test concentration: 10 µM; b Mean value of two screening sessions 
 
The most promising molecules (those compounds showing an inhibition of >70%) were then 
selected for determination of their IC50 values with respect to HDAC6 inhibition (Table 3). 
These assessments confirmed the presumption that molecules bearing a methoxy-substituted 
linker exhibit lower – but still moderate – activities, exemplified by compounds 8b and 8d (with 
IC50 values of 2.0 and 1.3 µM, respectively). Furthermore, sulfur oxidation indeed seems to be 
beneficial for bioactivity, as sulfones 8a and 8c show even more potent HDAC6 inhibition as 
compared to sulfides 5a and 5c. Overall, four compounds (5a, 5c, 8a and 8c) can be 
considered to be promising lead templates for further elaborate studies. Sulfides 5a and 5c 
(with IC50 values of 15 and 22 nM, respectively) display HDAC6 inhibitory activities similar to 
the reference compound Trichostatin A and to Tubastatin A, but sulfones 8a and 8c are even 
more potent than sulfides 5a and 5c with IC50 values of 1.9 and 3.7 nM, respectively. 
Table 3. IC50 values for HDAC6 inhibitiona 
Compound IC50 (µM) Compound IC50 (µM) 
5a 0.015 8b 2.0 
5c 0.022 8c 0.0037 
8a 0.0019 8d 1.3 
a Reference compound: Trichostatin A (IC50 = 0.012 µM) 
 
Finally, the HDAC inhibition selectivity of the two most active compounds 8a (R1 = R2 = H) and 
8c (R1 = F, R2 = H) against the other HDAC isoform classes was assessed and, to this end, a 
class I (HDAC1), a class IIa (HDAC4), a class IIb (HDAC6) and a class IV (HDAC11) isozyme 
was selected. Considering the fact that Tubastatin A has over 1000-fold selectivity against all 
HDAC isozymes except for HDAC8, where it has only a 57-fold selectivity, the HDAC8 
inhibitory activity of compounds 8a and 8c was also evaluated. 
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Table 4. Comparison of HDAC selectivity 
Compound HDAC1  
IC50 (µM)a 
HDAC4  
IC50 (µM)a 
HDAC6  
IC50 (µM)a 
HDAC11  
IC50 (µM)b 
HDAC8  
IC50 (µM)a 
8a 11 1.6 0.0019 NC 1.7 
8c 12 1.9 0.0037 NC 0.93 
Tub Ac 16.4 >30 0.015 >30 0.85 
a Reference compound: Trichostatin A, b Reference compound: Scriptaid, NC = Not Calculable (concentration-response curve 
shows less than 25% effect at the highest validated testing concentration) c Literature values for Tub A (Tubastatin A)13, caution 
should be taken when comparing the IC50 values of 8a and 8c to the literature values for Tubastatin A. 
 
The data in Table 4 point to a good to excellent HDAC6 selectivity of hydroxamic acids 8a and 
8c, with the HDAC6 versus HDAC11 and HDAC1 selectivity being the most pronounced. The 
HDAC11 inhibitory effect of 8a,c appeared to be very low and no IC50 values could be obtained. 
Furthermore, a 5789-fold and 3243-fold selectivity against HDAC1 was determined for 
compounds 8a and 8c, respectively, which substantially exceeds the selectivity of Tubastatin 
A (1093-fold selectivity).13 In addition, also a high HDAC6 versus HDAC4 selectivity was 
observed for sulfones 8a and 8c (842- and 513-fold, respectively). Finally, it is interesting to 
note that these compounds show a good HDAC6 versus HDAC8 selectivity, and both sulfone 
8a (895-fold) and sulfone 8c (251-fold) exhibited a considerably higher selectivity in that 
respect as compared to Tubastatin A (57-fold).13 
The experimental results listed in Tables 2-4 are in line with the structure-activity relationship 
insights provided by ligand docking. These data show that decoration of the N-(4-
hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene scaffold at the linker unit (in 
casu by a methoxy group) is unfavorable for HDAC6 inhibitory activity. On the other hand, 
introduction of a substituent (in casu a fluoro atom) at the cap group did not appear to have a 
significant effect on the activity profile. It should also be noted that replacement of the tertiary 
amine functionality (NMe moiety) in the tetrahydropyrido[4,3-b]indole core structure of 
Tubastatin A by a sulfide unit results in compounds with a comparable HDAC6 inhibitory 
activity (at least as concerns the IC50 value), whereas replacement by a sulfone moiety (SO2) 
affords even more potent HDAC6 inhibitors. The in silico observed occurrence of hydrogen 
bonds between the introduced oxygen atoms and the backbone nitrogen atom of residues 
Asp567 and Gly619 can account for the higher in vitro activity of these sulfone derivatives. 
In addition to their promising biological potential and their straightforward and easy synthesis 
and purification, sulfones 8a and 8c (designated as Tubathian A and Tubathian B, respectively) 
also show an interesting profile for further evaluation based on their predicted druglikeness 
(MW, cLogP, solubility).   
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2.3. Conclusions 
N-(4-Hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes were efficiently 
prepared and shown to be of interest as novel and selective HDAC6 inhibitors, culminating in 
the identification of two sulfone derivatives as interesting lead structures for further elaboration 
displaying potent and selective HDAC6 inhibition in the nanomolar range. 
The findings described in this chapter thus provide a platform for more elaborate studies with 
respect to the HDAC6 inhibitory activity of this new class of thiaheterocyclic compounds which, 
in combination with further optimization of drug-relevant molecular properties, might afford 
promising new lead structures. 
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2.4. Experimental Details 
2.4.1. Ligand docking 
All docking experiments were performed by the Centre for Industrial Biotechnology and 
Biocatalysis (Prof. Desmet). All manipulations were completed with the molecular modelling 
program YASARA and the YASARA/WHATIF twinset.93,94 The HDAC6 sequence was obtained 
from the UniProt database (www.uniprot.org; UniProt entry Q9UBN7). To increase the 
accuracy of the model, the sequence was limited to the major functional domain of HDAC6 
(Gly482-Gly800). Possible templates were identified by running 3 PSI-BLAST iterations to 
extract a position specific scoring matrix (PSSM) from UniRef90, and then searching the PDB 
for a match. To aid the alignment of the HDAC6 sequence and templates, and the modelling 
of the loops, a secondary structure prediction was performed, followed by multiple sequence 
alignments. All side chains were ionised or kept neutral according to their predicted pKa values. 
Initial models were created from different templates, each with several alignment variations 
and up to hundred conformations tried per loop. After the side-chains had been built, optimised 
and fine-tuned, all newly modelled parts were subjected to a combined steepest descent and 
simulated annealing minimisation, i.e. the backbone atoms of aligned residues were kept fixed 
to preserve the folding, followed by a full unrestrained simulated annealing minimisation for the 
entire model. The final model was obtained as a hybrid model of the best parts of the initial 
models, and checked once more for anomalies like incorrect configurations or colliding side 
chains. Furthermore, it was structurally aligned with known HDAC crystal structures to check 
if the chelating residues and the zinc atom were arranged correctly.  
The HDAC inhibitor structures were created with YASARA and energy minimised with the 
AMBER03 force field.95 The grid box used for docking had a dimension of 25 x 25 x 25 
angstrom with a grid spacing of 0.2 Å, and comprised the entire catalytic cavity including the 
Zn ion and the outer surface of the active site entrance. Docking was performed with AutoDock 
4.2 using the AMBER03 force field and default parameters.96 Ligands were allowed to freely 
rotate during docking. The figure was created with PyMol v1.3.97 
Ligplot diagrams were made with LigPlot+ v1.4. 
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Figure 2. Ligplot diagram of compound 5a (black: carbon, blue: nitrogen; red: oxygen; yellow: sulfur; green: zinc ion, values in Å).  
 
 
Figure 3. Ligplot diagram of compound 8a (black: carbon, blue: nitrogen; red: oxygen; yellow: sulfur; green: zinc ion, values in Å). 
The Glycin hydrogen bond is directed toward the oxygen atom of the sulfone and not to the sulfur atom (value 3.17 Å). 
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2.4.2. Enzyme inhibition assays 
The enzyme inhibition assays were performed by Eurofins Cerep Panlabs. In vitro IC50 values 
were determined by using human recombinant HDAC1-11 and fluorogenic HDAC substrate.98 
 
2.4.3. Synthetic procedures and spectral data 
1H NMR spectra were recorded at 300 MHz (JEOL ECLIPSE+) with CDCl3 or D6-DMSO as 
solvent and tetramethylsilane as internal standard. 13C NMR spectra were recorded at 75 MHz 
(JEOL ECLIPSE+) with CDCl3 or D6-DMSO as solvent and tetramethylsilane as internal 
standard. Mass spectra were obtained with a mass spectrometer Agilent 1100, 70 eV. IR 
spectra were measured with a Spectrum One FT-IR spectrophotometer. High resolution 
electron spray (ES) mass spectra were obtained with an Agilent Technologies 6210 series 
time-of-flight instrument. Melting points of crystalline compounds were measured with a Büchi 
540 apparatus. The purity of all tested compounds was assessed by HRMS analysis and/or 
HPLC analysis, confirming a purity of ≥95%. 
 
2.4.2.1. Synthesis of 1,2,4,9-tetrahydro-3-thia-9-azafluorenes 3 
General procedure: To a solution of phenyl hydrazine hydrochloride 1 (12 mmol) and 
tetrahydrothiopyran-4-one 2 (12 mmol) in methanol (50 mL) was added Bi(NO3)3·5H2O (2.4 
mmol). After being stirred for 2 h under reflux, the reaction mixture was poured into water (100 
mL), and bismuth nitrate was removed trough filtration. The crude product was extracted with 
ethyl acetate (100 mL), washed with saturated NaHCO3 (100 mL), brine (100 mL) and dried 
over anhydrous MgSO4. Filtration of the drying agent and removal of the solvent in vacuo 
afforded the crude thioether 3, which was purified by means of recrystallization from ethanol 
to provide pure 1,2,4,9-tetrahydro-3-thia-9-azafluorene 3 (10.2 mmol, 85%). 
 
1,2,4,9-tetrahydro-3-thia-9-azafluorene 3a (85%) 
Spectral data of 1,2,4,9-tetrahydro-3-thia-9-azafluorene 3a correspond with data described in 
the literature.99 
 
1,2,4,9-tetrahydro-3-thia-6-fluoro-9-azafluorene 3b (90%) 
White crystals. Recrystallization from EtOH. Mp = 137.3 °C. 1H NMR (300 
MHz, CDCl3): δ 2.98 (4H, s, CH2CH2S); 3.79 (2H, s, CquatCH2S); 6.87 (1H, t × 
d, J = 9.1, 2.8 Hz, CHarom); 7.07 (1H, d × d, J = 9.1, 2.8 Hz, CHarom); 7.16 (1H, 
d × d, J = 9.1, 4.4 Hz, CHarom); 7.80 (1H, s(br), NH). 19F NMR (282 MHz, 
CDCl3): δ (-124.46) – (-124.37) (m). 13C NMR (75 MHz, CDCl3): δ 22.7 (Carom,quatCH2S), 25.3 
and 25.7 (CH2CH2S), 102.9 (d, J = 24.2 Hz, CHarom), 107.1 (d, J = 4.6 Hz, Carom,quat), 109.7 (d, 
J = 26.6 Hz, CHarom), 111.1 (d, J = 10.4 Hz, CHarom), 127.4 (d, J = 9.2 Hz, Carom,quat), 131.0 and 
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135.3 (2 × Carom,quat), 158.0 (d, J = 234.2 Hz, Carom,quat). IR (ATR, cm-1): νNH = 3336; νmax = 1582, 
1480, 1453, 1434, 1330, 1102, 962, 841, 792. MS (70eV): m/z (%) 206 (M--1, 100). HRMS 
(ESI) Anal. Calcd. for C11H11FNS 208.0596 [M+H]+, Found 208.0595. 
 
2.4.2.2. Synthesis of sulfones 6 
General procedure: To a solution of 1,2,4,9-tetrahydro-3-thia-9-azafluorene 3a (5 mmol) in 
tetrahydrofuran (50 mL) was added m-chloroperbenzoic acid in tetrahydrofuran (>70%, 15 
mmol) at 0°C. The mixture was stirred at room temperature for 2 h. The solvent was removed 
in vacuo and the residue was dissolved in ethyl acetate (100 mL). The solution was washed 
with saturated aqueous sodium sulfite (30 mL), water (30 mL), brine (2 × 30 mL), and dried 
over anhydrous MgSO4. Filtration of the drying agent and removal of the solvent in vacuo 
afforded the crude sulfone 6a, which was purified by recrystallization from EtOH to provide 
pure 1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 6a (3.85 mmol, 77%). 
 
1,2,4,9-Tetrahydro-3-thia-9-azafluoreen-3,3-dioxide 6a (77%) 
Beige powder. Recrystallization from EtOH. Mp = 245.5 °C. 1H NMR (300 MHz, 
D6-DMSO): δ 3.26 (2H, t, J = 6.3 Hz, CH2CH2SO2); 3.48 (2H, t, J = 6.3 Hz, 
CH2CH2SO2); 4.44 (2H, s, CquatCH2SO2); 6.98-7.02 (1H, m, CHarom); 7.07-7.11 
(1H, m, CHarom); 7.32 (1H, d, J = 7.9 Hz, CHarom); 7.42 (1H, d, J = 7.9 Hz, CHarom); 
11.15 (1H, s(br), NH). 13C NMR (75 MHz, D6-DMSO): δ 23.1 (CH2CH2SO2), 47.2 
(CH2CH2SO2), 48.9 (CquatCH2SO2), 101.9 (Cquat,arom), 111.4, 117.8, 119.3 and 121.9 (4 × 
HCarom), 127.2, 130.6 and 136.5 (3 × Cquat,arom). IR (cm-1): νNH = 3350; νS=O = 1114, 1102; νmax 
= 1462, 1315, 1274, 1162, 892, 744 and 645. MS (70 eV): m/z (%) 222 (M++1, 47); 239 
(M++NH4, 85). HRMS (ESI) Anal. Calcd. for C11H10NO2S 220.0438 [M-H]-, Found 220.0433. 
 
6-Fluoro-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 6b (80%) 
Light brown powder. Recrystallization from EtOH. Mp = 260.4 °C. 1H NMR 
(300 MHz, D6-DMSO): δ 3.24 and 3.46 (2 × 2H, 2 × t, J = 6.1 Hz, CH2CH2S); 
4.40 (2H, s, CquatCH2S); 6.90 (1H, t × d, J = 9.1, 2.8 Hz, CHarom); 7.21 (1H, d 
× d, J = 9.1, 2.8 Hz, CHarom); 7.30 (1H, d × d, J = 9.1, 4.4 Hz, CHarom); 11.23 
(1H, s(br), NH). 19F NMR (282 MHz, D6-DMSO): δ (-124.67) – (-124.58) (m). 
13C NMR (75 MHz, D6-DMSO): δ 23.3 (CH2CH2S), 47.2 (CH2CH2S), 48.9 (Carom,quat CH2S), 
102.4 (d, J = 4.6 Hz, Carom,quat), 103.0 (d, J = 24.2 Hz, CHarom), 109.9 (d, J = 25.4 Hz, CHarom), 
112.5 (d, J = 10.4 Hz, CHarom), 127.6 (d, J = 10.3 Hz, Carom,quat), 132.9 and 133.3 (2 × Carom,quat), 
157.4 (d, J = 231.9 Hz, Carom,quat). IR (ATR, cm-1): νNH = 3359; νS=O = 1119, 1102. νmax = 1586, 
1489, 1300, 1280, 1170, 1130, 798. MS (70eV): m/z (%) 238 (M--1, 100). HRMS (ESI) Anal. 
Calcd. for C11H9FNO2S 238.0344 [M-H]-, Found 238.0344. 
 
2.4.2.3. Synthesis of esters 4 and 7 
General procedure: 1,2,4,9-Tetrahydro-3-thia-9-azafluorene 3a (6 mmol) and sodium hydride 
(60 wt % in mineral oil, 6 mmol) were placed under nitrogen and dissolved in DMF (10 mL). 
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After stirring for 30 minutes, methyl 4-(bromomethyl)benzoate (6 mmol) and potassium iodide 
(10 mg) were added to the reaction. The reaction was heated to 80 °C for 2 h, after which the 
reaction was quenched with water (30 mL) followed by addition of ethyl acetate (30 mL). The 
aqueous layer was extracted with ethyl acetate (2 × 10 mL) and the combined organic layers 
were washed with water (2 × 20 mL), brine (15 mL), dried (MgSO4) and concentrated in vacuo. 
Recrystallization from ethanol afforded pure N-(4-methoxycarbonylbenzyl)-1,2,4,9-tetrahydro-
3-thia-9-azafluorene 4a (3.12 mmol, 52%). 
 
N-(4-Methoxycarbonylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene 4a (52%) 
Light brown crystals. Recrystallization from EtOH. Mp = 120.8 °C. 1H NMR 
(300 MHz, CDCl3): δ 2.81 and 2.96 (2 × 2H, 2 × t, J = 5.7 Hz, CH2CH2S); 
3.85 (3H, s, CH3O); 3.88 (2H, s, CquatCH2S); 5.23 (2H, s, CH2N); 6.99 (2H, 
d, J = 8.2 Hz, 2 × CHarom); 7.10-7.15 and 7.47-7.50 (3H and 1H, 2 × m, 4 × 
CHarom); 7.91 (2H, d, J = 8.2 Hz, 2 × CHarom). 13C NMR (75 MHz, CDCl3): δ 
23.2 (Carom,quatCH2S), 24.1 and 26.0 (CH2CH2S), 46.1 (CH2N), 52.3 (CH3O), 
107.4 (Carom,quat), 109.1, 117.9, 119.7 and 121.8 (4 × CHarom), 126.2 (2 × 
CHarom), 126.9 and 129.5 (2 × Carom,quat), 130.3 (2 × CHarom), 134.7, 135.8 
and 143.1 (3 × Carom,quat), 166.8 (C=O). IR (ATR, cm-1): νC=O = 1717; νmax = 1462, 1276, 1105, 
741, 706. MS (70eV): m/z (%) 338 (M++1, 65). HRMS (ESI) Anal. Calcd. for C20H20NO2S 
338.1215 [M+H]+, Found 338.1218. 
 
N-(4-Methoxycarbonyl-2-methoxybenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene 4b 
(57%) 
Light yellow crystals. Recrystallization from EtOH/EtOAc (1/1). Mp = 155.1 
°C. 1H NMR (300 MHz, CDCl3): δ 2.86 and 3.00 (2 × 2H, 2 × t, J = 5.8 Hz, 
CH2CH2S); 3.88 (3H, s, CH3O); 3.94 (2H, s, CquatCH2S); 3.98 (3H, s, CH3O); 
5.27 (2H, s, CH2N); 6.34 (1H, d, J = 7.9 Hz, CHarom); 7.08-7.19 (3H, m, 3 × 
CHarom); 7.42 (1H, d × d, J = 7.9, 1.4 Hz, CHarom); 7.50-7.54 (1H, m, CHarom); 
7.56 (1H, d, J = 1.4 Hz, CHarom). 13C NMR (75 MHz, CDCl3): δ 23.2 
(Carom,quatCH2S), 23.9 and 26.0 (CH2CH2S), 41.6 (CH2N), 52.3 and 55.7 (2 × 
CH3O), 107.1 (Carom,quat), 109.1, 110.7, 117.7, 119.5, 121.6, 122.4 and 126.3 
(7 × CHarom), 126.9, 130.4, 131.3, 134.8 and 135.8 (5 × Carom,quat), 156.3 (Carom,quatO), 166.9 
(C=O). IR (ATR, cm-1): νC=O = 1716; νmax = 1465, 1435, 1411, 1290, 1269, 1228, 1190, 1099, 
1030, 983, 758, 738. MS (70eV): m/z (%) 368 (M++1, 67). HRMS (ESI) Anal. Calcd. for 
C21H22NO3S 368.1320 [M+H]+, Found 368.1318. 
 
N-(4-Methoxycarbonylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-9-azafluorene 4c (69%) 
White crystals. Recrystallization from EtOH. Mp = 125.4 °C. 1H NMR (300 
MHz, CDCl3): δ 2.86 and 2.99 (2 × 2H, 2 × t, J = 5.5 Hz, CH2CH2S); 3.85 
(2H, s, CquatCH2S); 3.88 (3H, s, CH3O); 5.28 (2H, s, CH2N); 6.87 (1H, t × d, 
J = 9.1, 2.8 Hz, CHarom); 7.00 (2H, d, J = 8.3 Hz, 2 × CHarom); 7.07 (1H, d × 
d, J = 9.1, 4.4 Hz, CHarom); 7.14 (1H, d × d, J = 9.1, 2.8 Hz, CHarom); 7.94 
(2H, d, J = 8.3 Hz, 2 × CHarom). 19F NMR (282 MHz, CDCl3): δ (-124.42) – (-
124.34) (m). 13C NMR (75 MHz, CDCl3): δ 23.0 (Carom,quatCH2S), 24.3 and 
25.9 (CH2CH2S), 46.3 (CH2N), 52.3 (CH3O), 103.1 (d, J = 24.2 Hz, CHarom), 
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107.5 (d, J = 4.6 Hz, Carom,quat), 109.6 (d, J = 9.2 Hz, CHarom), 109.8 (d, J = 26.5 Hz, CHarom), 
126.0 (2 × CHarom), 127.2 (d, J = 10.4 Hz, Carom,quat), 129.6 (Carom,quat), 130.3 (2 × CHarom), 132.3, 
136.4 and 142.6 (3 × Carom,quat), 158.0 (d, J = 235.4 Hz, Carom,quat), 166.7 (C=O). IR (ATR, cm-
1): νC=O = 1712; νmax = 1479, 1436, 1416, 1277, 1179, 1136, 1108, 1019, 848, 802, 765, 756. 
MS (70eV): m/z (%) 356 (M++1, 30). HRMS (ESI) Anal. Calcd. for C20H19FNO2S 356.1121 
[M+H]+, Found 356.1121. 
 
N-(4-Methoxycarbonyl-2-methoxybenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-9-
azafluorene 4d (78%) 
Yellow crystals. Recrystallization from EtOH. Mp = 139.0 °C. 1H NMR (300 
MHz, CDCl3): δ 2.86 and 3.00 (2 × 2H, 2 × t, J = 5.7 Hz, CH2CH2S); 3.87 
(2H, s, CquatCH2S); 3.89 and 3.98 (2 × 3H, 2 × s, 2 × CH3O); 5.25 (2H, s, 
CH2N); 6.31 (1H, d, J = 7.7 Hz, CHarom); 6.86 (1H, t × d, J = 9.1, 2.8 Hz, 
CHarom); 7.06 (1H, d × d, J = 9.1, 4.4 Hz, CHarom); 7.16 (1H, d × d, J = 9.1, 
2.8 Hz, CHarom); 7.43 (1H, d × d, J = 7.7, 1.1 Hz, CHarom); 7.56 (1H, d, J = 
1.1 Hz, CHarom). 19F NMR (282 MHz, CDCl3): δ (-124.68) – (-124.60) (m). 13C 
NMR (75 MHz, CDCl3): δ 23.1 (Carom,quatCH2S), 24.1 and 25.9 (CH2CH2S), 
41.8 (CH2N), 52.3 and 55.7 (2 × CH3O), 103.0 (d, J = 24.2 Hz, CHarom), 107.2 (d, J = 4.6 Hz, 
Carom,quat), 109.6 (d, J = 26.5 Hz, CHarom), 109.7 (d, J = 10.4 Hz, CHarom), 110.7, 122.4 and 126.2 
(3 × CHarom), 127.1 (d, J = 9.3 Hz, Carom,quat), 130.5, 131.0, 132.3 and 136.6 (4 × Carom,quat), 
156.3 (Carom,quatO), 158.0 (d, J = 235.4 Hz, Carom,quat), 166.8 (C=O). IR (ATR, cm-1): νC=O = 1714; 
νmax = 1584, 1480, 1464, 1435, 1411, 1292, 1266, 1231, 1102, 1032, 986, 800, 759. MS 
(70eV): m/z (%) 386 (M++1, 100). HRMS (ESI) Anal. Calcd. for C21H21FNO3S 386.1226 [M+H]+, 
Found 386.1218. 
 
N-(4-Methoxycarbonylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 7a 
(48%) 
Light brown crystals. Purification by column chromatography (EtOAc/PE 
1/2, Rf = 0.15). Mp = 163.1 °C. 1H NMR (300 MHz, CDCl3): δ 3.27 and 3.32 
(2 × 2H, 2 × t, J = 4.7 Hz, CH2CH2S); 3.89 (3H, s, CH3O); 4.44 (2H, s, 
CquatCH2S); 5.34 (2H, s, CH2N); 7.04 (2H, d, J = 8.2 Hz, 2 × CHarom); 7.15-
7.24 and 7.43-7.46 (3H and 1H, 2 × m, 4 × CHarom); 7.96 (2H, d, J = 8.2 
Hz, 2 × CHarom). 13C NMR (75 MHz, CDCl3): δ 22.3 (CH2CH2S), 46.6 
(CH2N), 47.5 (CH2CH2S), 49.0 (Carom,quatCH2S), 52.3 (CH3O), 102.6 
(Carom,quat), 109.6, 117.7, 120.6 and 123.1 (4 × CHarom), 126.0 (2 × CHarom), 
126.5, 129.9 and 130.1 (3 × Carom,quat), 130.5 (2 × CHarom), 137.3 and 142.0 
(2 × Carom,quat), 166.6 (C=O). IR (ATR, cm-1): νC=O = 1723; νS=O = 1162, 1111; νmax = 1461, 1311, 
1276, 760, 750, 713. MS (70eV): m/z (%) 370 (M++1, 100). HRMS (ESI) Anal. Calcd. for 
C20H20NO4S 370.1113 [M+H]+, Found 370.1118. 
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N-(4-Methoxycarbonyl-2-methoxybenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-
dioxide 7b (60%) 
Light brown crystals. Recrystallization from EtOH. Mp = 208.2 °C. 1H NMR 
(300 MHz, D6-DMSO): δ 3.17 and 3.47 (2 × 2H, 2 × t, J = 5.9 Hz, CH2CH2S); 
3.81 and 3.92 (2 × 3H, 2 × s, 2 × CH3O); 4.50 (2H, s, CquatCH2S); 5.38 (2H, 
s, CH2N); 6.46 (1H, d, J = 7.9 Hz, CHarom); 7.02-7.12 (2H, m, 2 × CHarom); 
7.33 (1H, d, J = 7.7 Hz, CHarom); 7.40 (1H, d × d, J = 7.9, 1.1 Hz, CHarom); 
7.49 (1H, d, J = 7.2 Hz, CHarom); 7.52 (1H, d, J = 1.1 Hz, CHarom). 13C NMR 
(75 MHz, D6-DMSO): δ 22.3 (CH2CH2S), 42.1 (CH2N), 46.9 (CH2CH2S), 
48.6 (CquatCH2S), 52.8 and 56.3 (2 × CH3O), 102.8 (Carom,quat), 110.4, 111.4, 
118.3, 120.1, 122.2 and 122.5 (6 × CHarom), 126.7 (Carom,quat), 127.3 
(CHarom), 130.6, 131.6, 131.9 and 137.1 (4 × Carom,quat), 157.0 (Carom,quatO), 166.5 (C=O). IR 
(ATR, cm-1): νC=O = 1719; νS=O = 1113, 1105; νmax = 1464, 1412, 1312, 1291, 1273, 1234, 1158, 
1034, 990, 762, 739. MS (70eV): m/z (%) 400 (M++1, 100). HRMS (ESI) Anal. Calcd. for 
C21H22NO5S 400.1219 [M+H]+, Found 400.1216. 
 
N-(4-Methoxycarbonylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-
dioxide 7c (47%) 
Light yellow crystals. Purification by column chromatography (EtOAc/PE 
1/2, Rf = 0.13). Mp = 163.8 °C. 1H NMR (300 MHz, CDCl3): δ 3.27-3.33 
(4H, m, CH2CH2S); 3.90 (3H, s, CH3O); 4.38 (2H, s, CquatCH2S); 5.32 (2H, 
s, CH2N); 6.96 (1H, t × d, J = 9.1, 2.8 Hz, CHarom); 7.02 (2H, d, J = 8.8 Hz, 
2 × CHarom); 7.09 (1H, d × d, J = 9.1, 2.8 Hz, CHarom); 7.12 (1H, d × d, J = 
9.1, 4.4 Hz, CHarom); 7.97 (2H, d, J = 8.8 Hz, 2 × CHarom). 19F NMR (282 
MHz, CDCl3): δ (-122.72) – (-122.64) (m). 13C NMR (75 MHz, CDCl3): δ 
22.4 (CH2CH2S), 46.8 (CH2N), 47.3 (CH2CH2S), 48.9 (Carom,quatCH2S), 52.4 
(CH3O), 102.6 (d, J = 4.6 Hz, Carom,quat), 103.1 (d, J = 24.2 Hz, CHarom), 
110.4 (d, J = 10.4 Hz, CHarom), 111.4 (d, J = 26.5 Hz, CHarom), 125.9 (2 × CHarom), 126.8 (d, J = 
10.4 Hz, Carom,quat), 130.0 (Carom,quat), 130.5 (2 × CHarom), 131.8, 133.7 and 141.6 (3 × Carom,quat), 
158.3 (d, J = 237.7 Hz, Carom,quat), 166.6 (C=O). IR (ATR, cm-1): νC=O = 1704; νS=O = 1136, 1121; 
νmax = 1480, 1311, 1281, 1258, 1176, 1149, 788. MS (70eV): m/z (%) 386 (M--1, 100). HRMS 
(ESI) Anal. Calcd. for C20H19FNO4S 388.1019 [M+H]+, Found 388.1014. 
 
N-(4-Methoxycarbonyl-2-methoxybenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-9-
azafluorene-3,3-dioxide 7d (40%) 
Light yellow crystals. Recrystallization from EtOH. Mp = 259.9 °C. 1H NMR 
(300 MHz, D6-DMSO): δ 3.17 and 3.47 (2 × 2H, 2 × t, J = 6.1 Hz, 
CH2CH2S); 3.81 and 3.91 (2 × 3H, 2 × s, 2 × CH3O); 4.47 (2H, s, 
CquatCH2S); 5.39 (2H, s, CH2N); 6.49 (1H, d, J = 7.7 Hz, CHarom); 6.94 (1H, 
t × d, J = 9.1, 2.8 Hz, CHarom); 7.30 (1H, d × d, J = 9.1, 2.8 Hz, CHarom); 
7.36 (1H, d × d, J = 9.1, 4.4 Hz, CHarom); 7.41 (1H, d × d, J = 7.7, 1.6 Hz, 
CHarom); 7.51 (1H, d, J = 1.6 Hz, CHarom). 19F NMR (282 MHz, D6-DMSO): 
δ (-124.02) – (-123.94) (m). 13C NMR (75 MHz, D6-DMSO): δ 22.5 
(CH2CH2S), 42.5 (CH2N), 46.7 (CH2CH2S), 48.4 (CquatCH2S), 52.8 and 
56.3 (2 × CH3O), 103.1 (d, J = 4.6 Hz, Carom,quat), 103.5 (d, J = 23.1 Hz, CHarom), 110.3 (d, J = 
25.4 Hz, CHarom), 111.4 (CHarom), 111.7 (d, J = 9.2 Hz, CHarom), 122.2 (CHarom), 127.0 (d, J = 
10.3 Hz, Carom,quat), 127.4 (CHarom), 130.7, 131.4, 133.8 and 133.9 (4 × Carom,quat), 157.0 
(Carom,quatO), 157.8 (d, J = 233.1 Hz, Carom,quat), 166.4 (C=O). IR (ATR, cm-1): νC=O = 1716; νS=O 
= 1114, 1104; νmax = 1462, 1439, 1414, 1313, 1286, 1274, 1236, 1160, 1147, 1033, 988, 765. 
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MS (70eV): m/z (%) 418 (M++1, 100). HRMS (ESI) Anal. Calcd. for C21H21FNO5S 418.1124 
[M+H]+, Found 418.1110. 
 
2.4.2.4. Synthesis of hydroxamic acids 5 and 8 
General procedure: To a solution of ester 4a (0.6 mmol) and hydroxylamine hydrochloride (3.6 
mmol) in DMF (5 mL) under nitrogen atmosphere was added NaOMe/MeOH (4M, 1.2 mL, 4.8 
mmol). The reaction was stirred for 16 h at room temperature and a white precipitate was 
formed. The reaction mixture was diluted with ethyl acetate (20 mL) and washed with saturated 
NaHCO3 (10 mL), brine (2 × 10mL), and dried with anhydrous MgSO4. Filtration of the drying 
agent and removal of the solvent in vacuo afforded the crude hydroxamic acid 5a, which was 
recrystallized from ethanol to afford pure N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-
thia-9-azafluorene 5a (0.23 mmol, 38%). 
 
N-(4-Hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene 5a (38%) 
White powder. Crystallization from EtOH. Mp = 149.6 °C. 1H NMR (300 
MHz, D6-DMSO): δ 2.87 and 2.98 (2 × 2H, 2 × t, J = 5.4 Hz, CH2CH2S); 
3.83 (2H, s, CquatCH2S); 5.42 (2H, s, CH2N); 6.99-7.10 and 7.39-7.41 (4H 
and 1H, 2 × m, 5 × CHarom); 7.47 (1H, d × d, J = 6.9, 1.4 Hz, CHarom); 7.65 
(2H, d, J = 8.3 Hz, 2 × CHarom); 9.02 (1H, s(br), OH); 11.14 (1H, s(br), NH). 
13C NMR (75 MHz, D6-DMSO): δ 22.8 (Carom,quatCH2S), 24.1 and 25.7 
(CH2CH2S), 45.7 (CH2N), 107.0 (Carom,quat), 110.0, 118.1, 119.5 and 121.7 
(4 × CHarom), 126.8 (2 × CHarom), 126.9 (Carom,quat), 127.8 (2 × CHarom), 132.4, 
135.5, 135.8 and 142.1 (4 × Carom,quat), 164.5 (C=O). IR (ATR, cm-1): νNH/OH = 3201; νC=O = 1636; 
νmax = 1612, 1464, 1414, 1356, 1311, 1014, 897, 740. MS (70eV): m/z (%) 339 (M++1, 100). 
HRMS (ESI) Anal. Calcd. for C19H19N2O2S 339.1167 [M+H]+, Found 339.1164. 
 
N-(4-Hydroxycarbamoyl-2-methoxybenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene 5b 
(65%) 
White powder. Crystallization from EtOH. Mp = 191.5 °C. 1H NMR (300 
MHz, D6-DMSO): δ 2.82 and 2.96 (2 × 2H, 2 × t, J = 5.4 Hz, CH2CH2S); 
3.84 (2H, s, CquatCH2S); 3.92 (3H, s, CH3O); 5.30 (2H, s, CH2N); 6.22 (1H, 
d, J = 7.7 Hz, CHarom); 6.99-7.08 (2H, m, 2 × CHarom); 7.15 (1H, d × d, J = 
7.7, 1.1 Hz, CHarom); 7.28-7.30 (1H, m, CHarom); 7.39 (1H, d, J = 1.1 Hz, 
CHarom); 7.46-7.49 (1H, m, CHarom); 9.04 (1H, s(br), OH); 11.16 (1H, s(br), 
NH). 13C NMR (75 MHz, D6-DMSO): δ 22.9 (Carom,quatCH2S), 23.9 and 25.7 
(CH2CH2S), 41.4 (CH2N), 56.2 (CH3O), 106.9 (Carom,quat), 109.7, 109.9 and 
118.1 (3 × CHarom), 119.5 (2 × CHarom), 121.6 and 126.5 (2 × CHarom), 126.8, 129.5, 133.6, 135.7 
and 135.8 (5 × Carom,quat), 156.6 (Carom,quatO), 164.3 (C=O). IR (ATR, cm-1): νNH/OH = 3220; νC=O 
= 1619; νmax = 1574, 1462, 1408, 1362, 1240, 1042, 1026, 824, 744. MS (70eV): m/z (%) 369 
(M++1, 100). HRMS (ESI) Anal. Calcd. for C20H21N2O3S 369.1273 [M+H]+, Found 369.1280. 
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N-(4-Hydroxycarbamoylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-9-azafluorene 5c 
(70%) 
White powder. Crystallization from ethanol. Mp = 194.5 °C. 1H NMR (300 
MHz, D6-DMSO): δ 2.86 and 2.97 (2 × 2H, 2 × t, J = 5.7 Hz, CH2CH2S); 
3.80 (2H, s, CquatCH2S); 5.42 (2H, s, CH2N); 6.91 (1H, t × d, J = 9.1, 2.8 Hz, 
CHarom); 7.03 (2H, d, J = 8.3 Hz, 2 × CHarom); 7.26 (1H, d × d, J = 9.1, 2.8 
Hz, CHarom); 7.41 (1H, d × d, J = 9.1, 4.4 Hz, CHarom); 7.65 (2H, d, J = 8.3 
Hz, 2 × CHarom), 9.01 (1H, s(br), OH); 11.13 (1H, s(br), NH). 19F NMR (282 
MHz, D6-DMSO): δ (-124.75) – (-124.66) (m). 13C NMR (75 MHz, D6-
DMSO): δ 22.7 (Carom,quatCH2S), 24.3 and 25.6 (CH2CH2S), 45.9 (CH2N), 
103.3 (d, J = 23.1 Hz, CHarom), 107.3 (d, J = 4.6 Hz, Carom,quat), 109.4 (d, J = 26.5 Hz, CHarom), 
111.0 (d, J = 10.4 Hz, CHarom), 126.8 (2 × CHarom), 127.1 (d, J = 10.4 Hz, Carom,quat), 127.8 (2 × 
CHarom), 132.4, 132.5, 137.6 and 141.9 (4 × Carom,quat), 157.6 (d, J = 230.7 Hz, Carom,quat), 164.5 
(C=O). IR (ATR, cm-1): νNH/OH = 3224; νC=O = 1613; νmax = 1567, 1478, 1459, 1137, 1016, 849, 
789. MS (70eV): m/z (%) 355 (M--1, 100). HRMS (ESI) Anal. Calcd. for C19H16FN2O2S 
355.0922 [M-H]-, Found 355.0924. 
 
N-(4-Hydroxycarbamoyl-2-methoxybenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-9-
azafluorene 5d (66%) 
Light yellow powder. Crystallization from EtOH. Mp = 148.1 °C. 1H NMR 
(300 MHz, D6-DMSO): δ 2.82 and 2.96 (2 × 2H, 2 × t, J = 5.5 Hz, CH2CH2S); 
3.80 (2H, s, CquatCH2S); 3.90 (3H, s, CH3O); 5.30 (2H, s, CH2N); 6.24 (1H, 
d, J = 7.7 Hz, CHarom); 6.87 (1H, t × d, J = 9.1, 2.8 Hz, CHarom); 7.15 (1H, d, 
J = 7.7 Hz, CHarom); 7.26 (1H, d × d, J = 9.1, 2.8 Hz, CHarom); 7.31 (1H, d × 
d, J = 9.1, 4.4 Hz, CHarom); 7. 38 (1H, s, CHarom); 9.03 (1H, s(br), OH); 11.15 
(1H, s(br), NH). 19F NMR (282 MHz, D6-DMSO): δ (-124.81) – (-124.73) 
(m). 13C NMR (75 MHz, D6-DMSO): δ 22.7 (Carom,quatCH2S), 24.1 and 25.6 
(CH2CH2S), 41.7 (CH2N), 56.2 (CH3O), 103.2 (d, J = 24.3 Hz, CHarom), 107.2 (d, J = 4.7 Hz, 
Carom,quat), 109.3 (d, J = 26.5 Hz, CHarom), 109.7 (CHarom), 111.0 (d, J = 10.4 Hz, CHarom), 119.6 
and 126.6 (2 × CHarom), 127.0 (d, J = 10.3 Hz, Carom,quat), 129.3, 132.5, 133.7 and 137.8 (4 × 
Carom,quat), 156.7 (Carom,quatO), 157.6 (d, J = 231.9 Hz, Carom,quat), 164.3 (C=O). IR (ATR, cm-1): 
νNH/OH = 3209; νC=O = 1636; νmax = 1576, 1479, 1462, 1409, 1249, 1142, 1034, 829. MS (70eV): 
m/z (%) 385 (M--1, 100). HRMS (ESI) Anal. Calcd. for C20H20FN2O3S 387.1179 [M+H]+, Found 
387.1180. 
 
N-(4-Hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 8a 
(51%) 
White powder. Crystallization from EtOH. Mp = 200.2 °C. 1H NMR (300 
MHz, D6-DMSO): δ 3.21 and 3.50 (2 × 2H, 2 × t, J = 6.1 Hz, CH2CH2S); 
4.49 (2H, s, CquatCH2S); 5.47 (2H, s, CH2N); 7.04-7.16 (4H, m, 4 × CHarom); 
7.45 (1H, d, J = 8.3 Hz, CHarom); 7.49 (1H, d, J = 7.7 Hz, CHarom); 7.66 (2H, 
d, J = 8.2 Hz, 2 × CHarom), 9.01 (1H, s(br), OH); 11.15 (1H, s(br), NH). 13C 
NMR (75 MHz, D6-DMSO): δ 22.5 (CH2CH2S), 46.1 (CH2N), 46.8 
(CH2CH2S), 48.6 (Carom,quatCH2S), 102.9 (Carom,quat), 110.5, 118.3, 120.1 
and 122.5 (4 × CHarom), 126.7 (Carom,quat), 126.9 and 127.9 (4 × CHarom), 
131.6, 132.5, 137.1 and 141.7 (4 × Carom,quat), 164.5 (C=O). IR (ATR, cm-
1): νNH/OH = 3192; νC=O = 1613; νS=O = 1126, 1114; νmax = 1467, 1413, 1310, 1284, 1192, 1166, 
1016, 885, 741. MS (70eV): m/z (%) 371 (M++1, 100). HRMS (ESI) Anal. Calcd. for 
C19H19N2O4S 371.1066 [M+H]+, Found 371.1062. 
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N-(4-Hydroxycarbamoyl-2-methoxybenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-
dioxide 8b (30%) 
White powder. Crystallization from EtOH. Mp = 174.9 °C. 1H NMR (300 
MHz, D6-DMSO): δ 3.20 and 3.48 (2 × 2H, 2 × t, J = 6.1 Hz, CH2CH2S); 
3.89 (3H, s, CH3O); 4.50 (2H, s, CquatCH2S); 5.34 (2H, s, CH2N); 6.38 (1H, 
d, J = 7.7 Hz, CHarom); 7.02-7.17 (3H, m, 3 × CHarom); 7,34 (1H, d, J = 7.7 
Hz, CHarom); 7.39 (1H, d, J = 1.1 Hz, CHarom); 7.49 (1H, d × d, J = 7.7, 1.1 
Hz, CHarom). 13C NMR (75 MHz, D6-DMSO): δ 22.3 (CH2CH2S), 42.0 
(CH2N), 46.9 (CH2CH2S), 48.6 (Carom,quatCH2S), 56.2 (CH3O), 102.7 
(Carom,quat), 109.8, 110.5, 118.3, 119.5, 120.0 and 122.4 (6 × CHarom), 126.7 
(Carom,quat), 127.0 (CHarom), 129.0, 131.9, 133.8 and 137.1 (4 × Carom,quat), 
156.8 (Carom,quatO), 164.2 (C=O). IR (ATR, cm-1): νNH/OH = 3186; νC=O = 1631; νS=O = 1126, 1113; 
νmax = 1572, 1463, 1416, 1366, 1330, 1292, 1247, 1163, 1036, 830, 743. MS (70eV): m/z (%) 
401 (M++1, 100). HRMS (ESI) Anal. Calcd. for C20H21N2O5S 401.1171 [M+H]+, Found 
401.1164. 
 
N-(4-Hydroxycarbamoylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-
dioxide 8c (69%) 
White powder. Crystallization from EtOH. Mp = 170.0 °C. 1H NMR (300 
MHz, D6-DMSO): δ 3.19 and 3.49 (2 × 2H, 2 × t, J = 6.1 Hz, CH2CH2S); 
4.46 (2H, s, CquatCH2S); 5.47 (2H, s, CH2N); 6.97 (1H, t × d, J = 9.1, 2.8 
Hz, CHarom); 7.06 (2H, d, J = 8.3 Hz, 2 × CHarom); 7.30 (1H, d × d, J = 9.6, 
2.8 Hz, CHarom); 7.46 (1H, d × d, J = 9.1, 4.4 Hz, CHarom); 7.65 (2H, d, J = 
8.3 Hz, 2 × CHarom), 9.01 (1H, s(br), OH); 11.14 (1H, s(br), NH). 19F NMR 
(282 MHz, D6-DMSO): δ (-123.94) – (-123.85) (m). 13C NMR (75 MHz, D6-
DMSO): δ 22.6 (CH2CH2S), 46.3 (CH2N), 46.7 (CH2CH2S), 48.4 
(Carom,quatCH2S), 103.1 (d, J = 4.6 Hz, Carom,quat), 103.5 (d, J = 24.2 Hz, 
CHarom), 110.4 (d, J = 25.4 Hz, CHarom), 111.6 (d, J = 9.3 Hz, CHarom), 126.9 (2 × CHarom), 127.0 
(d, J = 12.7 Hz, Carom,quat), 127.9 (2 × CHarom), 132.5, 133.7, 133.8 and 141.5 (4 × Carom,quat), 
157.8 (d, J = 233.0 Hz, Carom,quat), 164.4 (C=O). IR (ATR, cm-1): νNH/OH = 3200; νC=O = 1619; νS=O 
= 1146, 1123; νmax = 1571, 1480, 1463, 1434, 1311, 1284, 1174, 1016, 896, 864, 786. MS 
(70eV): m/z (%) 387 (M--1, 100). HRMS (ESI) Anal. Calcd. for C19H16FN2O4S 387.0820 [M-H]-
, Found 387.0824. 
 
N-(4-Hydroxycarbamoyl-2-methoxybenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-9-
azafluorene-3,3-dioxide 8d (72%) 
White powder. Crystallization from EtOH. Mp = 236.3 °C. 1H NMR (300 
MHz, D6-DMSO): δ 3.20 and 3.49 (2 × 2H, 2 × t, J = 6.1 Hz, CH2CH2S); 
3.88 (3H, s, CH3O); 4.48 (2H, s, CquatCH2S); 5.35 (2H, s, CH2N); 6.43 (1H, 
d, J = 8.3 Hz, CHarom); 6.94 (1H, t × d, J = 9.1, 2.8 Hz, CHarom); 7.17 (1H, 
d, J = 8.3 Hz, CHarom) 7.31 (1H, d × d, J = 9.6, 2.8 Hz, CHarom); 7.34-7.38 
(2H, m, 2 × CHarom); 9.04 (1H, s(br), OH); 11.17 (1H, s(br), NH). 19F NMR 
(282 MHz, D6-DMSO): δ (-124.07) – (-123.98) (m). 13C NMR (75 MHz, D6-
DMSO): δ 22.5 (CH2CH2S), 42.4 (CH2N), 46.7 (CH2CH2S), 48.4 
(Carom,quatCH2S), 56.2 (CH3O), 102.9 (d, J = 3.5 Hz, Carom,quat), 103.5 (d, J = 
24.3 Hz, CHarom), 109.9 (CHarom), 110.3 (d, J = 25.4 Hz, CHarom), 111.7 (d, J = 9.2 Hz, CHarom), 
119.5 (CHarom), 127.0 (d, J = 12.7 Hz, Carom,quat), 127.1 (CHarom), 128.8, 133.8, 133.9 and 134.0 
(4 × Carom,quat), 156.8 (Carom,quatO), 157.7 (d, J = 233.1 Hz, Carom,quat), 164.2 (C=O). IR (ATR, cm-
1): νNH/OH = 3313; νC=O = 1662; νS=O = 1139, 1114; νmax = 1578, 1483, 1463, 1407, 1309, 1275, 
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1246, 1153, 1039, 883, 823, 782. MS (70eV): m/z (%) 417 (M--1, 100). HRMS (ESI) Anal. 
Calcd. for C20H18FN2O5S 417.0926 [M-H]-, Found 417.0928. 
  
  
 
3. Synthesis and SAR assessment of novel 
Tubathian analogs in the pursuit of potent and 
selective HDAC6 inhibitors 
 
 
 
 
 
 
Abstract: The synthesis of novel isoform-selective HDAC inhibitors is considered to be an 
important, emerging field in medicinal chemistry. In this chapter, the preparation and 
assessment of thirteen selective HDAC6 inhibitors is disclosed, elaborating on the 
thiaheterocyclic Tubathian series discussed in chapter II. All compounds were evaluated in 
vitro for their ability to inhibit HDAC6, and a selection of five potent compounds was further 
screened toward all HDAC isoforms (HDAC1-11). The capability of these Tubathian analogs 
to inhibit α-tubulin deacetylation was assessed as well, and ADME/Tox data were collected. 
This thorough SAR evaluation revealed that the oxidized, para-substituted hydroxamic acids 
can be recognized as valuable lead structures in the pursuit of novel potent and selective 
HDAC6 inhibitors. 
 
 
 
 
 
 
 
 
 
Parts of the work described in this chapter have been published: 
De Vreese, R.; Depetter, Y.; Verhaeghe, T.; Desmet, T.; Benoy, V.; Haeck, W.; Van Den Bosch, L.; D’hooghe, M. “Synthesis and 
SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors” Org. Biomol. Chem. 2016, 
14, 2537-2549. (I.F. 3.56)  
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3.1. Introduction 
The interplay between histone acetyltransferases (HATs) and histone deacetylases (HDACs) 
represents an important epigenetic regulatory mechanism in the biochemistry of life 
processes.16 This epigenetic interaction controls the structural transformation of DNA between 
a compact, inactivated form and a loosely bound, activated form, and thus plays a major role 
in the functioning of cells.6 Besides the regulation of histone acetylation, HATs and HDACs 
mediate the acetylation of other proteins as well, and therefore these enzymes are more 
correctly referred to as lysine acetyltransferases (KATs) and deacetylases (KDACs).17 The 
KDAC family can be divided into four classes (I, IIa/IIb, III and IV), existing of 18 proteins.100 
Selective inhibition of these isoforms could significantly contribute to our knowledge on this 
family of epigenetic erasers (enzymes known to catalyze the removal of epigenetic marks), 
and potentially lead to new drugs. One of these proteins, defined as HDAC6, emerged in recent 
years as a valuable target in drug design and belongs to the class IIb HDACs. Because of its 
cytoplasmic location, HDAC6 has many interaction partners other than histones, and this 
feature renders it an interesting protein to study the acetylation status of proteins in cells.17 The 
use of small molecule inhibitors of HDAC6 has been proposed as an efficient strategy to block 
its catalytic activity, and is therefore considered to be a valuable new approach in 
neurodegenerative diseases,101 cancer79 and immunology research.10,102 
A milestone achievement in the quest for selective HDAC6 inhibitors concerned the 
development of Tubastatin A (1) in 2010, a molecule with a good ‘drug-likeness’ profile that 
showed great promise in vitro and in vivo.13,34,103 This discovery, together with the growing 
interest of academia and industry in the design of small molecule inhibitors, prompted us to 
pursue new analogs of this lead compound with possibly enhanced pharmacological 
properties. Based on available structure-activity relationships (SAR), sulfur analogs 2 of 
Tubastatin A (1) were constructed in the previous chapter, as shown in Figure 1, and tested 
for their ability to inhibit HDAC6 in vitro.104 Within this thiaheterocyclic series, sulfone 
derivatives 2c and 2d - designated as Tubathians - exhibited the most pronounced activity and 
selectivity toward HDAC6. 
The first major objective of the present study comprised a full and thorough biological 
evaluation of this Tubathian family 2 to shed more light on their potential as lead structures for 
HDAC6 inhibitor design. Furthermore, in view of the promising preliminary results of these 
Tubathian molecules, an expansion of compound library 2 to general structures 3 was 
envisioned as a second major objective to study structure-activity relationships in more detail. 
Guided by in-house docking studies and by the advancing progress made in the literature with 
regard to selective HDAC6 inhibitor development,105 three main structural modifications of 
template molecules 2 were proposed. First, modification of the ring size of the non-aromatic 
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C-ring (a six-membered versus a five-membered thiaheterocyclic ring) was pursued. A second 
key modification of the core scaffold molecule comprised assessment of the oxidation state of 
the sulfur atom, implying the selective synthesis of sulfides, sulfoxides and sulfones. Recently, 
also meta-substituted benzohydroxamic acids have been studied and showed dual HDAC6/8 
selectivity.69 Hence, the third structural variation involved the synthesis and evaluation of the 
meta-substituted counterparts of the Tubathian core structure. Once in hand, this set of 
compounds 2 and 3 will then be subjected to an elaborate biological investigation of their 
medicinal relevance as potential efficient and selective HDAC6 inhibitors. 
 
Figure 1. Expanded SAR of sulfur analogs of Tubastatin A (1). 
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3.2. Synthesis and biological evaluation of Tubathian analogs 
In silico docking studies of the proposed compounds 3 using a homology model of HDAC6 
revealed that all theoretical structures fit the binding pocket quite well and thus represent 
compounds worth to be studied (Figure 2). In general, the sulfone derivatives proved to have 
slightly higher predicted binding energies (better binding) than the corresponding sulfides, due 
to additional interactions of the sulfone group with surrounding residues. The para-substituted 
compounds resulted in better binding energies than the meta-substituted ones, and phenyl 
substitution (R = Ph) on the aromatic ring seemed to be preferred because of -stacking 
interactions with the side chain of a phenylalanine amino acid. However, it must be emphasized 
that the differences in calculated binding energies of these virtual complexes were small, 
pointing to the necessity of lab synthesis and detailed biological evaluation in vitro. 
 
 
Figure 2. Docking of selected molecules from class 3 (left: 3a; right: 3l) in a homology model of HDAC6 (green: carbon, blue: 
nitrogen, red: oxygen, yellow: sulfur). 
 
The synthesis of compounds 2 has been reported in the previous chapter, and the same 
approach was used here for the preparation of molecules 3 (Scheme 1, Figure 3).104 First, the 
tricyclic indole-containing ‘cap’-group was synthesized via a bismuth-nitrate catalyzed Fisher-
indole synthesis between aromatic hydrazines 4 and sulfur-containing cyclic ketones 5.92 The 
obtained tricycles 6 were modified through selective oxidation of the sulfur atom employing 
meta-chloroperbenzoic acid, with or without the addition of boron trifluoride, leading to the 
corresponding sulfoxides 7 and sulfones 8, respectively.  
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7-Bromo-2,3-dihydrothieno[3,2-b]indole 6f (R = Br, n = 0) appeared hard to purify because it 
contained the corresponding sulfoxide as a side product, which could not be removed by 
means of column chromatography. Therefore, this compound was used as an intermediate 
toward direct sulfoxidation, resulting in the synthesis of sulfoxide 7c (R = Br, n = 0). Phenyl-
containing sulfone 8f (R = Ph, n = 1) was obtained through full oxidation of sulfide 6c (R = Br, 
n = 1) to sulfone 8c (R = Br, n = 1), followed by a Suzuki-Miyaura cross coupling. The obtained 
thiaheterocycles 6, 7 and 8 were N-deprotonated with sodium hydride and the resulting anion 
subsequently quenched with methyl 4-(bromomethyl)benzoate or methyl 3-
(bromomethyl)benzoate 9 to give methyl esters 10. In the final step, esters 10 were converted 
to hydroxamic acids 3 upon treatment with a large excess of hydroxyl amine, which were 
subsequently used for pharmacological evaluation. 
 
Scheme 1. Synthesis of the expanded Tubathian library 3. Conditions: a: 1 equiv. ketone 5, 0.2 equiv. Bi(NO3)3·5H2O, MeOH, , 
3.5 h (30-90%, 6a-f). b: 1 equiv. mCPBA (≤77%), 4 equiv. BF3·O(C2H5)2, THF, -20°C, N2, 2 h (41-83%, 7a-c). c: 3 equiv. mCPBA 
(≤77%), THF, 0°C to rt, 2 h (52-80%, 8a-e). d: 2 equiv. phenylboronic acid, Na2CO3 (7 equiv), 0.04 equiv. Pd(PPh3)4, 
toluene/ethanol/H2O (2/1/1), , N2, 8 h (60%, 8f). e: 1) 1 equiv. NaH, DMF, rt, N2, 0.5 h 2) 1 equiv. methyl (bromomethyl)benzoate 
9, 0.01 equiv. KI, DMF, 80°C, N2, 2 h (21-80%, 10a-m). f: 100 equiv. NH2OH (50% in H2O), 50 equiv. KOH (4M in MeOH), THF, 
rt or , 10 min (5-70%, 3a-m). 
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As can be seen from Figure 3, no five-membered cyclic thioether-containing hydroxamic acids 
(with n = 0 and x = 0) were obtained, which was due to the fact that reaction of compound 6d 
(R = H, n = 0) with sodium hydride and methyl 3-(bromomethyl)benzoate or methyl 4-
(bromomethyl)benzoate always resulted in complex reaction mixtures. To circumvent this 
problem, an alternative approach toward the synthesis of these molecules was attempted, in 
which the synthesis of the ‘cap’-group was postponed to a later stage in the reaction pathway, 
however without any success.106 In total, a set of thirteen novel hydroxamic acids 3a-m was 
prepared and, together with the four earlier discovered Tubathian HDAC6 inhibitors 2a-d, 
evaluated for their ability to selectively inhibit HDAC6. 
 
Figure 3. Overview of the newly synthesized hydroxamic acids 3. 
 
A preliminary in vitro screening of their inhibitory potential toward HDAC6 at a concentration 
of 10 µM learned that the meta-substituted compounds 3a-h inhibited HDAC6 to a lesser extent 
than the para-substituted compounds 2a-d and 3i-m (34-74% vs 99-100% inhibition, 
respectively, Table 1). It must be noted that within the meta-substituted series, phenyl-
decorated compound 3e showed the highest inhibition percentage (74%), as predicted by the 
docking studies. Subsequently, the IC50 values of the five new para-substituted compounds 3i-
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m were determined and compared with the previously obtained results for compounds 2a-d 
(Table 2).104 All molecules exhibited low nanomolar IC50 values toward HDAC6 (≤ 22 nM), and 
the 6-membered sulfones 2c, 2d and 3k displayed the highest HDAC6 inhibitory activity (1.9, 
3.7 and 3.4 nM, respectively). As noted in our previous communication,104 this could be 
explained (and confirmed in silico) through hydrogen bond formation of both oxygen atoms on 
the sulfone moiety with surrounding residues. 
Table 1. % inhibition of control values with regard to HDAC6 inhibitory activitya,b 
Compound % inhibition 
HDAC6 
Compound % inhibition 
HDAC6 
Compound % inhibition 
HDAC6 
3a 34 3b 53 3c 65 
3d 65 3e 74 3f 51 
3g 40 3h 54 3i 99 
3j 100 3k 100 3l 99 
3m 100 2a 99 2b 99 
2c 99 2d 99   
a Test concentration: 10 µM; b Mean value of two screening sessions 
 
Table 2. In vitro enzyme inhibition data: IC50 values toward HDAC6 
Compound 2a 2b 2c 2d 3i 3j 3k 3l 3m 
HDAC6 IC50 (nM) 15 22 1.9 3.7 14 9.4 3.4 8.2 16 
 
The selectivity toward HDAC6 was assessed on the enzymatic level through a full-panel 
HDAC1-11 screening of representative compounds 2b, 2c, 2d, 3j and 3l. Compounds 2b, 2d 
and 3j were selected to compare the influence of the oxidation state of sulfur (R2S, R2SO and 
R2SO2) on the selectivity. The influence of the ring size (thiolane vs. thiane) on the inhibitory 
selectivity was studied by selection of hydroxamic acids 2c and 3l. The data in Table 3 reveal 
that all screened compounds display a similar selectivity profile. These molecular entities 
inhibit HDAC1, 2, 3, 10 and 11 at IC50 values higher than 5 µM, except for the five-membered 
sulfone 3j, which also shows a reasonable affinity for HDAC11 (IC50 = 0.52 µM). All compounds 
inhibit HDAC4, 5 and 8 with IC50 values around 1 µM, and HDAC7 and 9 at IC50 values between 
0.1 and 1 µM. In all cases, the lowest values can be observed with respect to HDAC6 inhibition, 
with IC50 values <30 nM. After this in-depth selectivity screening, it can be stated that this set 
of Tubathian and related compounds selectively inhibit HDAC6 in a potent and pronounced 
way, but also display some moderate affinity for class IIa HDACs (HDAC4, 5, 7 and 9) and 
HDAC8.  
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Table 3. HDAC1-11 screening of selected compounds 2b, 2c, 2d, 3j and 3l (IC50 values in 
µM)a,b 
HDAC  1 2 3 4 5 6 7 8 9 10 11 
2b 21 NC 23 1.5 1.8 0.0220 0.2 2.8 0.8 21 9.7 
2c 11 26 29 1.6 0.5 0.0019 0.1 1.7 0.3 7.7 NC 
2d 12 29 26 1.9 0.5 0.0037 0.1 0.9 0.5 5.9 NC 
3j 9.4 >30 24 1.2 1.3 0.0094 0.2 2.4 0.5 6.4 0.5 
3l 12 >30 NC 0.6 0.4 0.0082 0.1 1.9 0.2 13 17 
Tub A 16.4 >30 >30 >30 >30 0.015 >30 0.85 >30 >30 >30 
a Reference compound: Trichostatin A (HDAC6 IC50 = 0.0093 µM), NC : IC50 value not calculable. Concentration-response curve 
shows less than 25% effect at the highest validated testing concentration (30 µM). >30: IC50 value above the highest test 
concentration. Concentration-response curve shows less than 50 % effect at the highest validated testing concentration (30 µM). 
b Literature values for Tub A (Tubastatin A)13, caution should be taken when comparing the IC50 values of 2b, 2c, 2d, 3j and 3l to 
the literature values for Tubastatin A. 
 
Next, the potency and selectivity of compounds 2a-d, 3i-m together with control substance 
Tubastatin A was evaluated on a cellular level (Neuro-2a cells) by determining their ability to 
modify the acetylation level of α-tubulin (a specific HDAC6 substrate) and histones via Western 
Blots. First, all the compounds were tested at 1 µM for both assays. From Figure 4 it can be 
seen that the HDAC6 inhibitors clearly hyperacetylate α-tubulin at this concentration and do 
not affect the acetylation status of histones. Second, Tubathians 2a-d and control molecule 
Tubastatin A were tested at a range of concentrations (Figure 5, 10, 50, 100, 500 and 1000 
nM), revealing that these compounds already presented a maximal acetyl α-tubulin/α-tubulin 
ratio at a concentration of 100 nM. Finally, also the newly synthesized Tubathian analogs 3i-
m were tested at a lower concentration of 10 nM, pointing to the conclusion that compound 3k 
(together with control substance Tubastatin A) demonstrated an even more pronounced 
activity than the other compounds (Figure 6). 
 
 
Figure 4a,b. Comparison of α-tubulin and histone hyperacetylation of compounds 2a-d, 3i-m and control substance Tubastatin A 
(TubA, Neuro-2a cells, 1 µM). Acet α-tub (acetyl α-tubuline), GAPDH (Glyceraldehyde 3-phosphate dehydrogenase, loading 
control), Acet H3 (acetyl histone 3), H4 (histone 4). 
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Figure 5. Dose-response Western Blot of the acetalation status of α-tubulin in Neuro-2a-cells for compounds 2a-d and control 
substance Tubastatin A (10 - 1000 nM). 
 
 
Figure 6. Acetyl α-tubulin Western Blot screening at 10 nM for compounds 3i-k and control Tubastatin A. 
 
With a strong HDAC inhibition profile for this Tubathian family in hand, the following step 
involved acquirement of in vitro ‘ADME’ (Absorption, Distribution, Metabolism, and Excretion) 
and ‘Tox’ (toxicity) data to know whether further optimization of these compounds in the 
framework of drug development is appropriate. Therefore, molecules 2a-d as representative 
Tubathian ‘mother structures’ were preliminary screened for their capability to inhibit 
cytochrome P450 (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 were evaluated 
because of their ability to metabolize drugs in the liver, CYP inhibition can cause unanticipated 
adverse reactions or therapeutic failures), hERG safety (to exclude potential cardiotoxicity, as 
inhibition of the hERG might result in fatal ventricular tachyarrhythmia), microsomal stability in 
mouse and human (to measure in vitro intrinsic clearance), and plasma protein binding in 
mouse and human (PPB, the less bound a compound is to proteins in blood plasma, the more 
efficiently it can diffuse or traverse cell membranes) (Table 4). Apparently, whereas sulfides 
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2a and 2b were shown to inhibit the cytochrome P450 enzymes at low micromolar 
concentrations, which is harmful for possible drug-drug interactions in vivo, the sulfones 2c 
and 2d scored much better in this regard. The same can be stated for the hERG safety, 
showing sulfides 2a and 2b to be inferior as compared to sulfones 2c and 2d. In the microsomal 
stability assay and the plasma protein binding assay, sulfides 2a and 2b seemed difficult to 
detect, this in contrast to sulfones 2c and 2d which showed acceptable values in both assays. 
In summary, sulfones 2c and 2d clearly demonstrated a much better preliminary ADME/Tox 
profile than sulfides 2a and 2b and might thus be considered as potential lead compounds for 
further elaboration in future research.  
Table 4. Preliminary ADME/Tox screening of representative compounds 2a-d 
compound CYP1A2  
(IC50 µM) 
CYP2C9  
(IC50 µM) 
CYP2C19  
(IC50 µM) 
CYP2D6  
(IC50 µM) 
CYP3A4  
(IC50 µM) 
hERG  
(IC50 µM) 
2a >50 4.7 1.3 9.6 2.1 9.1 
2b >50 3.7 1.3 9.5 1.8 5.1 
2c >50 >50 19.9 >50 15 >11 
2d >50 11.8 >50 >50 9.7 >11 
compound Mouse MS  
(µl/min/mg) 
Mouse 
MS  
t1/2 (min) 
Human MS  
(µl/min/mg) 
Human 
MS  
t1/2 (min) 
Mouse 
PPB (%) 
Human 
PPB (%) 
2a <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
2b 58.3 11.9 28.7 24.1 <LOQ <LOQ 
2c 16.2 42.7 26.5 26.1 69.8 62.7 
2d 22.6 30.6 47.0 14.7 58.3 52.5 
<LOQ: peak areas below limit of quantification, CYP (cytochrome P450), hERG (human ether-a-go-go-related gene channel), MS 
(microsomal stability), t1/2 (half-life) PPB (plasma protein binding) 
 
Additional, a preliminary ADME/Tox screening of compounds 3i-m concerning cytochrome 
P450 inhibition and microsomal stability was conducted (Table 5). From the cytochrome P450 
inhibition data, it can be concluded that compounds 3j, 3l and 3m display the best profile, with 
compound 3m showing no P450 inhibition at all. The microsomal stability assays reveal that 
six-membered sulfoxides 3i and 3j, and five-membered sulfones 3l and 3m have an improved 
stability over six-membered sulfones 2c, 2d and 3k. In summary, further investigation of six-
membered sulfoxide 3j and five-membered sulfones 3l and 3m seems appropriate from an 
ADME/Tox point of view. 
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Table 5. Preliminary ADME/Tox screening of representative compounds 3i-m 
compound CYP1A2  
(IC50 µM) 
CYP2C9  
(IC50 µM) 
CYP2C19  
(IC50 µM) 
CYP2D6  
(IC50 µM) 
CYP3A4  
(IC50 µM) 
3i >50 36.9 15.4 39.8 8.5 
3j >50 >50 >50 >50 28.8 
3k >50 14.9 30.3 14.1 8.2 
3l >50 >50 16.3 >50 >50 
3m >50 >50 >50 >50 >50 
compound Mouse MS  
(µl/min/mg) 
Mouse MS  
t1/2 (min) 
Human MS  
(µl/min/mg) 
Human MS  
t1/2 (min) 
3i <2.1 >328 <2.3 >313 
3j 8.8 79.1 <2.1 >340 
3k 8.2 53.2 13.0 7.6 
3l 7.8 89.0 <2.1 >335 
3m 10.1 68.9 2.8 247.5 
 
In a final assay, the genotoxicity of six-membered sulfone 2c and five-membered sulfone 3l as 
representative examples was evaluated, bearing in mind the known potential mutagenicity 
associated with hydroxamic acids.107,108 The Ames fluctuation test toward four strains of 
Salmonella typhimurium (TA98, TA100, TA1535 and TA1537), with and without metabolic 
activation by using rat liver S9 fraction, revealed that both compounds were only mutagenic 
toward strain TA1537, with and without S9, starting at a concentration of 50 µM (more 
information in the experimental details). No mutagenicity was detected toward the other 
strains. 
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3.3. Conclusions 
Thirteen novel Tubathian analogs were synthesized and, together with four previously 
developed analogs, evaluated in depth as HDAC6 inhibitors. The nine para-substituted 
compounds showed the best HDAC6 IC50 values and proved to be selective inhibitors in cells. 
A detailed study of five selected representatives revealed that these Tubathian analogs 
preferentially inhibit HDAC6, although also a moderate affinity for class IIa HDACs (especially 
HDAC7 and 9) should be recognized. ADME/Tox evaluation demonstrated that sulfones 2c 
and 2d display a better preliminary ADME/Tox profile than the corresponding sulfides 2a and 
2b and pointed to six-membered sulfoxide 3j and five-membered sulfones 3l and 3m as 
promising chemical entities. Therefore, further research should be focused on the oxidized 
analogs as valuable lead structures in the pursuit of novel selective HDAC6 inhibitors. 
  
CHAPTER III  RESULTS AND DISCUSSION 
87 
 
3.4. Experimental details 
3.4.1. Ligand docking 
All docking experiments were performed by the Centre for Industrial Biotechnology and 
Biocatalysis (Prof. Desmet). All manipulations were completed with the molecular modelling 
program YASARA and the YASARA/WHATIF twinset,93,94 and the figure was created with 
PyMol v1.3.97 The HDAC6 sequence was obtained from the UniProt database 
(http://www.uniprot.org, UniProt entry Q9UBN7). To increase the accuracy of the model, the 
sequence was limited to the major functional domain of HDAC6 (Gly482-Gly800). Possible 
templates were identified by running 3 PSI-BLAST iterations to extract a position specific 
scoring matrix (PSSM) from UniRef90, and then searching the PDB for a match. To aid the 
alignment of the HDAC6 sequence and templates, and the modelling of the loops, a secondary 
structure prediction was performed, followed by multiple sequence alignments. All side chains 
were ionised or kept neutral according to their predicted pKa values. Initial models were 
created from different templates (pdb entry 2VQW, 2VQQ and 3C10), each with several 
alignment variations and up to hundred conformations tried per loop. After the side-chains had 
been built, optimised and fine-tuned, all newly modelled parts were subjected to a combined 
steepest descent and simulated annealing minimisation, i.e. the backbone atoms of aligned 
residues were kept fixed to preserve the folding, followed by a full unrestrained simulated 
annealing minimisation for the entire model. The final model was obtained as a hybrid model 
of the best parts of the initial models, and checked once more for anomalies like incorrect 
configurations or colliding side chains. Furthermore, it was structurally aligned with known 
HDAC crystal structures to check if the chelating residues and the zinc atom were arranged 
correctly.  
The HDAC inhibitor structures were created with YASARA Structure and energy minimised 
with the AMBER03 force field.95 The grid box used for docking had a dimension of 25 x 25 x 
25 angstrom, and comprised the entire catalytic cavity including the zinc ion and the outer 
surface of the active site entrance. Docking was performed with AutoDock VINA109 and default 
parameters. Ligands were allowed to freely rotate during docking. The first conformer from the 
cluster that has its zinc binding group in the vicinity of the zinc ion, was selected as the binding 
mode for analysis. 
 
3.4.2. Enzyme inhibition assays 
The enzyme inhibition assays were performed by Eurofins Cerep Panlabs. In vitro IC50 values 
were determined by using human recombinant HDAC1-11 and fluorogenic HDAC substrate.98 
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3.4.3. ADME/Tox assays 
The ADME/Tox Assays were performed by Karus Therapuetic Ltd. 
 
3.4.4. Western Blots 
The Western Blots were performed by the Laboratory of Neurobiology and Vesalius Research 
Center, VIB (Prof. Van Den Bosch). Values represent the normalized ratio acetyl α-tubulin/ α-
tubulin and acetyl histone 3/histone 4 against Tubastatin A (Tub A) in an established neuronal 
cell line (Neuro-2a cells: ATCC N° CCL-131).  
 
3.4.4.1. Cell culture 
Mouse neuroblastoma (Neuro-2a) cells were grown in a 1:1 mix of D-MEM (Dulbecco’s 
Modified Eagle Medium) and F12 medium supplemented with glutamax (Life Technologies), 
100 μg per ml streptomycin, 100 U per ml penicillin (Life Technologies), 10% fetal calf serum 
(Greiner Bio-one), 1% non-essential amino acids (Life Technologies) and 1.6% NaHCO3 (Life 
Technologies) at 37 °C and 7.5% CO2. To split the cells, cells were washed with Versene (Life 
Technologies) and dissociated with 0.05% Trypsine-EDTA (Life Technologies). The Neuro-2a 
cells were treated overnight at 37 °C with dosages ranging from 10 nM up to 1 μM of either 
Tubastatin A (Asclepia, Destelbergen, Belgium) or the candidate HDAC6 inhibitors, and the 
effect on the acetylation level of α-tubulin is determined by using Western Blot. 
 
3.4.4.2. Western Blot 
For sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis, treated 
cells were collected using the EpiQuik Total Histone Extraction Kit (EpiGentek) according to 
manufacturer’s instructions. Protein concentrations were determined using microBCA kit 
(Thermo Fisher Scientific Inc., Pittsburgh, PA, USA) according to manufacturer’s instructions. 
Before resolving the samples on a 12% SDS-PAGE gel, samples containing equal amounts of 
protein were supplemented with reducing sample buffer (Thermo Scientific) and boiled at 95 
°C for 5 min. After electrophoresis, the proteins were transferred to a polyvinylidene difluoride 
(PVDF) membrane (Millipore Corp.). The non-specific binding was blocked by incubation of 
the membrane in 5% bovine serum albumin (BSA), diluted in Tris Buffered Saline Tween 
(TBST, 50 mM TRIS, 150 mM NaCl, 0.1% Tween-20 (Applichem, Darmstadt, Germany) 
overnight followed by incubation with primary antibodies during one hour. The antibodies, 
diluted in TBS-T, were directed against α-tubulin (Sigma-Aldrich, T6199, 1/5000, 1h), against 
acetylated α-tubulin (Sigma-Aldrich, T6793, 1/5000, 1h), against glyceraldehyde 3-phosphate 
CHAPTER III  RESULTS AND DISCUSSION 
89 
 
dehydrogenase (GAPDH, Life Technologies, AM4300, 1/5000, 1h), against histone H3 acetyl 
k9-k14 (Cell Signaling, 9677L, 1/500, 1h) and against histone 4 (Abcam, ab10158, 1/500, 1h). 
The secondary antibodies, coupled to alkaline phosphatase (anti-mouse or anti-rabbit, Sigma-
Aldrich, 1/5000, 1h) were used. Blots were visualized by adding the ECF substrate (Enhanced 
Chemical Fluorescence, GE Healthcare, Uppsala, Sweden) and imaged with the 
ImageQuant_LAS 4000. A mild reblotting buffer (Millipore) was applied to strip the blots. 
ImageQuant TL version 7.0-software was used to quantify the blots. 
 
3.4.5. Ames fluctuation assays 
The Ames fluctuation assays were performed by Eurofins Cerep Panlabs. Wells that displayed 
bacteria growth due to the reversion of the histidine mutation (as judged by the ratio of OD430/ 
OD570 being greater than 1.0) are counted and recorded as positive counts. The significance 
of the positive counts between the treatment (in the presence of test compound) and the control 
(in the absence of test compound) are calculated using the one-tailed Fisher’s exact test. 
 
3.4.6. Synthetic procedures and spectral data 
1H NMR, 13C NMR and 19F NMR spectra were recorded at 400, 100.6 or 376.5 MHz (Bruker 
Avance III) with CDCl3 or D6-DMSO as the solvent and tetramethylsilane as the internal 
standard. Mass spectra were obtained with a mass spectrometer Agilent 1100, 70 eV. IR 
spectra were measured with a Spectrum One FT-IR spectrophotometer. High resolution 
electron spray (ES) mass spectra were obtained with an Agilent Technologies 6210 series 
time-of-flight instrument. Melting points of crystalline compounds were measured with a Kofler 
Bench, type WME Heizbank of Wagner & Munz. The purity of all tested compounds was 
assessed by 1H NMR analysis and/or HPLC analysis, confirming a purity of ≥95%. 
 
3.4.6.1. Synthesis of sulfides 6a-f 
General procedure: To a solution of phenyl hydrazine hydrochloride 4a (12 mmol) and 4,5-
dihydro-3(2H)-thiophenone 5b (12 mmol) in methanol (50 mL), was added Bi(NO3)3·5H2O (2.4 
mmol). After being stirred for 3.5 h under reflux, the reaction mixture was poured into water 
(100 mL), and bismuth nitrate was removed through filtration over celite. The crude product 
was extracted with ethyl acetate (100 mL), washed with saturated NaHCO3 (100 mL), brine 
(100 mL) and dried over anhydrous MgSO4. Filtration of the drying agent and removal of the 
solvent in vacuo afforded the crude cyclic thioether 6d, which was purified by means of column 
chromatography (EtOAc/PE 1/5) to provide pure 2,3-dihydrothieno[3,2-b]indole 6d (3.7 mmol, 
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31%). The synthesis of 1,2,4,9-tetrahydro-3-thia-9-azafluorene 6a and 6-fluoro-1,2,4,9-
tetrahydro-3-thia-9-azafluorene 6b has already been described in the previous chapter. The 
reaction time for the synthesis of 6-bromo-1,2,4,9-tetrahydro-3-thia-9-azafluorene 6c was 
prolonged to 22 h. 7-Bromo-2,3-dihydrothieno[3,2-b]indole 6f was not easily purified because 
it contained the corresponding sulfoxide as a side product and was therefore used as an 
intermediate for further transformation. 
 
6-Bromo-1,2,4,9-tetrahydro-3-thia-9-azafluorene 6c (43%) 
Yellow crystals. Recrystallization from EtOH. Mp = 169.5 °C. 1H NMR (400 
MHz, CDCl3): δ 3.00-3.02 (2 × 2H, m, CH2CH2S); 3.80 (2H, s, CquatCH2S); 
7.16 (1H, d, J = 8.5 Hz, CHarom); 7.23 (1H, d × d, J = 8.5, 1.9 Hz, CHarom); 7.57 
(1H, d, J = 1.9 Hz, CHarom); 7.83 (1H, s(br), NH). 13C NMR (100,6 MHz, 
CDCl3): δ 22.5 (CquatCH2S), 25.2 and 25.6 (CH2CH2S), 106.7 (Cquat,arom), 111.9 (CHarom), 112.8 
(Cquat,arom), 120.3 and 124.4 (2 × CHarom), 128.7, 133.1 and 134.6 (3 × Cquat,arom). IR (ATR, cm-
1): νNH = 3396; νmax = 1578, 1464, 1442, 1419, 1325, 1221, 1215, 1173, 1145, 1047, 983, 872, 
795, 746, 652. MS (70 eV): m/z (%) 268/70 (M++1, 58). HRMS (ESI) Anal. Calcd. for 
C11H11BrNS 267.9770 [M+H]+, Found 267.9735. 
 
2,3-Dihydrothieno[3,2-b]indole 6d (31%) 
Brown-orange crystals. Purification by column chromatography (EtOAc/PE 1/5, Rf 
= 0.23). Mp = 144.0 °C. 1H NMR (400 MHz, CDCl3): δ 3.20 and 3.83 (2 × 2H, 2 × 
t, J = 7.9 Hz, CH2CH2S); 7.07-7.15 (2H, m, 2 × CHarom); 7.28-7.31 (1H, m, CHarom); 
7.36-7.38 (1H, m, CHarom); 7.97 (1H, s(br), NH). 13C NMR (100.6 MHz, CDCl3): δ 
28.4 and 37.6 (CH2CH2S), 111.6 (CHarom),113.1 (Cquat,arom), 118.7, 120.0 and 121.4 (3 × 
CHarom), 123.1, 137.1 and 140.5 (3 × Cquat,arom). IR (ATR, cm-1): νNH = 3375; νmax = 1448, 1423, 
1301, 1235, 1043, 1003, 743, 692, 624. MS (70 eV): m/z (%) 174 (M-- 1, 100). HRMS (ESI) 
Anal. Calcd. for C10H10NS 176.0528 [M+H]+, Found 176.0526. 
 
7-Fluoro-2,3-dihydrothieno[3,2-b]indole 6e (30%) 
Brown-orange crystals. Purification by column chromatography (EtOAc/PE 1/4, 
Rf = 0.20). Mp = 133.5 °C. 1H NMR (400 MHz, CDCl3): δ 3.18 and 3.81 (2 × 2H, 
2 × t, J = 7.9 Hz, CH2CH2S); 6.86 (1H, t × d, J = 9.0, 2.5 Hz, CHarom); 7.02 (1H, 
d × d, J = 9.4, 2.5 Hz, CHarom); 7.18 (1H, d × d, J = 9.0, 4.3 Hz, CHarom); 7.95 
(1H, s(br), NH). 19F NMR (376.5 MHz, CDCl3): δ (-123.90)-(-123.84) (m). 13C NMR (100.6 MHz, 
CDCl3): δ 28.4 and 37.6 (CH2CH2S), 103.8 (d, J = 24.3 Hz, CHarom), 109.5 (d, J = 26.3 Hz, 
CHarom), 112.1 (d, J = 9.7 Hz, CHarom), 113.2 (d, J = 4.4 Hz, Cquat,arom), 123.2 (d, J = 10.5 Hz, 
Cquat,arom), 136.9 and 139.3 (2 × Cquat,arom), 157.9 (d, J = 234.9 Hz, FCquat,arom). IR (ATR, cm-1): 
νNH =3396; νmax = 2920, 1574, 1508, 1485, 1474, 1453, 1439, 1426, 1222, 1156, 1038, 844, 
825, 795. MS (70 eV): m/z (%) 192 (M--1, 100). HRMS (ESI) Anal. Calcd. for C10H7FNS 
192.0289 [M-H]-, Found 192.0291. 
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3.4.6.2. Synthesis of sulfoxides 7a-c 
General procedure: To a solution of 1,2,4,9-tetrahydro-3-thia-9-azafluorene 6a (5 mmol) in 
tetrahydrofuran (50 mL) was added boron trifluoride diethyl etherate (20 mmol) at -20 °C under 
nitrogen atmosphere. Then meta-chloroperbenzoic acid was added (5 mmol) at -20 °C and the 
mixture was stirred at -20 °C for two hours. After two hours the reaction mixture was poured 
into a saturated solution of NaHCO3 (100 mL) and subsequently extracted with ethyl acetate 
(100 mL). The organic phase was washed with water (2 × 50 mL), brine (50 mL) and dried over 
anhydrous MgSO4. Filtration of the drying agent and removal of the solvent in vacuo afforded 
the crude cyclic sulfoxide 7a, which was purified by recrystallization from EtOH to provide pure 
1,2,4,9-tetrahydro-3-thia-9-azafluorene-3-oxide 7a (4.15 mmol, 83%). 
 
1,2,4,9-Tetrahydro-3-thia-9-azafluorene-3-oxide 7a (83%) 
Beige powder. Recrystallization from EtOH. Mp > 260.0 °C. 1H NMR (400 MHz, 
D6-DMSO): δ 3.03-3.34 (4H, m, CH2CH2SO); 3.93 and 4.21 (2 × 1H, 2 × d, J = 
15.1 Hz, Cquat(HCH)SO); 6.98 (1H, t, J = 7.5 Hz, CHarom); 7.06 (1H, t, J = 7.5 Hz, 
CHarom); 7.30 (1H, d, J = 7.5 Hz, CHarom); 7.42 (1H, d, J = 7.5 Hz, CHarom); 11.10 
(1H, s(br), NH). 13C NMR (100.6 MHz, D6-DMSO): δ 17.7 (CH2CH2SO), 44.5 
(CH2CH2SO), 45.1 (CquatCH2SO), 98.9 (Cquat,arom), 111.3, 117.7, 119.1 and 121.5 (4 × CHarom), 
127.8, 132.3 and 136.1 (3 × Cquat,arom). IR (ATR, cm-1): νNH = 3190; νS=O = 1027; νmax = 1008, 
758, 711, 700. MS (70 eV): m/z (%) 206 (M++1, 90). HRMS (ESI) Anal. Calcd. for C11H12NOS 
206.0634 [M+H]+, Found 206.0638.  
 
6-Fluoro-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3-oxide 7b (68%) 
Yellow powder. Recrystallization from EtOH. Mp = 242.0 °C. 1H NMR (400 
MHz, D6-DMSO): δ 3.02-3.33 (4H, m, CH2CH2SO); 3.93 and 4.16 (2 × 1H, 2 
× d, J = 15.2 Hz, Cquat(HCH)SO); 6.89 (1H, t × d, J = 9.0, 2.6 Hz, CHarom); 7.22 
(1H, d × d, J = 9.9, 2.6 Hz, CHarom); 7.29 (1H, d × d, J = 9.0, 4.5 Hz, CHarom); 
11.14 (1H, s(br), NH). 19F NMR (376.5 MHz, D6-DMSO): δ (-125.11)-(-125.05) 
(m). 13C NMR (100.6 MHz, D6-DMSO): δ 17.5 (CH2CH2SO), 44.2 (CH2CH2SO), 44.8 
(CquatCH2SO), 99.4 (d, J = 4.4 Hz, Cquat,arom), 102.8 (d, J = 23.6 Hz, CHarom), 109.3 (d, J = 25.9 
Hz, CHarom), 112.2 (d, J = 9.7 Hz, CHarom), 128.2 (d, J = 10.0 Hz, Cquat,arom), 132.7 and 134.5 (2 
× Cquat,arom), 157.3 (d, J = 231.4 Hz, FCquat,arom). IR (ATR, cm-1): νNH = 3176; νS=O = 1022; νmax 
=1455, 1410, 1169, 1126, 1106, 991, 944, 838, 817, 710, 690. MS (70 eV): m/z (%) 224 (M++1, 
100). HRMS (ESI) Anal. Calcd. for C11H11FNOS 224.0540 [M+H]+, Found 224.0548. 
 
7-Bromo-2,3-dihydrothieno[3,2-b]indole-1-oxide 7c (41%) 
Black powder. Recrystallization from EtOH. Mp = 191.0 °C. 1H NMR (400 MHz, 
D6-DMSO): δ 3.15-3-22, 3.28-3.33, 3.59-3.67 and 3.96-4.03 (4 × 1H, 4 × m, 
CH2CH2S); 7.33 (1H, d × d, J = 8.6, 1.9 Hz, CHarom); 7.43 (1H, d, J = 8.6 Hz, 
CHarom); 7.83 (1H, d, J = 1.9 Hz, CHarom); 12.07 (1H, s(br), NH). 13C NMR (100.6 
MHz, D6-DMSO): δ 24.0 and 59.0 (CH2CH2S), 113.9 (Carom,quat), 115.0 and 
120.8 (2 × CHarom), 120.9 and 124.5 (2 × Carom,quat), 125.3 (CHarom), 140.1 and 153.4 (2 × 
Carom,quat). IR (ATR, cm-1): νNH = 3466; νS=O = 986; νmax = 1590, 1485, 1454, 1438, 1294, 1236, 
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1126, 1071,1040, 954, 815, 802, 715. MS (70eV): m/z (%) 270/2 (M++1, 100). HRMS (ESI) 
Anal. Calcd. for C10H9BrNOS 269.9583 [M+H]+, Found 269.9593. 
 
3.4.6.3. Synthesis of sulfones 8a-e 
General procedure: To a solution of 6-bromo-1,2,4,9-tetrahydro-3-thia-9-azafluorene 6c (5 
mmol) in tetrahydrofuran (50 mL) was added meta-chloroperbenzoic acid in tetrahydrofuran 
(15 mmol) at 0 °C. The mixture was stirred at room temperature for two hours. The solvent 
was removed in vacuo and the residue was dissolved in ethyl acetate (100 mL). The solution 
was washed with saturated aqueous sodium sulfite (30 mL), water (30 mL), brine (2 × 30 mL), 
and dried over anhydrous MgSO4. Filtration of the drying agent and removal of the solvent in 
vacuo afforded the crude cyclic sulfone 8c, which was purified by recrystallization from EtOH 
to provide pure 6-bromo-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 8c (3.05 mmol, 
61%). The synthesis of 1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 8a and 6-fluoro-
1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 8b has been described in the previous 
chapter. 
 
6-Bromo-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 8c (61%) 
Brown powder. Recrystallization from EtOH. Mp = 215.0 °C. 1H NMR (400 
MHz, D6-DMSO): δ 3.27 and 3.48 (2 × 2H, 2 × t, J = 6.1Hz, CH2CH2S); 4.44 
(2H, s, CquatCH2S); 7.20 (1H, d × d, J = 8.6, 1.5 Hz, CHarom); 7.30 (1H, d, J 
= 8.6 Hz, CHarom); 7.65 (1H, d, J = 1.5 Hz, CHarom); 11.36 (1H, s(br), NH). 
13C NMR (100.6 MHz, D6-DMSO): δ 23.1 and 47.1 (CH2CH2S), 48.6 
(Carom,quatCH2S), 101.9 and 111.9 (2 × Carom,quat), 113.4, 120.3 and 124.3 (3 × CHarom), 129.1, 
132.4 and 135.2 (3 × Carom,quat). IR (ATR, cm-1): νNH = 3350; νS=O = 1100; νmax = 1585, 1470, 
1454, 1432, 1311, 1273, 1252, 1162, 1048, 953, 894, 861, 802, 786, 769, 743. MS (70eV): 
m/z (%) 322/4 (M++23, 55). HRMS (ESI) Anal. Calcd. for C11H10BrNO2S 297.9543 [M-H]-, 
Found 297.9541. 
 
2,3-Dihydrothieno[3,2-b]indole-1,1-dioxide 8d (52%) 
Beige powder. Recrystallization from EtOH. Mp = 260.0 °C. 1H NMR (400 MHz, 
D6-DMSO): δ 3.44 (2H, t, J = 6.6 Hz, CH2CH2SO2); 3.90 (2H, t, J = 6.6 Hz, 
CH2CH2SO2); 7.17-7.21 (1H, m, CHarom); 7.24-7.28 (1H, m, CHarom); 7.48-7.50 (1H, 
m, CHarom); 7.54-7.56 (1H, m, CHarom); 12.00 (1H, s(br), NH). 13C NMR (100.6 MHz, 
D6-DMSO): δ 21.4 (CH2CH2SO2), 57.6 (CH2CH2SO2), 113.3 (CHarom), 116.1 
(Cquat,arom); 118.4 (CHarom), 119.4 (Cquat,arom), 121.9 and 123.7 (2 × CHarom), 140.8 and 147.7 (2 
× Cquat,arom). IR (ATR, cm-1): νNH =3355; νS=O = 1121, 1104; νmax = 1306, 1275, 1238, 1220, 
1134, 766, 658. MS (70 eV): m/z (%) 208 (M++1, 30); 225 (M+NH4+, 100). HRMS (ESI) Anal. 
Calcd. for C10H10NO2S 208.0427 [M+H]+, Found 208.0429. 
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7-Fluoro-2,3-dihydrothieno[3,2-b]indole-1,1-dioxide 8e (70%) 
Pink powder. Recrystallization from EtOH. Mp > 260.0 °C. 1H NMR (400 MHz, 
D6-DMSO): δ 3.44 (2H, t, J = 6.6 Hz, CH2CH2SO2); 3.89 (2H, t, J = 6.6 Hz, 
CH2CH2SO2); 7.12 (1H, t × d, J = 9.1, 2.5 Hz, CHarom); 7.33 (1H, d × d, J = 9.3, 
2.5 Hz, CHarom); 7.51 (1H, d × d, J = 9.1, 4.5 Hz, CHarom); 12.10 (1H, s(br), NH). 
19F NMR (376.5 MHz, D6-DMSO): δ (-121.35)-(-121.29) (m). 13C NMR (100.6 
MHz, D6-DMSO): δ 21.5 (CH2CH2SO2), 57.6 (CH2CH2SO2), 103.8 (d, J = 25.1 Hz, CHarom), 
111.7 (d, J = 25.7 Hz, CHarom), 114.6 (d, J = 9.8 Hz, CHarom), 116.2 (d, J = 4.4 Hz, Cquat,arom), 
119.6 (d, J = 11.3 Hz, Cquat,arom), 137.4 (Cquat,arom), 149.3 (Cquat,arom), 158.3 (d, J = 235.3 Hz, 
FCquat,arom). IR (ATR, cm-1): νNH =3243; νS=O = 1123, 1103; νmax = 1442, 1434, 1275, 1238, 1228, 
1193, 1163, 1142, 1054, 995, 847, 816, 749. MS (70 eV): m/z (%) 243 (M+NH4+, 100). HRMS 
(ESI) Anal. Calcd. for C10H9FNO2S 226.0333 [M+H]+, Found 226,0334. 
 
3.4.6.4. Synthesis of 6-phenyl-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 8f 
6-Bromo-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 8c (2 mmol) was dissolved in 
toluene (15 mL), and to this solution an aqueous solution of sodium carbonate (7 mL, 2 M) and 
a solution of phenylboronic acid (4 mmol) in ethanol (7 mL) were added. This mixture was then 
flushed with nitrogen gas for 10 minutes before tetrakis(triphenylphosphine)palladium(0) (0.08 
mmol) was added, and the reaction mixture was heated under reflux for 8 hour. The reaction 
mixture was then poured into brine (20 mL) and extracted with EtOAc (3 × 20 mL). The 
combined organic fraction was washed with brine (3 × 15 mL), dried (MgSO4), filtered and 
evaporated under vacuum. Purification through recrystallization from EtOH yielded 6-phenyl-
1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 8f (1.2 mmol, 60%) as a light brown 
powder. 
 
6-Phenyl-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 8f (60%) 
Light brown powder. Recrystallization from EtOH. Mp = 237.0 °C. 1H 
NMR (400 MHz, D6-DMSO): δ 3.29 and 3.50 (2 × 2H, 2 × t, J = 6.2 Hz, 
CH2CH2S); 4.51 (2H, s, CquatCH2S); 7.30 (1H, t, J = 7.4 Hz, CHarom); 7.39-
7.43 (2H, m, 2 × CHarom); 7.45 (2H, t, J = 7.4 Hz, 2 × CHarom); 7.68 (2H, 
d, J = 7.4 Hz, 2 × CHarom); 7.74 (1H, s, CHarom); 11.21 (1H, s(br), NH). 13C 
NMR (100.6 MHz, D6-DMSO): δ 23.2 and 47.2 (CH2CH2S), 48.9 (Carom,quatCH2S), 102.5 
(Carom,quat), 111.8, 116.1, 121.2, 126.8 and 127.1 (6 × CHarom), 127.9 (Carom,quat), 129.2 (2 × 
CHarom), 131.4, 131.9, 136.2 and 142.1 (4 × Carom,quat). IR (ATR, cm-1): νNH = 3347; νS=O = 1100; 
νmax = 1594, 1474, 1437, 1311, 1272, 1217, 1162, 895, 876, 812, 783, 760, 748, 696, 640. MS 
(70eV): m/z (%) 298 (M++1, 40). HRMS (ESI) Anal. Calcd. for C17H16NO2S 298.0896 [M+H]+, 
Found 298.0902. 
 
3.4.6.5. Synthesis of esters 10a-m 
General procedure: 1,2,4,9-Tetrahydro-3-thia-9-azafluorene 6a (6 mmol) and sodium hydride 
(60 wt% in mineral oil, 6 mmol) were placed under nitrogen and dissolved in DMF (10 mL). 
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After stirring for 30 minutes, methyl 3-(bromomethyl)benzoate 9 (6 mmol) and potassium iodide 
(0.06 mmol) were added. The mixture was heated to 80 °C for 2 h, after which it was quenched 
with water (30 mL), followed by addition of ethyl acetate (30 mL). The aqueous layer was 
extracted with ethyl acetate (2 × 10 mL) and the combined organic layers were washed with 
water (2 × 20 mL) and brine (15 mL), dried (MgSO4) and concentrated in vacuo. Purification 
by means of column chromatography (EtOAc/PE 1/10, Rf = 0.18) afforded pure N-(3-
methoxycarbonylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene 10a (2.46 mmol, 41%). 
 
N-(3-Methoxycarbonylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene 10a (41%) 
White-yellow crystals. Purification by column chromatography (EtOAc/PE 1/10, 
Rf = 0.18). Mp = 115.0 °C. 1H NMR (400 MHz, CDCl3): δ 2.92 and 3.04 (2 × 2H, 
2 × t, J = 5.8 Hz, CH2CH2S); 3.93 (3H, s, CH3O); 3.95 (2H, s, CquatCH2S); 5.33 
(2H, s, CH2N); 7.03-7.05 (1H, m, CHarom); 7.13-7.20 (2H, m, 2 × CHarom); 7.24-
7.26 (1H, m, CHarom); 7.33 (1H, t, J = 7.7 Hz, CHarom); 7.52-7.55 (1H, m, CHarom); 
7.90-7.95 (2H, m, 2 × CHarom). 13C NMR (100.6 MHz, CDCl3): δ 23.1 (CquatCH2S), 
24.1 and 25.9 (CH2CH2S), 46.0 (CH2N), 52.3 (CH3O), 107.3 (Cquat,arom), 108.9, 
117.7, 119.5 and 121.7 (4 × CHarom), 126.8 (Cquat,arom), 127.4, 128.7, 129.1 and 
130.5 (4 × CHarom), 130.6, 134.5, 135.7 and 138.2 (4 × Cquat,arom), 166.8 (C=O). IR (ATR, cm-1): 
νC=O = 1714; νmax = 2923, 1467, 1448, 1434, 1284, 1258, 1200, 1188, 1175, 992, 740. MS (70 
eV): m/z (%) 338 (M++1, 90); 376 (M+K+, 100). HRMS (ESI) Anal. Calcd. for C20H20NO2S 
338.1209 [M+H]+, Found 338.1219. 
 
N-(3-Methoxycarbonylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-9-azafluorene 10b 
(50%) 
White-yellow crystals. Purification by column chromatography (EtOAc/PE 
1/10, Rf = 0.16). Mp = 97.0 °C. 1H NMR (400 MHz, CDCl3): δ 2.89 and 3.00 (2 
× 2H, 2 × t, J = 5.7 Hz, CH2CH2S); 3.85 (2H, s, CquatCH2S); 3.90 (3H, s, CH3O); 
5.27 (2H, s, CH2N); 6.87 (1H, t × d, J = 9.1, 2.5 Hz, CHarom); 6.99-7.01 (1H, m, 
CHarom); 7.08-7.15 (2H, m, 2 × CHarom); 7.32 (1H, t, J = 7.7 Hz, CHarom); 7.84 
(1H, s, CHarom); 7.90-7.93 (1H, m, CHarom). 19F NMR (376.5 MHz, CDCl3): δ (-
124.64)-(-124.52) (m). 13C NMR (100.6 MHz, CDCl3): δ 22.9 (CquatCH2S), 24.2 
and 25.8 (CH2CH2S), 46.2 (CH2N), 52.3 (CH3O), 103.0 (d, J = 23.6 Hz, CHarom), 
107.4 (d, J = 4.4 Hz, Cquat,arom), 109.5 (d, J = 9.6 Hz, CHarom), 109.7 (d, J = 26.0 Hz, CHarom), 
127.1 (d, J = 9.7 Hz, Cquat,arom), 127.3, 128.8, 129.2 and 130.4 (4 × CHarom), 130.8, 132.2, 136.3 
and 137.9 (4 × Cquat,arom), 157.9 (d, J = 235.0 Hz, FCquat,arom), 166.7 (C=O). IR (ATR, cm-1): νC=O 
= 1717; νS=O = 1147, 1134; νmax = 3415, 2923, 1583, 1479, 1449, 1431, 1300, 1284, 1260, 
1196, 1184, 1122, 1104, 857, 844, 780, 763, 473. MS (70 eV): m/z (%) 356 (M++1, 100). HRMS 
(ESI) Anal. Calcd. for C20H19FNO2S 356.1115 [M+H]+, Found 356.1131. 
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N-(3-Methoxycarbonylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 10c 
(21%) 
Dark yellow powder. Purification by column chromatography (EtOAc/PE 4/5, Rf 
= 0.26). Mp = 200.0 °C. 1H NMR (400 MHz, D6-DMSO): δ 3.21 (2H, t, J = 6.2 
Hz, CH2CH2SO2); 3.51 (2H, t, J = 6.2 Hz, CH2CH2SO2); 3.82 (3H, s, CH3O); 
4.51 (2H, s, CquatCH2SO2); 5.53 (2H, s, CH2N); 7.06-7.10 (1H, m, CHarom); 7.14-
7.18 (1H, m, CHarom); 7.22-7.25 (1H, m, CHarom); 7.45-7.52 (3H, m, 3 × CHarom); 
7.78 (1H, s, CHarom); 7.85 (1H, d, J = 7.9 Hz, CHarom). 13C NMR (100.6 MHz, D6-
DMSO): δ 22.4 (CH2CH2SO2), 45.9 (CH2N), 46.7 (CH2CH2SO2), 48.4 (CH2SO2), 
52.7 (CH3O), 102.8 (Cquat,arom), 110.3, 118.3, 120.0 and 122.5 (4 × CHarom), 
126.6 (Cquat,arom), 127.7, 128.6 and 129.8 (3 × CHarom), 130.5 (Cquat,arom), 131.5 
(CHarom), 131.6, 137.1 and 139.3 (3 × Cquat,arom), 166.4 (C=O). IR (ATR, cm-1): νC=O = 1712; νS=O 
= 1125, 1113; νmax = 2922, 2852, 1464, 1302, 1283, 1237, 1205, 1188, 1162, 1083, 750, 713, 
702. MS (70 eV): m/z (%) 370 (M++1, 7); 387 (M+NH4+, 100). HRMS (ESI) Anal. Calcd. for 
C20H20NO4S 370.1108 [M+H]+, Found 370.1111. 
 
N-(3-Methoxycarbonylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-
dioxide 10d (67%) 
Beige powder. Recrystallization from EtOH. Mp = 214.0 °C.  1H NMR (400 
MHz, D6-DMSO): δ 3.21 (2H, t, J = 6.1 Hz, CH2CH2SO2); 3.50 (2H, t, J = 6.1 
Hz, CH2CH2SO2); 3.83 (3H, s, CH3O); 4.48 (2H, s, CquatCH2SO2); 5.54 (2H, 
s, CH2N); 7.01 (1H, t × d, J = 9.2, 2.5 Hz, CHarom); 7.22 (1H, d, J = 7.9 Hz, 
CHarom); 7.33 (1H, d × d, J = 9.3, 2.5 Hz, CHarom); 7.47 (1H, t, J = 7.9 Hz, 
CHarom); 7.51 (1H, d × d, J = 9.2, 4.3 Hz, CHarom); 7.77 (1H, s, CHarom); 7.86 
(1H, d, J = 7.9 Hz, CHarom). 19F NMR (376.5 MHz, D6-DMSO): δ (-124.05)-(-
123.99) (m). 13C NMR (100.6 MHz, D6-DMSO): δ 22.5 (CH2CH2SO2), 46.1 
(CH2N), 46.6 (CH2CH2SO2), 48.3 (CquatCH2SO2), 52.7 (CH3O), 103.1 (d, J = 
4.6 Hz, Cquat,arom), 103.5 (d, J = 24.0 Hz, CHarom), 110.4 (d, J = 25.9 Hz, CHarom), 111.5 (d, J = 
9.6 Hz, CHarom), 126.9 (d, J = 10.3 Hz, Cquat,arom), 127.7, 128.7 and 129.8 (3 × CHarom), 130.5 
(Cquat,arom), 131.6 (CHarom), 133.5, 133.8 and 139.1 (3 × Cquat,arom), 157.7 (d, J = 233.0 Hz, 
FCquat,arom), 166.4 (C=O). IR (ATR, cm-1): νC=O = 1713; νS=O = 1128, 1112; νmax = 2951, 1480, 
1459, 1427, 1312, 1283, 1242, 1206, 1165, 1150, 1128, 1112, 1083, 877, 790, 739. MS (70 
eV): m/z (%) 405 (M+NH4+, 100). HRMS (ESI) Anal. Calcd. for C20H19FNO4S 388.1013 [M+H]+, 
Found 388.1019. 
 
N-(3-Methoxycarbonylbenzyl)-6-phenyl-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-
dioxide 10e (60%) 
Light brown powder. Recrystallization from EtOH. Mp = 201.0 °C. 1H 
NMR (400 MHz, D6-DMSO): δ 3.24 and 3.52 (2 × 2H, 2 × t, J = 5.9 Hz, 
CH2CH2S); 3.83 (3H, s, CH3O); 4.57 (2H, s, CquatCH2S); 5.57 (2H, s, 
CH2N); 7.26 (1H, d, J = 7.7 Hz, CHarom); 7.32 (1H, t, J = 7.3 Hz, CHarom); 
7.44-7.50 (4H, m, 4 × CHarom); 7.58 (1H, d, J = 8.6 Hz, CHarom); 7.70 (2H, 
d, J = 7.3 Hz, 2 × CHarom); 7.81-7.83 (2H, m, 2 × CHarom); 7.87 (1H, d, J 
= 7.7 Hz, CHarom). 13C NMR (100.6 MHz, D6-DMSO): δ 22.5 (CH2CH2S), 
46.1 (CH2N), 46.7 (CH2CH2S), 48.5 (Carom,quatCH2S), 52.7 (CH3O), 103.4 
(Carom,quat), 110.7, 116.6, 121.7 and 126.9 (4 × CHarom), 127.2 (2 × CHarom 
and Carom,quat), 127.7, 128.6, 129.3 and 129.8 (5 × CHarom), 130.5 (Carom,quat), 131.6 (CHarom), 
132.3, 132.6, 136.7, 139.3 and 141.8 (5 × Carom,quat), 166.4 (C=O). IR (ATR, cm-1): νC=O = 1716; 
νS=O = 1117; νmax = 1473, 1446, 1430, 1313, 1286, 1260, 1233, 1198, 1167, 1135, 982, 890, 
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878, 758, 745, 723, 693. MS (70eV): m/z (%) 446 (M++1, 80). HRMS (ESI) Anal. Calcd. for 
C26H27N2O4S 463.1686 [M+NH4]+, Found 463.1694. 
 
N-(3-Methoxycarbonylbenzyl)-2,3-dihydrothieno[3,2-b]indole-1,1-dioxide 10f (72%) 
White powder. Recrystallization from EtOH. Mp = 210.5 °C.1H NMR (400 MHz, 
D6-DMSO): δ 3.44 (2H, t, J = 6.5 Hz, CH2CH2SO2); 3.84 (3H, s, OCH3); 3.95 (2H, 
t, J = 6.5 Hz, CH2CH2SO2); 5.57 (2H, s, CH2N); 7.23-7.32 (2H, m, 2 × CHarom); 
7.42-7.45 (1H, m, CHarom); 7.49-7.53 (1H, m, CHarom); 7.59-7.62 (2H, m, 2 × 
CHarom); 7.88-7.91 (2H, m, 2 × CHarom). 13C NMR (100.6 MHz, D6-DMSO): δ 21.0 
(CH2CH2SO2), 46.9 (CH2N), 52.7 (CH3O), 57.4 (CH2CH2SO2), 112.3 (CHarom), 
116.2 (Cquat,arom), 118.8 (CHarom), 119.3 (Cquat,arom), 122.5, 124.0, 128.2, 129.0 and 
129.9 (5 × CHarom), 130.6 (Cquat,arom), 132.3 (CHarom), 137.9, 141.0 and 148.5 (3 × 
Cquat,arom), 166.4 (C=O). IR (ATR, cm-1): νC=O = 1718; νS=O = 1124, 1107; νmax = 
2948, 2923, 2854, 1292, 1277, 1261, 1235, 1195, 755, 746. MS (70 eV): m/z (%) 373 (M+NH4+, 
100). HRMS (ESI) Anal. Calcd. for C19H18NO4S 356.0951 [M+H]+, Found 356.0958.  
 
N-(3-Methoxycarbonylbenzyl)-7-fluoro-2,3-dihydrothieno[3,2-b]indole-1,1-dioxide 10g 
(60%) 
White powder. Recrystallization from EtOH. Mp = 222.0 °C.1H NMR (400 MHz, 
D6-DMSO): δ 3.44 (2H, t, J = 6.5 Hz, CH2CH2SO2); 3.84 (3H, s, OCH3); 3.95 
(2H, t, J = 6.5 Hz, CH2CH2SO2); 5.57 (2H, s, CH2N); 7.18 (1H, t × d, J = 9.2, 
2.5 Hz, CHarom); 7.39-7.44 (2H, m, 2 × CHarom); 7.49-7.53 (1H, m, CHarom); 7.63 
(1H, d × d, J = 9.2, 4.3 Hz, CHarom); 7.89-7.91 (2H, m, 2 × CHarom). 19F NMR 
(376.5 MHz, D6-DMSO): δ (-120.57)-(-120.50) (m). 13C NMR (100.6 MHz, D6-
DMSO): δ 21.1 (CH2CH2SO2), 47.1 (CH2N), 52.7 (CH3O), 57.3 (CH2CH2SO2), 
104.3 (d, J = 25.2 Hz, CHarom), 112.1 (d, J = 26.0 Hz, CHarom), 113.7 (d, J = 9.9 
Hz, CHarom), 116.2 (d, J = 4.4 Hz, Cquat,arom), 119.5 (d, J = 11.2 Hz, Cquat,arom), 
128.2, 129.1 and 130.0 (3 × CHarom), 130.6 (Cquat,arom), 132.3 (CHarom), 137.6, 137.7 and 150.1 
(3 × Cquat,arom), 158.7 (d, J = 236.9 Hz, FCquat,arom), 166.4 (C=O). IR (ATR, cm-1): νC=O = 1723; 
νS=O = 1127, 1111; νmax = 2980, 1479, 1443, 1287, 1265, 1198, 1188, 1145, 748. MS (70 eV): 
m/z (%) 391 (M+NH4+, 100). HRMS (ESI) Anal. Calcd. for C19H17FNO4S 374.0857 [M+H]+, 
Found 374.0857. 
 
N-(3-Methoxycarbonylbenzyl)-7-bromo-2,3-dihydrothieno[3,2-b]indole-1-oxide 10h 
(54%) 
Brown powder. Purification by column chromatography (acetone/PE 1/1, Rf = 
0.23). Mp = 187.5 °C. 1H NMR (400 MHz, CDCl3): δ 3.01-3-07, 3.45-3.51, 
3.61-3.69 and 3.91-4.00 (4 × 1H, 4 × m, CH2CH2S); 3.91 (3H, s, CH3O); 5.29 
and 5.35 (2 × 1H, 2 × d, J = 16.4 Hz, CH2N); 7.13 (1H, d, J = 8.8 Hz, CHarom); 
7.19 (1H, d, J = 7.7 Hz, CHarom); 7.34 (1H, d × d, J = 8.8, 1.8 Hz, CHarom); 7.40 
(1H, t, J = 7.7 Hz, CHarom); 7.90 (1H, s, CHarom); 7.96 (1H, d, J = 1.8 Hz, 
CHarom); 7.99 (1H, d, J = 7.7 Hz, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 23.8 
(CH2CH2S), 48.9 (CH2N), 52.4 (CH3O), 58.3 (CH2CH2S), 112.0 (CHarom), 
115.5 and 120.9 (2 × Carom,quat), 122.1 (CHarom), 124.3 (Carom,quat), 126.3, 127.8, 
129.5, 129.6 and 130.9 (5 × CHarom), 131.2, 135.8, 140.1 and 152.4 (4 × Carom,quat), 166.4 (C=O). 
IR (ATR, cm-1): νC=O = 1715; νS=O = 1032; νmax = 1435, 1424, 1352, 1303, 1258, 1198, 1100, 
1084, 1050, 973, 926, 805, 748, 691. MS (70eV): m/z (%) 418/20 (M++1, 100). HRMS (ESI) 
Anal. Calcd. for C19H17BrNO3S 418.0107 [M+H]+, Found 418.0125. 
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N-(4-Methoxycarbonylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3-oxide 10i (47%) 
Brown powder. Recrystallization from EtOH. Mp = 78.0 °C.1H NMR (400 
MHz, D6-DMSO): δ 2.98-3.16 and 3.28-3.38 (3H and 1H, 2 × m, 
CH2CH2SO); 3.82 (3H, s, CH3O); 4.03 and 4.23 (2 × 1H, 2 × d, J = 15.4 Hz, 
Cquat(HCH)SO); 5.53 (2H, s, CH2N); 7.05-7.14 (2H, m, 2 × CHarom); 7.17 (2H, 
d, J = 8.3 Hz, 2 × CHarom); 7.43 (1H, d, J = 8.0 Hz, CHarom); 7.52 (1H, d, J = 
7.5 Hz, CHarom); 7.90 (2H, d, J = 8.3 Hz, 2 × CHarom). 13C NMR (100.6 MHz, 
D6-DMSO): δ 16.6 (CH2CH2SO), 44.0 (CH2CH2SO), 44.8 (CquatCH2SO), 
45.9 (CH2N), 52.6 (CH3O), 99.8 (Cquat,arom), 110.1, 118.1, 119.8 and 122.0 (4 
× CHarom), 127.1 (2 × CHarom), 127.6 and 129.1 (2 × Cquat,arom), 130.1 (2 × 
CHarom), 133.2, 136.7 and 144.2 (3 × Cquat,arom), 166.4 (C=O). IR (ATR, cm-1): νC=O = 1715 ; νS=O 
= 1107; νmax = 1464, 1434, 1414, 1277, 1174, 1038, 1018, 999, 744, 713. MS (70 eV): m/z (%) 
354 (M++1, 70). HRMS (ESI) Anal. Calcd. for C20H20NO3S 354.1158 [M+H]+, Found 354.1153.  
 
N-(4-Methoxycarbonylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3-oxide 
10j (42%) 
Brown powder. Recrystallization from EtOH. Mp = 135.5 °C. 1H NMR (400 
MHz, D6-DMSO): δ 2.97-3.14 and 3.32-3.36 (3H and 1H, 2 × m, 
CH2CH2SO); 3.82 (3H, s, CH3O); 4.02 and 4.18 (2 × 1H, 2 × d, J = 15.3 Hz, 
Cquat(HCH)SO); 5.53 (2H, s, CH2N); 6.96 (1H, t × d, J = 9.0, 2.5 Hz, CHarom); 
7.16 (2H, d, J = 8.3 Hz, 2 × CHarom); 7.33 (1H, d × d, J = 9.7, 2.5 Hz, CHarom); 
7.45 (1H, d × d, J = 9.0, 4.3 Hz, CHarom); 7.90 (2H, d, J = 8.3 Hz, 2 × CHarom). 
19F NMR (376.5 MHz, D6-DMSO): δ (-124.41)-(-124.34) (m). 13C NMR (100.6 
MHz, D6-DMSO): δ 16.5 (CH2CH2SO), 43.7 (CH2CH2SO), 44.6 
(CquatCH2SO), 46.1 (CH2N), 52.6 (CH3O), 100.1 (d, J = 4.4 Hz, Cquat,arom), 
103.3 (d, J = 23.8 Hz, CHarom), 109.8 (d, J = 26.0 Hz, CHarom), 111.2 (d, J = 9.6 Hz, CHarom), 
127.1 (2 × CHarom), 128.0 (d, J = 10.2 Hz, Cquat,arom), 129.1 (Cquat,arom), 130.1 (2 × CHarom), 133.4, 
135.3 and 143.9 (3 × Cquat,arom), 157.7 (d, J = 232.6 Hz, FCquat,arom), 166.4 (C=O). IR (ATR, cm-
1): νC=O = 1709; νS=O = 1035; νmax = 1478, 1464, 1438, 1417, 1307, 1282, 1256, 1181, 1147, 
1139, 1109, 1018, 860, 795, 770, 722. MS (70 eV): m/z (%) 372 (M++1, 77). HRMS (ESI) Anal. 
Calcd. for C20H19FNO3S 372.1064 [M+H]+, Found 372.1065. 
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N-(4-Methoxycarbonylbenzyl)-6-bromo-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-
dioxide 10k (80%) 
Light brown powder. Purification by column chromatography (EtOAc/PE 
1/1, Rf = 0.25). Mp = 191.0 °C. 1H NMR (400 MHz, CDCl3): δ 3.25-3.28 
and 3.30-3.33 (2 × 2H, 2 × m, CH2CH2S); 3.90 (3H, s, CH3O); 4.37 (2H, s, 
CquatCH2S); 5.32 (2H, s, CH2N); 7.01 (2H, d, J = 8.5 Hz, 2 × CHarom); 7.09 
(1H, d, J = 8.7 Hz, CHarom); 7.30 (1H, d × d, J = 8.7, 1.8 Hz, CHarom); 7.57 
(1H, d, J = 1.8 Hz, CHarom); 7.97 (2H, d, J = 8.5 Hz, 2 × CHarom). 13C NMR 
(100.6 MHz, CDCl3): δ 22.2 (CH2CH2S), 46.7 (CH2N), 47.2 (CH2CH2S), 
48.7 (Carom,quatCH2S), 52.3 (CH3O), 102.2 (Carom,quat), 111.0 (CHarom), 113.8 
(Carom,quat), 120.4, 125.8 and 125.9 (4 × CHarom), 128.0 and 130.0 (2 × 
Carom,quat), 130.5 (2 × CHarom), 131.4, 135.9 and 141.3 (3 × Carom,quat), 166.4 (C=O). IR (ATR, 
cm-1): νC=O = 1715; νS=O = 1113; νmax = 1463, 1433, 1408, 1315, 1277, 1240, 1190, 1160, 1058, 
888, 868, 802, 779, 769, 760, 718. MS (70eV): m/z (%) 448/50 (M++1, 70). HRMS (ESI) Anal. 
Calcd. for C20H22BrN2O4S 465.0478 [M+NH4]+, Found 465.0473. 
 
N-(4-Methoxycarbonylbenzyl)-2,3-dihydrothieno[3,2-b]indole-1,1-dioxide 10l (60%) 
White powder. Recrystallization from EtOH. Mp = 226.5 °C. 1H NMR (400 
MHz, D6-DMSO): δ 3.44 (2H, t, J = 6.5 Hz, CH2CH2SO2); 3.83 (3H, s, OCH3); 
3.95 (2H, t, J = 6.5 Hz, CH2CH2SO2); 5.57 (2H, s, CH2N); 7.23-7.31 (2H, m, 
2 × CHarom); 7.35 (2H, d, J = 8.4 Hz, 2 × CHarom); 7.55-7.62 (2H, m, 2 × CHarom); 
7.94 (2H, d, J = 8.4 Hz, 2 × CHarom). 13C NMR (100.6 MHz, D6-DMSO): δ 20.9 
(CH2CH2SO2), 47.0 (CH2N), 52.6 (CH3O), 57.4 (CH2CH2SO2), 112.2 (CHarom), 
116.3 (Cquat,arom), 118.8 (CHarom), 119.3 (Cquat,arom), 122.5 and 124.0 (2 × 
CHarom), 127.8 (2 × CHarom), 129.5 (Cquat,arom), 130.2 (2 × CHarom), 141.0, 142.5 
and 148.6 (3 × Cquat,arom), 166.3 (C=O). IR (ATR, cm-1): νC=O = 1714; νS=O = 
1131, 1107; νmax = 1446, 1432, 1277, 1237, 757, 741, 708. MS (70 eV): m/z (%) 356 (M++1, 
41); 373 (M+NH4+, 100). HRMS (ESI) Anal. Calcd. for C19H18NO4S 356.0951 [M+H]+, Found 
356.0954. 
 
N-(4-Methoxycarbonylbenzyl)-7-fluoro-2,3-dihydrothieno[3,2-b]indole-1,1-dioxide 10m 
(80%) 
White powder. Recrystallization from EtOH. Mp = 243.0 °C. 1H NMR (400 
MHz, D6-DMSO): δ 3.44 (2H, t, J = 6.5 Hz, CH2CH2SO2); 3.84 (3H, s, OCH3); 
3.95 (2H, t, J = 6.5 Hz, CH2CH2SO2); 5.57 (2H, s, CH2N); 7.16 (1H, t × d, J = 
9.2, 2.5 Hz, CHarom); 7.34 (2H, d, J = 8.3 Hz, 2 × CHarom); 7.41 (1H, d × d, J = 
9.1, 2.5 Hz, CHarom); 7.59 (1H, d × d, J = 9.2, 4.3 Hz, CHarom); 7.94 (2H, d, J 
= 8.3 Hz, 2 × CHarom). 19F NMR (376.5 MHz, D6-DMSO): δ (-120.57)-(-120.51) 
(m). 13C NMR (100.6 MHz, D6-DMSO): δ 21.0 (CH2CH2SO2), 47.2 (CH2N), 
52.7 (CH3O), 57.3 (CH2CH2SO2), 104.3 (d, J = 25.1 Hz, CHarom), 112.1 (d, J 
= 25.8 Hz, CHarom), 113.7 (d, J = 9.9 Hz, CHarom), 116.3 (d, J = 4.5 Hz, 
Cquat,arom), 119.5 (d, J = 11.3 Hz, Cquat,arom), 127.8 (2 × CHarom), 129.6 (Cquat,arom), 130.2 (2 × 
CHarom), 137.6, 142.2 and 150.1 (3 × Cquat,arom), 158.7 (d, J = 236.9 Hz, FCquat,arom), 166.3 (C=O). 
IR (ATR, cm-1): νC=0 = 1708; νS=0 = 1124, 1105; νmax = 1729, 1483, 1442, 1430, 1288, 1270, 
1235, 1188, 1145, 850, 808, 802, 768, 724, 699. MS (70 eV): m/z (%) 391 (M+NH4+, 100). 
HRMS (ESI) Anal. Calcd. for C19H17FNO4S 374.0857 [M+H]+, Found 374.0852. 
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3.4.6.6. Synthesis of hydroxamic acids 3a-m 
General procedure: N-(3-Methoxycarbonylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene 10a 
(1 mmol) was dissolved in THF (10 mL), and to this solution was added hydroxylamine (100 
mmol) and subsequently potassium hydroxide in methanol (4 M, 50 mmol). The resulting 
mixture was stirred for an additional 10 minutes at room temperature, before it was poured into 
a saturated aqueous solution of NaHCO3 (10 mL). This aqueous solution was extracted two 
times with ethyl acetate, after which the combined organic fractions were washed with water 
(10 mL) and a saturated brine solution (10 mL), dried (MgSO4), filtered and evaporated. 
Purification through crystallization from EtOH yielded N-(3-hydroxycarbamoylbenzyl)-1,2,4,9-
tetrahydro-3-thia-9-azafluorene 3a (0.57 mmol, 57%) as a white-yellow powder. Note: the 
mixture was stirred at reflux temperature for the synthesis of hydroxamic acids 3d, 3g and 3m. 
 
N-(3-Hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene 3a (57%) 
White-yellow powder. Crystallization from EtOH. Mp = 124.5 °C. 1H NMR (400 
MHz, D6-DMSO): δ 2.90 and 3.00 (2 × 2H, 2 × t, J = 5.5 Hz, CH2CH2S); 3.84 
(2H, s, CquatCH2S); 5.42 (2H, s, CH2N); 7.01-7.05 (1H, m, CHarom); 7.07-7.11 (2H, 
m, 2 × CHarom); 7.36 (1H, t, J = 7.7 Hz, CHarom); 7.42 (1H, d, J = 7.7 Hz, CHarom); 
7.48 (1H, d, J = 7.3 Hz, CHarom); 7.54 (1H, s, CHarom); 7.58 (1H, d, J = 7.7, 
CHarom); 9.00 (1H, s(br), OH); 11.19 (1H, s(br), NH). 13C NMR (100.6 MHz, D6-
DMSO): δ 22.7 (CquatCH2S), 24.0 and 25.6 (CH2CH2S), 45.7 (CH2N), 106.8 
(Cquat,arom), 109.9, 118.0, 119.4, 121.5, 125.8 and 125.9 (6 × CHarom), 126.7 
(Cquat,arom), 129.2 and 129.5 (2 × CHarom), 133.7, 135.4, 135.7 and 139.3 (4 × 
Cquat,arom), 164.6 (C=O). IR (ATR, cm-1): νNHOH = 3182; νC=O = 1634; νmax = 1584, 1464, 1417, 
1345, 907, 734. MS (70 eV): m/z (%) 339 (M++1, 100). HRMS (ESI) Anal. Calcd. for 
C19H19N2O2S 339.1162 [M+H]+, Found 339.1159. 
 
N-(3-Hydroxycarbamoylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-9-azafluorene 3b 
(63%) 
Yellow powder. Crystallization from diethyl ether. Mp = 190.0 °C. 1H NMR 
(400 MHz, D6-DMSO): δ 2.89 and 2.99 (2 × 2H, 2 × t, J = 5.4 Hz, CH2CH2S); 
3.81 (2H, s, CquatCH2S); 5.42 (2H, s, CH2N); 6.92 (1H, t × d, J = 9.1, 2.5 Hz, 
CHarom); 7.07 (1H, d, J = 7.7 Hz, CHarom); 7.26 (1H, d × d, J = 9.7, 2.5 Hz, 
CHarom); 7.36 (1H, t, J = 7.7 Hz, CHarom); 7.44 (1H, d × d, J = 9.1, 4.4 Hz, 
CHarom); 7.51 (1H, s, CHarom); 7.59 (1H, d, J = 7.7 Hz, CHarom); 9.04 (1H, s(br), 
OH); 11.14 (1H, s(br), NH). 19F NMR (376.5 MHz, D6-DMSO): δ (-124.92)-(-
124.86) (m). 13C NMR (100.6 MHz, D6-DMSO): δ 22.6 (CquatCH2S), 24.2 and 
25.5 (CH2CH2S), 45.9 (CH2N), 103.1 (d, J = 23.4 Hz, CHarom), 107.1 (d, J = 4.4 Hz, Cquat,arom), 
109.3 (d, J = 25.8 Hz, CHarom), 110.9 (d, J = 9.8 Hz, CHarom), 125.7 and 125.9 (2 × CHarom), 
127.0 (d, J = 10.1 Hz, Cquat,arom), 129.2 and 129.4 (2 × CHarom), 132.4, 133.7, 137.5 and 139.0 
(4 × Cquat,arom), 157.5 (d, J = 232.0 Hz, FCquat,arom), 164.5 (C=O). IR (ATR, cm-1): νNHOH = 3222; 
νC=O = 1581; νmax = 1612, 1598, 1538, 1478, 1458, 1435, 1418, 1182, 1145, 1135, 1035. MS 
(70 eV): m/z (%) 357 (M++1, 100). HRMS (ESI) Anal. Calcd. for C19H18FN2O2S 357.1068 
[M+H]+, Found 357.1062. 
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N-(3-Hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-dioxide 3c 
(32%) 
Yellow powder. Crystallization from diethyl ether. Mp = 229.5 °C. 1H NMR (400 
MHz, D6-DMSO): δ 3.24 (2H, t, J = 6.0 Hz, CH2CH2SO2); 3.51 (2H, t, J = 6.0 
Hz, CH2CH2SO2); 4.50 (2H, s, CquatCH2SO2); 5.47 (2H, s, CH2N); 7.06-7.11 (2H, 
m, 2 × CHarom); 7.14-7.18 (1H, m, CHarom); 7.37 (1H, t, J = 7.9 Hz, CHarom); 7.48-
7.51 (2H, m, 2 × CHarom); 7.59-7.61 (2H, m, 2 × CHarom); 9.04 (1H, s(br), OH); 
11.22 (1H, s(br), NH). 13C NMR (100.6 MHz, D6-DMSO): δ 22.4 (CH2CH2SO2), 
46.2 (CH2N), 46.7 (CH2CH2SO2), 48.4 (CquatCH2SO2), 102.7 (Cquat,arom), 110.4, 
118.2, 120.0, 122.4, 126.0 and 126.1 (6 × CHarom), 126.6 (Cquat,arom), 129.3 and 
129.5 (2 × CHarom), 131.5, 133.8, 137.1 and 138.9 (4 × Cquat,arom), 164.5 (C=O). 
IR (ATR, cm-1): νNHOH = 3196; νC=O = 1641; νS=O = 1124, 1113; νmax = 1466, 1307, 1282, 1165, 
1038, 744, 714. MS (70 eV): m/z (%) 371 (M++1, 95). HRMS (ESI) Anal. Calcd. for 
C19H19N2O4S 371.1060 [M+H]+, Found 371.1066. 
 
N-(3-Hydroxycarbamoylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-
dioxide 3d (35%) 
White powder. Crystallization from EtOH. Mp = 237.0 °C. 1H NMR (400 MHz, 
D6-DMSO): δ 3.23 (2H, t, J = 5.9 Hz, CH2CH2SO2); 3.50 (2H, t, J = 5.9 Hz, 
CH2CH2SO2); 4.48 (2H, s, CquatCH2SO2); 5.47 (2H, s, CH2N); 7.00 (1H, t × d, 
J = 9.1, 2.5 Hz, CHarom); 7.08 (1H, d, J = 7.5 Hz, CHarom); 7.32 (1H, d × d, J = 
9.7, 2.5 Hz, CHarom); 7.34-7.38 (1H, m, CHarom); 7.50 (1H, d × d, J = 9.1, 4.3 
Hz, CHarom); 7.58 (1H, s, CHarom); 7.61 (1H, d, J = 7.5 Hz, CHarom); 9.05 (1H, 
s(br), OH); 11.21 (1H, s(br), NH). 19F NMR (376.5 MHz, D6-DMSO): δ (-
124.15)-(-124.09) (m). 13C NMR (100.6 MHz, D6-DMSO): δ 22.5 
(CH2CH2SO2), 46.4 (CH2N), 46.6 (CH2CH2SO2), 48.3 (CquatCH2SO2), 102.9 
(d, J = 4.6 Hz, Cquat,arom), 103.4 (d, J = 24.0 Hz, CHarom), 110.3 (d, J = 26.1 Hz, CHarom), 111.5 
(d, J = 9.5 Hz, CHarom), 125.9 and 126.1 (2 × CHarom), 126.9 (d, J = 10.2 Hz, Cquat,arom), 129.2 
and 129.4 (2 × CHarom), 133.5, 133.7, 133.8 and 138.6 (4 × Cquat,arom), 157.7 (d, J = 232.9 Hz, 
FCquat,arom), 164.3 (C=O). IR (ATR, cm-1): νNHOH = 3252; νC=O = 1627; νS=O = 1146, 1114; νmax = 
1481, 1461, 1316, 1284, 1260, 1165, 793. MS (70 eV): m/z (%) 389 (M++1, 100). HRMS (ESI) 
Anal. Calcd. for C19H18FN2O4S 389.0966 [M+H]+, Found 389.0967. 
 
N-(3-Hydroxycarbamoylbenzyl)-6-phenyl-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-
dioxide 3e (63%) 
White powder. Crystallization from CH2Cl2. Mp = 214 °C. 1H NMR (400 
MHz, D6-DMSO): δ 3.25 and 3.52 (2 × 2H, 2 × t, J = 5.8 Hz, CH2CH2S); 
4.57 (2H, s, CquatCH2S); 5.49 (2H, s, CH2N); 7.10 (1H, d, J = 7.4 Hz, 
CHarom); 7.30-7.36 (2H, m, 2 × CHarom); 7.44-7.48 (3H, m, 3 × CHarom); 
7.57 (1H, d, J = 8.6 Hz, CHarom); 7.61-7.63 (2H, m, 2 × CHarom); 7.70 (2H, 
d, J = 7.2 Hz, 2 × CHarom); 7.81 (1H, s, CHarom) 9.02 (1H, s(br), OH); 11.17 
(1H, s(br), NH). 13C NMR (100.6 MHz, D6-DMSO): δ 22.5 (CH2CH2S), 
46.4 (CH2N), 46.7 (CH2CH2S), 48.5 (Carom,quatCH2S), 103.2 (Carom,quat), 
110.8, 116.5, 121.6, 125.7, 126.0 and 126.9 (6 × CHarom), 127.17 
(Carom,quat), 127.20 (2 × CHarom), 129.1, 129.2 and 129.3 (4 × CHarom), 132.3, 132.5, 134.2, 
136.7, 138.6 and 141.8 (6 × Carom,quat), 164.0 (C=O). IR (ATR, cm-1): νNH/OH = 3240; νC=O = 1614; 
νS=O = 1116; νmax = 1583, 1472, 1315, 1283, 1164, 1044, 889, 806, 762, 724, 698. MS (70eV): 
m/z (%) 447 (M++1, 85). HRMS (ESI) Anal. Calcd. for C25H23N2O4S 447.1373 [M+H]+, Found 
447.1361. 
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N-(3-Hydroxycarbamoylbenzyl)-2,3-dihydrothieno[3,2-b]indole-1,1-dioxide 3f (25%) 
White powder. Crystallization from EtOH. Mp = 236.5 °C. 1H NMR (400 MHz, 
D6-DMSO): δ 3.47 (2H, t, J = 6.5 Hz, CH2CH2SO2); 3.96 (2H, t, J = 6.5 Hz, 
CH2CH2SO2); 5.50 (2H, s, CH2N); 7.22-7.34 (3H, m, 3 × CHarom); 7.43 (1H, t, J 
= 7.9 Hz, CHarom); 7.58-7.61 (2H, m, 2 × CHarom); 7.65-7.66 (2H, m, 2 × CHarom); 
9.04 (1H, s(br), OH); 11.24 (1H, s(br), NH). 13C NMR (100.6 MHz, D6-DMSO): 
δ 21.0 (CH2CH2SO2), 47.1 (CH2N), 57.4 (CH2CH2SO2), 112.3 (CHarom), 116.1 
(Cquat,arom), 118.7 (CHarom), 119.3 (Cquat,arom), 122.5, 123.9, 126.3, 126.6, 129.4 
and 130.3 (6 × CHarom), 133.8, 137.4, 141.0 and 148.5 (4 × Cquat,arom), 164.3 
(C=O). IR (ATR, cm-1): νNHOH = 3330; νC=O = 1655; νS=O = 1123, 1108; νmax = 
2954, 2921, 2853, 1584, 1544, 1474, 1443, 1374, 1326, 1269, 1235, 1036, 1018, 914, 744, 
702. MS (70 eV): m/z (%) 357 (M++1, 100). HRMS (ESI) Anal. Calcd. for C18H17N2O4S 
357.0904 [M+H]+, Found 357.0907. 
 
N-(3-Hydroxycarbamoylbenzyl)-7-fluoro-2,3-dihydrothieno[3,2-b]indole-1,1-dioxide 3g 
(40%) 
White powder. Crystallization from diethyl ether. Mp > 260.0 °C. 1H NMR (400 
MHz, D6-DMSO): δ 3.47 (2H, t, J = 6.5 Hz, CH2CH2SO2); 3.96 (2H, t, J = 6.5 
Hz, CH2CH2SO2); 5.51 (2H, s, CH2N); 7.17 (1H, t × d, J = 9.2, 2.5 Hz, CHarom); 
7.33 (1H, d, J = 7.8 Hz, CHarom); 7.38-7.45 (2H, m, 2 × CHarom); 7.61 (1H, d × 
d, J = 9.2, 4.3 Hz, CHarom); 7.65-7.67 (2H, m, 2 × CHarom); 9.04 (1H, s(br), 
OH); 11.23 (1H, s(br), NH). 19F NMR (376.5 MHz, D6-DMSO): δ (-120.64)-(-
120.58) (m). 13C NMR (100.6 MHz, D6-DMSO): δ 21.1 (CH2CH2SO2), 47.3 
(CH2N), 57.3 (CH2CH2SO2), 104.2 (d, J = 25.4 Hz, CHarom), 112.0 (d, J = 25.8 
Hz, CHarom), 113.8 (d, J = 9.7 Hz, CHarom), 116.1 (d, J = 4.4 Hz, Cquat,arom), 
119.5 (d, J = 11.2 Hz, Cquat,arom), 126.3, 126.7, 129.5 and 130.3 (4 × CHarom), 133.9, 137.2, 
137.6 and 150.1 (4 × Cquat,arom), 158.7 (d, J = 236.6 Hz, FCquat,arom), 164.3 (C=O). IR (ATR, cm-
1): νNHOH = 3238; νC=O = 1630; νS=O = 1126, 1109; νmax = 1585, 1482, 1442, 1276, 1145, 692. 
MS (70 eV): m/z (%) 375 (M++1, 87). HRMS (ESI) Anal. Calcd. for C18H16FN2O4S 375.0809 
[M+H]+, Found 375.0810. 
 
N-(3-Hydroxycarbamoylbenzyl)-7-bromo-2,3-dihydrothieno[3,2-b]indole-1-oxide 3h 
(70%) 
White powder. Crystallization from CH2Cl2. Mp = 218.5 °C. 1H NMR (400 
MHz, D6-DMSO): δ 3.24-3-31, 3.36-3.43, 3.57-3.64 and 4.00-4.07 (4 × 1H, 
4 × m, CH2CH2S); 5.51 and 5.57 (2 × 1H, 2 × d, J = 16.3 Hz, CH2N); 7.31 
(1H, d, J = 7.9 Hz, CHarom); 7.38 (1H, d × d, J = 8.8, 1.9 Hz, CHarom); 7.42 
(1H, t, J = 7.9 Hz, CHarom); 7.56 (1H, d, J = 8.8 Hz, CHarom); 7.64-7.66 (2H, 
m, 2 × CHarom); 7.90 (1H, d, J = 1.9 Hz, CHarom); 9.04 (1H, s(br), OH); 11.23 
(1H, s(br), NH). 13C NMR (100.6 MHz, D6-DMSO): δ 23.9 (CH2CH2S), 48.5 
(CH2N), 58.5 (CH2CH2S), 114.1 (CHarom), 114.6 and 120.4 (2 × Carom,quat), 
121.2 (CHarom), 124.4 (Carom,quat), 125.5, 126.3, 126.6, 129.4 and 130.2 (5 × 
CHarom), 133.9, 137.4, 140.2 and 154.6 (4 × Carom,quat), 166.3 (C=O). IR (ATR, cm-1): νNH/OH = 
3235; νC=O = 1646; νS=O = 987; νmax = 1604, 1588, 1531, 1478, 1428, 1353, 1328, 1135, 955, 
921, 791, 741, 704. MS (70eV): m/z (%) 419/21 (M++1, 100). HRMS (ESI) Anal. Calcd. for 
C18H16BrN2O3S 419.0060 [M+H]+, Found 419.0056. 
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N-(4-Hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3-oxide 3i (13%) 
White powder. Crystallization from ethanol. Mp = 258.5 °C. 1H NMR (400 MHz, 
D6-DMSO): δ 3.02-3.16 and 3.32-3.38 (3H and 1H, 2 × m, CH2CH2SO); 4.03 
and 4.22 (2 × 1H, 2 × d, J = 15.2 Hz, Cquat(HCH)SO); 5.48 (2H, s, CH2N); 7.04-
7.15 (4H, m, 4 × CHarom); 7.44 (1H, d , J = 8.1 Hz, CHarom); 7.51 (1H, d, J = 7.6 
Hz, CHarom); 7.66 (2H, d, J = 8.2 Hz, 2 × CHarom); 9.00 (1H, s(br), OH); 11.14 
(1H, s(br), NH). 13C NMR (100.6 MHz, D6-DMSO): δ 16.6 and 43.9 
(CH2CH2SO), 44.8 (CquatCH2SO), 45.9 (CH2N), 99.7 (Cquat,arom), 110.1, 118.1, 
119.8 and 122.0 (4 × CHarom), 126.8 (2 × CHarom), 127.6 (Cquat,arom), 127.7 (2 × 
CHarom), 132.3, 133.2, 136.7 and 141.7 (4 × Cquat,arom), 164.4 (C=O). IR (ATR, 
cm-1): νNHOH = 3172; νC=O = 1639; νS=O = 1014; νmax = 1465, 1314, 896, 743. MS (70 eV): m/z 
(%) 355 (M++1, 100). HRMS (ESI) Anal. Calcd. for C19H19N2O3S 355.1111 [M+H]+, Found 
255.1112. 
 
N-(4-Hydroxycarbamoylbenzyl)-6-fluoro-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3-oxide 
3j (28%) 
White powder. Crystallization from ethanol. Mp = 244.5 °C. 1H NMR (400 MHz, 
D6-DMSO): δ 3.01-3.15 and 3.28-3.38 (3H and 1H, 2 × m, CH2CH2SO); 4.02 
and 4.17 (2 × 1H, 2 × d, J = 15.6 Hz, Cquat(HCH)SO); 5.44 (2H, s, CH2N); 6.95 
(1H, t × d, J = 9.0, 2.5 Hz, CHarom); 7.09 (2H, d, J = 8.2 Hz, 2 × CHarom); 7.32 
(1H, d × d, J = 9.7, 2.5 Hz, CHarom); 7.45 (1H, d × d, J = 9.0, 4.3 Hz, CHarom); 
7.67 (2H, d, J = 8.2 Hz, 2 × CHarom); 9.00 (1H, s(br), OH); 11.15 (1H, s(br), 
NH). 19F NMR (376.5 MHz, D6-DMSO): δ (-124.45)-(-124.39) (m). 13C NMR 
(100.6 MHz, D6-DMSO): δ 16.5 and 43.7 (CH2CH2SO), 44.6 (CquatCH2SO), 
46.0 (CH2N), 100.0 (d, J = 4.3 Hz, Cquat,arom), 103.3 (d, J = 23.7 Hz, CHarom), 
109.8 (d, J = 26.1 Hz, CHarom), 111.2 (d, J = 9.7 Hz, CHarom), 126.8 (2 × CHarom), 127.8 (2 × 
CHarom), 128.0 (d, J = 10.0 Hz, Cquat,arom), 132.4, 133.3, 135.3 and 141.5 (4 × Cquat,arom), 157.7 
(d, J = 231.9 Hz, FCquat,arom), 164.4 (C=O). IR (ATR, cm-1): νNHOH = 3180; νC=O = 1636; νS=O = 
1013; νmax = 1480, 1459, 1414, 1307, 1143, 1123, 895, 848, 796. MS (70 eV): m/z (%) 373 
(M++1, 100). HRMS (ESI) Anal. Calcd. for C19H18FN2O3S 373, 1017 [M+H]+, Found 373.1014. 
 
N-(4-Hydroxycarbamoylbenzyl)-6-bromo-1,2,4,9-tetrahydro-3-thia-9-azafluorene-3,3-
dioxide 3k (70%) 
White powder. Crystallization from CH2Cl2. Mp = 230.0 °C. 1H NMR (400 
MHz, D6-DMSO): δ 3.22 and 3.51 (2 × 2H, 2 × t, J = 5.9 Hz, CH2CH2S); 4.51 
(2H, s, CquatCH2S); 5.50 (2H, s, CH2N); 7.07 (2H, d, J = 8.2 Hz, 2 × CHarom); 
7.27 (1H, d × d, J = 8.7, 1.7 Hz, CHarom); 7.47 (1H, d, J = 8.7 Hz, CHarom); 
7.67 (2H, d, J = 8.2 Hz, 2 × CHarom); 7.75 (1H, d, J = 1.7 Hz, CHarom); 9.01 
(1H, s(br), OH); 11.16 (1H, s(br), NH). 13C NMR (100.6 MHz, D6-DMSO): δ 
22.4 (CH2CH2S), 46.2 (CH2N), 46.5 (CH2CH2S), 48.2 (Carom,quatCH2S), 102.7 
(Carom,quat), 112.5 (CHarom), 112.7 (Carom,quat), 120.8, 124.8, 126.8 and 127.8 
(6 × CHarom), 128.3, 132,5, 133.3, 135.8 and 141.2 (5 × Carom,quat), 164.3 
(C=O). IR (ATR, cm-1): νNH/OH = 3371; νC=O = 1645; νS=O = 1114; νmax = 1533, 1463, 1428, 1348, 
1312, 1284, 1240, 1163, 1013, 885, 864, 852, 798, 779, 762, 700, 662. MS (70eV): m/z (%) 
449/51 (M++1, 5). HRMS (ESI) Anal. Calcd. for C19H18BrN2O4S 449.0165 [M+H]+, Found 
449.0148. 
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N-(4-Hydroxycarbamoylbenzyl)-2,3-dihydrothieno[3,2-b]indole-1,1-dioxide 3l (25%) 
White powder. Crystallization from ethanol. Mp = 198.0 °C. 1H NMR (400 MHz, 
D6-DMSO): δ 3.46 (2H, t, J = 6.3 Hz, CH2CH2SO2); 3.96 (2H, t, J = 6.3 Hz, 
CH2CH2SO2); 5.51 (2H, s, CH2N); 7.22-7.30 (4H, m, 4 × CHarom); 7.56-7.61 (2H, 
m, 2 × CHarom); 7.71 (2H, d, J = 8.2 Hz, 2 × CHarom); 9.03 (1H, s(br), OH); 11.17 
(1H, s(br), NH). 13C NMR (100.6 MHz, D6-DMSO): δ 20.9 (CH2CH2SO2), 47.0 
(CH2N), 57.4 (CH2CH2SO2), 112.3 (CHarom), 116.1 (Cquat,arom), 118.7 (CHarom), 
119.3 (Cquat,arom), 122.5 and 123.9 (2 × CHarom), 127.5 (2 × CHarom), 127.9 (2 × 
CHarom), 132.7, 140.1, 140.9 and 148.5 (4 × Cquat,arom), 164.2 (C=O). IR (ATR, 
cm-1): νNHOH = 3316; νC=O = 1668; νS=O = 1123, 1094; νmax = 1446, 1436, 1412, 
1260, 1012, 749. MS (70 eV): m/z (%) 357 (M++1, 33); 374 (M+NH4+, 100). HRMS (ESI) Anal. 
Calcd. for C18H17N2O4S 357.0904 [M+H]+, Found 357.0900. 
 
N-(4-Hydroxycarbamoylbenzyl)-7-fluoro-2,3-dihydrothieno[3,2-b]indole-1,1-dioxide 3m 
(5%) 
White powder. Crystallization from diethyl ether. Mp = 240.5 °C. 1H NMR (400 
MHz, D6-DMSO): δ 3.47 (2H, t, J = 6.5 Hz, CH2CH2SO2); 3.96 (2H, t, J = 6.5 
Hz, CH2CH2SO2); 5.51 (2H, s, CH2N); 7.16 (1H, t × d, J = 9.2, 2.5 Hz, CHarom); 
7.29 (2H, d, J = 8.2 Hz, 2 × CHarom); 7.40 (1H, d × d, J = 9.1, 2.5 Hz, CHarom); 
7.60 (1H, d × d, J = 9.2, 4.3 Hz, CHarom); 7.72 (2H, d, J = 8.2 Hz, 2 × CHarom); 
9.03 (1H, s(br), OH); 11.19 (1H, s(br), NH). 19F NMR (376.5 MHz, D6-DMSO): 
δ (-120.60)-(-120.54) (m). 13C NMR (100.6 MHz, D6-DMSO): δ 21.0 
(CH2CH2SO2), 47.2 (CH2N), 57.3 (CH2CH2SO2), 104.3 (d, J = 25.3 Hz, CHarom), 
112.0 (d, J = 26.2 Hz, CHarom), 113.7 (d, J = 9.8 Hz, CHarom), 116.2 (d, J = 5.3 
Hz, Cquat,arom), 119.5 (d, J = 11.1 Hz, Cquat,arom), 127.5 (2 × CHarom), 127.9 (2 × CHarom), 132.8, 
137.6, 139.9 and 150.1 (4 × Cquat,arom), 158.7 (d, J = 235.5 Hz, FCquat,arom), 164.2 (C=O). IR 
(ATR, cm-1): νNHOH = 3417; νC=O = 1614; νS=O = 1127, 1110; νmax = 3092, 1476, 1441, 1282, 
1144, 853, 806, 699. MS (70 eV): m/z (%) 392 (M+NH4+, 100). HRMS (ESI) Anal. Calcd. for 
C18H19FN3O4S 392.1075 [M+NH4]+, Found 392.1075. 
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4. Synthesis of benzothiophene-based 
hydroxamic acids as potent and selective 
HDAC6 inhibitors 
 
 
 
 
 
 
 
 
Abstract: A small library of 3-[(4-hydroxycarbamoylphenyl)aminomethyl]benzothiophenes 
was prepared and assessed as a novel class of HDAC6 inhibitors, leading to the identification 
of three representatives as potent and selective HDAC6 inhibitors. Further tests with regard to 
inflammatory responses indicated that HDAC6 inhibition can be uncoupled from transcriptional 
inhibition at the level of activated NF-κB, AP-1, and GR. 
 
 
 
 
 
 
 
 
 
 
 
Parts of the work described in this chapter have been published: 
De Vreese, R.; Van Steen, N.; Verhaeghe, T.; Desmet, T.; Bougarne, N.; De Bosscher, K.; Benoy, V.; Haeck, W.; Van Den Bosch, 
L.; D’hooghe, M. “Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors.” Chem. 
Commun. 2015, 51, 9868-9871. (I.F. 6.57) 
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4.1. Introduction 
The research field dealing with histone deacetylases (HDACs) has expanded rapidly in recent 
years, initiated by the original identification of HDAC1 in 1996.110 Although HDACs were initially 
recognized as enzymes responsible for the removal of acetyl groups from ε-N-acetylated lysine 
residues of histones, it is now established that HDACs1-11 not only employ histones as 
substrates but also many non-histone proteins (hormone receptors, chaperone proteins, 
transcription factors,. . .).3,111 In that respect, HDACs are sometimes referred to as lysine 
deacetylases to better reflect their substrate scope.5 Although HDAC inhibitors recently 
emerged as promising new drugs, the consequences of inhibiting this family of enzymes are 
not yet fully understood, and potential toxicities associated with non-selective inhibitors hamper 
their clinical usefulness.75,112 Of particular interest is the mainly cytoplasmic deacetylase 
HDAC6, as inhibition of this HDAC isoform is believed to be accompanied by minimal toxicity 
to the cell.11 Furthermore, its impact on various cellular functions, such as arranging the 
acetylation status of α-tubulin and Hsp90, has contributed to the rise of HDAC6 as an attractive 
drug target for the treatment of e.g. neurodegenerative disorders, autoimmunity and cancer.113 
The development of potent and selective HDAC6 inhibitors thus represent an important 
challenge in chemical research, as witnessed by the high interest of scientists active in diverse 
therapeutic fields (oncology, immunology, neurology,. . .) and the pharmaceutical industry in 
new HDAC6 inhibitors. 
HDAC inhibitors are typically composed of a zinc-binding group (ZBG), a linker and a group 
for protein surface recognition or interaction (cap group). The hydroxamate functional group 
has amply proven its good zinc chelating properties, as exemplified by the marketed 
hydroxamate suberanilohydroxamic acid (SAHA, Zolinza, vorinostat). Recent studies have 
also shown that a branched sp2 carbon atom in α-position with respect to the hydroxamate 
ZBG gives rise to a good HDAC6 selectivity profile.23 This has been confirmed by different 
recently developed HDAC6 selective inhibitors with an N-hydroxybenzamide group in their 
molecular structure.13,24,31,32,38,104 On the other hand, exploring the chemical space with regard 
to the cap groups seems to provide an excellent anchor point within the quest for new HDAC6 
inhibitors. In that respect, the evaluation of benzothiophene as a template for cap group design 
could provide new opportunities. Benzothiophene is more hydrophobic as compared to the 
‘privileged’ scaffolds indole and benzofuran, and this hydrophobic character could possibly 
allow for an improved binding profile since the protein surface in the area of the cap group 
accommodates several hydrophobic amino acid residues. The known use of benzothiophene 
as a scaffold in drug development, for example as a central part in the commercial 
pharmaceuticals raloxifene, zileuton, and sertaconazole, further supported the selection of this 
heterocycle as a building block to develop new bioactive molecules. Furthermore, 
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benzothiophene has been used as a cap group in a cinnamyl hydroxamide scaffold for HDAC 
inhibition, where it showed interesting potency.114 
In this part, the synthesis and evaluation of 3-[(4-hydroxycarbamoylphenyl)-
aminomethyl]benzothiophenes 1 as a new class of potential HDAC6 inhibitors was proposed 
(Figure 1). A short linker between the benzothiophene ring and the benzenehydroxamic acid 
should account for optimal interactions with the surface of the enzyme, and the presence of a 
nitrogen atom could be employed as a handle for further derivatization. 
 
Figure 1. Proposed new family of benzothiophene-based hydroxamic acids as potential HDAC6 inhibitors. 
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4.2. Synthesis and biological evaluation of benzothiophene-
based benzohydroxamic acids 
In order to explore the theoretical potential of these new compounds in silico, a set of 
representative virtual structures was subjected to docking studies. These studies 
acknowledged the inhibitory potential of structures 1 and revealed that expansion of the cap 
group (R1 = Ph) and the introduction of a benzylic group (R2 = Bn) could result in a more 
complete occupation of the binding pocket (Figure 2). Three new compounds were also 
subjected toward docking studies in the catalytic pocket of HDAC2 and 4 to address the 
selectivity in silico. This revealed a clear preference for HDAC6, with significantly lower 
affinities for the other isoforms (more information can be found in the experimental details). 
 
 
 
 
 
 
Figure 2. Docking of N-benzyl substituted hydroxamic acid 2 in a homology model of HDAC6 (green = carbon, blue = nitrogen, 
red = oxygen, yellow = sulfur, magenta = zinc) and presence of the hydrophobic amino acid residues in the vicinity of the catalytic 
pocket (orange, Phe620, Phe679, Phe680 and Leu749). 
 
Given the in silico predicted good affinities, the focus was pointed toward the synthesis of this 
family of structures 1. In addition, the indole counterpart of the ‘mother’ structure was pursued 
as well to verify the hypothesis that the protein surface close to the cap group preferably binds 
to a more hydrophobic scaffold. Finally, also the influence of a methyl group in the aromatic 
linker part was assessed.  
To that end, the commercially available benzothiophene-3-carbaldehyde 3a (R1 = H) and 5-
bromobenzothiophene-3-carbaldehyde 3b (R1 = Br) were used as substrates. First, 5-
phenylbenzothiophene-3-carbaldehyde 4 was prepared via a Suzuki-Miyaura cross-coupling 
using 5-bromobenzothiophene 3b, Pd(PPh3)4, phenylboronic acid and Na2CO3 in a 
toluene/EtOH/H2O (2/1/1) mixture. Reductive amination of carbaldehydes 3a-b and 4 
employing methyl 4-aminobenzoates and NaCNBH3 resulted in the synthesis of methyl 4-
aminobenzoate esters 5a-d.114 Secondary amines 5a-c were further N-benzylated using 
benzyl bromide and NaH in DMF to give tertiary amines 6a-c. As a last step, hydroxamic acids 
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7a-d and 8a-c were synthesized upon treatment of methyl esters 5a-d and 6a-c with an excess 
of hydroxyl amine and potassium hydroxide in THF (Scheme 1).  
 
 
Scheme 1. a: phenylboronic acid (2 equiv), Na2CO3 (6.5 equiv), Pd(PPh3)4 (4 mol %), toluene/ethanol/H2O (2/1/1), , 8h, N2, 72%. 
b: methyl 4-aminobenzoate or methyl 4-amino-3-methylbenzoate (1.2 equiv), glacial acetic acid (5 equiv), ethanol or 
ethanol/CH2Cl2, , 1h -> NaCNBH3 (3 equiv), 0°C -> r.t., 1h, 50-75%. c: NaH (60% in mineral oil, 1.2 equiv), DMF, r.t., 30’ -> 
benzyl bromide (2 equiv), KI (5 mg), 2h, r.t., 65-79%. d: NH2OH (50% in H2O, 100 equiv), KOH (4M in MeOH, 50 equiv), THF, r.t., 
10’, 13-85%. 
 
The synthesis of the second group of substituted benzothiophene-based hydroxamic acids 
commenced with the bromination of benzothiophene-3-carbaldehyde 3a in CH3CN to yield 6-
bromobenzothiophene-3-carbaldehyde 9 as the main isomer (60%, 1H NMR, CDCl3) in an 
isolated yield of 40%.115 The latter aldehyde 9 was subjected to the same strategy as described 
above (involving (b) Suzuki-Miyaura coupling, (c) reductive amination, (d) N-benzylation, and 
(e) ester to hydroxamic acid conversion) and provided novel compounds 10, 11a-b, 12a-b, 
13a-b and 14a-b (Scheme 2). 
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Scheme 2. a: Br2 (5 equiv), CH3CN, r.t., 18h, 40%. b: phenylboronic acid (2 equiv), Na2CO3 (6.5 equiv), Pd(PPh3)4 (4 mol %), 
toluene/ethanol/H2O (2/1/1), , 8h, N2, 96%. c: methyl 4-aminobenzoate (1.2 equiv), glacial acetic acid (5 equiv), ethanol, , 1h -
> NaCNBH3 (3 equiv), 0°C -> r.t., 1h, 50-66%. d: NaH (60% in mineral oil, 1.2 equiv), DMF, r.t., 30’ -> benzyl bromide (2 equiv), 
KI (5 mg), 2h, r.t., 87-91%. e: NH2OH (50% in H2O, 100 equiv), KOH (4M in MeOH, 50 equiv), THF, r.t., 10’, 56-80%. 
 
Application of these strategies (Scheme 1 and 2) thus resulted in a small set of eleven novel 
benzothiophene-based hydroxamic acids with potential HDAC6 inhibitory activity. The short 
and easy synthetic route toward these compounds provides an added value in terms of 
upscaling and industrial synthesis. 
Several attempts to obtain 18 as the indole counterpart of benzothiophene 7a starting from 
indole-3-carbaldehyde 15 using the procedure described above failed at the imination stage. 
However, a Dean Stark-mediated procedure using a catalytic amount of pTsOH did effect the 
desired imination, and NaBH4-assisted reduction of the latter imine then afforded the indole-
based methyl 4-aminobenzoate ester 17. Finally, ester to hydroxamic acid conversion 
produced the desired target structure 18 in a good yield (Scheme 3).  
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Scheme 3. a: methyl 4-aminobenzoate (1.2 equiv), p-toluenesulfonic acid monohydrate (0.05 equiv), toluene, Dean Stark, 18h, 
85%. b: NaBH4 (5 equiv), MeOH, , 90’, 88%. c: NH2OH (50% in H2O, 100 equiv), KOH (4M in MeOH, 50 equiv), THF, r.t., 10’, 
77%. 
In vitro studies of novel hydroxamic acids 7a-d, 8a-c, 13a-b, 14a-b and 18 with regard to their 
HDAC6 inhibitory activity revealed interesting SAR information (Table 1). Surprisingly, and in 
contrast with the predicted binding mode in Figure 2, N-benzylation of secondary amines 
drastically reduced the inhibitory activity. The same holds for the introduction of a phenyl group 
on the benzothiophene ring and a methyl group in the linker. The indole-containing hydroxamic 
acid 18 showed promising HDAC6 inhibitory activity with an IC50 value of 0.2 µM, albeit 
considerably less as compared to its benzothiophene counterpart 7a (IC50 = 0.014 µM). 
Table 1. In vitro pharmacological data: HDAC6 inhibitiona 
Compound R1 R2 % Inhibition (10 µM) IC50 (µM) 
7a H H 99.8 0.014 
7b Br H 99.2 0.037 
7c Ph H 95.1 0.31 
7d H Me 73.4 2.4 
8a H - 89.9 0.47 
8b Br - 84.9 0.85 
8c Ph - 47.9 N.D.b 
13a Br - 99.3 0.064 
13b Ph - 89.8 0.66 
14a Br - 70.7 2.1 
14b Ph - 61.1 N.D.b 
18 - - 99.0 0.2 
a Reference compound: Trichostatin A (IC50 = 0.014 µM) 
b Not Determined (< 70% inhibition at 10 µM) 
 
The selectivity of the most potent HDAC6 inhibitors 7a, 7b and 13a was then assessed through 
screening of their affinity toward all zinc-containing HDAC isozymes (Table 2). These results 
reveal an explicit selectivity profile for all three molecules taking their low nanomolar HDAC6 
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IC50 values (< 100 nM) and micromolar IC50 values for all other HDAC isozymes into account. 
The least pronounced selectivity is observed toward HDAC8, which is in line with the activity 
of other HDAC6 inhibitors.13,24,31,32,38,104 For example, Tubastatin A (HDAC6 IC50 = 0.015 µM) 
displays a high selectivity against all HDAC isozymes except for HDAC8, where it has only a 
57-fold selectivity (data compared with literature data).10 In that respect, benzothiophene 7a 
(HDAC6 IC50 = 0.014 µM) performs very well with a 100-fold selectivity toward HDAC8 and 
high selectivities toward all other HDAC isoforms. 
Table 2. In vitro enzyme inhibition data: IC50 values for 7a, 7b and 13a toward HDAC1-11 
(µM)a,b 
Compound 1 2 3 4 5 
7a 7.5 30 10 10 17 
7b >10 N.C. >10  N.C. N.C. 
13a 3.4 20 6.6 31 45 
Tub A 16.4 >30 >30 >30 >30 
6 7 8 9 10 11 
0.014 5.2 1.4 7.1 9.9 31 
0.037 >10 2.1 N.C. 33 15 
0.064 12 1.9 25 7.6 1.2 
0.015 >30 0.85 >30 >30 >30 
a
 Reference compound: trichostatin A. N.C.: IC50 value not calculable. Concentration-response curve shows less than 25% effect 
at the highest validated testing concentration (100 µM). Conc.: IC50 value above the highest test concentration. Concentration-
response curve shows less than 50% effect at the highest validated testing concentration (100 µM). b Literature values for Tub A 
(Tubastatin A)13, caution should be taken when comparing the IC50 values of 7a, 7b and 13a to the literature values for Tubastatin 
A. 
 
Next, the ability of the most potent HDAC6 inhibitors 7a, 7b and 13a to modify the acetylation 
level of α-tubulin in Neuro-2a cells was compared with Tubastatin A. Neuro-2a cells were 
treated overnight with different concentrations of the HDAC6 inhibitors and the effect on the 
acetylation level of α-tubulin was determined using Western Blots (Figure 3). These results 
showed that compounds 7a, 7b and 13a have the same effect on the acetylation level of α-
tubulin as Tubastatin A, proving that the compounds inhibit the deacetylation of acetylated α-
tubulin in a more complex cellular environment. 
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Figure 3. Potency of inhibiting the deacetylation of acetylated α-tubulin by compounds 7a, 7b, 13a and Tubastatin A in Neuro-2a 
cells. ImageQuant TL version 7.0-software was used to quantify the blots. 
 
HDAC6 is known to regulate Hsp90 acetylation and consequently also controls the chaperone-
dependent activation of the glucocorticoid receptor, GR.116 This means that hypoacetylated 
Hsp90 complexes with the GR and assists the translocation of the GR to the nucleus when a 
glucocoticoid binds the GR. Hyperacetylated Hsp90 (due to the absence or inhibition of 
HDAC6) on the contrary is not able to bind the GR and therefore the transcriptional activation 
of the GR is compromised. To study whether compounds 7a, 7b and 13a exhibit a direct effect 
on the transcriptional activity of GR, we used a glucocorticoid response element-dependent 
promoter fragment coupled to luciferase, stably integrated in A549 cells (adenocarcinomic 
human alveolar basal epithelial cells). As expected, the strong GR agonist dexamethasone 
(DEX) is able to activate the reporter gene (Figure 4A). In accord with previous findings, the 
selective GR modulator compound A (CpdA),117 which does not support transactivation, is able 
to partially compete with DEX and as such able to lower the GRE-dependent reporter gene 
activity. Remarkably, none of the HDAC6-inhibiting compounds were able to significantly inhibit 
DEX-activated GR-driven gene expression. On the contrary, both 7a and 7b were able to 
significantly stimulate GRE-dependent promoter activities, with 13a showing the same trend 
at the same concentration. These results indicate that compounds 7a, 7b and 13a are able to 
inhibit HDAC6 at a concentration that does not influence the transcriptional activity of GR in a 
negative manner. With regard to inflammatory responses, the HDAC6 inhibitor Tubastatin A 
has been reported to significantly inhibit TNF-α and IL-6 in LPS stimulated human THP-1 
macrophages.118 Therefore, we addressed whether compounds 7a, 7b and 13a are able to 
interfere with the activity of pro-inflammatory transcription factors, NF-κB and AP-1 (Figure 4B 
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and C). As NF-κB was identified before as the main key transcription factor driving IL-6,119 we 
investigated first whether the HDAC6 inhibitors may directly target this pro-inflammatory 
transcription factor. Surprisingly and in contrast to the reference compounds DEX and CpdA, 
7a, 7b and 13a were not able to block the activity of NF-κB and by extension, did not show any 
anti-inflammatory activity, at least at the transcriptional level. Since besides NF-κB, both the 
IL-6 and TNF-α promoters also contain response elements for the transcription factor AP-1, 
we decided to also test whether the compounds could target this transcription factor instead, 
potentially explaining the previously reported inhibitory effect of HDAC6 inhibitors on cytokine 
production. On the AP1-dependent luciferase reporter gene construct, pCollagenase-luc, 
treatment with the AP-1 activating phorbol ester PMA (phorbol 12-myristate 13-acetate) 
resulted in enhanced promoter activity, as expected. It was published before that CpdA does 
not target AP-1-driven promoters, in contrast to DEX. None of the hydroxamic acid HDAC6 
inhibitors were able to repress the AP-1-driven reporter gene. On the contrary, compounds 7b 
and 13a, both at 10 µM, clearly induced the AP1-dependent promoter activity as compared to 
solvent control (DMSO).  
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Figure 4. Influence of HDAC6 inhibitors 7a, 7b and 13a on the transcriptional level of a GRE-dependent luciferase reporter gene 
construct (A), an NF-κ-dependent recombinant promoter construct (B) and an AP1-dependent luciferase reporter gene construct 
(C). Averaged results of four independent experiments are shown ± SD. ****p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05. 
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As an extra control, we tested the effect of Tubastatin A on the same reporter genes (Figure 
5). Also for this well-known HDAC6 inhibitor, we could not find any evidence that NF-κB or AP-
1 are directly targeted at the transcriptional level. Only at the highest dose of 50 µM, an 
inhibition of the luciferase activity could be noted. However, since this was apparent for all 
reporter genes tested, and since the corresponding dilution of DMSO (1/200) also gave rise to 
a substantial inhibition, we regard this effect as potentially nonspecific and given the high dose, 
also as non-physiological. Of note, none of the compounds at all concentrations used 
demonstrated cell toxicity, as assayed using a Cell Titer Glo assay (Promega, data not shown). 
Overall, our results indicate that HDAC6 inhibition by the hydroxamic structures or Tubastatin 
A targets neither NF-κB nor AP-1 in a direct manner, i.e. at the transcriptional level. Overall, 
our results demonstrate that a potent HDAC6 inhibition can be uncoupled from transcriptional 
inhibition at the level of activated NF-κB, AP-1, and GR. These preliminary results require 
further in-depth investigation, which will be the topic of an elaborate study in the future. 
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Figure 5. Influence of HDAC6 inhibitor Tubastatin A on the transcriptional level of a GRE-dependent luciferase reporter gene 
construct (A), an NF--dependent recombinant promoter construct (B) and an AP1-dependent luciferase reporter gene construct 
(C). Averaged results of four independent experiments are shown ± SD. ****p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05. 
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A concern with regard to the use of hydroxamic acid-based pharmaceuticals is the potential 
mutagenicity associated with these compounds.107,108 Assessment of the novel ‘mother 
structure’ benzothiophene 7a in the Ames fluctuation test toward four strains of Salmonella 
typhimurium (TA98, TA100, TA1535 and TA1537), with and without metabolic activation by 
using rat liver S9 fraction, revealed no mutagenicity at first sight. However, as cytotoxicity was 
observed at concentrations of ≥ 50 µM, this result can obscure the genotoxicity of the 
compound, and further evaluation by other assay systems is advisable to ensure that the 
compound is not mutagenic. 
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4.3. Conclusions 
In summary, a set of novel 3-[(4-hydroxycarbamoylphenyl)aminomethyl]benzothiophenes was 
prepared, leading to the identification of three potent HDAC6 inhibitors as interesting lead 
structures with an activity/selectivity profile comparable to Tubastatin A. Adding additional 
substituents decreased the affinity for HDAC6, this in contrast to what was expected from 
docking studies (also pointing to the limitations associated with homology-based ligand 
docking in the HDAC6 area). The three most potent HDAC6 inhibitors performed well at α-
tubulin acetylation and demonstrated that HDAC6 inhibition can be uncoupled from 
transcriptional inhibition at the level of activated NF-κB, AP-1, and GR. 
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4.4. Experimental details 
4.4.1. Ligand docking 
All docking experiments were performed by the Centre for Industrial Biotechnology and 
Biocatalysis (Prof. Desmet). All manipulations were performed with the molecular modelling 
program YASARA and the YASARA/WHATIF93,94 twinset and the figure was created with 
PyMol v1.3.97 The HDAC6 sequence was obtained from the UniProt database 
(www.uniprot.org; UniProt entry Q9UBN7). To increase the accuracy of the model, the 
sequence was limited to the major functional domain of HDAC6 (Gly482-Gly800). Possible 
templates were identified by running 3 PSI-BLAST iterations to extract a position specific 
scoring matrix (PSSM) from UniRef90, and then searching the PDB for a match. To aid the 
alignment of the HDAC6 sequence and templates, and the modelling of the loops, a secondary 
structure prediction was performed, followed by multiple sequence alignments. All side chains 
were ionised or kept neutral according to their predicted pKa values. Initial models were 
created from different templates (pdb entry 2VQW, 2VQQ and 3C10), each with several 
alignment variations and up to hundred conformations tried per loop. After the side-chains had 
been built, optimised and fine-tuned, all newly modelled parts were subjected to a combined 
steepest descent and simulated annealing minimisation, i.e. the backbone atoms of aligned 
residues were kept fixed to preserve the folding, followed by a full unrestrained simulated 
annealing minimisation for the entire model. The final model was obtained as a hybrid model 
of the best parts of the initial models, and checked once more for anomalies like incorrect 
configurations or colliding side chains. Furthermore, it was structurally aligned with known 
HDAC crystal structures to check if the chelating residues and the zinc atom were arranged 
correctly. 
The HDAC inhibitor structures were created with YASARA Structure and energy minimised 
with the AMBER03 force field.95 The grid box used for docking had a dimension of 25 x 25 x 
25 angstrom, and comprised the entire catalytic cavity including the Zn ion and the outer 
surface of the active site entrance. Docking was performed with AutoDock VINA109 and default 
parameters. Ligands were allowed to freely rotate during docking. The first conformer from the 
cluster that has its zinc binding group in the vicinity of the zinc ion, was selected as the binding 
mode for further analysis. The associated cluster was moreover always the highest populated 
and had the highest average binding energy, proving that the selected docking pose is highly 
preferred. Docking was in addition redone with a grid covering the whole protein extended by 
5 Å on each side (~60x60x60) and the results were consistent with those obtained with the 
smaller grid. The docking experiments thus showed that the preferred binding mode is the one 
in which the phenylhydroxamate group occupies the tubular access channel (with the zinc 
binding group close to the zinc atom) and the cap group interacts with the protein surface. For 
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the most potent inhibitors (7a, 7b and 13a), the cap group was somehow sandwiched between 
Phe620 and Phe680, interacting via pi-pi stacking and hydrophobic contacts. Similar 
interactions were found for the cap group of the less potent N-substituted compounds, with 
additional contacts between the extra phenyl group and Phe679 and Leu749. There is 
accordingly no obvious reason for the lower in vitro activity. The selectivity for HDAC6 in 
contrast could be captured by molecular docking experiments. To that end, the most potent 
and selective HDAC6 inhibitors (7a, 7b and 13a) were docked in HDAC2 (class I) and HDAC4 
(class IIa) and predicted binding energies were compared with HDAC6 (class IIb) (Figure 6). 
A clear preference for HDAC6 was observed, with significantly lower affinities for the other 
isoforms (in accordance with the in vitro tests).  
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Predicted binding energies for the most potent and selective HDAC6 inhibitors (7a, 7b and 13a) against HDAC2 (class 
I), HDAC4 (class IIa) and HDAC6 (class IIb) (structures used for ligand docking: pdb entry 4LY1 chain A (HDAC2), 4CBY chain A 
(HDAC4) and the model created in this study (HDAC6); average binding energy from the cluster having its zinc binding group in 
the vicinity of the zinc ion (the higher the Eb the better the binding); ** p<0.01, * p<0.05). 
 
4.4.2. Enzyme inhibition assays 
The enzyme inhibition assays were performed by Eurofins Cerep Panlabs. In vitro IC50 values 
were determined by using human recombinant HDAC1-11 and fluorogenic HDAC substrate.98 
 
4.4.3. Western Blots 
The Western Blots were performed by the Laboratory of Neurobiology and Vesalius Research 
Center, VIB (Prof. Van Den Bosch). Values represent the normalized ratio Acetyl α-Tubulin/α-
Tubulin against Tubastatin A (Tub A) in an established neuronal cell line (Neuro-2a cells: ATCC 
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N° CCL-131). Neuro-2a cells are treated overnight with different concentrations of the HDAC6 
inhibitors and the effect on the acetylation level of α-tubulin is determined by using Western 
Blot. 
 
4.4.3.1. Cell culture  
Mouse neuroblastoma (Neuro-2a) cells were grown in a 1:1 mix of D-MEM (Dulbecco's 
Modified Eagle Medium) and F12 medium supplemented with glutamax (Invitrogen), 100 μg/ml 
streptomycin, 100 U/ml penicillin (Invitrogen), 10% fetal calf serum (Greiner Bio-one), 1% non-
essential amino acids (Invitrogen) and 1.6% NaHCO3 (Invitrogen) at 37 °C and 7.5% CO2. To 
split the cells, cells were washed with Versene (Invitrogen) and dissociated with 0.05% 
Trypsine-EDTA (Invitrogen). The Neuro-2a cells were treated overnight at 37°C with dosages 
ranging from 10 nM up to 1 µM of either Tubastatin A (Sigma-Aldrich) or the candidate HDAC6 
inhibitors. 
 
4.4.3.2. Western Blot 
For sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis, 
transfected cells were collected using the EpiQuik Total Histone Extraction Kit (EpiGentek) 
according to manufacturer’s instructions. Protein concentrations were determined using 
microBCA kit (Thermo Fisher Scientific Inc., Pittsburgh, PA, USA) according to manufacturer’s 
instructions. Before resolving the samples on a 12% SDS-PAGE gel, samples containing equal 
amounts of protein were supplemented with reducing sample buffer (Thermo Scientific) and 
boiled at 95 °C for 5 min. After electrophoresis, the proteins were transferred to a 
polyvinylidene difluoride (PVDF) membrane (Millipore Corp., Bedford, MA, USA). The non-
specific binding was blocked by incubation of the membrane in 5% bovine serum albumin 
(BSA), diluted in Tris Buffered Saline Tween (TBST, 50 mM TRIS, 150 mM NaCl, 0,1% Tween-
20 (Applichem, Darmstadt, Duitsland) for 1h at room temperature followed by incubation with 
primary antibodies overnight. The antibodies, diluted in TBS-T, were directed against α-tubulin 
(1/5000, T6199, Sigma-Aldrich), and acetylated α-tubulin (1/5000, T6793 monoclonal, Sigma-
Aldrich). The secondary antibodies, coupled to alkaline phosphatase (anti-mouse or anti-
rabbit, 1/5000, Sigma-Aldrich) were used. Blots were visualized by adding the ECF substrate 
(Enhanced Chemical Fluorescence, GE Healthcare, Uppsala, Sweden) and imaged with the 
ImageQuant_LAS 4000. A mild reblotting buffer (Millipore) was applied to strip the blots. 
ImageQuant TL version 7.0-software was used to quantify the blots. 
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4.4.4. GRE/NF-κB/AP-1 assays 
These bioassays were performed by the Cytokine Receptor Lab, VIB (Prof. De Bosscher). 
A549 cells with the stably integrated recombinant reporter gene p(GRE)2-50-luc (A) were pre-
incubated with respective solvents, the selective Glucocorticoid Receptor modulator CpdA (10 
µM), 7a (1µM or 10µM), 7b (1µM or 10µM), 13a (1µM or 10µM) and Tubastatin A (0.5, 1, 5, 
10, 50 µM) for 1h after which the synthetic glucocorticoid dexamethasone (DEX,1µM) was 
added, where indicated, for 5h. An extra DMSO control at the highest dose was included 
(1/200), whereas the level of DMSO for the other concentrations corresponded to the one-
before highest dose, i.e. of the 10 µM set-up. A549 cells with the stably integrated recombinant 
reporter gene p(IL6κB)350hu.IL6P-luc (B)120 or Collagenase-luc (C) were pre-incubated with 
respective solvents, DEX (1µM), CpdA (10 µM), 7a (1µM or 10 µM), 7b (1µM or 10 µM), 13a 
(1µM or 10 µM) and Tubastatin A (0.5, 1, 5, 10, 50 µM) for 1h after which TNF (2000 units/ml) 
or PMA (20 nM) were added, where indicated, for 5h. Cell lysates were assayed for luciferase 
activities. Promoter activities are expressed as relative induction factor calculated as 
percentage of maximal DEX (A), TNF (B) or PMA (C) responses. Averaged results of four 
independent experiments are shown ± SD. ****p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05. 
Statistical significance was determined on the averaged results, and analysis performed using 
one-way ANOVA tests followed by a Tukey multiple comparison post test. 
 
4.4.5. Ames fluctuation assays 
The Ames fluctuation assays were performed by Eurofins Cerep Panlabs. Wells that displayed 
bacteria growth due to the reversion of the histidine mutation (as judged by the ratio of OD430/ 
OD570 being greater than 1.0) are counted and recorded as positive counts. The significance 
of the positive counts between the treatment (in the presence of test compound) and the control 
(in the absence of test compound) are calculated using the one-tailed Fisher’s exact test. 
 
4.4.6. Synthetic procedures and spectral data 
1H NMR spectra were recorded at 300 MHz (JEOL ECLIPSE+) or 400 MHz (Bruker Avance 
III) with CDCl3 or D6-DMSO as solvent and tetramethylsilane as internal standard. 13C NMR 
spectra were recorded at 75 MHz (JEOL ECLIPSE+) or 100.6 MHz (Bruker Avance III) with 
CDCl3 or D6-DMSO as solvent and tetramethylsilane as internal standard. Mass spectra were 
obtained with a mass spectrometer Agilent 1100, 70 eV. IR spectra were measured with a 
Spectrum One FT-IR spectrophotometer. High resolution electron spray (ES) mass spectra 
were obtained with an Agilent Technologies 6210 series time-of-flight instrument. Melting 
points of crystalline compounds were measured with a Büchi 540 apparatus or with a Kofler 
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Bench, type WME Heizbank of Wagner & Munz. The purity of all tested compounds was 
assessed by HRMS analysis and/or HPLC analysis, confirming a purity of ≥95%. 
 
4.4.6.1. Synthesis of 6-bromobenzothiophene-3-carbaldehyde 9115 
Benzothiophene-3-carbaldehyde (811 mg, 5 mmol, 1 equiv) 3a was dissolved in acetonitrile 
(15 mL) and to this solution was slowly added bromine (1,29 mL, 25 mmol, 5 equiv). The 
resulting reaction mixture was stirred at room temperature for 18 hour after which it was 
partitioned between an aqueous sodium bicarbonate solution (50 mL) and EtOAc (50 mL). To 
this biphasic solution was added dropwise, under vigorous stirring, a saturated aqueous 
sodium thiosulfate solution until discoloration of the organic medium. The organic layer was 
separated, and the aqueous layer was extracted with EtOAc (25 mL). The organic fractions 
were combined, dried (MgSO4), filtered and concentrated under vacuum. Purification through 
column chromatography yielded 6-bromobenzothiophene-3-carbaldehyde 9 (482 mg, 2 mmol, 
40%) as a white powder.  
 
6-Bromobenzothiophene-3-carbaldehyde 9 (40%) 
White powder. Purification by column chromatography (EtOAc/PE 1/13, Rf = 
0.14). Mp = 111 °C. 1H NMR (400 MHz, CDCl3): δ 7.63 (1H, d × d, J = 8.7, 1.7 
Hz, CHarom); 8.04 (1H, d, J = 1.7 Hz, CHarom); 8.30 (1H, s, CHaromS); 8.56 (1H, 
d, J = 8.7 Hz, CHarom); 10.12 (1H, s, CHO). 13C NMR (100.6 MHz, CDCl3): δ 
120.2 (Cquat,arom), 125.0, 125.9 and 129.6 (3 × CHarom), 134.0, 136.1 and 141.8 (3 × Cquat,arom), 
143.2 (CHarom), 185.1 (C=O). IR (ATR, cm-1): νC=O = 1662; νmax = 3074, 2851, 1583, 1492, 1454, 
1389, 1358, 1182, 1135, 1110, 1040, 862, 854, 809, 796, 727, 714. Anal. Calcd. For 
C9H5BrOS: C 44.84 H 2.09. Found C 45.17 H 1.71. 
 
4.4.6.2. Synthesis of phenylbenzothiophene-3-carbaldehydes 4 and 10 
General procedure: 5-Bromobenzothiophene-3-carbaldehyde 3b (482 mg, 2 mmol, 1 equiv) 
was dissolved in toluene (15 mL) and to this solution were added an aqueous solution of 
sodium carbonate (7 mL, 2M) and a solution of phenylboronic acid (488 mg, 4 mmol, 2 equiv) 
in ethanol (7 mL). This mixture was flushed with nitrogen for 10 minutes before 
tetrakis(triphenylphosphine)palladium(0) (92 mg, 0.08 mmol, 0.04 equiv) was added and the 
reaction mixture was heated to its boiling temperature for 8 hour. The reaction mixture was 
poured in to brine (20 mL) and three times extracted with EtOAc (20 mL). The combined 
organic fraction was thereafter three times washed with brine (15 mL), dried (MgSO4), filtered 
and evaporated under vacuum. Purification through column chromatography yielded 5-
phenylbenzothiophene-3-carbaldehyde 4 (343 mg, 1.44 mmol, 72%) as an orange powder. 
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5-Phenylbenzothiophene-3-carbaldehyde 4 (72%) 
Orange powder. Purification by column chromatography (EtOAc/PE 1/5, Rf 
= 0.35). Mp = 102 °C. 1H NMR (300 MHz, CDCl3): δ 7.36-7.41, 7.46-7.51 
and 7.69-7.72 (1H, 2H and 3H, 3 × m, 6 × CHarom); 7.94 (1H, d, J = 8.3 Hz, 
CHarom); 8.35 and 8.92 (2 × 1H, 2 × s, 2 × CHarom); 10.17 (1H, s, CHO). 13C 
NMR (75 MHz, CDCl3): δ 122.7, 123.3, 125.9, 127.6, 127.7 and 129.0 (8 × CHarom), 135.9, 
136.7, 139.5, 139.8 and 140.8 (5 × Cquat,arom), 144.0 (CHarom), 185.5 (C=O). IR (ATR, cm-1): νC=O 
= 1671; νmax = 3076, 2923, 2796, 2718, 1600, 1507, 1494, 1451, 1428, 1381, 1284, 1246, 
1156, 1104, 904, 856, 802, 765, 729, 702, 664. MS (70 eV): m/z (%) 239 (M++1, 35). HRMS 
(ESI) Anal. Calcd. for C15H11OS 239.0525 [M+H]+, Found 239.0524.  
 
6-Phenylbenzothiophene-3-carbaldehyde 10 (96%) 
Orange powder. Purification by column chromatography (EtOAc/PE 1/13, 
Rf = 0.20). (96%). Mp = 94 °C. 1H NMR (400 MHz, CDCl3): δ 7.37-7.41, 
7.46-7.50 and 7.65-7.68 (1H, 2H and 2H, 3 × m, 5 × CHarom); 7.76 (1H, d × 
d, J = 8.4, 1.4 Hz, CHarom); 8.08 (1H, d, J = 1.4 Hz, CHarom); 8.33 (1H, s, 
CHarom); 8.72 (1H, d, J = 8.4 Hz, CHarom); 10.16 (1H, s, CHO). 13C NMR 
(100.6 MHz, CDCl3): δ 120.6, 125.0, 125.8, 127.4, 127.7 and 129.0 (8 × 
CHarom), 134.2, 136.4, 139.6, 140.5 and 141.3 (5 × Cquat,arom), 143.2 (CHarom), 185.4 (C=O). IR 
(ATR, cm-1): νC=O = 1662; νmax = 3082, 1542, 1491, 1463, 1390, 1147, 1102, 1052, 856, 821, 
761, 715, 691. MS (70 eV): m/z (%) 239 (M++1, 100). HRMS (ESI) Anal. Calcd. for C15H11OS 
239.0525 [M+H]+, Found 239.0524. 
 
4.4.6.3. Synthesis of methyl 4-aminobenzoate esters 5a-d and 11a-b 
General procedure: Benzothiophene-3-carbaldehyde 3a (406 mg, 2.5 mmol, 1 equiv) was 
dissolved in ethanol (15 mL) and to this solution were added glacial acetic acid (751 mg, 12.5 
mmol, 5 equiv) and methyl 4-aminobenzoate (454 mg, 3 mmol, 1.2 equiv). This reaction 
mixture was stirred for one hour at refluxing conditions after which it was cooled to 0°C. Sodium 
cyanoborohydride (471 mg, 7.5 mmol, 3 equiv) was added and the reaction mixture was 
allowed to warm to room temperature. After one hour the mixture was poured in to brine (15 
mL) and three times extracted with EtOAc (15 mL). The combined organic fraction was 
thereafter three times washed with brine (15 mL), dried (MgSO4), filtered and evaporated under 
vacuum. Purification through recrystallization from ethanol yielded 3-[(4-
methoxycarbonylphenyl)aminomethyl]-benzothiophene 5a (520 mg, 1.75 mmol, 70%) as a 
white powder. For secondary amine 5b a solvent mixture of ethanol/CH2Cl2 (1/1) was used as 
solvent for the reaction. 
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3-[(4-Methoxycarbonylphenyl)aminomethyl]benzothiophene 5a (70%) 
White powder. Recrystallization from EtOH. Mp = 127 °C. 1H NMR (300 MHz, 
CDCl3): δ 3.84 (3H, s, CH3O); 4.48 (1H, s(br), NH); 4.58 (2H, d, J = 5.0 Hz, 
CH2NH); 6.62 (2H, d, J = 8.8 Hz, 2 × CHarom); 7.32 (1H, s, CHS); 7.35-7.43, 7.73-
7.81 and 7.86-7.90 (2H, 1H and 3H, 3 × m, 6 × CHarom). 13C NMR (75 MHz, 
CDCl3): δ 42.2 (CH2NH), 51.7 (CH3O), 111.8 (2 × CHarom), 119.0 (Cquat,arom), 121.7 
and 123.2 (2 × CHarom), 124.1 (CHS), 124.4, 124.8 and 131.7 (4 × CHarom), 132.8, 
137.8, 141.0 and 151.7 (4 × Cquat,arom), 167.4 (C=O). IR (ATR, cm-1): νNH = 3379; 
νC=O = 1685; νmax = 2944, 1598, 1524, 1431, 1334, 1275, 1260, 1170, 1113, 840, 
769, 756, 732. MS (70 eV): m/z (%) 296 (M--1, 100). HRMS (ESI) Anal. Calcd. for C17H14NO2S 
296.0751 [M-1]-, Found 296.0760.  
 
5-Bromo-3-[(4-methoxycarbonylphenyl)aminomethyl]benzothiophene 5b (70%) 
Brown powder. Recrystallization from EtOH. Mp = 143 °C. 1H NMR (300 MHz, 
CDCl3): δ 3.86 (3H, s, CH3O); 4.48 (1H, s(br), NH); 4.56 (2H, s, CH2NH); 6.64 
(2H, d, J = 8.5 Hz, 2 × CHarom); 7.37 (1H, s, CHS); 7.48 (1H, d, J = 8.3 Hz, 
CHarom); 7.74 (1H, d, J = 8.3 Hz, CHarom); 7.89 (2H, d, J = 8.5 Hz, CHarom); 7.92 
(1H, s, CHarom). 13C NMR (75 MHz, CDCl3): δ 42.1 (CH2NH), 51.7 (CH3O), 
111.9 (2 × CHarom), 118.6 and 119.3 (2 × Cquat,arom), 124.4, 124.5, 125.8, 127.9 
and 131.7 (6 × CHarom), 132.3, 139.4, 139.6 and 151.5 (4 × Cquat,arom), 167.3 
(C=O). IR (ATR, cm-1): νNH = 3376; νC=O = 1683; νmax = 2945, 1600, 1576, 
1532, 1434, 1341, 1315, 1286, 1273, 1195, 1174, 1118, 1068, 970, 769, 698. 
MS (70 eV): m/z (%) 374/6 (M--1, 100). HRMS (ESI) Anal. Calcd. for C17H13BrNO2S 373.9856 
[M-H]-, Found 373.9869. 
 
3-[(4-Methoxycarbonylphenyl)aminomethyl]-5-phenylbenzothiophene 5c (75%) 
Brown powder. Purification by column chromatography (EtOAc/PE 1/5, Rf 
= 0.29). Mp = 154° C. 1H NMR (300 MHz, CDCl3): δ 3.85 (3H, s, CH3O); 
4.49 (1H, s(br), NH); 4.65 (2H, d, J = 4.9 Hz, CH2NH); 6.65 (2H, d, J = 8.8 
Hz, 2 × CHarom); 7.33-7.48, 7.62-7.65 and 7.88-7.96 (4H, 3H and 4H, 3 × 
m, 11 × CHarom). 13C NMR (75 MHz, CDCl3): δ 42.3 (CH2NH), 51.7 (CH3O), 
111.9 (2 × CHarom), 119.1 (Cquat,arom), 120.0, 123.4, 124.5, 124.9, 127.5, 
127.6, 129.0 and 131.7 (11 × CHarom), 133.0, 138.1, 138.3, 140.0, 141.2 
and 151.7 (6 × Cquat,arom), 167.3 (C=O). IR (ATR, cm-1): νNH = 3389; νC=O = 
1697; νmax = 3076, 2922, 2852, 1609, 1530, 1496, 1445, 1430, 1350, 1310, 1285, 1170, 1104, 
1081, 1020, 832, 767, 756, 694. MS (70 eV): m/z (%) 372 (M--1, 25). HRMS (ESI) Anal. Calcd. 
for C23H18NO2S 372.1064 [M-H]-, Found 372.1069. 
 
3-[(4-Methoxycarbonyl-2-methylphenyl)aminomethyl]benzothiophene 5d (50%) 
White powder. Recrystallization from EtOH. Mp = 148 °C. 1H NMR (300 MHz, 
CDCl3): δ 2.15 (3H, s, CH3Cquat); 3.85 (3H, s, CH3O); 4.29 (1H, s(br), NH); 4.64 
(2H, s, CH2NH); 6.66 (1H, d, J = 8.8 Hz, CHarom); 7.33 (1H, s, CHS); 7.37-7.43 
and 7.78-7.89 (2H and 4H, 2 × m, 6 × CHarom). 13C NMR (75 MHz, CDCl3): δ 17.5 
(CH3Cquat), 42.4 (CH2NH), 51.7 (CH3O), 108.9 (CHarom), 118.5 and 121.2 (2 × 
Cquat,arom), 121.7 and 123.2 (2 × CHarom), 124.2 (CHS), 124.5, 124.8, 129.9 and 
131.7 (4 × CHarom), 132.8, 137.8, 141.0 and 149.8 (4 × Cquat,arom), 167.6 (C=O). 
IR (ATR, cm-1): νNH = 3442; νC=O = 1702; νmax = 2939, 1601, 1513, 1459, 1430, 
1379, 1342, 1286, 1266, 1258, 1230, 1189, 1146, 1113, 1004, 828, 771, 762, 728. MS (70 
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eV): m/z (%) 310 (M--1, 100). HRMS (ESI) Anal. Calcd. for C18H16NO2S 310.0907 [M-H]-, Found 
310.0917. 
 
6-Bromo-3-[(4-methoxycarbonylphenyl)aminomethyl]benzothiophene 11a (50%) 
Light yellow powder. Recrystallization from EtOH. Mp = 155 °C. 1H NMR (400 
MHz, D6-DMSO): δ 3.74 (3H, s, CH3O); 4.57 (2H, d, J = 5.5 Hz, CH2NH); 6.70 
(2H, d, J = 8.8 Hz, 2 × CHarom); 7.12 (1H, t, J = 5.5 Hz, CH2NH); 7.58 (1H, d 
× d, J = 8.6, 1.8 Hz, CHarom); 7.65 (1H, s, CHarom); 7.69 (2H, d, J = 8.8 Hz, 2 
× CHarom); 7.89 (1H, d, J = 8.6 Hz, CHarom); 8.30 (1H, d, J = 1.8 Hz, CHarom). 
13C NMR (100.6 MHz, D6-DMSO): δ 41.1 (CH2NH), 51.7 (CH3O), 111.8 (2 × 
CHarom), 116.6 and 118.1 (2 × Cquat,arom), 124.2, 125.7, 125.8, 127.7 and 131.4 
(6 × CHarom), 133.8, 137.4, 142.4 and 153.0 (4 × Cquat,arom), 166.8 (C=O). IR 
(ATR, cm-1): νNH = 3346; νC=O = 1672; νmax = 1600, 1526, 1431, 1337, 1287, 
1264, 1176, 1114, 1057, 837, 820, 772. MS (70 eV): m/z (%) 374/6 (M--1, 20). HRMS (ESI) 
Anal. Calcd. for C17H13BrNO2S 373.9856 [M-1]-, Found 373.9862. 
 
3-[(4-Methoxycarbonylphenyl)aminomethyl]-6-phenyl-benzothiophene 11b (66%) 
White powder. Recrystallization from EtOH. Mp = 169 °C. 1H NMR (400 
MHz, CDCl3): δ 3.86 (3H, s, CH3O); 4.48 (1H, t, J = 5.0 Hz, NH); 4.64 (2H, 
d, J = 5.0 Hz, CH2NH); 6.66 (2H, d, J = 8.8 Hz, 2 × CHarom); 7.36-7.40 (2H, 
m, 2 × CHarom); 7.48 (2H, t, J = 7.6 Hz, 2 × CHarom); 7.64-7.67 (3H, m, 3 × 
CHarom); 7.85 (1H, d, J = 8.4 Hz, CHarom); 7.90 (2H, d, J = 8.8 Hz, 2 × 
CHarom); 8.09 (1H, d, J = 1.2 Hz, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 
42.2 (CH2NH), 51.6 (CH3O), 111.7 (2 × CHarom), 119.0 (Cquat,arom), 121.4, 
121.8, 124.1, 124.4, 127.4, 127.5, 128.9 and 131.6 (11 × CHarom), 132.5, 
136.8, 138.2, 140.8, 141.6 and 151.6 (6 × Cquat,arom), 167.3 (C=O). IR (ATR, 
cm-1): νNH = 3390; νC=O = 1683; νmax = 1600, 1524, 1490, 1436, 1341, 1310, 
1275, 1177, 1105, 1074, 784, 764, 692. MS (70 eV): m/z (%) 396 (M+Na+, 30). 
 
4.4.6.4. Synthesis of tertiary amines 6a-c and 12a-b 
General procedure: 3-[(4-Methoxycarbonylphenyl)aminomethyl]-benzothiophene 5a (297 mg, 
1 mmol, 1 equiv) was dissolved in DMF (10 mL) and to this solution was sodium hydride (40 
mg, 60 % dispersion in mineral oil, 1 mmol, 1 equiv) added. The reaction mixture was stirred 
for 30 minutes at room temperature under nitrogen atmosphere after which benzyl bromide 
(342 mg, 2 mmol, 2 equiv) and potassium iodide (5 mg) were added. After two hours the 
reaction mixture was poured in to brine (20 mL) and three times extracted with EtOAc (20 mL). 
The combined organic fraction was thereafter three times washed with brine (15 mL), dried 
(MgSO4), filtered and evaporated under vacuum. Purification through column chromatography 
yielded 3-[N-benzyl-N-(4-methoxycarbonylphenyl)-aminomethyl]benzothiophene 6a (271 
mg,0.7 mmol, 70%) as a yellow powder.  
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3-[N-Benzyl-N-(4-methoxycarbonylphenyl)aminomethyl]-benzothiophene 6a (70%) 
Yellow powder. Purification by column chromatography (EtOAc/PE 1/5, Rf = 
0.30). Mp = 126 °C. 1H NMR (300 MHz, CDCl3): δ 3.84 (3H, s, CH3O); 4.76 
and 4.87 (2 × 2H, 2 × s, 2 × CH2N); 6.76 (2H, d, J = 8.8 Hz, 2 × CHarom); 7.11 
(1H, s, CHS); 7.21-7.40, 7.65-7.68 and 7.85-7.90 (7H, 1H and 3H, 3 × m, 11 × 
CHarom). 13C NMR (75 MHz, CDCl3): δ 49.6 (CH2N), 51.7 (CH3O), 54.0 (CH2N), 
111.5 (2 × CHarom), 118.3 (Cquat,arom), 121.3, 122.8, 123.2, 124.3, 124.8, 126.6, 
127.4 and 129.0 (10 × CHarom), 131.4 (Cquat,arom), 131.6 (2 × CHarom), 137.5, 
137.6, 141.3 and 152.4 (4 × Cquat,arom), 167.3 (C=O). IR (ATR, cm-1): νC=O = 
1701; νmax = 2921, 2852, 1602, 1520, 1494, 1432, 1398, 1357, 1318, 1282, 1234, 1183, 1109, 
1072, 1026, 962, 946, 817, 768, 729, 696. MS (70 eV): m/z (%) 388 (M++1, 85). HRMS (ESI) 
Anal. Calcd. for C24H22NO2S 388.1366 [M+H]+, Found 388.1374. 
 
5-Bromo-3-[N-benzyl-N-(4-methoxycarbonylphenyl)aminomethyl]-benzothiophene 6b 
(79%) 
Yellow powder. Purification by column chromatography (EtOAc/PE 1/5, Rf = 
0.37). Mp = 130 °C. 1H NMR (300 MHz, CDCl3): δ 3.84 (3H, s, CH3O); 4.76 
and 4.87 (2 × 2H, 2 × s, 2 × CH2N); 6.76 (2H, d, J = 8.8 Hz, 2 × CHarom); 7.11 
(1H, s, CHS); 7.22-7.41, 7.65-7.68 and 7.85-7.91 (6H, 1H and 3H, 3 × m, 10 
× CHarom). 13C NMR (75 MHz, CDCl3): δ 49.4 (CH2N), 51.7 (CH3O), 54.1 
(CH2N), 111.5 (2 × CHarom), 118.5 (2 × Cquat,arom), 124.2, 124.5, 126.6, 127.5, 
127.8 and 129.0 (9 × CHarom), 130.9 (Cquat,arom), 131.6 (2 × CHarom), 137.3, 
139.2, 139.9 and 152.2 (4 × Cquat,arom), 167.3 (C=O). IR (ATR, cm-1): νC=O = 
1702; νmax = 2943, 1598, 1522, 1451, 1434, 1410, 1365, 1318, 1280, 1231, 1186, 1109, 1073, 
943, 818, 769, 742, 728, 698. MS (70 eV): m/z (%) 466/8 (M++1, 100). HRMS (ESI) Anal. 
Calcd. for C24H21BrNO2S 466.0471 [M+H]+, Found 466.0483.  
 
3-[N-Benzyl-N-(4-methoxycarbonylphenyl)aminomethyl]-5-phenyl-benzothiophene 6c 
(65%) 
Yellow powder. Purification by column chromatography (EtOAc/PE 1/5, Rf 
= 0.31). Mp = 82 °C. 1H NMR (300 MHz, CDCl3): δ 3.83 (3H, s, CH3O); 
4.76 and 4.90 (2 × 2H, 2 × s, 2 × CH2N); 6.76 (2H, d, J = 8.8 Hz, 2 × 
CHarom); 7.13 (1H, s, CHS); 7.22-7.46, 7.59-7.63 and 7.83-7.93 (8H, 3H 
and 4H, 3 × m, 15 × CHarom). 13C NMR (75 MHz, CDCl3): δ 49.7 (CH2N), 
51.7 (CH3O), 54.1 (CH2N), 111.6 (2 × CHarom), 118.4 (Cquat,arom), 119.8, 
123.4, 123.5, 124.5, 126.6, 127.4, 127.5 and 129.0 (14 × HCarom), 131.6 
(Cquat,arom), 131.7 (2 × HCarom), 137.5, 138.0, 138.2, 140.4, 141.2 and 152.4 
(6 × Cquat,arom), 167.3 (C=O). IR (ATR, cm-1): νC=O = 1702; νmax = 2969, 
2923, 1604, 1519, 1494, 1451, 1434, 1396, 1360, 1317, 1279, 1233, 1183, 1155, 1108, 1074, 
1026, 947, 895, 819, 759, 730, 696. MS (70 eV): m/z (%) 464 (M++1, 70). HRMS (ESI) Anal. 
Calcd. for C30H26NO2S 464.1679 [M+H]+, Found 464.1698. 
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6-Bromo-3-[N-benzyl-N-(4-methoxycarbonylphenyl)aminomethyl]-benzothiophene 12a 
(87%) 
White powder. Purification by column chromatography (EtOAc/PE 1/10, Rf = 
0.21). Mp = 63 °C. 1H NMR (400 MHz, D6-DMSO): δ 3.74 (3H, s, CH3O); 4.83 
and 5.01 (2 × 2H, 2 × s, 2 × CH2N); 6.79 (2H, d, J = 9.1 Hz, 2 × CHarom); 7.24-
2.28 and 7.32-7.36 (3H and 2H, 2 × m, 5 × CHarom); 7.38 (1H, s, CHarom); 7.58 
(1H, d × d, J = 8.6, 1.8 Hz, CHarom); 7.71 (2H, d, J = 9.1 Hz, 2 × CHarom); 7.80 
(1H, d, J = 8.6 Hz, CHarom); 8.31 (1H, d, J = 1.8 Hz, CHarom). 13C NMR (100.6 
MHz, D6-DMSO): δ 49.7 (CH2N), 51.8 (CH3O), 54.1 (CH2N), 112.1 (2 × 
CHarom), 117.1 and 118.2 (2 × Cquat,arom), 124.0, 124.6, 125.9, 127.0, 127.4, 
127.7, 129.1 and 131.3 (11 × CHarom), 132.4, 137.0, 138.5, 142.6 and 152.2 
(5 × Cquat,arom), 166.6 (C=O). IR (ATR, cm-1): νC=O = 1702; νmax = 2922, 1602, 1520, 1433, 1281, 
1233, 1184, 1109, 946, 808, 797, 768, 730, 696. MS (70 eV): m/z (%) 466/8 (M++1, 100). 
HRMS (ESI) Anal. Calcd. for C24H21BrNO2S 466.0471 [M+H]+, Found 466.0482. 
 
3-[N-Benzyl-N-(4-methoxycarbonylphenyl)aminomethyl]-6-phenyl-benzothiophene 12b 
(91%) 
White powder. Purification by column chromatography (EtOAc/PE 1/10, Rf 
= 0.13). Mp = 66 °C. 1H NMR (400 MHz, CDCl3): δ 3.84 (3H, s, CH3O); 
4.76 and 4.88 (2 × 2H, 2 × s, 2 × CH2N); 6.77 (2H, d, J = 9.1 Hz, 2 × 
CHarom); 7.11 (1H, s, CHS); .7.23-7.39, 7.45-7.48, 7.61-7.66 and 7.70-7.72 
(6H, 2H, 3H and 1H, 4 × m, 12 × CHarom); 7.87 (2H, d, J = 9.1 Hz, 2 × 
CHarom); 8.08 (1H, d, J = 1.0 Hz, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 
49.5 (CH2N), 51.6 (CH3O), 53.9 (CH2N), 111.5 (2 × CHarom), 118.2 
(Cquat,arom), 121.4, 121.5, 123.1, 124.0, 126.5, 127.36, 127.42, 127.5, 
128.92 and 128.94 (14 × CHarom), 131.2 (Cquat,arom), 131.6 (2 × CHarom), 
136.6, 137.4, 138.1, 140.9, 142.0 and 152.3 (6 × Cquat,arom), 167.2 (C=O). 
IR (ATR, cm-1): νC=O = 1702; νmax = 2923, 1601, 1521, 1495, 1451, 1433, 1398, 1318, 1282, 
1233, 1184, 1109, 945, 823, 767, 731, 696. MS (70 eV): m/z (%) 464 (M++1, 100). HRMS (ESI) 
Anal. Calcd. for C30H26NO2S 464.1679 [M+H]+, Found 464.1672.  
 
4.4.6.5. Synthesis of 3-[(4-methoxycarbonylphenyl)iminomethyl]indole 16 
Indole-3-carbaldehyde 15 (435 mg, 3 mmol, 1 equiv), methyl 4-aminobenzoate (544 mg, 3.6 
mmol, 1.2 equiv) and p-toluenesulfonic acid monohydrate (29 mg, 0.15 mmol, 0.05 equiv) were 
added to toluene (25 mL) in a Dean Stark apparatus. After 18 hour refluxing the mixture was 
extracted with EtOAc (25 mL) and washed with a saturated aqueous solution of sodium 
bicarbonate (25 mL), water (25 mL) and brine (25 mL). Drying (MgSO4), filtering and 
evaporating of the organic layer yielded a yellow crude reaction mixture which was 
recrystallized from EtOAc/hexane to obtain 3-[(4-methoxycarbonylphenyl)iminomethyl]indole 
16 (710 mg, 2.55 mmol, 85%) as a light yellow powder. 
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3-[(4-Methoxycarbonylphenyl)iminomethyl]indole 16 (85%) 
Light yellow powder. Recrystallization from EtOAc/Hexane. Mp = 159 °C. 1H 
NMR (400 MHz, CDCl3): δ 3.92 (3H, s, CH3O); 7.24 (2H, d, J = 8.2 Hz, 2 × 
CHarom); 7.29-7.31 and 7.38-7.40 (2H and 1H, 2 × m, 3 × CHarom); 7.64 (1H, s, 
CHNH); 8.07 (2H, d, J = 8.2 Hz, 2 × CHarom); 8.49-8.51 (1H, m, CHarom); 8.62 (1H, 
s, CHN); 8.83 (1H, s(br), NH). 13C NMR (100.6 MHz, CDCl3): δ 52.0 (CH3O), 
111.4 (CHarom), 116.5 (Cquat,arom), 120.9, 122.1, 122.3 and 123.9 (5 × CHarom), 
125.1 and 126.3 (2 × Cquat,arom), 130.9 and 131.2 (3 × CHarom), 136.9 (Cquat,arom), 
155.7 (C=N), 157.7 (Cquat,arom), 167.2 (C=O). IR (ATR, cm-1): νNH = 3292; νC=O = 
1698; νmax = 1622, 1586, 1573, 1431, 1415, 1367, 1310, 1280, 1247, 1194, 1165, 
1115, 1101, 851, 772, 748, 700. MS (70 eV): m/z (%) 279 (M++1, 100). HRMS (ESI) Anal. 
Calcd. for C17H15N2O2 279.1128 [M+H]+, Found 279.1135.  
 
4.4.6.6. Synthesis of 3-[(4-methoxycarbonylphenyl)aminomethyl]indole 17  
3-[(4-Methoxycarbonylphenyl)iminomethyl]indole 16 (417 mg, 1.5 mmol, 1 equiv) was 
dissolved in methanol (20 mL). To this solution was sodium borohydride (284 mg, 7.5 mmol, 5 
equiv) added after which the mixture was heated to its boiling point. After 90 minutes of stirring 
the mixture was cooled to room temperature and quenched with water. The obtained mixture 
was extracted with EtOAc (2 x 25 mL), washed with water (25 mL) and brine (25 mL), dried 
(MgSO4), filtered and evaporated under vacuum. After recrystallization from EtOAc/hexane 3-
[(4-methoxycarbonylphenyl)-aminomethyl]indole 17 (370 mg, 1.32 mmol, 88%) was obtained 
as a yellow powder.  
 
3-[(4-Methoxycarbonylphenyl)aminomethyl]indole 17 (88%) 
Yellow powder. Recrystallization from EtOAc/Hexane. Mp = 115.5 °C. 1H NMR 
(400 MHz, D6-DMSO): δ 3.74 (3H, s, CH3O); 4.45 (2H, d, J = 5.3 Hz, CH2NH); 
6.72 (2H, d, J = 8.8 Hz, 2 × CHarom); 6.87 (1H, t, J = 5.3 Hz, CH2NH); 7.01 and 
7.10 (2 × 1H, 2 × t, J = 7.5 Hz, 2 × CHarom); 7.35-7.39 and 7.62-7.64 (2H and 1H, 
2 × m, 3 × CHarom); 7.70 (2H, d, J = 8.8 Hz, 2 × CHarom); 10.95 (1H, s(br), NH) . 
13C NMR (100.6 MHz, D6-DMSO): δ 38.7 (CH2NH), 51.6 (CH3O), 111.6 and 
111.9 (3 × CHarom), 112.2 and 116.0 (2 × Cquat,arom), 119.0, 119.2, 121.6 and 124.4 
(4 × CHarom), 127.1 (Cquat,arom), 131.3 (2 × CHarom), 136.9 and 153.4 (2 × Cquat,arom), 
166.9 (C=O). IR (ATR, cm-1): νNH = 3408, 3360; νC=O = 1685; νmax = 1598, 1526, 
1438, 1422, 1345, 1314, 1279, 1241, 1194, 1169, 1114, 1094, 840, 765, 738, 700. MS (70 
eV): m/z (%) 279 (M--1, 20). HRMS (ESI) Anal. Calcd. for C17H15N2O2 279.1139 [M-H]-, Found 
279.1146.  
 
4.4.6.7. Synthesis of hydroxamic acids 7a-d, 8a-c, 13a-b, 14a-b and 18 
General procedure: 3-[(4-Methoxycarbonylphenyl)aminomethyl]benzothiophene 6a (400 mg, 
1.35 mmol, 1 equiv) was dissolved in ethanol (10 mL) and to this solution was firstly 
hydroxylamine (8.3 mL, 50% in water, 135 mmol, 100 equiv) added and secondly potassium 
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hydroxide (16.9 mL, 4M in methanol, 67.5 mmol, 50 equiv). The resulting mixture was stirred 
for an additional 10 minutes at room temperature before it was poured in a saturated aqueous 
solution of sodium bicarbonate (10 mL). This aqueous solution was extracted two times with 
ethyl acetate, after which the combined organic fractions were washed with water (10 mL) and 
brine (10 mL). After drying (MgSO4), filtering and evaporating a very viscous colorless liquid 
was obtained which was recrystallized overnight from CHCl3 to obtain 3-[(4-
hydroxycarbamoylphenyl)aminomethyl]benzothiophene 7a (161 mg, 0.54 mmol, 40%) as a 
white powder. For hydroxamic acids 7b-d and 8a-c the mixture was stirred for 10 minutes in 
ethanol at refluxing conditions and for hydroxamic acids 13a-b, 14a-b and 18 the mixture was 
stirred for 10 minutes in THF at room temperature. 
 
3-[(4-Hydroxycarbamoylphenyl)aminomethyl]benzothiophene 7a (40%) 
White powder. Crystallization from CHCl3. Mp = 191 °C. 1H NMR (300 MHz, D6-
DMSO): δ 4.53 (2H, d, J = 5.5 Hz, CH2NH); 6.64 (2H, d, J = 8.6 Hz, 2 × CHarom); 
6.78 (1H, t, J = 5.5 Hz, CH2NH); 7.35-7.43 (2H, m, 2 × CHarom); 7.50 (2H, d, J = 
8.6 Hz, 2 × CHarom); 7.59 (1H, s, CHS); 7.90-8.00 (2H, m, 2 × CHarom); 8.67 (1H, 
s(br), NHOH); 10.76 (1H, s(br), NHOH). 13C NMR (75 MHz, D6-DMSO): δ 41.4 
(CH2NH), 111.7 (2 × CHarom), 120.1 (Cquat,arom), 122.7 and 123.5 (2 × CHarom), 
124.5 (CHS), 124.7, 125.0 and 128.8 (4 × CHarom), 134.5, 138.5, 140.6 and 151.6 
(4 × Cquat,arom), 165.5 (C=O). IR (ATR, cm-1): νNH/OH = 3380, 3255, 3105; νC=O = 
1600; νmax = 2862, 1620, 1568, 1500, 1480, 1464, 1340, 1314, 1307, 1259, 1156, 
1022, 899, 831, 760, 729, 678. MS (70 eV): m/z (%) 299 (M++1, 100). HRMS (ESI) Anal. Calcd. 
for C16H15N2O2S 299.0849 [M+H]+, Found 299.0862.  
 
5-Bromo-3-[(4-hydroxycarbamoylphenyl)aminomethyl]benzothiophene 7b (85%) 
White powder. Crystallization from CHCl3. Mp = 199 °C. 1H NMR (300 MHz, 
D6-DMSO): δ 4.52 (2H, d, J = 5.5 Hz, CH2NH); 6.64 (2H, d, J = 8.5 Hz, 2 × 
CHarom); 6.82 (1H, t, J = 5.5 Hz, CH2NH); 7.50 (2H and 1H, d, J = 8.5 Hz, 3 × 
CHarom); 7.69 (1H, s, CHarom); 7.96 (1H, d, J = 8.5 Hz, CHarom); 8.17 (1H, s, 
CHarom); 8.67 (1H, s(br), NHOH); 10,75 (1H, s(br), NHOH). 13C NMR (75 MHz, 
D6-DMSO): δ 41.2 (CH2NH), 111.8 (2 × CHarom), 118.2 and 120.2 (2 × 
Cquat,arom), 125.3, 125.5, 126.7, 127.7 and 128.8 (6 × CHarom), 134.1, 139.6, 
140.4 and 151.5 (4 × Cquat,arom), 165.5 (C=O). IR (ATR, cm-1): νNH/OH = 3376, 
3235; νC=O = 1604; νmax = 2928, 1512, 1433, 1418, 1357, 1322, 1269, 1227, 
1192, 1153, 1132, 1063, 1024, 970, 896, 873, 828, 807, 775, 621. MS (70 eV): m/z (%) 377/9 
(M++1, 100). HRMS (ESI) Anal. Calcd. for C16H14BrN2O2S 376.9954 [M+H]+, Found 376.9943. 
 
  
CHAPTER IV  RESULTS AND DISCUSSION 
132 
3-[(4-Hydroxycarbamoylphenyl)aminomethyl]-5-phenyl-benzothiophene 7c (33%) 
White powder. Crystallization from CHCl3. Mp = 181 °C. 1H NMR (300 
MHz, D6-DMSO): δ 4.62 (2H, d, J = 5.5 Hz, CH2NH); 6.68 (2H, d, J = 8.8 
Hz, 2 × CHarom); 6.87 (1H, t, J = 5.5 Hz, CH2NH); 7.35-7.40, 7.46-7.53 and 
7.65-7.76 (1H, 4H and 4H, 3 × m, 9 × CHarom); 8.05 (1H, d, J = 8.8 Hz, 
CHarom); 8.19 (1H, s, CHarom); 8.67 (1H, s(br), NHOH); 10.76 (1H, s(br), 
NHOH). 13C NMR (75 MHz, D6-DMSO): δ 41.4 (CH2NH), 111.8 (2 × 
CHarom), 120.0 (Cquat,arom), 120.8, 123.9, 124.1, 125.3, 127.7, 127.9, 128.8 
and 129.5 (11 × CHarom), 134.8, 137.1, 139.2, 139.8, 140.9 and 151.7 (6 × 
Cquat,arom), 165.5 (C=O). IR (ATR, cm-1): νNH/OH = 3403, 3202; νC=O = 1608; 
νmax = 3056, 2902, 1661, 1573, 1505, 1442, 1422, 1342, 1319, 1299, 1279, 1260, 1162, 1135, 
1033, 898, 830, 758, 698. MS (70 eV): m/z (%) 375 (M++1, 100). HRMS (ESI) Anal. Calcd. for 
C22H19N2O2S 375.1162 [M+H]+, Found 375.1171. 
 
3-[(4-Hydroxycarbamoyl-2-methylphenyl)aminomethyl]benzothiophene 7d (40%) 
White powder. Crystallization from CHCl3. Mp = 190 °C. 1H NMR (300 MHz, D6-
DMSO): δ 2.16 (3H, s, CH3); 4.63 (2H, d, J = 5.5 Hz, CH2NH); 6.17 (1H, t, J = 
5.5 Hz, CH2NH); 6.51 (1H, d, J = 8.2 Hz, CHarom); 7.36-7.43 (4H, m, 4 × CHarom); 
7.51 (1H, s, CHarom); 7.96 (1H, d, J = 7.7 Hz, CHarom); 8.05 (1H, d, J = 7.7 Hz, 
CHarom); 8.66 (1H, s(br), NHOH); 10,73 (1H, s(br), NHOH). 13C NMR (75 MHz, 
D6-DMSO): δ 18.5 (CH3), 41.7 (CH2NH), 109.0 (CHarom), 119.9 and 121.6 (2 × 
Cquat,arom), 122.7, 123.5, 124.1, 124.6, 125.0, 126.5 and 129.4 (7 × CHarom), 134.7, 
138.4, 140.7 and 149.2 (4 × Cquat,arom), 165.6 (C=O). IR (ATR, cm-1): νNH/OH = 
3396, 3366, 3260; νC=O = 1604; νmax = 3078, 2900, 2860, 1564, 1498, 1479, 
1429, 1339, 1316, 1289, 1233, 1128, 1035, 983, 975, 832, 812, 798, 756, 724, 665. MS (70 
eV): m/z (%) 313 (M++1, 100). HRMS (ESI) Anal. Calcd. for C17H17N2O2S 313.1005 [M+H]+, 
Found 313.1019.  
 
3-[N-Benzyl-N-(4-hydroxycarbamoylphenyl)aminomethyl]benzothiophene 8a (17%) 
Brown powder. Purification by column chromatography (CH2Cl2/MeOH/Et3N 
95/5/2, Rf = 0.14). Mp = 178 °C. 1H NMR (300 MHz, CDCl3): δ 4.74 and 4.85 
(2 × 2H, 2 × s, 2 × CH2N); 6.74-6.76 (2H, m, 2 × CHarom); 7.09 (1H, s, CHS); 
7.20-7.40, 7.57-7.67 and 7.87-7.90 (7H, 3H and 1H, 3 × m, 11 × CHarom). 13C 
NMR (75 MHz, CDCl3): δ 49.5 and 54.0 (2 × CH2N), 111.9 (2 × CHarom), 118.6 
(Cquat,arom), 121.4, 122.8, 123.2, 124.3, 124.8, 126.6, 127.4, 128.8 and 128.9 
(12 × CHarom), 131.4, 137.5, 137.6, 141.3 and 151.8 (5 × Cquat,arom), 167.4 
(C=O). IR (ATR, cm-1): νNH/OH = 3059; νC=O = 1604; νmax = 3029, 2970, 2929, 
2871, 1702, 1556, 1519, 1494, 1451, 1434, 1396, 1357, 1280, 1233, 1184, 
1155, 1108, 1073, 1026, 947, 894, 821, 758, 730, 696. MS (70 eV): m/z (%) 389 (M++1, 100). 
HRMS (ESI) Anal. Calcd. for C23H21N2O2S 389.1318 [M+H]+, Found 389.1334.  
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5-Bromo-3-[N-benzyl-N-(4-hydroxycarbamoylphenyl)aminomethyl]-benzothiophene 8b 
(13%) 
White powder. Purification by column chromatography (CH2Cl2/MeOH/Et3N 
95/5/2, Rf = 0.14). Mp = 179 °C. 1H NMR (300 MHz, (CD3)2CO): δ 4.84 and 
5.03 (2 × 2H, 2 × s, 2 × CH2N); 6.82 (2H, d, J = 8.8 Hz, 2 × CHarom); 7.24-7.37 
(6H, m, 6 × CHarom); 7.53 (1H, d, J = 8.8 Hz, CHarom); 7.66 (2H, d, J = 8.8 Hz, 
2 × CHarom); 7.93 (1H, d, J = 8.8 Hz, CHarom); 8.05 (1H, s, CHarom); 10.45 (1H, 
s(br), NHOH). 13C NMR (75 MHz, (CD3)2CO): δ 49.6 and 54.1 (2 × CH2N), 
111.9 (2 × CHarom), 117.9 and 119.7 (2 × Cquat,arom), 124.7, 124.8, 126.7, 127.0, 
127.5, 128.4 and 128.7 (11 × CHarom), 132.2, 138.5, 139.8, 140.0 and 151.2 
(5 × Cquat,arom), 165.7 (C=O). IR (ATR, cm-1): νNH/OH = 3199; νC=O = 1605; νmax 
= 2970, 2924, 1703, 1556, 1513, 1505, 1494, 1452, 1393, 1359, 1232, 1203, 1154, 1072, 
1026, 946, 894, 863, 818, 732, 696. MS (70 eV): m/z (%) 465/7 (M--1, 22). HRMS (ESI) Anal. 
Calcd. for C23H18BrN2O2S 465.0278 [M-H]-, Found 465.0287.  
 
3-[N-Benzyl-N-(4-hydroxycarbamoylphenyl)aminomethyl]-5-phenyl-benzothiophene 8c 
(13%)  
Yellow powder. Purification by column chromatography 
(CH2Cl2/MeOH/Et3N 95/5/2, Rf = 0.14). Mp = 126 °C. 1H NMR (300 MHz, 
CDCl3): δ 4.73 and 4.88 (2 × 2H, 2 × s, 2 × CH2N); 6.73-3.79 (2H, m, 2 × 
CHarom); 7.11-7.46 and 7.59-7.63 (10H and 4H, 2 × m, 14 × CHarom); 7.81 
(1H, s, CHarom); 7.92 (1H, d, J = 8.3 Hz, CHarom); 8.63 (1H, s(br), NHOH). 
13C NMR (75 MHz): δ 49.7 and 54.0 (2 × CH2N), 112.0 (2 × CHarom), 118.4 
(Cquat,arom), 119.8, 123.4, 123.5, 124.4, 126.6, 127.4, 127.5, 128.8 and 
129.0 (16 × CHarom), 131.5, 137.4, 137.9, 138.1, 140.3, 141.1 and 152.0 (7 
× Cquat,arom), 167.6 (C=O). IR (ATR, cm-1): νNH/OH = 3198; νC=O = 1604; νmax 
= 2969, 2926, 1702, 1556, 1519, 1494, 1451, 1434, 1396, 1357, 1318, 1280, 1233, 1184, 
1155, 1108, 1073, 1026, 947, 894, 822, 758, 730, 696. MS (70 eV): m/z (%) 465 (M++1, 100). 
HRMS (ESI) Anal. Calcd. for C29H25N2O2S 465.1631 [M+H]+, Found 465.1639.  
 
6-Bromo-3-[(4-hydroxycarbamoylphenyl)aminomethyl]benzothiophene 13a (80%) 
White powder. Crystallization from CHCl3. Mp = 179.5 °C. 1H NMR (400 MHz, 
D6-DMSO): δ 4.54 (2H, d, J = 5.5 Hz, CH2NH); 6.65 (2H, d, J = 8.6 Hz, 2 × 
CHarom); 6.80 (1H, t, J = 5.5 Hz, CH2NH); 7.52 (2H, d, J = 8.6 Hz, 2 × CHarom); 
7.58 (1H, d × d, J = 8.6, 1.7 Hz, CHarom); 7.64 (1H, s, CHarom); 7.90 (1H, d, J 
= 8.6 Hz, CHarom); 8.30 (1H, d, J = 1.6 Hz, CHarom); 8.69 (1H, s(br), NHOH); 
10,78 (1H, s(br), NHOH). 13C NMR (100.6 MHz, D6-DMSO): δ 41.2 (CH2NH), 
111.6 (2 × CHarom), 118.0 and 120.0 (2 × Cquat,arom), 124.2, 125.5, 125.8, 127.6 
and 128.7 (6 × CHarom), 134.2, 137.4, 142.4 and 151.5 (4 × Cquat,arom), 165.3 
(C=O). IR (ATR, cm-1): νNH/OH = 3417, 3220; νC=O = 1604; νmax = 1501, 1466, 
1426, 1312, 1261, 1224, 1196, 1155, 1022, 891, 834, 812, 793, 765. MS (70 eV): m/z (%) 
375/7 (M--1, 100). HRMS (ESI) Anal. Calcd. for C16H12BrN2O2S 374.9808 [M-1]-, Found 
374.9815. 
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3-[(4-Hydroxycarbamoylphenyl)aminomethyl]-6-phenyl-benzothiophene 13b (68%) 
White powder. Crystallization from CHCl3. Mp = 190.5 °C. 1H NMR (400 
MHz, D6-DMSO): δ 4.58 (2H, d, J = 5.6 Hz, CH2NH); 6.68 (2H, d, J = 8.8 
Hz, 2 × CHarom); 6.82 (1H, t, J = 5.6 Hz, CH2NH); 7.39 (1H, t, J = 7.3 Hz, 
CHarom); 7.48-7.55 (4H, m, 4 × CHarom); 7.64 (1H, s, CHarom); 7.72-7.78 (3H, 
m, 3 × CHarom); 8.03 (1H, d, J = 8.4 Hz , CHarom); 8.67 (1H, s(br), NHOH); 
10.77 (1H, s(br), NHOH). 13C NMR (100.6 MHz, D6-DMSO): δ 41.4 
(CH2NH), 111.7 (2 × CHarom), 120.0 (Cquat,arom), 121.3, 123.0, 123.7, 125.0, 
127.4, 127.9, 128.7 and 129.5 (11 × CHarom), 134.2, 137.1, 137.7, 140.5, 
141.5 and 151.5 (6 × Cquat,arom), 165.4 (C=O). IR (ATR, cm-1): νNH/OH = 3411, 
3254; νC=O = 1604; νmax = 1567, 1499, 1462, 1420, 1336, 1308, 1259, 
1195, 1153, 1020, 892, 829, 765, 745, 692. MS (70 eV): m/z (%) 375 
(M++1, 35). HRMS (ESI) Anal. Calcd. for C22H19N2O2S 375.1162 [M+H]+, Found 375.1154. 
 
6-Bromo-3-[N-benzyl-N-(4-hydroxycarbamoylphenyl)aminomethyl]benzothiophene 14a 
(56%) 
Light brown powder. Recrystallization from CHCl3/ether. Mp = 97.5 °C. 1H 
NMR (400 MHz, CDCl3): δ 4.73 and 4.83 (2 × 2H, 2 × s, 2 × CH2N); 6.76 (2H, 
d, J = 8.2 Hz, 2 × CHarom); 7.08 (1H, s, CHarom); 7.21 (2H, d, J = 7.1 Hz, 2 × 
CHarom); 7.29-7.36 (3H, m, 3 × CHarom); 7.50 (2H, s, 2 × CHarom); 7.59 (2H, d, 
J = 8.2 Hz, 2 × CHarom); 8.02 (1H, s, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 
49.3 and 53.9 (2 × CH2N), 111.9 (2 × CHarom), 118.2 and 118.8 (2 × Cquat,arom), 
122.3, 123.2, 125.6, 126.4, 127.4, 127.7, 128.7 and 128.9 (11 × CHarom), 
131.1, 136.2, 137.1, 142.6 and 151.8 (5 × Cquat,arom), 167.6 (C=O). IR (ATR, 
cm-1): νNH/OH = 3061; νC=O = 1602; νmax = 2873, 2924, 1494, 1451, 1397, 1375, 
1355, 1310, 1233, 1157, 1027, 944, 823, 811, 797, 755, 732, 696. MS (70 eV): m/z (%) 467/9 
(M++1, 100). HRMS (ESI) Anal. Calcd. for C23H18BrN2O2S 467.0423 [M+H]+, Found 467.0423.  
 
3-[N-Benzyl-N-(4-hydroxycarbamoylphenyl)aminomethyl]-6-phenyl-benzothiophene 
14b (74%) 
White powder. Recrystallization from CHCl3/ether. Mp = 102 °C. 1H NMR 
(400 MHz, D6-DMSO): δ 4.82 and 5.02 (2 × 2H, 2 × s, 2 × CH2N); 6.75 
(2H, d, J = 9.0 Hz, 2 × CHarom); 7.24-7.41 (7H, m, 7 × CHarom); 7.50 (2H, t, 
J = 7.6 Hz, 2 × CHarom); 7.55 (2H, d, J = 9.0 Hz, 2 × CHarom); 7.74 (1H, d × 
d, J = 8.4, 1.6 Hz, CHarom); 7.77 (2H, d, J = 7.3 Hz, 2 × CHarom); 7.94 (1H, 
d, J = 8.4 Hz, CHarom); 8.33 (1H, s, CHarom); 8.76 (1H, s(br), NHOH); 10.82 
(1H, s(br), NHOH). 13C NMR (100.6 MHz, D6-DMSO): δ 49.9 and 54.1 (2 
× CH2N), 112.0 (2 × CHarom), 120.4 (Cquat,arom), 121.4, 122.8, 123.8, 124.1, 
127.0, 127.3, 127.4, 127.9, 128.7, 129.0 and 129.5 (16 × CHarom), 132.8, 
137.2, 137.3, 139.0, 140.4, 141.7 and 150.7 (7 × Cquat,arom), 165.1 (C=O). 
IR (ATR, cm-1): νNH/OH = 3026; νC=O = 1602; νmax = 1556, 1519, 1495, 1461, 
1397, 1376, 1356, 1287, 1232, 1186, 1157, 1027, 945, 897, 823, 762, 732, 696. MS (70 eV): 
m/z (%) 465 (M++1, 100). HRMS (ESI) Anal. Calcd. for C29H25N2O2S 465.1631 [M+H]+, Found 
465.1640. 
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3-[(4-Hydroxycarbamoylphenyl)aminomethyl]indole 18 (77%) 
Yellow powder. Crystallization from CHCl3. Mp = 132.5 °C. 1H NMR (400 MHz, 
D6-DMSO): δ 4.40 (2H, d, J = 5.3 Hz, CH2NH); 6.52 (1H, t, J = 5.3 Hz, CH2NH); 
6.66 (2H, d, J = 8.8 Hz, 2 × CHarom); 6.97-7.01, 7.06-7.10 and 7.33-7.37 (1H, 1H 
and 2H, 3 × m, 4 × CHarom); 7.51 (2H, d, J = 8.8 Hz, 2 × CHarom); 7.62 (1H, d, J = 
7.8 Hz, CHarom); 8.66 (1H, s(br), OH); 10.74 and 10.93 (2 × 1H, 2 × s(br), 2 × 
NH). 13C NMR (100.6 MHz, D6-DMSO): δ 38.8 (CH2NH), 111.5 and 111.9 (3 × 
CHarom), 112.5 (Cquat,arom), 118.9 and 119.2 (2 × CHarom), 119.4 (Cquat,arom), 121.6 
and 124.3 (2 × CHarom), 127.1 (Cquat,arom), 128.6 (2 × CHarom), 136.8 and 151.8 (2 
× Cquat,arom), 165.5 (C=O). IR (ATR, cm-1): νNH/OH = 3407; νC=O = 1601; νmax = 2860, 
1567, 1524, 1456, 1419, 1346, 1319, 1284, 1241, 1160, 1034, 896, 826, 741. 
MS (70 eV): m/z (%) 282 (M++1, 20). HRMS (ESI) Anal. Calcd. for C16H16N3O2 282.1237 
[M+H]+, Found 282.1236. 
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5. Synthesis of potent and selective HDAC6 
inhibitors bearing a cyclohexane- or 
cycloheptane-annulated 1,5-benzothiazepine 
scaffold 
 
 
 
 
Abstract: In this chapter, the synthesis of ten new benzohydroxamic acids, constructed by 
employing the tetrahydrobenzothiazepine core as a privileged pharmacophoric unit, is 
described. This is the first report on the synthesis and isolation of octahydrodibenzothiazepines 
and octahydro-6H-benzocycloheptathiazepines, which were then used to develop a new class 
of HDAC6 inhibitors. Evaluations of their HDAC-inhibiting activity resulted in the identification 
of cis-N-(4-hydroxycarbamoylbenzyl)-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]-
thiazepine-10,10-dioxide and cis-N-(4-hydroxycarbamoylbenzyl)-7-trifluoromethyl-
1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]-thiazepine-10,10-dioxide as highly potent and 
selective HDAC6 inhibitors with activity in the low nanomolar range, which also show excellent 
selectivity on the enzymatic and cellular levels. Furthermore, four promising inhibitors were 
subjected to an Ames fluctuation assay, which revealed no mutagenic effects associated with 
these structures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parts of the work described in this chapter have been published: 
De Vreese, R.; Galle, L.; Depetter, Y.; Franceus, J.; Desmet, T.; Van Hecke, K.; Benoy, V.; Van Den Bosch, L.; D’hooghe, M. 
“Synthesis of potent and selective HDAC6 inhibitors bearing a cyclohexane- or cycloheptane-annulated 1,5-benzothiazepine 
scaffold” Chem. Eur. J. 2017, 23, 128-136. (I.F. 5.77) 
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5.1. Introduction 
Histone deacetylases (HDACs), together with histone acetyltransferases (HATs), regulate the 
acetylation status of histones and other proteins through lysine acetylation and 
deacetylation.121-123 This ability to modify the ε-amino tail of lysine residues allows the net 
charge of proteins to be changed, which makes HDACs valuable regulatory enzymes and 
explains the broad biological relevance of HDAC inhibitors, which have potential applications 
in the treatment of cancer, neurodegenerative diseases, depression, inflammatory diseases, 
and so forth.19,124-128 Unfortunately, commercially available pan-HDAC inhibitors, which inhibit 
multiple classes of zinc-dependent HDACs (class I: HDAC1, 2, 3, and 8; class IIa: HDAC4, 5, 
7, and 9; class IIb: HDAC6 and 10; class IV: HDAC11), have been reported to show toxic side 
effects, which hamper their broad clinical usability.129,130 Therefore, many efforts are now 
devoted to the design and discovery of isozyme-selective HDAC inhibitors, which potentially 
have fewer toxic side effects while maintaining pronounced specific activity. In this regard, 
HDAC6, a member of HDAC class IIb, has been identified as an interesting pharmaceutical 
target, since its activity is associated with biological pathways operating in neurodegenerative 
diseases, cancer, and immunology.8,10,79,101,105,131 Because of its cytoplasmic location, HDAC6 
has several non-histone substrates (α-tubulin, cortactin, etc.), and this makes it an interesting 
protein for studying the acetylation status of proteins in cells. Hence, several groups embarked 
on a journey to discover selective HDAC6 inhibitors, which resulted in a variety of new 
compounds with promising potencies, as exemplified by inhibitors 1-8 (Figure 
1).13,23,24,30,36,82,132-140 
 
Figure 1. A selection of selective HDAC6 inhibitors reported in the literature.13,24,36,82,132-135 
CHAPTER V  RESULTS AND DISCUSSION 
139 
Of these compounds, our attention was initially drawn by Tubastatin A (1), a highly potent and 
selective HDAC6 inhibitor accommodating a tricyclic protein-surface recognition group (cap 
group) and a benzohydroxamic acid linker/zinc-binding group. In our first attempts to pursue 
new potent and selective HDAC6 inhibitors, the nitrogen-containing tricyclic 
tetrahydropyridoindole group in 1 was replaced by a sulfur-containing 
tetrahydrothiopyranoindole framework in compounds 9 (Figure 2) to give several S-oxidized 
analogues (denoted Tubathians) demonstrating excellent in vitro potency, selectivity, and 
pharmacokinetics.104,141 The higher potency of these S-oxidized analogues with respect to 
HDAC6 was rationalized in silico through ligand-docking studies, which showed that sulfoxides 
9 (x=1) and sulfones 9 (x=2) can establish an additional hydrogen bond with the surface of 
HDAC6. Inspired by these interesting findings, the present work aimed at expanding our 
thiaheterocyclic library of HDAC6 inhibitors through the design of new structures bearing a 
benzohydroxamic acid functionality and an unprecedented sulfur-containing tricyclic cap 
group. In this respect, 1,5-benzothiazepine was identified and selected as a suitable privileged 
scaffold for elaboration into a new class of HDAC6 inhibitors. Indeed, 1,5-benzothiazepine is 
a well-known pharmacophore exhibiting a broad range of biological activities (Ca2+ channel 
blockers, CNS-acting agents, anti-platelet aggregation, anti-HIV, angiotensin-converting 
enzyme inhibitors, antimicrobial, antifungal, calmodulin antagonist, bradykinin receptor 
agonist, anticancer) and is present in several FDA-approved drugs (diltiazem, clentiazem, 
thiazesim, quetiapine hemifumarate, and clotiapine).142-144 Moreover, tetrahydro-1,5-
benzothiazepine contains a secondary amino group and an oxidizable sulfur atom, which 
makes it an ideal building block for further synthetic elaboration into functionalized target 
structures. Considering that the cap group in previously developed HDAC6 inhibitors consists 
of a tricyclic structure bearing an aromatic A ring, an azaheterocyclic B ring, and a saturated 
C ring, the main objective of the present study was the development of a new tricyclic scaffold 
by annulation of a cyclohexane or cycloheptane ring to the 1,5-benzothiazepine unit en route 
to the synthesis of a series of octahydrodibenzo- (n=1) or octahydro-6H-
benzocycloheptathiazepine-based (n=2) HDAC6 inhibitors 10. 
 
Figure 2. Synthesis rationale of this chapter. 
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5.2. Synthesis and biological evaluation of benzothiazepine-
based benzohydroxamic acids 
Only one report on the synthesis of tricyclic benzothiazepine 14 is available in the literature, 
starting from 2-(piperidin-1-ylmethyl)cyclohexan-1-one 11 or its HCl salt (Scheme 1).145 
Mannich base 11 was treated with 2-aminothiophenol 12 in refluxing benzene to furnish 
tricyclic imine 13 in 80% yield. After hydride reduction of cyclic imine 13, the corresponding 
thiazepine 14 was obtained, although no reaction details were provided in the original report. 
We made several attempts to reproduce these results by using the same or slightly modified 
protocols, but we could never obtain cyclic imine 13.  
 
Scheme 1. Synthesis of octahydrodibenzo[b,e][1,4]thiazepine 14 reported by Hideg et al.145 
 
Therefore, the literature procedure was modified, and 2-(tosyloxymethyl)cyclohexanone 17 
was evaluated as starting material for the synthesis of secondary amines 19a-c, bearing in 
mind the better leaving-group potential of the tosyloxy group compared to the piperidine ring 
(Scheme 2). To synthesize 2-(tosyloxymethyl)cyclohexanone 17, β-hydroxyketone 16a first 
had to be prepared from cyclohexanone 15a (n=1). To that end, a literature procedure using 
paraformaldehyde instead of 37% aqueous formaldehyde was applied, and 2-
(hydroxymethyl)cyclohexanone 16a was obtained in 30% yield after column 
chromatography.146 Ketone 16a was subsequently tosylated in pyridine with 1.5 equiv of p-
toluenesulfonyl chloride to provide 17 in 70% yield. We then attempted to produce imine 13 by 
heating tosylate 17 to reflux in toluene in the presence of 2-aminothiophenol 18a. Although the 
formation of tricyclic imine 13 could be observed by LC-MS, only a mixture of products was 
obtained after workup. To circumvent this problem, a one-pot reductive amination was 
performed by treatment of tosyloxyketone 17 with 2-aminothiophenol 18a in toluene under 
reflux for 45 min, after which the mixture was cooled to room temperature and 3 equiv of 
sodium cyanoborohydride were added. Then, the reaction medium was heated to boiling 
temperature, and after 1 h a mixture of diastereomers 19a1 and 19a2 was formed with a 
19a1/19a2 ratio of 65:35 (determined by 1H NMR and based on the correct assignment of the 
relative stereochemistry of diastereomer 19a1 by X-ray crystallography). 
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Separation and purification by column chromatography provided pure samples of both 
diastereomers 19a1 and 19a2 in 12% and 3% yield, respectively. The same protocol was used 
for the attempted synthesis of chloro- and trifluoromethyl-substituted benzothiazepines 19b,c, 
but no conversion toward products 19b,c could be realized. Moreover, during the synthesis of 
19a1,a2, β-tosyloxyketone 17 appeared to be unstable at elevated temperatures; therefore, 
the one-pot approach was expanded (scheme 2), and β-hydroxyketone 16a was converted to 
1,5-benzothiazepine 19avia β-tosyloxyketone 17 prepared in situ. It was necessary to quench 
the excess of p-toluenesulfonyl chloride with water to prevent side reactions with 2-
aminothiophenol. In this way, and after column-chromatographic purification, all six 
compounds 19a1-c2 (n=1) were obtained in pure form and acceptable yields (11-39%), taking 
into account the losses during chromatography resulting from similar Rf-values for all 
diastereomers. Moreover, a cycloheptanone derivative 19d (n=2) was assembled from seven-
membered β-hydroxyketone 16b, which was synthesized in 15% yield from cycloheptanone 
15b (n=2) in the same manner as β-hydroxyketone 16a, except the reaction solvent was 
changed from water to ethanol. In total, four pairs of diastereomers 19a1-d2 were thus 
prepared and isolated, whereby cis isomers 19a1-c1 were formed as the major products (d.r. 
cis/trans = 60-70:30-40, determined via 1H NMR spectroscopy), except for diastereomers 19d, 
which were obtained in a 1:1 ratio. The relative stereochemistry of heterotricyclic compounds 
19a1-d2 was secured by X-ray crystallography of 1,5-benzothiazepine 19a1 and based on the 
characteristic signals present in the 1H NMR spectra (CDCl3) of compounds 19a1-d2 (Figure 
3). 
 
 
Figure 3. X-ray structure of 1,5-benzothiazepine 19a1. 
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Scheme 2. Synthesis of 1,5-benzothiazepines 19a1-d2. 
 
In a following step, the tricyclic core fragment was connected to methyl 4-
(bromomethyl)benzoate by a nucleophilic substitution reaction at nitrogen (Scheme 3). To 
efficiently perform this transformation a broad range of reaction conditions was tested, 
including the use of different bases (K2CO3, Cs2CO3, triethylamine, NaH, KHMDS, LiHMDS, 
butyllithium), solvents (THF, CH3CN, DMF, DMSO), varying amounts of electrophile, and 
methyl 4-(iodomethyl)benzoate as a substitute electrophile; however, none of the tested 
conditions could affect the desired N-functionalization of 1,5-benzothiazepines 19a1-d2 to an 
extent greater than 50% (determined by 1H NMR, CDCl3). The highest conversion was 
obtained with 5 equiv of potassium carbonate in DMF at 120 °C after 16 h of reaction. To 
improve this degree of conversion, 1 equiv of methyl 4-(bromomethyl)benzoate was treated 
with 1,5-benzothiazepine 19a1 under neat conditions in the melt at 120 °C. After 2 h of reaction 
at 120 °C, 85% conversion was observed by 1H NMR spectroscopy (CDCl3). Unfortunately, 
due to the release of hydrogen bromide, traces of carboxylic acid were formed as well. Hence, 
the released hydrogen bromide was trapped by means of 3 equiv of potassium carbonate. 
Finally, an excellent conversion of 99% could be achieved, without the formation of any 
carboxylic acid, under neat reaction conditions for 3 h at 120 °C. By utilizing a similar strategy, 
esters 20a-d and 23a,b were also obtained from secondary amines 19a1-d1,b2 and d2 in 
acceptable yields after column chromatography by varying the reaction time and temperature 
(37-66%, Scheme 3). 
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Oxidized sulfur analogues (e.g., sulfoxides and sulfones) of hydroxamic acids 10 could be of 
great value, given our previous observations that sulfur-oxidized analogues show a higher 
affinity for HDAC6 than their non-oxidized counterparts due to additional hydrogen bonding.104 
First, compounds 19a1-c1 were converted to the corresponding sulfones by using 3 equiv of 
m-chloroperbenzoic acid (mCPBA, Scheme 3). In this way, three sulfones 21a-c were obtained 
in low to moderate yields (22-48%) after crystallization from ethanol. However, only 21a could 
be transformed into N-benzylated compound 22a by using a high reaction temperature (205 
°C). This could be attributed to the high melting points of 21a-c (234, 260 and 252 °C, 
respectively), and the fact that compounds 21b,c, as opposed to sulfone 21a, did not form a 
liquefied reaction mixture at 205 °C. In addition, the introduction of a strongly electron 
withdrawing sulfonyl group in ortho position with respect to the aromatic amino group results 
in a significant decrease in nucleophilicity of the nitrogen lone pair, which hinders smooth 
nucleophilic substitution. Higher reaction temperatures could possibly overcome this problem, 
but we chose to investigate the possibility to obtain sulfones 22b,c by direct oxidation of esters 
20b,c instead. Thus, esters 20a-c were subjected to the same conditions as cyclic sulfides 
19a1-c1, and as a result sulfones 22a-c (x=2) were produced and isolated in high to excellent 
yields after crystallization from ethanol (73-97 %, Scheme 3). This strategy is clearly superior 
to the previous approach, since higher yields were obtained for the oxidation step (22-48 
versus 73-97 %), and the sulfur derivatization takes place in a later stage of the synthesis 
pathway. When only 1 equiv of mCPBA was added to sulfide 20a at 20 °C and a reaction time 
of 2 h was applied, sulfoxide 22d (x=1) was obtained in 26% yield after crystallization from 
ethanol. The selective synthesis of these S-oxidized analogues provides the opportunity to 
compare the influence of the oxidation state of sulfur (sulfide, sulfoxide, or sulfone) on the 
biological profile of these compounds. 
CHAPTER V  RESULTS AND DISCUSSION 
144 
 
Scheme 3. Synthesis of the target hydroxamic acids 24-26. 
 
The synthesis of the cap group and the formation of the linker unit to furnish methyl esters 
20/22/23 starting from the diastereomerically pure cyclohexane- or cycloheptane-annulated 
1,5-benzothiazepine scaffolds 19a1-d1 and 19b2,d2 was described above. Hence, only the 
zinc complexing hydroxamic acid moiety had to be introduced through functional group 
conversion of esters 20/22/23 to complete the synthesis (Scheme 3). By using an excess of 
hydroxylamine and potassium hydroxide, methyl carboxylates 20/22/23 were converted to the 
target hydroxamic acids 24-26 in good yields (69-96 %, except 25% for 25a). Thus, ten 1,5-
benzothiazepine-containing benzohydroxamic acids 24-26 were prepared starting from 
tricyclic 1,5-benzothiazepines 19a1-d2. These compounds were biologically screened for their 
capability to selectively inhibit HDAC6. 
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First, hydroxamic acids 24-26 were tested for their in vitro potential to inhibit HDAC6 at a 
concentration of 10 µM. This preliminary evaluation revealed that all compounds 24-26 strongly 
inhibited HDAC6 at this concentration (96-100% inhibition, Table 1), and hence their IC50 
values toward HDAC6 were determined (Table 1). Compounds 24-26 are highly potent 
inhibitors with IC50 values in the nanomolar range, and the S-oxidized compounds 25 have 
even higher HDAC6 inhibitory activity than their non-oxidized analogues 24 (6.3-68 nM for 25 
and 33-650 nM for 24). The unsubstituted compounds 24a and 25a (R=H) have better IC50 
values (36 and 8.3 nM, respectively) than the trifluoromethyl-substituted compounds 24c and 
25c (R=CF3; 200 and 11 nM, respectively), and chlorinated compounds 24b and 25b (R=Cl) 
show the lowest, yet still submicromolar, activity (650 and 68 nM, respectively). Hydroxamic 
acid 24d containing a seven-membered ring shows the strongest inhibition of all sulfides (33 
nM), and trans isomers 26 show intermediate potency with respect to the other compounds. 
Table 1. In vitro enzyme inhibition data toward HDAC6 
Compound 24a 24b 24c 24d 25a 25b 25c 25d 26a 26b 
% inhibition of 
HDAC6 (10 µM) 
98 97 96 100 99 98 100 99 99 97 
HDAC6 IC50 
(µM) 
0.036 0.650 0.200 0.033 0.008 0.068 0.011 0.006 0.160 0.092 
 
Next, the selectivity of the five most potent HDAC6 inhibitors 24a,d and 25a,c,d was evaluated 
by determining the IC50 values toward the other zinc-dependent HDAC isoforms (HDAC1-11, 
Table 2). Sulfides 24a and d show similar selectivity profiles, with high micromolar IC50 values 
for HDAC1-5, 7, 9 and 10 (IC50 ≥ 25 µM) and low micromolar activities for HDAC8 and 11 (5.3-
6.7 µM and 1.2-1.5 µM, respectively). Sulfones 25a,c and sulfoxide 25d show a somewhat 
lower selectivity profile compared to compounds 24a,d, but still should be regarded as highly 
selective HDAC6 inhibitors. These compounds show low micromolar IC50 values for HDAC8 
and 11 (1.1-2.9 and 0.54-2.4 µM, respectively), and exhibit some affinity for HDAC1 (4.9-8.8 
µM). For HDAC2-5, 7, 9, and 10, higher IC50 values were obtained (IC50 ≥ 8.9 µM). In general, 
taking the low nanomolar (toward HDAC6) and (high) micromolar (toward all other HDAC 
isozymes) IC50 values into account, it is fair to conclude that tricyclic benzothiazepine-based 
hydroxamic acids 24a,d and 25a,c,d can be regarded as highly potent and selective HDAC6 
inhibitors suitable for further assessment. 
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Table 2. HDAC1-11 screening of selected compounds 24a,d and 25a,c,d (IC50 values in 
μM)a,b,c 
HDAC1-11 1 2 3 4 5 6 7 8 9 10 11 
24a >30 N.C. N.C. >30 27 0.036 >30 5.3 25 >30 1.5 
24d >30 N.C. >30 >30 >30 0.033 N.C. 6.7 >30 >30 1.2 
25a 8.1 24 24 >30 9.1 0.008 22 1.1 13 10 2.4 
25c 8.8 16 18 N.C. 22 0.011 15 2.0 >30 9.4 0.82 
25d 4.9 26 >30 >30 12 0.006 >30 2.9 8.9 14 0.54 
Tub A 16.4 >30 >30 >30 >30 0.015 >30 0.85 >30 >30 >30 
a Reference compound: Trichostatin A (HDAC6 IC50 = 0.0093 μM). 
b NC: IC50 value not calculable. Concentration-response curve 
shows less than 25% effect at the highest validated testing concentration (30 μM). >30: IC50 value above the highest test 
concentration. Concentration-response curve shows less than 50% effect at the highest validated testing concentration (30 μM). 
c Literature values for Tub A (Tubastatin A)13, caution should be taken when comparing the IC50 values of 24a, 24d, 25a, 25c and 
25d to the literature values for Tubastatin A. 
 
The obtained in vitro HDAC6 inhibition data also confirmed the suggested improved affinity of 
oxidized analogues 25 in contrast to their non-oxidized counterparts 24 and 26. This was 
further rationalized by in silico ligand docking and molecular dynamics simulation. Ligand 
docking was performed with a homology model of the functional domain of HDAC6 (Gly482-
Gly800). Three initial models were built from different templates (pdb entry 2VQW, 2VQQ, 
3C10), after which the best parts of each were combined into one hybrid model. The most 
likely conformation for both compounds was found to have the hydroxamate group positioned 
near the zinc ion, the linker in the tubular access channel and the cap group contacting the 
protein surface, which is in agreement with previous docking studies. The positions of the 
hydroxamate and linker groups in the docked structures of 24a and 25a are very similar, 
whereas the cap groups are rotated with respect to each other and form a few different apolar 
interactions. However, these do not result in significantly different binding energies (8.4 ± 0.5 
and 8.5 ± 0.5 kcal mol-1). Because docking alone could not explain the preference of HDAC6 
for inhibitors carrying a sulfone moiety in the cap group, a molecular dynamics simulation was 
run. The entrance to the active site is surrounded by a few highly flexible loops that may 
influence binding, but this dynamic structure was not taken into account during the ligand 
docking experiment. The simulation of the complex with HDAC6 inhibitor 25a revealed that a 
serine residue at position 564 has a clear tendency to move toward one of the oxygen atoms 
of the sulfone group, forming a hydrogen bond (Figure 4 and Figure 7 in the Experimental 
Details). This additional interaction might increase the affinity of HDAC6 for sulfone 25a and 
other sulfone ligands, and account for experimentally observed lower IC50 values. 
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Figure 4. Molecular dynamics simulation of compound 25a in HDAC6. 
 
To evaluate the effectiveness of these compounds on a cellular level, HDAC6 inhibitors 24a,d 
and 25a,c,d were tested in N2a cells, a neuronal cell line, to determine their potency toward 
HDAC6 and their selectivity against class I HDACs. This was done by using Western Blots to 
detect the acetylation status of known substrates of HDAC6 and class I HDACs, that is, α-
tubulin and histones, respectively. In vehicle-treated cells, α-tubulin is mainly present in its 
non-acetylated form (Figure 5A). Tubastatin A (1) was used as a positive control, as it 
increased the acetylation of α-tubulin at 1 µM (Figure 5A). Additionally, a sub-optimal 
concentration of 10 nM was chosen for the further characterization of the potency of the 
compounds. HDAC6 inhibitors 24a,d and 25a,c,d induced a significant increase in α-tubulin 
acetylation, as shown by Western Blot (Figure 5A, B). At the lower concentration of 10 nM, 25a 
and 25c induced a significant increase in the acetylation of α-tubulin (Figure 5A, C). Although 
for 25a,c,d a low nanomolar potency toward HDAC6 was measured in the enzymatic assay, 
25d failed to induce a similar increase in α-tubulin acetylation at 10 nM, as compared to 25a 
and 25c. This indicates that in this more complex cellular environment additional cues, such 
as cell permeability, may lower the inhibitory capacity of 25d.  
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Figure 5. Assessment of the potency of the HDAC6 inhibitors 24a,d and 25a,c,d in a neuronal cell line (N2a cells). A. Using 
Western Blot, the acetylation of α-tubulin was checked in N2a cells treated with different HDAC6 inhibitors. Tubastatin A (tubA) 
was used as a positive control. B,C. Densitometry was used to quantify the levels of acetylated α-tubulin relative to the amount of 
total α-tubulin present in the cells, treated with 1 µM or 10 nM of the HDAC6 inhibitors or tubastatin A. All values were normalized 
to the tubA-samples. N = 4. One-way Analysis-of-Covariance. *p<0.05, **p<0.01. 
 
To evaluate the specificity of these compounds, the acetylation of histone 3 was also 
determined by Western blot as an indicator of class I HDAC inhibition. The rationale for this 
experiment relates to the fact that Tubastatin A, as a known selective HDAC6 inhibitor, does 
not affect the acetylation of histones (Figure 6A). None of the HDAC6 inhibitors tested 
interfered with histone acetylation, as expected and desired (Figure 6A, B). This observation 
further confirms the selectivity of the compounds toward HDAC6. 
There is increasing concern about the potential genotoxicity of hydroxamic acids and their 
clinical use beyond oncology. Indeed, already in 1977 hydroxamic acids were reported to 
possibly exert genotoxic effects,107,108 and mutagenic activities have been documented for 
three approved hydroxamic acid HDAC inhibitors (Vorinostat, Belinostat, and Panobinostat), 
which is less of an issue in cancer therapy.147 Hence, compounds 24a,d and 25a,c were tested 
in the Ames fluctuation test against four strains of Salmonella typhimurium (TA98, TA100, 
TA1535, and TA1537), with and without the addition of rat liver S9 fraction. Surprisingly, no 
statistically significant positive effects could be detected in this in vitro reverse mutation assay 
at the concentrations tested (5, 10, 50 and 100 µM). This leads to the conclusion that our 
tricyclic benzothiazepine-based hydroxamic acids − in contrast to other hydroxamic acids 
described in the literature − may have a beneficial profile for further optimization studies toward 
new HDAC6 inhibitors for oncological and non-oncological applications. No bacterial 
cytotoxicity was observed at these concentrations, but other and more elaborate genotoxic 
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tests, for example, in vitro micronucleus and comet assays, should be performed in the future 
to exclude any potential genotoxicity of these compounds. 
 
Figure 6. Assessment of the selectivity of the HDAC6 inhibitors 24a,d and 25a,c,d in a neuronal cell line. A. Using Western Blot, 
the acetylation of histone 3 (H3) was checked in N2a cells treated with different HDAC6 inhibitors (1 µM). Tubastatin A (tubA) was 
used as a control and an antibody directed against histone 4 was used as a loading control. B. Densitometry was used to quantify 
the levels of acetylated histone 3 relative to the amount histone 4 present in the cells, treated with 1 µM of the HDAC6 inhibitors 
or tubastatin A. All values were normalized to the vehicle-samples. N = 5. One-way Analysis-of-Covariance. 
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5.3. Conclusions 
This is the first report on a detailed synthesis and isolation of both diastereomers of tricyclic 
cyclohexane- and cycloheptane-fused tetrahydrobenzothiazepines as new heterocyclic 
scaffolds, for which the correct structure was secured by X-ray crystallography. Starting from 
benzothiazepine building blocks 19a1-d2, ten benzohydroxamic acids 24-26 were efficiently 
synthesized and tested for their ability to inhibit HDAC6. In accordance with previous 
observations regarding the effect of S-oxidation, oxidized sulfur analogues 25 proved to be 
more potent HDAC6 inhibitors than their non-oxidized counterparts 24 and 26. This superior 
HDAC6 inhibitory activity of sulfoxide and sulfones 25 was supported by a molecular dynamics 
simulation, which revealed an additional hydrogen bond between the sulfur-bound oxygen 
atom and a serine residue. The most promising HDAC6 inhibitors 24a,d and 25a,c,d were 
further tested to assess their selectivity on both an enzymatic and a cellular level, and these 
studies revealed that compounds 25a (cis-N-(4-hydroxycarbamoylbenzyl)-
1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]thiazepine-10,10-dioxide) and 25c (cis-N-(4-
hydroxycarbamoylbenzyl)-7-trifluoromethyl-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]-
thiazepine-10,10-dioxide) demonstrated very potent activity and selectivity in both assays. 
Considering the reported genotoxicity of hydroxamic acids, four representatives 24a,d and 
25a,c were tested in an Ames fluctuation assay, which showed safe profiles in that respect. 
This new class of tricyclic tetrahydrobenzothiazepine hydroxamic acids can thus be considered 
to be a valuable pool of new lead structures for further medicinal chemistry optimization studies 
in the pursuit of new therapeutic HDAC6 inhibitors. 
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5.4. Experimental details 
5.4.1. Ligand docking 
All docking experiments were performed by the Centre for Industrial Biotechnology and 
Biocatalysis (Prof. Desmet). All manipulations were performed with the molecular modelling 
program YASARA and the YASARA/WHATIF twinset93,94 and the figure was created with 
PyMol v1.3.97 The HDAC6 sequence was obtained from the UniProt database 
(www.uniprot.org, UniProt entry Q9UBN7). To increase the accuracy of the model, the 
sequence was limited to the major functional domain of HDAC6 (Gly482-Gly800). Possible 
templates were identified by running 3 PSI-BLAST iterations to extract a position specific 
scoring matrix (PSSM) from UniRef90, and then searching the PDB for a match. To aid the 
alignment of the HDAC6 sequence and templates, and the modelling of the loops, a secondary 
structure prediction was performed, followed by multiple sequence alignments. All side chains 
were ionised or kept neutral according to their predicted pKa values. Initial models were 
created from different templates (pdb entry 2VQW, 2VQQ and 3C10), each with several 
alignment variations and up to hundred conformations tried per loop. After the side-chains had 
been built, optimised and fine-tuned, all newly modelled parts were subjected to a combined 
steepest descent and simulated annealing minimisation, i.e. the backbone atoms of aligned 
residues were kept fixed to preserve the folding, followed by a full unrestrained simulated 
annealing minimisation for the entire model. The final model was obtained as a hybrid model 
of the best parts of the initial models, and checked once more for anomalies like incorrect 
configurations or colliding side chains. Furthermore, it was structurally aligned with known 
HDAC crystal structures to check if the chelating residues and the zinc atom were arranged 
correctly.  
The HDAC inhibitor structures were created with YASARA Structure and energy minimised 
with the AMBER03 force field.95 The grid box used for docking had a dimension of 25 x 25 x 
25 angstrom, and comprised the entire catalytic cavity including the zinc ion and the outer 
surface of the active site entrance. Docking was performed with AutoDock VINA109 and default 
parameters. Ligands were allowed to freely rotate during docking. The first conformer from the 
cluster that has its zinc binding group in the vicinity of the zinc ion, was selected as the binding 
mode for further analysis.  
A 2ns MD simulation of the complex with HDAC6 inhibitor 25a was conducted using the 
md_run macro implemented within YASARA with the AMBER03 force field. The standard 
parameters were maintained. Snapshots of the simulation were taken at regular time intervals. 
Ligplot diagrams were made with LigPlot+ v1.4. 
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Figure 7. Ligplot diagram of compound 24a (black: carbon, blue: nitrogen; red: oxygen; yellow: sulfur; green: zinc ion, values in 
Å). 
 
 
Figure 8. Ligplot diagram of compound 25a (black: carbon, blue: nitrogen; red: oxygen; yellow: sulfur; green: zinc ion, values in 
Å). 
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5.4.2. Enzyme inhibition assays 
The enzyme inhibition assays were performed by Eurofins Cerep Panlabs. In vitro IC50 values 
were determined by using human recombinant HDAC1-11 and fluorogenic HDAC substrate.98 
 
5.4.3. Western Blots 
The Western Blots were performed by the Laboratory of Neurobiology and Vesalius Research 
Center, VIB (Prof. Van Den Bosch). Values represent the normalized ratio acetyl α-tubulin/α-
tubulin and acetyl histone 3/histone 4 against Tubastatin A (Tub A) in an established neuronal 
cell line (Neuro-2a cells: ATCC N° CCL-131). Neuro-2a cells are treated overnight with 
different concentrations of the HDAC6 inhibitors and the effect on the acetylation level of α-
tubulin is determined by using Western blot. 
 
5.4.3.1. Cell culture 
Mouse neuroblastoma (Neuro-2a) cells were grown in a 1:1 mix of D-MEM (Dulbecco's 
Modified Eagle Medium) and F12 medium supplemented with glutamax (Thermo Fisher 
Scientific, Waltham, MA, USA), 100 μg/ml streptomycin (Thermo Fisher Scientific), 100 U/ml 
penicillin (Thermo Fisher Scientific), 10% fetal calf serum (Greiner Bio-one, Kremsmünster, 
Austria), 1% non-essential amino acids (Thermo Fisher Scientific) and 1.6% NaHCO3 (Thermo 
Fisher Scientific) at 37 °C and 7.5% CO2. To split the cells, cells were washed with Versene 
(Thermo Fisher Scientific) and dissociated with 0.05% Trypsine-EDTA (Thermo Fisher 
Scientific). The Neuro-2a cells were treated overnight at 37°C with dosages ranging from 10 
nM up to 1 µM of either Tubastatin A (Destelbergen, Belgium) or the candidate HDAC6 
inhibitors. 
 
4.4.3.2. Western Blot 
For sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis, 
transfected cells were collected using the EpiQuik Total Histone Extraction Kit (EpiGentek, 
Farmingdale, NY, USA) according to manufacturer’s instructions. Protein concentrations were 
determined using microBCA kit (Thermo Fisher Scientific) according to manufacturer’s 
instructions. Before resolving the samples on a 12% SDS-PAGE gel, samples containing equal 
amounts of protein were supplemented with reducing sample buffer (Thermo Scientific) and 
boiled at 95 °C for 5 min. After electrophoresis, the proteins were transferred to a 
polyvinylidene difluoride (PVDF) membrane (Millipore Corp., Bedford, MA, USA). The non-
specific binding was blocked by incubation of the membrane in 5% bovine serum albumin 
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(BSA), diluted in Tris Buffered Saline Tween (TBST, 50 mM TRIS, 150 mM NaCl, 0,1% Tween-
20 (Applichem, Darmstadt, Duitsland) for 1h at room temperature followed by incubation with 
primary antibodies overnight. The antibodies, diluted in TBS-T, were directed against α-tubulin 
(1/5000, T6199, Sigma-Aldrich), and acetylated α-tubulin (1/5000, T6793 monoclonal, Sigma-
Aldrich). The secondary antibodies, coupled to horseradish peroxidase (anti-mouse or anti-
rabbit, 1/5000, Dako) were used. Blots were visualized by adding the ECF substrate 
(Enhanced Chemical Fluorescence, GE Healthcare, Uppsala, Sweden) and imaged with the 
ImageQuant_LAS 4000. A mild reblotting buffer (Millipore) was applied to strip the blots. 
ImageQuant TL version 7.0-software was used to quantify the blots. 
 
5.4.4. Ames fluctuation assays 
The Ames fluctuation assays were performed by Eurofins Cerep Panlabs. Wells that displayed 
bacteria growth due to the reversion of the histidine mutation (as judged by the ratio of OD430/ 
OD570 being greater than 1.0) are counted and recorded as positive counts. The significance 
of the positive counts between the treatment (in the presence of test compound) and the control 
(in the absence of test compound) are calculated using the one-tailed Fisher’s exact test. 
 
5.4.5. X-ray crystallography 
X-ray analysis was performed by the Department of Inorganic and Physical Chemistry (Ghent 
University, Prof. K. Van Hecke). For the structure of 19a1, X-ray intensity data were collected 
at 100 K on an Agilent Supernova Dual Source (Cu at zero) diffractometer equipped with an 
Atlas CCD detector using ω scans and CuKα (λ = 1.54184 Å) radiation. The images were 
interpreted and integrated with the program CrysAlisPro (Agilent Technologies, Agilent, 
CrysAlis Pro; Agilent Technologies UK Ltd, Yarnton, England: 2013). Using Olex2,148 the 
structure was solved by direct methods using the ShelXS structure solution program and 
refined by full-matrix least-squares on F2 using the ShelXL program package.149 Non-hydrogen 
atoms were anisotropically refined and the hydrogen atoms in the riding mode and isotropic 
temperature factors fixed at 1.2 times U(eq) of the parent atoms. The amine N-H hydrogen 
atom was unrestrained refined with an isotropic temperature factors fixed at 1.2 times U(eq) of 
the parent atom. The asymmetric unit has chirality at C3 (S) and C4 (R), but because of the 
centro-symmetric space group, also the inverse configuration is present in the crystal structure. 
Crystal data for compound 19a1. C13H17NS, M = 219.34, monoclinic, space group P21/c (No. 
14), a = 6.94615(11) Å, b = 15.8167(3) Å, c = 10.49482(20) Å, β = 103.9924(18), V = 
1118.80(4) Å3, Z = 4, T = 100 K, calc = 1.302 g cm-3, μ(Cu-Kα) = 2.261 mm-1, F(000) = 472, 
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10704 reflections measured, 2270 unique (Rint = 0.0317) which were used in all calculations. 
The final R1 was 0.0336 (I >2 (I)) and wR2 was 0.0891 (all data). 
CCDC 1494789 contains the supplementary crystallographic data for this molecule and can 
be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the 
Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44-
1223-336033; or deposit@ccdc.cam.ac.uk). 
 
5.4.6. Synthetic procedures and spectral data 
1H, 13C and 19F NMR spectra were recorded at 400, 100.6, and 376.5 MHz (Bruker Avance III) 
with CDCl3 or D6-DMSO as solvent and TMS as internal standard. Mass spectra were obtained 
with an Agilent 1100 mass spectrometer (70 eV). IR spectra were measured with a Spectrum 
One FTIR spectrophotometer. High-resolution ES mass spectra were obtained with an Agilent 
Technologies 6210 series time-of-flight instrument. Melting points of crystalline compounds 
were measured with a Kofler Bench, type WME Heizbank of Wagner & Munz. Column 
chromatography was performed on silica gel (SiO2), by using TLC plates and a UV lamp to 
identify the correct products. The purity of all tested compounds was assessed by 1H NMR 
analysis and/or HPLC analysis, which confirmed a purity of ≥95%. 
 
5.4.6.1. Synthesis of (hydroxymethyl)cycloalkanones 16 
General procedure: A mixture of cycloheptanone (22.43 g, 0.2 mol) and K2CO3 (0.41 g, 2.97 
mmol, 0.015 equiv) in 50 mL of ethanol was stirred vigorously at 40 °C while paraformaldehyde 
(6.42 g, 0.214 mol, 1.07 equiv.) was added. Stirring was continued for 2 h, after which the 
cooled reaction mixture was extracted with 100 mL ethyl acetate and 100 mL water. The 
aqueous phase was three times extracted with 50 mL of ethyl acetate, and then the combined 
organic fractions were dried (MgSO4) and concentrated under reduced pressure. The crude 
product was purified by column chromatography (SiO2) to give 2-(hydroxymethyl)cycloheptan-
1-one 16b (4.26 g, 0.03 mmol, 15 %). For the synthesis of 2-(hydroxymethyl)cyclohexan-1-
one 16a water was used as the reaction solvent. 
 
2-(Hydroxymethyl)cyclohexan-1-one 16a (30%) 
Spectral data of 1,2,4,9-tetrahydro-3-thia-9-azafluorene 16a correspond with data described 
in the literature.146 
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2-(Hydroxymethyl)cycloheptan-1-one 16b (15%) 
Colorless liquid. Purification by column chromatography (EtOAc/PE 1/1, Rf = 0.29). 
1H NMR (400 MHz, CDCl3): δ 1.31-1.44, 1.50-1.60, 1.65-1.77 and 1.79-1.96 (2H, 1H, 
2H and 3H, 4 × m, CH2CH2CH2CH2); 2.42-2.50 and 2.55-2.62 (2 × 1H, 2 × m, 
CH2C=O); 2.75-2.82 (1H, m, CHC=O); 3.61 (1H, d × d, J = 11.2, 4.2 Hz, (HCH)O); 
3.78 (1H, d × d, J = 11.2, 7.9 Hz, (HCH)O). 13C NMR (100.6 MHz, CDCl3): δ 23.8, 27.9, 29.1 
and 29.6 (CH2CH2CH2CH2), 43.9 (CH2C=O), 53.4 (CHC=O), 64.1 (CH2O), 217.4 (C=O). IR 
(ATR, cm-1): νOH = 3402; νC=O = 1688; νmax = 1454, 1377, 1344, 1217, 1167, 1138, 1057, 1015, 
984, 935, 920, 752. MS (70eV): m/z (%) 143 (M++1, 55). 
 
5.4.6.2. Synthesis of 2-tosyloxymethylcyclohexanone 17a 
In a 250 mL flask was added α-(hydroxymethyl)cyclohexanone 16a (6.70 g, 52 mmol) 
dissolved in 67 mL of pyridine. To this solution was added para-toluenesulfonyl chloride (14.87 
g, 78 mmol, 1.5 equiv.), and the reaction mixture was stirred at room temperature for 16 hours. 
The resulting mixture was quenched with 20 mL of ice water to convert the excess of para-
toluenesulfonyl chloride to para-toluenesulfonic acid. The mixture was dissolved in 100 mL of 
ethyl acetate, and washed with 100 mL of HCl solution (1M), 100 mL of water and 100 mL of 
a saturated brine solution, dried over magnesium sulfate, filtered and evaporated. This 
afforded pure α-(tosyloxymethyl)cyclohexanone 17a. (10.16 g, 36 mmol, 70 %). 
 
2-(Tosyloxymethyl)cyclohexanone 17a (70%) 
Colorless liquid. No purification needed. 1H NMR (400 MHz, CDCl3): δ 1.32-
1.43, 1.56-1.71, 1.89-1.93, 2.05-2.13, 2.24-2.33 and 2.35-2.40 (1H, 2H, 1H, 1H, 
2H and 1H, 6 × m, CH2CH2CH2CH2); 2.45 (3H, s, CH3); 2.67-2.75 (1H, m, 
CHC=O); 3.95 (1H, d × d, J = 10.1, 7.6 Hz, (HCH)O); 4.32 (1H, d × d, J = 10.1, 
5.0 Hz, (HCH)O); 7.35 and 7.80 (2 × 2H, 2 × d, J = 8.1 Hz, 4 × CHarom). 13C NMR (100.6 MHz, 
CDCl3): δ 21.7 (CH3), 24.5, 27.5, 30.9 and 42.0 (CH2CH2CH2CH2), 49.6 (CHC=O), 69.3 
(CH2O), 128.1 and 129.9 (4 × CHarom), 132.7 and 144.9 (2 × Carom,quat), 209.5 (C=O). IR (ATR, 
cm-1): νC=O = 1707; νS=O = 1173; νmax = 1450, 1357, 1188, 1121, 1096, 960, 863, 814, 791, 750, 
706, 644. MS (70eV): m/z (%) 300 (M++NH4, 100). HRMS (ESI) Anal. Calcd. for C14H22NO4S 
300.1264 [M+NH4]+, Found 300.1259. 
 
5.4.6.3. Synthesis of benzothiazepines 19 
General procedure: α-(Hydroxymethyl)cyclohexanone 16a (6.70 g, 52 mmol) was dissolved in 
pyridine (67 mL). p-Toluenesulfonyl chloride (14.87 g, 78 mmol, 1.5 equiv) was added to this 
solution, and the reaction mixture was stirred at room temperature for 16 h. Then, the reaction 
mixture was quenched with ice water (20 mL), after which 2-aminothiophenol (5.6 mL, 52 
mmol, 1 equiv) was added. After stirring for 45 min under reflux conditions, the reaction mixture 
was cooled, and sodium cyanoborohydride (9.80 g, 0.156 mol, 3 equiv) was added portion-
wise. After a reaction time of 1 h under reflux conditions, the reaction mixture was quenched 
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with water (20 mL) and then extracted with ethyl acetate (100 mL). The organic phase was 
washed with water (100 mL), a solution of NaCl (100 mL), and then dried with magnesium 
sulfate, filtered, and evaporated. Purification by column chromatography yielded cis-
1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]thiazepine 19a1 (1.94 g, 8.84 mmol, 17%) and 
trans-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]thiazepine 19a2 (1.25 g, 5.72 mmol, 
11%). 
 
cis-1,2,3,4,4a,5,11,11a-Octahydrodibenzo[b,e][1,4]thiazepine 19a1 (17%) 
Yellow crystals. Purification by column chromatography (EtOAc/PE 3/97, Rf = 
0.19). Mp = 82 °C. 1H NMR (400 MHz, CDCl3): δ 1.20-1.89 (9H, m, 
CH2CH2CH2CH2CH); 2.77 (1H, d × d, J = 14.3, 5.4 Hz, (HCH)S); 3.11 (1H, d × 
d, J = 14.3, 9.6 Hz, (HCH)S); 3.18 (1H, s(br), NH); 4.35 (1H, s(br), CHN); 6.55 
(1H, d × d, J = 7.7, 1.4 Hz, CHarom); 6.66 (1H, t × d, J = 7.7, 1.4 Hz, CHarom); 6.94 (1H, t × d, J 
= 7.7, 1.4 Hz, CHarom); 7.16 (1H, d × d, J = 7.7, 1.4 Hz, CHarom). 13C NMR (100.6 MHz, CDCl3): 
δ 20.8, 25.4, 27.8 and 32.6 (CH2CH2CH2CH2), 37.4 (CH2S), 40.2 (CHCH2S), 52.7 (CHN), 118.6 
and 119.4 (2 × CHarom), 122.6 (Carom,quat), 126.9 and 131.7 (2 × CHarom), 148.9 (Carom,quat). IR 
(ATR, cm-1): νNH = 2914; νmax = 1584, 1468, 1456, 1446, 1420, 1407, 1368, 1299, 1260, 1246, 
1238, 1124, 1041, 740, 716. MS (70eV): m/z (%) 220 (M++1, 100). HRMS (ESI) Anal. Calcd. 
for C13H18NS 220.1155 [M+H]+, Found 220.1162. 
 
trans-1,2,3,4,4a,5,11,11a-Octahydrodibenzo[b,e][1,4]thiazepine 19a2 (11%) 
White crystals. Purification by column chromatography (EtOAc/PE 3/97, Rf = 
0.11). Mp = 97 °C. 1H NMR (400 MHz, CDCl3): δ 1.09-1.19, 1.24-1.40, 1.44-
1.54 and 1.64-1.90 (1H, 2H, 1H and 5H, 4 × m, CH(CH2)4); 2.36 (1H, d × d, J 
= 14.4, 7.2 Hz, (HCH)S); 2.92-2.98 (1H, m, CHN); 3.14 (1H, d × d, J = 14.4, 
3.8 Hz, (HCH)S); 3.36 (1H, s(br), NH); 6.71 (1H, d, J = 7.6 Hz, CHarom); 6.78 (1H, t, J = 7.6 Hz, 
CHarom); 7.04 (1H, t × d, J = 7.6, 1.2 Hz, CHarom); 7.34 (1H, d × d, J = 7.6, 1.2 Hz, CHarom). 13C 
NMR (100.6 MHz, CDCl3): δ 25.5, 25.6, 32.0 and 34.6 ((CH2)4), 38.3 (CH2S), 47.4 (CHCH2S), 
60.5 (CHN), 120.2 and 120.8 (2 × CHarom), 125.5 (Carom,quat), 127.7 and 132.4 (2 × CHarom), 
150.2 (Carom,quat). IR (ATR, cm-1): νNH = 3332; νmax  = 2915, 2848, 1471, 1442, 1367, 1302, 1238, 
1072, 870, 746, 732, 717. MS (70eV): m/z (%) 220 (M++1, 100). HRMS (ESI) Anal. Calcd. for 
C13H18NS 220.1155 [M+H]+, Found 220.1162. 
 
cis-7-Chloro-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]thiazepine 19b1 (16%) 
White crystals. Purification by column chromatography (EtOAc/PE 3/97, Rf 
= 0.19). Mp = 132 °C. 1H NMR (400 MHz, CDCl3): δ 1.20-1.32, 1.34-1.45, 
1.51-1.61 and 1.65-1.88 (1H, 1H, 3H and 4H, 4 × m, CH(CH2)4); 2.78 (1H, 
d × d, J = 14.4, 5.7 Hz, (HCH)S); 3.09 (1H, d × d, J = 14.4, 9.8 Hz, (HCH)S); 
3.22 (1H, s(br), NH); 4.46 (1H, s(br), CHN); 6.54 (1H, d, J = 2.2 Hz, CHarom); 6.61 (1H, d × d, J 
= 8.3, 2.2 Hz, CHarom); 7.04 (1H, d, J = 8.3 Hz, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 20.6, 
25.3, 27.8 and 32.3 ((CH2)4), 37.5 (CH2S), 40.1 (CHCH2S), 52.4 (CHN), 117.9 and 119.0 (2 x 
CHarom), 120.7 and 132.1 (2 × Carom,quat), 132.5 (CHarom), 149.7 (Carom,quat). IR (ATR, cm-1): νNH = 
3387; νmax = 2926, 1582, 1564, 1469, 1436, 1372, 1309, 1245, 1229, 1098, 1050, 1008, 846, 
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780. MS (70eV): m/z (%) 254 (M++1, 100). HRMS (ESI) Anal. Calcd. for C13H17ClNS 254.0765 
[M+H]+, Found 254.0764. 
 
trans-7-Chloro-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]thiazepine 19b2 (13%) 
White crystals. Purification by column chromatography (EtOAc/PE 3/97, Rf 
= 0.11). Mp = 158 °C. 1H NMR (400 MHz, CDCl3): δ 1.12-1.51, 1.64-1.75 
and 1.81-1.89 (4H, 3H and 2H, 3 × m, CH(CH2)4); 2.36 (1H, d × d, J = 14.4, 
6.5 Hz, (HCH)S); 3.06-3.13 (1H, m, CHN); 3.20 (1H, d × d, J = 14.4, 4.1 Hz, 
(HCH)S); 3.37 (1H, s(br), NH); 6.69 (1H, d, J = 2.1 Hz, CHarom); 6.72 (1H, d × d, J = 8.2, 2.1 
Hz, CHarom); 7.21 (1H, d, J = 8.2 Hz, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 25.4, 25.5, 31.9 
and 34.3 ((CH2)4), 38.2 (CH2S), 47.0 (CHCH2S), 60.0 (CHN), 119.5 and 120.4 (2 x CHarom), 
123.4 and 132.8 (2 × Carom,quat), 133.2 (CHarom), 150.9 (Carom,quat). IR (ATR, cm-1): νNH = 3318; 
νmax = 2931, 1574, 1462, 1443, 1234, 1098, 1073, 893, 870, 799, 754, 716. MS (70eV): m/z 
(%) 254/6 (M++1, 100). HRMS (ESI) Anal. Calcd. for C13H17ClNS 254.0765 [M+H]+, Found 
254.0781.  
 
cis-7-Trifluoromethyl-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]thiazepine 19c1 
(38%) 
White crystals. Purification by column chromatography (EtOAc/PE 3/97, 
Rf = 0.5). Mp = 120 °C. 1H NMR (400 MHz, CDCl3): δ 1.20-1.52, 1.56-
1.62, 1.67-1.77 and 1.81-1.87 (3H and 3 × 2H, 4 × m, CH(CH2)4); 2.80 
(1H, d × d, J = 14.4, 5.8 Hz, (HCH)S); 3.19 (1H, d × d, J = 14.4, 10.2 Hz, 
(HCH)S); 3.34 (1H, s(br), NH); 4.59 (1H, s(br), CHN); 6.73 (1H, s, CHarom); 6.84 (1H, d, J = 8.0 
Hz, CHarom); 7.18 (1H, d, J = 8.0 Hz, CHarom). 19F NMR (376.5 MHz, CDCl3): δ (-62.8) (s). 13C 
NMR (100.6 MHz, CDCl3): δ 20.5, 25.3, 28.0 and 32.1 ((CH2)4), 37.2 (CH2S), 39.5 (CHCH2S), 
52.1 (CHN), 114.4 (q, J = 3.7 Hz, CHarom), 115.3 (q, J = 3.7 Hz, CHarom), 124.1 (q, J = 271.9 
Hz, F3Cquat), 126.1 (Carom,quat), 128.8 (q, J = 32.3 Hz, F3CCarom,quat), 131.7 (CHarom), 148.5 
(Carom,quat). IR (ATR, cm-1): νNH = 3398, νmax = 2935, 1471, 1334, 1310, 1296, 1232, 1164, 1131, 
1108, 1086, 1037, 1009, 856, 810. MS(70eV): m/z (%) 288 (M++1, 100). HRMS (ESI) Anal. 
Calcd. for C14H17F3NS 288.1028 [M+H]+, Found 288.1025. 
 
trans-7-Trifluoromethyl-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]thiazepine 19c2 
(14%) 
White crystals. Purification by column chromatography (EtOAc/PE 3/97, Rf 
= 0.36). Mp = 132 °C. 1H NMR (400 MHz, CDCl3): δ 1.21-1.53, 1.65-1.79 
and 1.84-1.93 (4H, 3H and 2H, 3 x m, CH(CH2)4); 2.43 (1H, d x d, J = 14.5, 
5.4 Hz, (HCH)S); 3.32-3.38 (1H, m, CHN); 3.44 (1H, d x d, J = 14.5, 4.5 
Hz, (HCH)S); 3.51 (1H, s(br), NH); 6.87 (1H, d, J = 1.3 Hz, CHarom); 6.96 (1H, d × d, J = 8.1, 
1.3 Hz, CHarom); 7.37 (1H, d, J = 8.1 Hz, CHarom). 19F NMR (376.5 MHz, CDCl3): δ (-62.7) (s). 
13C NMR (100.6 MHz, CDCl3): δ 25.4, 25.5, 31.7 and 34.0 ((CH2)4), 38.0 (CH2S), 46.4 
(CHCH2S), 59.5 (CHN), 115.8 (q, J = 3.7 Hz, CHarom), 116.4 (q, J = 3.7 Hz, CHarom), 123.8 (q, 
J = 271.9 Hz, F3Cquat), 128.4 (Carom,quat), 129.5 (q, J = 32.3 Hz, F3CCarom,quat), 132.4 (CHarom), 
149.5 (Carom,quat). IR (ATR, cm-1): νNH = 3329; νmax = 2937, 1330, 1292, 1236, 1162, 1140, 1123, 
1108, 1090, 1080, 1055, 735. MS (70eV): m/z (%) 288 (M++1, 100). HRMS (ESI) Anal. Calcd. 
for C14H17F3NS 288.1028 [M+H]+, Found 288.1033. 
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cis-6,6a,7,8,9,10,11,11a-Octahydro-12H-benzo[b]cyclohepta[e][1,4]thiazepine 19d1 
(15%) 
Yellow crystals. Purification by column chromatography (EtOAc/PE 2/98, Rf = 
0.27). Mp = 87 °C. 1H NMR (400 MHz, CDCl3): δ 1.23-1.44, 1.58-1.76, 1.83-
1.89, 2.03-2.11 and 2.18-2.25 (5H, 2H, 2H, 1H and 1H, 5 × m, 
CH2CH2CH2CH2CH2CH); 2.73 (1H, d × d, J = 14.1, 5.4 Hz, (HCH)S); 2.92 (1H, 
s(br), NH); 3.51 (1H, d × d, J = 14.1, 11.4 Hz, (HCH)S); 4.58-4.64 (1H, m, CHN); 6.48 (1H, d 
× d, J = 7.9, 1.3 Hz, CHarom); 6.65 (1H, t × d, J = 11.3, 1.3 Hz, CHarom); 6.91 (1H, t × d, J = 11.3, 
1.3 Hz, CHarom); 7.09 (1H, d × d, J = 7.9, 1.3 Hz, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 23.3, 
28.6, 29.3, 31.1 and 35.6 (CH2CH2CH2CH2CH2), 37.0 (CH2S), 45.0 (CHCH2S), 56.3 (CHN), 
118.2 and 119.2 (2 × CHarom), 121.1 (Carom,quat), 126.3 and 130.5 (2 × CHarom), 147.9 (Carom,quat). 
IR (ATR, cm-1): νNH = 3375; νmax = 1584, 1458, 1312, 1300, 1246, 1120, 743, 721, 446. MS 
(70eV): m/z (%) 234 (M++1, 100). 
 
trans-6,6a,7,8,9,10,11,11a-Octahydro-12H-benzo[b]cyclohepta[e][1,4]thiazepine 19d2 
(12%) 
Yellow crystals. Purification by column chromatography (EtOAc/PE 2/98, Rf = 
0.21). Mp < 50 °C. 1H NMR (400 MHz, CDCl3): δ 1.54-1.64, 1.66-1.75 and 
1.91-2.00 (6H, 3H and 2H, 3 × m, CH2CH2CH2CH2CH2CH); 2.45 (1H, d × d, J 
= 14.0, 3.5 Hz, (HCH)S); 3.13 (1H, s(br), NH); 3.71-3.77 (1H, m, CHN); 3.88 
(1H, d × d, J = 14.0, 4.3 Hz, (HCH)S); 6.49 (1H, d × d, J = 7.8, 1.4 Hz, CHarom); 6.65-6.69 (1H, 
m, CHarom); 6.90-6.94 (1H, m, CHarom); 7.11 (1H, d × d, J = 7.8, 1.4 Hz, CHarom). 13C NMR (100.6 
MHz, CDCl3): δ 24.8, 26.4, 26.6, 32.8 and 37.6 (CH2CH2CH2CH2CH2), 39.2 (CH2S), 45.2 
(CHCH2S), 61.3 (CHN), 118.5 and 119.7 (2 × CHarom), 121.4 (Carom,quat), 126.4 and 130.6 (2 × 
CHarom), 148.3 (Carom,quat). IR (ATR, cm-1): νNH = 3395; νmax = 1585, 1466, 1414, 1371, 1302, 
1244, 1082, 1069, 745, 669, 420. MS (70eV): m/z (%) 234 (M++1, 100). 
 
5.4.6.4. Synthesis of sulfones and sulfoxide 21 and 22 
General procedure: m-Chloroperbenzoic acid (≤77%, 3.36 g, 15 mmol) was added to a solution 
of 19a1 (1.10 g, 5 mmol) in THF (50 mL) at 0 °C, and the mixture was stirred at room 
temperature for 2 h. The solvent was then removed in vacuo and the residue was dissolved in 
ethyl acetate (100 mL). Afterwards, the solution was washed with saturated aqueous sodium 
sulfite (30 mL), water (30 mL) and brine (2 × 30 mL), and dried with anhydrous magnesium 
sulfate. Filtration to remove the drying agent and removal of the solvent in vacuo afforded 
crude sulfone 21a, which was purified by recrystallization from EtOH to provide pure cis-
1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]thiazepine-10,10-dioxide 21a (0.27 g, 1.05 
mmol, 22%). For the synthesis of sulfoxide 22d, only 1 equiv of m-chloroperbenzoic acid was 
added and the reaction temperature was maintained at -20 °C. 
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cis-1,2,3,4,4a,5,11,11a-Octahydrodibenzo[b,e][1,4]thiazepine-10,10-dioxide 21a (22%) 
Light brown crystals. Recrystallization from EtOH. Mp = 234 °C. 1H NMR (400 
MHz, CDCl3): δ 1.30-1.69 and 1.75-1.90 (5H and 3H, 2 × m, (CH2)4); 2.29-
2.38 (1H, m, CHCH2S); 3.19 (1H, d × d, J = 15.0, 10.6 Hz, (HCH)S); 3.37 
(1H, d × d, J = 15.0, 6.2 Hz, (HCH)S); 3.99 (1H, s(br), NH); 4.22 (1H, s(br), 
CHN); 6.75 (1H, d × d, J = 7.9, 0.7 Hz, CHarom ); 6.92 (1H, t × d , J = 7.9, 0.7 
Hz, CHarom); 7.28 (1H, t × d, J = 7.9, 1.4 Hz, CHarom); 7.91 (1H, d × d, J = 7.9, 1.4 Hz, CHarom). 
13C NMR (100.6 MHz, CDCl3): δ 20.8, 24.7, 27.2 and 31.3 ((CH2)4), 37.7 (CHCH2S), 54.2 
(CHN), 58.1 (CH2S), 118.7 and 119.2 (2 × CHarom), 126.9 (CHarom), 128.8 (Carom,quat), 132.8 
(CHarom), 146.8 (Carom,quat). IR (ATR, cm-1): νNH = 3349; νmax = 2932, 1599, 1478, 1279, 1252, 
1177, 1123, 1098, 932, 788, 764, 642. MS (70eV): m/z (%) 252 (M++1, 100). HRMS (ESI) Anal. 
Calcd. for C13H18NO2S 252.1053 [M+H]+, Found 252.1042. 
 
cis-7-Chloro-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]thiazepine-10,10-dioxide 
21b (48%) 
White crystals. Recrystallization from EtOH. Mp = 260 °C. 1H NMR (400 
MHz, CDCl3): δ 1.25-1.53, 1.60-1.67 and 1.73-1.87 (3H, 2H and 3H, 3 × m, 
(CH2)4); 2.29-2.31 (1H, m, CHCH2S); 3.12 (1H, d × d, J = 15.0, 10.6 Hz, 
(HCH)S); 3.36 (1H, d × d, J = 15.0, 6.4 Hz, (HCH)S); 4.02 (1H, s(br), NH); 
4.25 (1H, s(br), CHN); 6.75 (1H, d, J = 1.5 Hz, CHarom); 6.85 (1H, d × d, J = 
8.6, 1.5 Hz, CHarom); 7.81 (1H, d, J = 8.6 Hz, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 20.6, 
24.7, 27.1 and 31.2 ((CH2)4), 37.7 (CHCH2S), 54.0 (CHN), 58.1 (CH2S), 118.0 and 119.3 (2 x 
CHarom), 127.2 (Carom,quat), 128.5 (CHarom), 138.7 and 147.8 (2 × Carom,quat). IR (ATR, cm-1): νNH = 
3346; νmax = 2938, 1588, 1451, 1283, 1253, 1126, 1094, 1007, 864, 783. MS (70eV): m/z (%) 
286/8 (M++1, 100). HRMS (ESI) Anal. Calcd. for C13H17ClNO2S 286.0663 [M+H]+, Found 
286.0669. 
 
cis-7-Trifluoromethyl-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]thiazepine-10,10-
dioxide 21c (45%) 
White crystals. Recrystallization from EtOH. Mp = 252 °C. 1H NMR (400 
MHz, CDCl3): δ 1.30-1.55, 1.63-1.70, 1.76-1.84 and 1.88-1.92 (3H, 2H, 2H 
and 1H, 4 × m, (CH2)4); 2.29-2.38 (1H, m, CHCH2S); 3.14 (1H, d × d, J = 
15.1, 10.7 Hz, (HCH)S); 3.40 (1H, d × d, J = 15.1, 6.4 Hz, (HCH)S); 4.19 
(1H, s(br), NH); 4.32 (1H, s(br), CHN); 7.00 (1H, s, CHarom); 7.10 (1H, d , J 
= 8.4 Hz, CHarom); 8.00 (1H, d, J = 8.4 Hz, CHarom). 19F NMR (376.5 MHz, CDCl3): δ (-63.6) (s). 
13C NMR (100.6 MHz, CDCl3): δ 20.5, 24.8, 27.1 and 31.3 ((CH2)4), 37.9 (CHCH2S), 54.1 
(CHN), 58.1 (CH2S), 115.2 (q, J = 3.4 Hz, CHarom), 115.5 (q, J = 3.4 Hz, CHarom), 123.0 (q, J = 
273.0 Hz, F3Cquat), 128.2 (CHarom), 131.1 (Carom,quat), 134.6 (q, J = 33.0 Hz, F3CCarom,quat), 147.0 
(Carom,quat). IR (ATR, cm-1): νNH = 3350; νmax = 2933, 1346, 1305, 1286, 1261, 1173, 1138, 1122, 
1087, 1007, 884, 808, 784, 688. MS (70eV): m/z (%) 320 (M++1, 100). HRMS (ESI) Anal. 
Calcd. for C14H17F3NO2S 320.0927 [M+H]+, Found 320.0939. 
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cis-N-(4-Methoxycarbonylbenzyl)-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]-
thiazepine-10,10-dioxide 22a (73%) 
White powder. Recrystallization from EtOH. Mp = 78 °C. 1H NMR (400 
MHz, CDCl3): δ 0.83-0.94, 1.01-1.13, 1.17-1.28, 1.37-1.48, 1.57-1.60 and 
1.70-1.74 (3 × 1H, 3H, 2 × 1H, 6 × m, (CH2)4); 2.68-2.71 (1H, m, 
CHCH2SO2); 3.06-3.12 (2H, m, (HCH)S and CHN); 3.42 (1H, d × d, J = 
14.7, 13.4 Hz, (HCH)S); 3.91 (3H, s, CH3O); 4.38 and 4.59 (2 × 1H, 2 × d, 
J = 14.1 Hz, CH2N); 7.16-7.19 (2H, m, CHarom); 7.48-7.52 (1H, m, CHarom); 
7.69 (2H, d, J = 8.2 Hz, CHarom); 8.02-8.05 (3H, m, CHarom). 13C NMR (100.6 
MHz, CDCl3): δ 19.9, 23.8, 26.2 and 31.2 ((CH2)4); 35.1 (CHCH2S); 52.1 
(CH3O); 53.1 (CH2S); 58.9 (CH2N); 62.0 (CHN); 122.9, 123.8, 128.3 and 
128.5 (5 × CHarom); 129.4 (Carom,quat,); 129.9 and 134.2 (3 × CHarom); 135.4, 144.2 and 147.6 (3 
× Carom,quat); 167.0 (C=O). IR (ATR, cm-1): νC=O = 1717; νmax = 2931, 1478, 1438, 1308, 1277, 
1152, 1131, 1071, 878, 770, 743, 702. MS (70eV): m/z (%) 400 (M++1, 100). HRMS (ESI) Anal. 
Calcd. for C22H26NO4S 400.1577 [M+H]+, Found 400.1581. 
 
cis-7-Chloro-N-(4-methoxycarbonylbenzyl)-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e]-
[1,4]thiazepine-10,10-dioxide 22b (97%) 
White powder. Recrystallization from EtOH. Mp = 182 °C. 1H NMR (400 
MHz, CDCl3): δ 0.91-0.98, 1.03-1.12, 1.39-1.51 and 1.73-1.76 (1H, 2H, 
4H and 1H,  4 × m, (CH2)4); 2.64-2.67 (1H, m, CHCH2S); 3.07-3.13 (2H, 
m, (HCH)S and CHN); 2.38-2.45 (1H, m, (HCH)S); 3.92 (3H, s, CH3O); 
4.35 and 4.56 (2 × 1H, 2 × d, J = 13.9 Hz, CH2N); 7.11-7.15 (2H, m, 
CHarom); 7.66 (2H, d, J = 8.2 Hz, CHarom); 7.96 (1H, d, J = 9.1 Hz, 
CHarom); 8.05 (2H, d, J = 8.2 Hz, CHarom). 13C NMR (100.6 MHz, CDCl3): 
δ 19.8, 23.8, 26.2 and 31.2 ((CH2)4), 34.9 (CHCH2S), 52.1 (CH3O), 52.9 
(CH2S), 58.8 (CH2N), 62.3 (CHN), 123.0, 123.8, 128.5, 129.6, 129.6 
and 130.0 (7 × CHarom), 133.6, 140.5, 143.4 and 148.9 (4 × Carom,quat), 167.0 (C=O). IR (ATR, 
cm-1): νC=O = 1716; νmax  = 2930, 1579, 1309, 1278, 1151, 1132, 1094, 1071, 889, 792, 760, 
729. MS (70eV): m/z (%) 434/436 (M++1, 100). HRMS (ESI) Anal. Calcd. for C22H25ClNO4S 
434.1187 [M+H]+, Found 434.1170. 
 
cis-N-(4-Methoxycarbonylbenzyl)-7-trifluoromethyl-1,2,3,4,4a,5,11,11a-octahydro-
dibenzo[b,e][1,4]thiazepine-10,10-dioxide 22c (96%) 
White powder. Recrystallization from EtOH. Mp = 174 °C. 1H NMR 
(400 MHz, CDCl3): δ 0.84-0.95, 1.02-1.13, 1.19-1.29, 1.40-1.50, 1.58-
1.62 and 1.73-1.77 (1H, 1H, 1H, 3H, 1H and 1H, 6 × m, (CH2)4); 2.66-
2.70 (1H, m, CHCH2S); 3.12-3.18 (2H, m, (HCH)S and CHN); 3.40-
3.47 (1H, m, (HCH)S); 3.92 (3H, s, CH3O); 4.43 and 4.61 (2 × 1H, 2 × 
d, J = 13.9 Hz, (HCH)N); 7.39 (1H, s, CHarom); 7.41 (1H, d, J = 8.2 Hz, 
CHarom); 7.67 (2H, d, J = 8.2 Hz, CHarom); 8.05 (2H, d, J = 8.2 Hz, 
CHarom); 8.16 (1H, d, J = 8.2 Hz, CHarom). 13C NMR (100.6 MHz, CDCl3): 
δ 19.8, 23.9, 26.2 and 31.2 ((CH2)4), 34.9 (CHCH2S), 52.1 (CH3O), 
52.7 (CH2S), 58.9 (CH2N), 62.3 (CHN), 119.4 (q, J = 3.5 Hz, CHarom), 120.4 (q, J = 3.5 Hz, 
CHarom), 123.2 (q, J = 273.3 Hz, F3Cquat), 128.6 and 129.2 (3 × CHarom), 129.7 (Carom,quat), 130.0 
(2 × CHarom), 136.0 (q, J = 32.8 Hz, F3CCarom,quat), 138.1, 143.2 and 148.3 (3 × Carom,quat), 166.9 
(C=O). 19F NMR (376.5 MHz, CDCl3): δ (-63.2) (s). IR (ATR, cm-1): νC=O = 1728; νmax = 2941, 
1428, 1312, 1279, 1172, 1156, 1134, 1086, 1068, 1057, 892, 835, 795. MS (70eV): m/z (%) 
468 (M++1, 100). HRMS (ESI) Anal. Calcd. for C23H25F3NO4S 468.1451 [M+H]+, Found 
468.1470. 
CHAPTER V  RESULTS AND DISCUSSION 
162 
cis-N-(4-Methoxycarbonylbenzyl)-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]-
thiazepine-10-oxide 22d (26%) 
White powder. Recrystallization from EtOH. Mp = 182 °C. 1H NMR (400 
MHz, CDCl3): δ 0.61-0.72, 1.01-1.22, 1.32-1.35, 1.41-1.50 and 1.60-1.70 
(1H, 2H, 1H, 2H and 2H, 5 × m, (CH2)4); 2.52-2.56 (1H, m, CHCH2S); 2.85-
2.90 (2H, m, (HCH)S and CHN); 3.30 (1H, t, J = 13.0 Hz, (HCH)S); 3.92 
(3H, s, CH3O); 4.34 and 4.47 (2 × 1H, 2 × d, J = 14.0 Hz, (HCH)N); 7.13 
(1H, d, J = 7.5 Hz, CHarom); 7.32 (1H, t, J = 7.5 Hz, CHarom); 7.38 (1H, t × d, 
J = 7.5, 1.5 Hz, CHarom); 7.51 (2H, d, J = 8.2 Hz, CHarom); 7.79 (1H, d × d, 
J = 7.5, 1.5 Hz, CHarom); 8.01 (2H, d, J = 8.2 Hz, CHarom). 13C NMR (100.6 
MHz, CDCl3): δ 20.1, 24.3, 26.3 and 32.2 ((CH2)4), 36.7 (CHCH2S), 52.1 
(CH3O), 53.1 (CH2S), 58.7 (CH2N), 60.3 (CHN), 122.6, 124.0, 124.8 and 128.4 (5 × CHarom), 
129.4 (Carom,quat), 129.8 and 130.3 (3 × CHarom), 140.5, 144.1 and 144.8 (3 × Carom,quat), 166.9 
(C=O). IR (ATR, cm-1): νC=O = 1713; νmax = 2927, 1279, 1110, 1070, 1036, 1024, 948, 860, 774, 
761, 747, 702. MS (70eV): m/z (%) 384 (M++1, 100). HRMS (ESI) Anal. Calcd. for C22H26NO3S 
384.1628 [M+H]+, Found 384.1639. 
 
5.4.6.5. Synthesis of esters 20 and 23 
General procedure: A flask (25 mL) was charged with 19a1 (219 mg, 1 mmol), potassium 
carbonate (415 mg, 3 mmol, 3 equiv), and methyl 4-(bromomethyl)benzoate (687 mg, 3 mmol, 
3 equiv). The reaction mixture (neat) was placed under nitrogen atmosphere and stirred for 3 
h at 120 °C, after which it was cooled to room temperature and dissolved in ethyl acetate (20 
mL). After extraction with water (20 mL) and saturated brine (15 mL), the organic fraction was 
dried with magnesium sulfate, filtered, and evaporated. The excess of methyl 4-
(bromomethyl)benzoate was removed by vacuum distillation (0.5 mbar, 120 °C), and further 
purification was done by means of column chromatography, which afforded pure cis-N-(4-
methoxycarbonylbenzyl)-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]-thiazepine 20a (235 
mg, 0.64 mmol, 64%). When reversed-phase column chromatography was used, no initial 
high-vacuum distillation had to be performed. Different reaction temperatures were necessary 
to synthesize the different compounds to obtain a liquefied melt (120-150 °C). 
 
cis-N-(4-Methoxycarbonylbenzyl)-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]-
thiazepine 20a (64%) 
Very viscous colorless liquid. Purification by column chromatography 
(EtOAc/PE 3/97, Rf = 0.04). 1H NMR (400 MHz, CDCl3): δ 0.86-0.97, 1.07-
1.32, 1.36-1.45, 1.49-1.53, 1.57-1.63 and 1.67-1.72 (1H, 3H, 1H, 1H, 1H 
and 1H, 6 × m, CH2CH2CH2CH2); 2.29-2.36 (1H, m, CHCH2S); 2.42 (1H, 
d × d, J = 14.1, 3.2 Hz, (HCH)S); 2.93 (1H, d × d, J = 14.1, 12.8 Hz, 
(HCH)S); 3.02 (1H, d × t, J = 12.6, 3.9 Hz, CHN); 3.93 (3H, s, CH3O); 4.42 
and 4.56 (2 × 1H, 2 × d, J = 14.4 Hz, CH2N); 6.95 (1H, t × d, J = 7.7, 1.3 
Hz, CHarom); 7.08 (1H, d × d, J = 7.7, 1.3 Hz, CHarom); 7.22 (1H, t × d, J = 
7.7, 1.6 Hz, CHarom); 7.59 (1H, d × d, J = 7.7, 1.6 Hz, CHarom); 7.65 and 8.02 (2 × 2H, 2 × d, J 
= 8.3 Hz, 4 × CHarom). 13C NMR (100.6 MHz, CDCl3): δ 20.3, 24.2 and 26.6 (CH2CH2CH2CH2), 
30.6 (CH2S), 32.7 (CH2CH2CH2CH2), 42.5 (CHCH2S), 52.0 (CH3O), 59.3 (CH2N), 61.3 (CHN), 
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122.8, 123.6, 128.2 and 128.3 (5 × CHarom), 128.9 (Carom,quat), 129.6 (2 × CHarom), 132.1 
(Carom,quat), 133.3 (CHarom), 145.7 and 152.0 (2 × Carom,quat), 167.1 (C=O). IR (ATR, cm-1): νC=O = 
1717; νmax = 1610, 1474, 1433, 1414, 1314, 1274, 1218, 1192, 1173, 1139, 1099, 1019, 878, 
857, 767, 754, 739, 700. MS (70eV): m/z (%) 368 (M++1, 100). HRMS (ESI) Anal. Calcd. for 
C22H26NO2S 368.1679 [M+H]+, Found 368.1680. 
 
cis-7-Chloro-N-(4-methoxycarbonylbenzyl)-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e]-
[1,4]thiazepine 20b (58%) 
Light brwon oil. Purification by column chromatography (EtOAc/PE 
3/97, Rf = 0.19). 1H NMR (400 MHz, CDCl3): δ 0.88-0.95, 1.08-1.23, 
1.29-1.40, 1.46-1.57 and 1.67-1.70 (1H, 2H, 2H, 2H and 1H, 5 × m, 
(CH2)4); 2.25-2.28 (1H, m, CHCH2S); 2.37 (1H, d × d, J = 14.2, 3.2 Hz, 
(HCH)S); 2.84-2.90 (1H, m, (HCH)S); 2.99 (1H, d × t, J = 12.5, 3.6 Hz, 
CHN); 3.90 (3H, s, CH3O); 4.36 and 4.48 (2 × 1H, 2 × d, J = 14.3 Hz, 
(HCH)N); 6.90 (1H, d × d, J = 8.2, 2.0 Hz, CHarom); 7.03 (1H, d, J = 2.0 
Hz, CHarom); 7.47 (1H, d, J = 8.2 Hz, CHarom); 7.61 (2H, d, J = 8.1 Hz 
CHarom); 8.01 (2H, d, J = 8.1 Hz, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 20.2, 24.2 and 26.5 
((CH2)3), 30.3 (CH2S), 32.7 (CH2), 42.5 (CHCH2S), 52.0 (CH3O), 59.3 (CH2N), 61.4 (CHN), 
122.8, 123.5 and 128.2 (4 × CHarom), 129.1 (Carom,quat), 129.7 (2 × CHarom), 130.3 and 133.9 (2 
× Carom,quat), 134.0 (CHarom), 145.0 and 153.3 (2 × Carom,quat), 167.0 (C=O). IR (ATR, cm-1): νC=O 
= 1718; νmax = 2923, 1570, 1470, 1434, 1275, 1098, 898, 886, 807, 759, 731. MS (70eV): m/z 
(%) 402/4 (M++1, 100). HRMS (ESI) Anal. Calcd. for C22H25ClNO2S 402.1289 [M+H]+, Found 
402.1297. 
 
cis-N-(4-Methoxycarbonylbenzyl)-7-trifluoromethyl-1,2,3,4,4a,5,11,11a-octahydro-
dibenzo[b,e][1,4]thiazepine 20c (66%) 
Light brown oil. Purification by column chromatography (EtOAc/PE 
3/97, Rf = 0.10). 1H NMR (400 MHz, CDCl3): δ 0.87-0.94, 1.08-1.21, 
1.30-1.43, 1.46-1.52, 1.56-1.61 and 1.68-1.72 (1H, 2H, 2H, 1H, 1H 
and 1H, 6 × m, (CH2)4); 2.27-2.30 (1H, m, CHCH2S); 2.43 (1H, d × d, 
J = 14.2, 3.4 Hz, (HCH)S); 2.92 (1H, d × d, J = 14.2, 12.9 Hz, (HCH)S); 
3.04 (1H, d × t, J = 12.5, 3.9 Hz, CHN); 3.91 (3H, s, CH3O); 4.43 and 
4.53 (2 × 1H, 2 × d, J = 14.2 Hz, (HCH)N); 7.15-7.17 (1H, m, CHarom); 
7.24-7.25 (1H, m, CHarom); 7.61 (2H, d, J = 8.2 Hz, CHarom); 7.66 (1H, 
d, J = 7.8 Hz, CHarom); 8.01 (2H, d, J = 8.2 Hz, CHarom). 19F NMR (376.5 MHz, D6-DMSO): δ (-
62.5) (s). 13C NMR (100.6 MHz, CDCl3): δ 20.2, 24.3 and 26.5 ((CH2)3), 30.2 (CH2S), 32.6 
(CH2), 42.2 (CHCH2S), 52.1 (CH3O), 59.4 (CH2N), 61.2 (CHN), 119.2 (q, J = 3.7 Hz, CHarom), 
119.8 (q, J = 3.7 Hz, CHarom), 124.0 (q, J = 272.4 Hz, F3Cquat), 128.2 (2 × CHarom), 129.2 
(Carom,quat), 129.7 (2 × CHarom), 129.9 (q, J = 35.0 Hz, F3CCarom,quat), 133.5 (CHarom), 136.2, 144.8 
and 152.5 (3 × Carom,quat), 167.1 (C=O). IR (ATR, cm-1): νC=O = 1719; νmax = 2926, 1322, 1276, 
1164, 1118, 1089, 900, 890, 824, 761, 735. MS (70eV): m/z (%) 436 (M++1, 100). 
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cis-N-(4-Methoxycarbonylbenzyl)-6,6a,7,8,9,10,11,11a-octahydro-12H-benzo[b]-
cyclohepta[e][1,4]thiazepine 20d (56%) 
Very viscous yellow oil. Purification by column chromatography 
(EtOAc/PE 3/97, Rf = 0.21). 1H NMR (400 MHz, CDCl3): δ 1.14-1.38 and 
1.50-1.75 (5H and 5H, 2 × m, CH2CH2CH2CH2CH2); 2.29-2.37 (1H, m, 
CHCH2S); 2.57 (1H, d × d, J = 13.9, 10.0 Hz, (HCH)S); 2.86 (1H, d × d, J 
= 13.9, 2.9 Hz, (HCH)S); 3.12-3.16 (1H, m, CHN); 3.91 (3H, s, CH3O); 
4.37 and 4.50 (2 × 1H, 2 × d, J = 14.6 Hz, CH2N); 6.88 (1H, t × d, J = 7.6, 
1.4 Hz, CHarom); 6.98 (1H, d × d, J = 7.6, 1.4 Hz, CHarom); 7.13 (1H, t × d, 
J = 7.6, 1.4 Hz, CHarom); 7.41 (1H, d × d, J = 7.6, 1.4 Hz, CHarom); 7.56 and 
8.00 (2 × 2H, 2 × d, J = 8.2 Hz, 4 × CHarom). 13C NMR (100.6 MHz, CDCl3): δ 24.4, 26.7, 28.0, 
29.2 and 31.8 (CH2CH2CH2CH2CH2), 33.2 (CH2S), 44.1 (CHCH2S), 52.0 (CH3O), 59.1 (CH2N), 
63.9 (CHN), 122.4, 123.2, 127.4 and 128.2 (5 × CHarom), 129.0 (Carom,quat), 129.7 (2 × CHarom), 
131.1 (Carom,quat), 131.9 (CHarom), 145.5 and 150.7 (2 × Carom,quat), 167.1 (C=O). IR (ATR, cm-1): 
νC=O = 1717; νmax = 1474, 1454, 1431, 1412, 1271, 1098, 1016, 964, 851, 752, 735, 700, 457. 
MS (70eV): m/z (%) 382 (M++1, 100). 
 
trans-7-Chloro-N-(4-methoxycarbonylbenzyl)-1,2,3,4,4a,5,11,11a-octahydrodibenzo-
[b,e][1,4]thiazepine 23a (47%) 
White powder. Purification by automated reverse-phase column 
chromatography (CH3CN/H2O 30-100%). Mp = 134 °C. 1H NMR (400 
MHz, CDCl3): δ 1.04-1.25, 1.58-1.70, 1.75-1.78 and 2.00-2.05 (4H, 3H, 
1H and 1H, 4 × m, (CH2)4CH); 2.82 and 2.96 (2H and 1H, 2 × s(br), 
CH2S and CHN); 3.90 (3H, s, CH3O); 4.40 (2H, s, CH2N); 6.85-6.90 
(2H, m, CHarom); 7.19 (1H, d, J = 8.2 Hz, CHarom); 7.54 and 7.99 (2 × 
2H, 2 × d, J = 8.1 Hz, CHarom). 13C NMR (100.6 MHz, CDCl3): δ 25.5, 
25.8, 26.5 and 33.0 ((CH2)4, 1 × s(br)), 34.8 (CH2S, s(br)), 41.1 
(CHCH2S, s(br)), 52.0 (CH3O), 54.3 (CH2N, s(br)), 65.6 (CHN, s(br)), 123.3 (2 × CHarom, s(br)), 
127.9 (2 × CHarom, s(br)), 129.0 (Carom,quat), 129.8 (2 × CHarom and Carom,quat), 131.7 (CHarom), 
132.3, 144.9 and 148.7 (3 × Carom,quat, 2 × s(br)), 167.0 (C=O). IR (cm-1): C=O = 1717; max  = 
1431, 1273, 1173, 1096, 1018, 860, 750, 702, 592. MS (70eV): m/z (%) 402/4 (M++1, 100). 
 
trans-N-(4-Methoxycarbonylbenzyl)-6,6a,7,8,9,10,11,11a-octahydro-12H-benzo[b]-
cyclohepta[e][1,4]thiazepine 23b (37%) 
Very viscous yellow oil. Purification by automated reverse-phase column 
chromatography (CH3CN/H2O 30-100%). 1H NMR (400 MHz, CDCl3): δ 
1.18-1.28, 1.34-1.57, 1.61-1.75, 1.81-1.88 and 2.08-2.14 (2H, 5H, 2H, 1H 
and 1H, 5 × m, CH2CH2CH2CH2CH2CH); 2.66 (1H, d, J = 11.4 Hz, 
(HCH)S); 2.84 (1H, t, J = 9.1 Hz, CHN); 3.17 (1H, d × d, J = 11.4, 8.8 Hz, 
(HCH)S); 3.88 (3H, s, CH3O); 4.28 and 4.37 (2 × 1H, 2 × d, J = 14.8 Hz, 
CH2N); 6.88 (1H, t × d, J = 7.6, 1.3 Hz, CHarom); 6.94 (1H, d × d, J = 7.6, 
1.3 Hz, CHarom); 7.01 (1H, t × d, J = 7.6, 1.3 Hz, CHarom); 7.21 (1H, d × d, 
J = 7.6, 1.3 Hz, CHarom); 7.55 and 7.98 (2 × 2H, 2 × d, J = 8.2 Hz, 4 × CHarom). 13C NMR (100.6 
MHz, CDCl3): δ 24.6, 25.5, 26.0, 28.6 and 34.9 (CH2CH2CH2CH2CH2), 36.7 (CH2S), 44.8 
(CHCH2S), 52.0 (CH3O), 55.9 (CH2N), 67.0 (CHN), 123.8, 123.9, 126.1 and 128.5 (5 × CHarom), 
128.9 (Carom,quat), 129.6 and 129.7 (3 × CHarom), 132.4 (Carom,quat), 145.2 and 147.3 (2 × Carom,quat), 
167.1 (C=O). IR (ATR, cm-1): νC=O = 1715; νmax = 1472, 1431, 1269, 1098, 1016, 951, 853, 748, 
731, 700, 459. MS (70eV): m/z (%) 382 (M++1, 100). 
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5.4.6.6. Synthesis of hydroxamic acids 24-26 
General procedure: Compound 20a (0.367 g, 1 mmol) was dissolved in THF (10 mL), and to 
this solution was added hydroxylamine (50% in water, 6.1 mL, 100 mmol, 100 equiv) followed 
by potassium hydroxide in methanol (4M, 12.5 mL, 50 mmol). The resulting mixture was stirred 
for 10 min at room temperature before it was poured into a saturated aqueous solution of 
NaHCO3 (10 mL). This aqueous solution was extracted twice with ethyl acetate, after which 
the combined organic fractions were washed with water (10 mL) and a saturated brine solution 
(10 mL), dried (MgSO4), filtered, and evaporated. Purification by crystallization from EtOH 
yielded cis-N-(4-hydroxycarbamoylbenzyl)-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]-
thiazepine 24a (0.287 g, 0.78 mmol, 78%) as a white powder. 
 
cis-N-(4-Hydroxycarbamoylbenzyl)-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]-
thiazepine 24a (78%) 
White powder. Recrystallization from EtOH. Mp = 116.5 °C. 1H NMR (400 
MHz, D6-DMSO): δ 0.73-0.83, 1.11-1.21, 1.30-1.38, 1.44-1.47 and 1.59-
1.62 (1H, 3H, 1H, 1H and 2H, 5 × m, CH2CH2CH2CH2); 2.19-2.23 (1H, m, 
CHCH2S); 2.47 (1H, d × d, J = 13.8, 3.4 Hz, (HCH)S); 2.83 (1H, t, J = 13.8 
Hz, (HCH)S); 3.04 (1H, d × t, J = 12.5, 3.6 Hz, CHN); 4.43 and 4.53 (2 × 
1H, 2 × d, J = 14.8 Hz, CH2N); 6.90 (1H, t × d, J = 7.6, 1.3 Hz, CHarom); 
7.15 (1H, d × d, J = 7.6, 1.3 Hz, CHarom); 7.22 (1H, t × d, J = 7.6, 1.3 Hz, 
CHarom); 7.47 (1H, d × d, J = 7.6, 1.3 Hz, CHarom); 7.54 and 7.68 (2 × 2H, 
2 × d, J = 8.1 Hz, 4 × CHarom); 9.03 (1H, s(br), OH); 11.13 (1H, s(br), NH). 13C NMR (100.6 
MHz, D6-DMSO): δ 20.2, 24.4 and 26.5 (CH2CH2CH2CH2), 29.9 (CH2S), 32.6 
(CH2CH2CH2CH2), 42.6 (CHCH2S), 58.8 (CH2N), 61.6 (CHN), 122.9, 124.0, 127.2, 128.2 and 
128.8 (7 × CHarom), 131.5 and 131.9 (2 × Carom,quat), 133.3 (CHarom), 143.8 and 152.0 (2 × 
Carom,quat), 164.4 (C=O). IR (ATR, cm-1): νNH/OH = 3206; νC=O = 1614; νmax = 1568, 1472, 1448, 
1314, 1218, 1140, 1122, 1096, 1030, 1015, 897, 878, 844, 764, 738. MS (70eV): m/z (%) 369 
(M++1, 100). HRMS (ESI) Anal. Calcd. for C21H25N2O2S 369.1631 [M+H]+, Found 369.1638. 
 
cis-7-Chloro-N-(4-hydroxycarbamoylbenzyl)-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e]-
[1,4]thiazepine 24b (73%) 
White powder. Recrystallization from EtOH. Mp = 111 °C. 1H NMR 
(400 MHz, D6-DMSO): δ 0.77-0.86, 1.14-1.24, 1.30-1.36, 1.48-1.51 
and 1.57-1.61 (1H, 3H, 1H, 1H and 2H, 5 × m, (CH2)4); 2.18-2.21 (1H, 
m, CHCH2S); 2.46-2.51 (1H, m, (HCH)S); 2.80-2.87 (1H, m, (HCH)S); 
3.05-3.10 (1H, m, CHN); 4.44 and 4.53 (2 × 1H, 2 × d, J = 14.7 Hz, 
(HCH)N); 6.95 (1H, d × d, J = 8.1, 2.1 Hz, CHarom); 7.18 (1H, d, J = 2.1 
Hz, CHarom); 7.46-7.51 (3H, m, CHarom); 7.69 (2H, d, J = 8.1 Hz, CHarom); 
8.99 (1H, s(br), OH); 11.16 (1H, s(br), NH). 13C NMR (100.6 MHz, D6-
DMSO): δ 20.2, 24.3 and 26.5 ((CH2)3), 29.5 (CH2S), 32.5 (CH2), 42.6 (CHCH2S), 58.8 (CH2N), 
61.9 (CHN), 122.7, 123.7, 127.1 and 128.1 (5 × CHarom), 130.1, 132.0 and 133.2 (3 × Carom,quat,), 
134.4 (2 × CHarom), 143.2 and 153.5 (2 × Carom,quat), 164.2 (C=O). IR (ATR, cm-1): νNH/OH = 3204; 
νC=O = 1613; νmax = 2923, 2853, 1613, 1568, 1550, 1470, 1449, 1378, 1097, 899, 886, 806, 
729 . MS (70eV): m/z (%) 403/5 (M++1, 100). HRMS (ESI) Anal. Calcd. for C21H24ClN2O2S 
403.1242 [M+H]+, Found 403.1247. 
CHAPTER V  RESULTS AND DISCUSSION 
166 
cis-N-(4-Hydroxycarbamoylbenzyl)-7-trifluoromethyl-1,2,3,4,4a,5,11,11a-octahydro-
dibenzo[b,e][1,4]thiazepine 24c (91%) 
White powder. Recrystallization from EtOH. Mp = 92 °C. 1H NMR (400 
MHz, D6-DMSO): δ 0.77-0.83, 1.16-1.22, 1.32-1.38, 1.48-1.51 and 
1.58-1.61 (1H, 3H, 1H, 1H and 2H, 5 × m, (CH2)4); 2.20-2.23 (1H, m, 
CHCH2S); 2.53-2.56 (1H, m, (HCH)S); 2.84-2.91 (1H, m, (HCH)S); 
3.10-3.13 (1H, m, CHN); 4.51 and 4.58 (2 × 1H, 2 × d, J = 14.7 Hz, 
(HCH)N); 7.21 (1H, d, J = 7.8 Hz, CHarom); 7.39 (1H, s, CHarom); 7.52 
(2H, d, J = 8.0 Hz, CHarom); 7.66-7.68 (3H, m, CHarom); 9.08 (1H, s(br), 
OH); 11.18 (1H, s(br), NH). 13C NMR (100.6 MHz, D6-DMSO): δ 20.1, 
24.4 and 26.4 ((CH2)3), 29.3 (CH2S), 32.4 (CH2), 42.3 (CHCH2S), 58.8 (CH2N), 61.8 (CHN), 
119.2 (q, J = 3.8 Hz, CHarom), 120.1 (q, J = 3.8 Hz, CHarom), 124.5 (q, J = 272.2 Hz, F3Cquat), 
127.2 and 128.3 (4 × CHarom), 129.2 (q, J = 31.6 Hz, F3CCarom,quat), 131.8 (Carom,quat), 133.9 
(CHarom), 136.4, 143.3 and 152.5 (3 × Carom,quat), 164.5 (C=O). 19F NMR (376.5 MHz, D6-DMSO): 
δ (-60.9) (s). IR (ATR, cm-1): νNH/OH = 3208; νC=O = 1614; νmax = 2925, 1422, 1322, 1164, 1120, 
1090, 1039, 1016, 899, 824, 733. MS (70eV): m/z (%) 437 (M++1, 100). HRMS (ESI) Anal. 
Calcd. for C22H24F3N2O2S 437.1505 [M+H]+, Found 437.1514. 
 
cis-N-(4-Hydroxycarbamoylbenzyl)-6,6a,7,8,9,10,11,11a-octahydro-12H-
benzo[b]cyclohepta[e][1,4]thiazepine 24d (95%) 
White powder. Recrystallization from ethanol. Mp = 95 °C. 1H NMR (400 
MHz, D6-DMSO): δ 1.12-1.26, 1.28-1.35 and 1.48-1.71 (4H, 1H and 5H, 
3 × m, (CH2)5); 2.27-2.33 (1H, m, CHCH2S); 2.51-2.57 (1H, m, (HCH)S); 
2.91-2.95 (1H, m, (HCH)S); 3.18-3.23 (1H, m, CHN); 4.39 and 4.50 (2 × 
1H, 2 × d, J = 14.8 Hz, CH2N); 6.85 (1H, t, J = 7.4 Hz, CHarom); 7.06 (1H, 
d, J = 7.4 Hz, CHarom); 7.12 (1H, t, J = 7.4 Hz, CHarom); 7.31 (1H, d, J = 7.4 
Hz, CHarom); 7.50 and 7.69 (2 × 2H, 2 × d, J = 8.1 Hz, 4 × CHarom); 8.98 
(1H, s(br), OH); 11.14 (1H, s(br), NH). 13C NMR (100.6 MHz, D6-DMSO): 
δ 24.7, 26.3, 28.0, 29.2 and 31.5 ((CH2)5), 32.7 (CH2S), 44.1 (CHCH2S), 58.4 (CH2N), 64.3 
(CHN), 122.6, 123.7, 127.3, 127.8 and 128.3 (7 × CHarom), 130.7 (Carom,quat), 131.7 (CHarom), 
131.8 (Carom,quat), 143.7 and 150.5 (2 × Carom,quat), 164.6 (C=O). IR (ATR, cm-1): νNH/OH = 3179; 
νC=O = 1611; νmax = 1566, 1474, 1454, 1300, 1275, 1215, 1101, 1013, 895, 847, 733, 457. MS 
(70eV): m/z (%) 383 (M++1, 100). HRMS (ESI) Anal. Calcd. for C22H27N2O2S 383.1788 [M+H]+, 
Found 383.1789. 
 
cis-N-(4-Hydroxycarbamoylbenzyl)-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]-
thiazepine-10,10-dioxide 25a (25%) 
White powder. Recrystallization from EtOH. Mp = 242 °C. 1H NMR (400 
MHz, D6-DMSO): δ 0.82-0.91, 1.15-1.24, 1.38-1.40 and 1.61-1.64 (1H, 
3H, 2H and 2H, 4 × m, (CH2)4); 2.55-2.58 (1H, m, CHCH2S); 3.13-3.16 
(1H, m, CHN); 3.27-3.30 (1H, m, (HCH)S); 3.57-3.64 (1H, m, (HCH)S); 
4.46 and 4.62 (2 × 1H, 2 × d, J = 14.8 Hz, (HCH)N); 7.16-7.20 (1H, m, 
CHarom); 7.28-7.30 (1H, m, CHarom); 7.52-7.56 (1H, m, CHarom), 7.62-7.69 
(4H, m, 4 × CHarom); 7.83-7.86 (1H, m, CHarom); 9.00 (1H, s(br), OH); 11.13 
(1H, s(br), NH). 13C NMR (100.6 MHz, D6-DMSO): δ 19.7, 23.7, 26.4 and 
31.0 ((CH2)4), 35.6 (CHCH2S), 52.3 (CH2S), 58.3 (CH2N), 63.0 (CHN), 
122.8, 124.5, 127.2, 127.7 and 128.5 (7 x CHarom), 131.9 (Carom,quat), 134.5 (CHarom), 135.4, 
143.2 and 147.6 (3 × Carom,quat), 164.5 (C=O). IR (ATR, cm-1): νNH/OH = 3298; νC=O = 1644; νmax 
= 2926, 2854, 1478, 1464, 1446, 1307, 1273, 1243, 1150, 1126, 1092, 1070, 1015, 876, 768, 
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745. MS (70eV): m/z (%) 401 (M++1, 100). HRMS (ESI) Anal. Calcd. for C21H25N2O4S 401.1530 
[M+H]+, Found 401.1540.  
 
cis-7-Chloro-N-(4-hydroxycarbamoylbenzyl)-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e]-
[1,4]thiazepine-10,10-dioxide 25b (79%) 
White powder. Recrystallization from EtOH. Mp = 222 °C. 1H NMR 
(400 MHz, D6-DMSO): δ 0.92-0.98, 1.15-1.23, 1.34-1.44 and 1.61-
1.64 (1H, 3H, 2H and 2H, 4 × m, (CH2)4); 2.52-2.54 (1H, m, CHCH2S); 
3.16-3.19 (1H, m, CHN); 3.32-3.37 (1H, m, (HCH)S); 3.63-3.70 (1H, 
m, (HCH)S); 4.47 and 4.65 (2 × 1H, 2 × d, J = 14.8 Hz, (HCH)N); 7.24 
(1H, d, J = 8.4 Hz, CHarom); 7.35 (1H, s, CHarom); 7.60 (2H, d, J = 7.9 
Hz, CHarom); 7.70 (2H, d, J = 7.9 Hz, CHarom); 7.83 (1H, d, J = 8.4 Hz, 
CHarom); 9.08 (1H, s(br), OH); 11.20 (1H, s(br), NH). 13C NMR (100.6 
MHz, D6-DMSO): δ 19.6, 23.7, 26.4 and 31.0 ((CH2)4), 35.4 (CHCH2S), 
52.0 (CH2S), 58.2 (CH2N), 63.4 (CHN), 122.7, 124.3, 127.3, 128.4 and 129.5 (7 x CHarom), 
132.1, 134.1, 139.2, 142.6 and 149.0 (5 × Carom,quat), 164.3 (C=O). IR (ATR, cm-1): νNH/OH = 
3271; νC=O = 1641; νmax = 2927, 2856, 1579, 1555, 1450, 1382, 1307, 1287, 1150, 1130, 1093, 
885, 793, 728. MS (70eV): m/z (%) 435/7 (M++1, 100). HRMS (ESI) Anal. Calcd. for 
C21H24ClN2O4S 435.1140 [M+H]+, Found 435.1123. 
 
cis-N-(4-Hydroxycarbamoylbenzyl)-7-trifluoromethyl-1,2,3,4,4a,5,11,11a-octahydro-
dibenzo[b,e][1,4]thiazepine-10,10-dioxide 25c (69%) 
White powder. Recrystallization from EtOH. Mp = 228 °C. 1H NMR 
(400 MHz, D6-DMSO): δ 0.88-0.97, 1.16-1.24, 1.36-1.44 and 1.60-
1.67 (1H, 3H, 2H and 2H, 4 × m, (CH2)4); 2.54-2.57 (1H, m, CHCH2S); 
3.20-3.25 (1H, m, CHN); 3.42 (1H, d × d, J = 15.2, 3.2 Hz, (HCH)S); 
3.71-3.78 (1H, m, (HCH)S); 4.56 and 4.72 (2 × 1H, 2 × d, J = 14.7 
Hz, (HCH)N); 7.53 (1H, d, J = 8.2 Hz, CHarom); 7.57 (1H, s, CHarom); 
7.61 (2H, d, J = 8.2 Hz, CHarom); 7.69 (2H, d, J = 8.2 Hz, CHarom); 8.04 
(1H, d, J = 8.2 Hz, CHarom); 9.02 (1H, s(br), OH); 11.17 (1H, s(br), 
NH). 13C NMR (100.6 MHz, D6-DMSO): δ 19.5, 23.8, 26.4 and 30.9 
((CH2)4), 35.4 (CHCH2S), 51.8 (CH2S), 58.2 (CH2N), 63.4 (CHN), 119.2 (q, J = 3.6 Hz, CHarom), 
121.2 (q, J = 3.6 Hz, CHarom), 123.8 (q, J = 273.5 Hz, F3Cquat), 127.3, 128.5 and 129.2 (5 × 
CHarom), 132.0 (Carom,quat), 134.2 (q, J = 32.0 Hz, F3CCarom,quat), 138.6, 142.6 and 148.3 (3 × 
Carom,quat), 164.4 (C=O). 19F NMR (376.5 MHz, D6-DMSO): δ (-61.7) (s). IR (ATR, cm-1): νNH/OH 
= 3300; νC=O = 1644; νmax  = 2928, 1432, 1393, 1324, 1291, 1172, 1155, 1130, 1085, 1068, 
1016, 894, 827, 794. MS (70eV): m/z (%) 469 (M++1, 100). HRMS (ESI) Anal. Calcd. for 
C22H24F3N2O4S 469.1403 [M+H]+, Found 469.1414. 
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cis-N-(4-Hydroxycarbamoylbenzyl)-1,2,3,4,4a,5,11,11a-octahydrodibenzo[b,e][1,4]-
thiazepine-10-oxide 25d (96%) 
White powder. Recrystallization from EtOH. Mp = 202 °C. 1H NMR (400 
MHz, D6-DMSO): δ 0.49-0.60, 1.06-1.22, 1.40-1.47 and 1.58-1.66 (1H, 
3H, 2H and 2H, 4 × m, (CH2)4); 2.54-2.57 (1H, m, CHCH2S); 2.91-3.01 
(2H, m, (HCH)S and CHN); 3.15-3.22 (1H, m, (HCH)S); 4.39 and 4.56 (2 
× 1H, 2 × d, J = 14.5 Hz, (HCH)N); 7.27-7.30 (2H, m, CHarom); 7.36-7.40 
(1H, m, CHarom); 7.46 (2H, d, J = 8.1 Hz, CHarom), 7.55-7.57 (1H, m, 
CHarom); 7.68 (2H, d, J = 8.1 Hz, CHarom); 8.98 (1H, s(br), OH); 11.13 (1H, 
s(br), NH). 13C NMR (100.6 MHz, D6-DMSO): δ 24.8, 29.3, 31.1 and 36.7 
((CH2)4), 41.4 (CHCH2S), 57.1 (CH2S), 62.7 (CH2N), 65.6 (CHN), 128.2, 
128.3, 129.4, 132.1, 133.2 and 135.3 (8 x CHarom), 136.8, 145.8, 147.6 and 149.5 (4 × Carom,quat), 
169.4 (C=O). IR (ATR, cm-1): νNH/OH = 3213; νC=O = 1641; νmax = 2925, 2850, 1571, 1474, 1445, 
1410, 1373, 1280, 1155, 1013, 898, 862, 769, 742. MS (70eV): m/z (%) 385 (M++1, 40). HRMS 
(ESI) Anal. Calcd. for C21H25N2O3S 385.1580 [M+H]+, Found 385.1569. 
 
trans-7-Chloro-N-(4-hydroxycarbamoylbenzyl)-1,2,3,4,4a,5,11,11a-octahydrodibenzo-
[b,e][1,4]thiazepine 26a (77%) 
White powder. Crystallization from acetonitrile. Mp = 111 °C. 1H NMR 
(400 MHz, CDCl3): δ0.98-1.22, 1.56-1.67, 1.72-1.75 and 1.98-2.01 
(4H, 3H, 1H and 1H, 4 × m, (CH2)4CH); 2.79 and 2.92 (2H and 1H, 2 
× s(br), CH2S and CHN); 4.33 (2H, s, CH2N); 6.84-6.87 (2H, m, 
CHarom); 7.18 (1H, d, J = 8.1 Hz, CHarom); 7.47-7.48 (2H, m, CHarom); 
7.64 (2H, d, J = 7.5 Hz CHarom); 9,19 (1H, s(br), OH). 13C NMR (100.6 
MHz, CDCl3): δ 25.4, 25.8, 26.3 and 33.0 ((CH2)4, 1 × s(br)), 34.6 
(CH2S, s(br)), 41.0 (CHCH2S, s(br)), 54.2 (CH2N, s(br)), 65.5 (CHN, s(br)), 123.4 (2 × CHarom, 
s(br)), 127.1 (2 × CHarom), 128.2 (2 × CHarom and Carom,quat), 129.6 (Carom,quat), 131.7 (CHarom), 
132.3, 144.1 and 148.6 (3 × Carom,quat, 2 × s(br)), 166.9 (C=O). IR (ATR, cm-1): νNH/OH = 3179; 
νC=O = 1611; νmax = 1568, 1470, 1098, 1013, 895, 843, 729, 457. MS (70eV): m/z (%) 403/5 
(M++1, 100). HRMS (ESI) Anal. Calcd. for C21H24ClN2O2S 403.1242 [M+H]+, Found 403.1259. 
 
trans-N-(4-Hydroxycarbamoylbenzyl)-6,6a,7,8,9,10,11,11a-octahydro-12H-
benzo[b]cyclohepta[e][1,4]thiazepine 26b (78%) 
White powder. Recrystallization from acetonitrile. Mp = 90 °C. 1H NMR 
(400 MHz, D6-DMSO): δ 1.12-1.21, 1.23-1.29, 1.36-1.46, 1.50-1.55, 1.57-
1.63, 1.74-1.80 and 2.10-2.14 (1H, 1H, 4H, 1H, 1H, 2H and 1H, 7 × m, 
(CH2)5CH); 2.73 (1H, d, J = 11.4 Hz, (HCH)S); 2.96 (1H, t, J = 9.1 Hz, 
CHN); 3.21 (1H, d × d, J = 11.4, 8.6 Hz, (HCH)S); 4.29 and 4.44 (2 × 1H, 
2 × d, J = 15.1 Hz, CH2N); 6.84 (1H, t × d, J = 7.6, 1.2 Hz, CHarom); 7.01 
(1H, t × d, J = 7.6, 1.2 Hz, CHarom); 7.07 (1H, t × d, J = 7.6, 1.2 Hz, CHarom); 
7.11 (1H, d × d, J = 7.6, 1.2 Hz, CHarom); 7.51 and 7.65 (2 × 2H, 2 × d, J 
= 8.1 Hz, 4 × CHarom); 8.99 (1H, s(br), OH); 11.13 (1H, s(br), NH). 13C NMR (100.6 MHz, D6-
DMSO): δ 24.5, 25.5, 26.1, 28.8 and 34.7 ((CH2)5), 36.2 (CH2S), 45.0 (CHCH2S), 55.1 (CH2N), 
68.1 (CHN), 124.0, 124.2, 126.4, 127.2, 128.5 and 129.5 (8 × CHarom), 131.7, 132.0, 143.5 and 
147.0 (4 × Carom,quat), 164.5 (C=O). IR (ATR, cm-1): νNH/OH = 3200; νC=O = 1624; νmax = 1566, 
1472, 1306, 1152, 1113, 1015, 899, 851, 748, 611, 463. MS (70eV): m/z (%) 383 (M++1, 100). 
HRMS (ESI) Anal. Calcd. for C22H27N2O2S 383.1788 [M+H]+, Found 383.1797. 
  
6. Exploration of thiaheterocyclic hHDAC6 
inhibitors as potential antiplasmodial agents 
 
 
 
 
 
 
Abstract: The recurring resistance of the malaria parasite to many antimalarial drugs compels 
the discovery of innovative chemical entities with new modes of action. Pan-HDAC inhibitors 
have recently been presented as powerful novel antimalarials, although their application is 
hampered due to possible toxic side effects. This drawback might be neutralized by the 
deployment of isoform-selective HDAC inhibitors. In this chapter, 42 thiaheterocyclic 
benzohydroxamic acids, 17 of them being potent and selective hHDAC6 inhibitors, were tested 
to investigate a possible correlation between hHDAC6 inhibition and antiplasmodial activity. 
Four HDAC6 inhibitors showed submicromolar potency against a chloroquine-sensitive and a 
chloroquine-resistant strain of Plasmodium falciparum with high Selectivity Indices, pointing to 
the importance and relevance of exploring hHDAC6 inhibitors as potential antiplasmodial 
drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parts of the work described in this chapter will be published: 
De Vreese, R.; de Kock, C.; Smith, P. J.; Chibale, K.; D’hooghe, M. “Exploration of thiaheterocyclic hHDAC6 inhibitors as potential 
antiplasmodial agents” Future Med. Chem. 2017, 9, 357-364. (I.F. 3.35) 
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6.1. Introduction 
Malaria is a devastating parasitic disease, exemplified by the fact that roughly 3.2 billion people 
are at risk of contracting malaria and that this disease caused roughly 438 000 deaths in 2015, 
with an estimated 306 000 casualties in the group of children under the age of five (WHO).150 
The main culprit causing this infection is the protozoan species Plasmodium falciparum, 
transmitted by mosquitoes of the genus Anopheles.151 In the past fifteen years (2000-2015), 
considerable progress has been made toward revoking this infection, as illustrated by a 
declining the number of malaria cases and deaths (18 and 48%, respectively).150 However, 
there still is a pressing need to reduce the number of victims even further and to find solutions 
to address all challenges associated with this disease. A pertinent challenge relates to the 
expanding resistance of the Plasmodium parasite toward several treatment regimes. Indeed, 
resistance has emerged with respect to the standard antimalarials chloroquine, sulfadoxine, 
pyrimethamine and, more recently, artemisinin.152 The acquired artemisinin resistance is 
particularly alarming, since artemisinin combination therapies represent the first-in-line 
treatment option for malaria nowadays. 
A consequence of this recurring resistance is the urgent need to develop new medicines with 
alternative mechanisms of action, in order to impede or deter the parasite from developing 
resistance by applying combination therapies. In that regard, histone deacetylase inhibitors 
(HDACi’s) might offer new treatment opportunities, as several known HDAC inhibitors have 
recently been shown to demonstrate a promising activity against Plasmodium falciparum and 
other malarial strains.14,153-155 HDACs (histone deacetylases) and HATs (histone acetyl 
transferases) function as regulators of lysine acetylation, an important posttranslational 
modification responsible for the neutralization of the positive charges on lysine residues, and 
as such adjusting the exact mode of action of the targeted protein.124 HDAC’s were first been 
discovered as histone lysine modifying enzymes but are now generally accepted to be lysine 
deacetylases (KDACs), also deacetylating several non-histone proteins.121 In humans, this 
group of enzymes comprises four classes, with class I (HDAC1, 2, 3 and 8), IIa (HDAC4, 5, 7 
and 9), IIb (HDAC6 and 10) and IV (HDAC11) employing zinc as an essential cofactor, while 
class III (sirtuins1-7) uses NAD+ for its deacetylase activity.6 On the other hand, five HDAC 
isoforms are known for Plasmodium falciparum: PfHDAC1, with homology to human class I, 
PfHDAC2 and 3, with homology to human class II, and PfSir2A and PfSir2B, with homology to 
human class III.156 So far, mainly broad-spectrum HDAC inhibitors (pan-HDACi’s) have been 
tested for their activity against P. falciparum, revealing high toxicities in the (low) nanomolar 
range toward the malaria parasite.11, 113 A major drawback associated with these broad-
spectrum HDAC inhibitors involves the interaction with all human Zn2+-dependent HDACs, 
culminating in a higher risk to elicit toxic side effects upon administration. Therefore, the 
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selective inhibition of pfHDACs over hHDAC isoforms represents a relevant challenge in 
antimalarial drug discovery and has led to the assessment of many hHDAC inhibitors as 
potential antiplasmodial agents. In that respect, a library screen of 2000 compounds has 
revealed (E)-7-[2-(2-bromobenzylidene)hydrazinyl]-N-hydroxy-7-oxoheptanamide to be such 
a selective compound and, in another report, a specific class of methylamides has been shown 
to be pfHDAC selective.157,158  
An alternative strategy could imply the examination of selective hHDAC inhibitors (instead of 
pan-hHDAC inhibitors) as novel antimalarial compounds. This approach lowers the risk of host 
toxicity without potentially compromising a pronounced antiplasmodial activity.159 Selective 
human HDAC6 inhibitors could possibly serve this goal as it is known that mice lacking HDAC6 
develop rather normally,11 so minor to no side effects are expected upon deployment of these 
agents. Bearing this rationale in mind, we decided to test all benzohydroxamic acids (described 
in previous parts II-V) for their antiplasmodial activity, with several representatives being highly 
potent and selective hHDAC6 inhibitors. Indeed, a systematic exploration of the possible 
correlation between hHDAC6 inhibitors and antiplasmodial activity has not been performed so 
far and could reveal new opportunities in antimalarial drug development. 
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6.2. Antimalarial evaluation of thiaheterocyclic 
benzohydroxamic acids 
This brief chapter focusses on the antiplasmodial evaluation of three innovative classes of 
benzohydroxamic acids 1-3, all featuring a different thiahetero(bi- or tri-)cyclic ‘cap group’ 
(Figure 1). Class 1 consists of molecules containing a saturated thiaheterocyclic ring annulated 
onto an indole core (designated as Tubathians), class 2 comprises benzothiophenes 
embodying a nitrogen atom in the linker region, and class 3 includes cycloalkane-annulated 
1,5-benzothiazepine scaffolds. Because of small structural modifications with respect to the 
‘mother structure’ within each class (Figure 1, Table 1), a broad set of 42 compounds with 
divergent decoration patterns is synthetically available. The preparation of these compounds 
1-3 has been described in previous parts II-V, together with a detailed account on their HDAC6 
selectivity, cellular activity (α-tubulin acetylation, a known substrate of HDAC6) and 
mutagenicity. These different classes include a number of highly potent and selective hHDAC6 
inhibitors (Table 2), which have in common a para-substituted benzohydroxamic acid 
fragment, no substituents in the meta-position with respect to the hydroxamic acid group, and 
superior HDAC6 inhibitory activity for sulfoxides and sulfones over the corresponding sulfides. 
 
Figure 1. Available thiaheterocyclic benzohydroxamic acids 1-3. 
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Table 1. Substitution pattern of thiaheterocyclic benzohydroxamic acids 1-3 
cmpd R1 R2 R3 x n config.a cmpd R1 R2 R3 x n config.a 
1a H H - 0 1 para 2a H H H - - - 
1b H OMe - 0 1 para 2b H Bn H - - - 
1c F H - 0 1 para 2c 5-Br H H - - - 
1d F OMe - 0 1 para 2d 5-Br Bn H - - - 
1e H H - 2 1 para 2e 5-Ph H H - - - 
1f H OMe - 2 1 para 2f 5-Ph Bn H - - - 
1g F H - 2 1 para 2g 6-Br H H - - - 
1h F OMe - 2 1 para 2h 6-Br Bn H - - - 
1i Br H - 2 1 para 2i 6-Ph H H - - - 
1j H H - 1 1 para 2j 6-Ph Bn H - - - 
1k F H - 1 1 para 2k H H Me - - - 
1l H H - 2 0 para 3a H - - 0 1 cis 
1m F H - 2 0 para 3b Cl - - 0 1 cis 
1n H H - 0 1 meta 3c CF3 - - 0 1 cis 
1o F H - 0 1 meta 3d H - - 2 1 cis 
1p H H - 2 1 meta 3e Cl - - 2 1 cis 
1q F H - 2 1 meta 3f CF3 - - 2 1 cis 
1r Ph H - 2 1 meta 3g H - - 1 1 cis 
1s H H - 2 0 meta 3h H - - 0 2 cis 
1t F H - 2 0 meta 3i Cl - - 0 1 trans 
1u Br H - 1 0 meta 3j H - - 0 2 trans 
a The para- and meta-configuration for compounds 1 refers to the position of the hydroxamic acid group on the aromatic ring with 
respect to the aminomethyl substituent. 
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The antiplasmodial activity of this set of structures was first determined through a modified 
parasite lactate dehydrogenase assay against a chloroquine-sensitive (CQS) strain of P. 
falciparum (NF54).160,161 When the molecules proved to be reasonably active against this strain 
(IC50 < 5 µM), a second assay was performed against a chloroquine-resistant (CQR) strain of 
P. falciparum (Dd2), as well as an MTT-assay (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) on CHO cells (Chinese Hamster Ovarian) to assess their 
mammalian cytotoxicity (Table 2).162 Finally, a selectivity index (SI = IC50 CHO/IC50 NF54) and 
a resistance index (RI = IC50 Dd2/IC50 NF54) was calculated to be able to easily compare the 
therapeutic window (active concentration vs. toxic concentration) and sensitivity toward 
resistance developing. Table 2 shows that all 42 benzohydroxamic acids 1-3 display interesting 
antiplasmodial activities (IC50 values against the CQS strain between 0.11 and 37.5 µM). The 
potent HDAC6 inhibitors 1i, 1k, 1l, 3d, 3e and 3f were also found to be highly active against 
both CQS and CQR parasitic strains (dark blue tinted, IC50 CQS and CQR < 1 µM, IC50 HDAC6 
< 0.07 µM). However, other active HDAC6 inhibitors did not demonstrate a distinct 
submicromolar parasitic toxicity (for example 1a, 1e and 1g). Thus, no consistent correlation 
can be drawn between hHDAC6 inhibition and antiplasmodial activity, which could be expected 
considering the inevitable differences between human and parasite HDAC isoforms.156 On the 
other hand, it is remarkable to note that the most effective antiplasmodial compounds all are 
powerful hHDAC6 inhibitors, and none of the less active hHDAC6 inhibitors showed 
submicromolar antiplasmodial potency. Based on these observations, it can be suggested that 
strong hHDAC6 inhibitory activity is a necessary but not a sufficient condition for 
thiaheterocyclic benzohydroxamic acids to exert submicromolar antiplasmodial activity as well. 
From the six compounds showing the most promising antiplasmodial activity, four molecules 
have excellent selectivity indices higher than 300 (1i, 1k, 1l and 3d), which means that the 
concentration at which they kill the parasite is at least 300 times lower than their toxic 
concentration for CHO cells. Comparison of the resistance indices (RI) suggests that the tested 
molecules have comparable activity (RI = 0.3 - 3.9) against both strains (CQS and CQR). This 
is in marked contrast to the control drug chloroquine, which is 17 times less active against the 
CQR strain (RI = 17.5). 
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Table 2. IC50 values (µM) of compounds 1-3 determined for a normal (NF54) and chloroquine-
resistant (Dd2) Plasmodium falciparum strain, CHO cells and HDAC6a 
cmpd NF54 Dd2 CHO SIb RIc HDAC6 cmpd NF54 Dd2 CHO SIb RIc HDAC6 
1a 37.5 - - - - 0.015 2a 1.60 2.13 12.7 8 1.3 0.014 
1b 14.0 - - - - - 2b 32.4 - - - - - 
1c 2.2 3.1 105.2 48 1.4 0.022 2c 1.02 2.4 31.0 30 2.4 0.037 
1d 23.2 - - - - - 2d 17.8 - - - - - 
1e 10.8 - - - - 0.002 2e 5.07 - - - - - 
1f 21.0 - - - - 2.0 2f 5.75 - - - - - 
1g 15.8 - - - - 0.004 2g 1.30 1.58 46.1 35 1.2 0.064 
1h 32.7 - - - - 1.3 2h 8.45 - - - - - 
1i 0.11 0.43 109.0 991 3.9 0.003 2i 3.34 1.14 31.2 9 0.3 - 
1j 1.28 1.3 >282 >217 1.0 0.014 2j 5.02 - - - - - 
1k 0.40 0.80 >269 >673 2.0 0.009 2k 36.8 - - - - - 
1l 0.92 0.66 >281 >305 0.7 0.008 3a 1.59 >2.7 103.9 65 - 0.036 
1m 1.07 1.55 >267 >250 1.7 0.016 3b >2.48 >2.48 41.4 - - 0.650 
1n 1.48 2.18 >295 >199 1.5 - 3c 1.53 >2.29 61.5 40 - 0.200 
1o 1.32 1.44 48.1 36 1.1 - 3d 0.36 0.94 107.6 303 2.6 0.008 
1p 5.45 - - - - - 3e 0.47 0.44 35.4 75 0.9 0.068 
1q 7.84 - - - - - 3f 0.87 0.70 56.8 65 0.8 0.011 
1r 8.13 - - - - - 3g 1.25 >2.60 172.9 138 - 0.006 
1s 12.2 - - - - - 3h >2.61 >2.61 87.0 - - 0.033 
1t 9.80 - - - - - 3i >2.48 1.57 50.9 - - 0.160 
1u 11.9 - - - - - 3j >2.61 >2.61 61.7 - - 0.092 
a Dark blue: IC50 value of the hydroxamic acid lower than 1 µM against both P. falciparum strains. -: not determined.
 References: 
Chloroquine IC50-NF54 = 0.01 µM, IC50-Dd2 = 0.175 µM; Artesunate IC50-NF54 < 0.01 µM, IC50-Dd2 = 0.016 µM; Emetine IC50-
CHO = 0.112 µM.b SI (Selectivity Index) = IC50 (CHO)/IC50 (NF54). 
c RI (Resistance Index) = IC50 (Dd2)/IC50 (NF54). 
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6.3. Conclusions 
42 Thiaheterocyclic benzohydroxamic acids 1-3, 17 of them previously being identified as 
highly potent and selective hHDAC6 inhibitors, were assessed in terms of their antiplasmodial 
profile. This study revealed six selective HDAC6 inhibitors to demonstrate submicromolar 
antiplasmodial potency against both a chloroquine-sensitive and a chloroquine-resistant strain, 
and four of these structures (1i, 1k, 1l and 3d) also proved to have an excellent therapeutic 
window (SI > 300). On the other hand, hydroxamic acids which do not strongly inhibit hHDAC6, 
appear to possess only moderate antiplasmodial effects. Thus, potent and selective hHDAC6 
inhibitory activity of thiaheterocyclic benzohydroxamic acids seems to be a necessary but not 
a sufficient condition to elicit pronounced antiplasmodial activity as well. Moreover, selective 
hHDAC6 inhibitors can induce powerful P. falciparum toxicity without being toxic for CHO cells 
(as a model for mammalian cytotoxicity). In conclusion, hHDAC6 inhibitory activity and 
antiplasmodial activity are somehow interconnected, and these HDAC6i new chemical entities 
can certainly be considered a valuable starting point for further medicinal chemistry 
investigation en route to novel types of antiplasmodial drugs. 
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6.4. Experimental details 
6.4.1. Antiplasmodial assays 
The antiplasmodial assays were performed by the Department of Medicine, University of Cape 
Town and the Department of Chemistry and Institute of Infectious Disease and Molecular 
Medicine, University of Cape Town (Prof. K. Chibale). Continuous in vitro cultures of asexual 
erythrocyte stages of P. falciparum were maintained using a modified method of Trager and 
Jensen.160 Quantitative assessment of antiplasmodial activity in vitro was determined via the 
parasite lactate dehydrogenase assay using a modified method described by Makler.161 The 
test samples were prepared to a 20 mg/mL stock solution in 100% DMSO. Stock solutions 
were stored at -20 °C. Further dilutions were prepared in complete medium on the day of the 
experiment. Chloroquine (CQ) and artesunate were used as the reference drugs. A full dose-
response was performed to determine the concentration inhibiting 50% of parasite growth (IC50 
value). Test samples were tested at a starting concentration of 100 µg/mL, which was then 
serially diluted twofold in complete medium to give 10 concentrations; with the lowest 
concentration being 0.2 µg/mL. The same dilution technique was used for all samples. 
References were tested at a starting concentration of 1 µg/mL. The highest concentration of 
solvent to which the parasites were exposed to had no measurable effect on the parasite 
viability (data not shown). 
 
6.4.2. MTT assays 
The MTT assays were performed by the Department of Medicine, University of Cape Town 
and the Department of Chemistry and Institute of Infectious Disease and Molecular Medicine, 
University of Cape Town (Prof. K. Chibale). Test samples were screened for in vitro cytotoxicity 
against a mammalian cell-line, Chinese Hamster Ovarian (CHO), using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-assay. The MTT-assay is used 
as a colorimetric assay for cellular growth and survival, and compares well with other available 
assays.162,163 The tetrazolium salt MTT was used to measure all growth and chemosensitivity. 
The test samples were tested in triplicate on one occasion. The same stock solutions prepared 
for antiplasmodial evaluation were used for cytotoxicity testing. Test compounds were stored 
at -20 °C until use. Dilutions were prepared on the day of the experiment. Emetine was used 
as the reference drug in all experiments. The starting concentration was 100 µg/mL, which was 
serially diluted in complete medium with 10-fold dilutions to give 6 concentrations, the lowest 
being 0.001 µg/mL. The highest concentration of solvent to which the cells were exposed to 
had no measurable effect on the cell viability (data not shown). The 50% inhibitory 
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concentration (IC50) values were obtained from full dose-response curves, using a non-linear 
dose-response curve fitting analysis via GraphPad Prism v.4 software. 
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This PhD thesis was devoted to the target-based early-phased drug discovery of novel 
selective HDAC6 inhibitors. Following up on Tubastatin A, one of the most selective HDAC6 
inhibitors discovered to date, analogues structures bearing a thiaheterocyclic 
benzohydroxamic acid structure were proposed and synthesized. In attempts to completely fill 
the tubular space of HDAC6, structures 1 and 2 were synthesized carrying extra substituents 
(methoxy and methyl groups) on the aromatic linker (Figure 1). However, the tubular space to 
the catalytic site of HDAC6 appeared to be too small, and thus these kinds of transformations 
were not tolerated. On the other hand, bicyclic-capped HDAC6 inhibitor 3 substituted with a 
fluorine atom in the linker has been developed in a recent publication and appeared to be the 
most potent HDAC6 inhibitor with excellent selectivity over the other HDAC isoforms in a series 
of similar compounds.36 Therefore, in future research it would be interesting to synthesize 
derivatives of the most potent compounds described in this PhD thesis substituted with a 
fluorine atom on the aromatic linker, e.g. structures 4 and 5 (Figure 1). 
 
Figure 1. Rational design of fluoro-substituted HDAC6 inhibitors 4-5 to exploit the tubular channel of HDAC6. 
 
Another problem regarding the development of hydroxamic acid-based HDAC inhibitors for 
therapeutic uses outside the field of oncology, is their potential mutagenicity.147 The most 
logical strategy to circumvent this issue, is to develop alternatives with other zinc-binding 
groups. More precisely, the replacement of the hydroxamic acid functionality in 6 with a 
trifluoromethylketone in 7, a silanediol in 8, and a mercaptoacetamide in 9 (Figure 2) would 
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represent reasonable strategies for the development of potent and selective HDAC6 
inhibitors.164,165 Undoubtedly, also the combination of the first and second approach (Figure 1 
and 2) would result in interesting molecules for evaluation as potent and selective HDAC6 
inhibitors. 
 
Figure 2. Rational-design of potential HDAC6 inhibitors holding alternative zinc-binding groups. 
As this PhD thesis started from a target-based drug discovery approach, it would certainly be 
valuable to merge this with phenotypic assays discovered in the HDAC6 field. As such, the 
high biological complexity of a disease state would be integrated in the drug discovery 
program. A first start was already presented regarding the antiplasmodial activity of the 
benzohydroxamic acids synthesized during this PhD, which indeed resulted in novel structure-
activity relationships specific for this parasitic infection. Currently, also other phenotypic assays 
are evaluated in the oncology field by our group at the Laboratory Experimental Cancer 
Research (UZGent, Prof. De Wever), and it would be interesting to see this expanded to the 
field of immunology and neurology. As such, the three main medicinal areas concerning 
HDAC6 would be covered.10 
In parallel with the discovery of an adequate phenotypic assay for HDAC6 inhibition, the most 
promising structures presented in this manuscript should be further evaluated for their 
ADME/Tox properties (CYP inhibition, hERG channel inhibition, microsomal stability, plasma 
protein binding, CACO-2 permeability, micronucleus test, growth inhibition, metalloproteinase 
screen) as a selection tool to determine which compounds should be further evaluated for their 
in vivo pharmacokinetic properties. When a compound is obtained with favourable properties, 
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this drug should be further tested in an animal model which is selected from the most promising 
phenotypic assay. 
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The non-selective inhibition profile of marketed HDAC inhibitors is associated with undesired 
toxicities, and therefore the design and development of isozyme-selective inhibitors has 
emerged as an important challenge. In that regard, HDAC6 (belonging to HDAC class IIb) has 
arisen as an interesting target since its activity is associated with biological pathways in 
neurodegenerative diseases, cancer and immunology. One of the first druglike and selective 
HDAC6 inhibitors reported is Tubastatin A (i, Figure 1), a benzohydroxamic acid moiety linked 
to a γ-tetrahydrocarboline heterocycle. The benzohydroxamic acid skeleton is wider than the 
alkyl chain typically observed in pan-HDAC inhibitors and ensures selectivity toward HDAC6. 
Therefore, it was chosen to keep this benzohydroxamic acid scaffold intact while exploring 
variation at the cap-region. In that mind-set, the evaluation of thiaheterocyclic 
benzohydroxamic acids was identified as an unexplored field within HDAC6 inhibitor design. 
Therefore, during this PhD thesis three novel classes of thiaheterocyclic benzohydroxamic 
acids were synthesized (ii, iii and iv, Figure 1) and evaluated for their potential to act as 
selective HDAC6 inhibitors.  
 
Figure 1. Synthesized thiaheterocyclic benzohydroxamic acids ii, iii and iv. 
 
In the first chapter of this dissertation, a literature overview was presented concerning the 
synthesis and biological activity of the most representative benzohydroxamic acid-based 
histone deacetylase inhibitors published to date. Based on this information we discovered that 
careful optimization of the part following the benzohydroxamic acid, i.e., the linker region and 
the cap-group, can lead to inhibitors which are HDAC6 selective, non-selective, HDAC8 
selective or dual HDAC6/8 selective. Moreover, the importance of the benzohydroxamic acid 
building block in the chemical architecture of HDAC inhibitors is demonstrated. 
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In the second and third chapter, the synthesis and biological evaluation of structures ii was 
discussed (Scheme 1). The synthetic pathway started with the formation of heterocycles vii 
via a bismuth nitrate-catalyzed Fisher indole synthesis employing hydrazines v and cyclic 
ketones vi. The sulfur atom present in these heterocycles was then selectively oxidized toward 
sulfoxides viii or sulfones ix. In one case, a Suzuki-Miyaura coupling was successfully 
performed to obtain a phenyl-substituted heterocyclic cap-group ix (R1 = Ph, n = 1, 60%). 
These indole-containing heterocycles vii-ix were then N-deprotonated by sodium hydride and 
subsequently reacted with benzyl bromides x. This route produced 21 esters xi which, in a 
final step, were converted toward a set of 21 novel thiaheterocyclic benzohydroxamic acids ii.  
 
Scheme 1. Synthetic pathway presented in chapters II and III. 
 
From these 21 potential HDAC6 inhibitors ii, 11 compounds demonstrated more than 70% 
inhibition of HDAC6 at a concentration of 10 µM and nine of them had an IC50 value lower than 
0.1 µM. These nine inhibitors all bear a para-substituted hydroxamic acid moiety with respect 
to the heterocyclic cap-group and do not hold an extra methoxy group on the aromatic linker. 
Moreover, the oxidized sulfur analogs (x = 1 or 2) demonstrated an improved HDAC6 inhibition 
potency, which was explained in silico by the extra hydrogen bond potential of the oxygen 
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atoms on the sulfur atom with neighbouring amino acid residues. Through enzyme and cellular 
assays, the selectivity for HDAC6 was determined, and all nine inhibitors proved to be potent 
and selective inhibitors. ADME/Tox evaluation of these nine potent HDAC6 inhibitors revealed 
that the sulfur oxidized analogs had an improved profile over the non-oxidized derivatives, 
which directs future lead optimization toward para-substituted sulfoxides ans sulfones ii. 
In chapter IV, the synthesis and biological activity of benzohydroxamic acids iii was evaluated 
(Scheme 2). From commercially available benzothiophene-3-carbaldehyde xii, 6-bromo-
benzothiophene-3-carbaldehyde xiii was formed applying five equiv of bromine. Then, 
commercially available 5-bromobenzothiophene-3-carbaldehyde xiv and the synthesized 
carbaldehyde xiii were subjected to a Suzuki-Miyaura coupling yielding phenyl-substituted 
compounds xv and xvi. These precursors xii-xvi were subjected to a reductive amination 
employing consequtively methyl 4-aminobenzoate xvii and sodium cyanoborohydride. The 
secondary amino group present in esters xviii was further derivatized with benzyl bromide and 
gave tertiairy amines xix in good yields. Final conversion of the 11 available esters xviii-xix 
with hydroxylamine resulted in the formation of the premised benzohydroxamic acids iii.  
 
Scheme 2. Synthetic pathway presented in chapter IV. 
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In total 11 benzothiophene benzohydroxamic acids iii were evaluated for their potential to 
selectively inhibit HDAC6. Nine of these compounds showed more than 70% inhibition of the 
HDAC6 activity at 10 µM, and three of them had an IC50 value lower than 0.1 µM. These highly 
potent structures iii (R1 = H, 5-Br, 6-Br, R2 = H, R3 = H) contained a secondary amino group 
and were substituted with a bromine or hydrogen atom on the cap-group. Furthermore, these 
structures showed a selectivity profile comparable with that of Tubastatin A, and it was 
demonstrated that HDAC6 inhibition can be uncoupled from transcriptional inhibition at the 
level of activated NF-κB, AP-1, and GR. 
In Chapter V, a detailed description of the synthesis and biological evaluation of 
benzohydroxamic acids iv was presented (Scheme 3). Via an aldol condensation, β-
hydroxyketones xxi were prepared from ketones xx employing paraformaldehyde. In the next 
step, a tosylation, a reaction with 2-aminothiophenol xxii and a reduction using sodium 
cyanoborohydride were performed in one pot, and this resulted in the formation of cis- and 
trans-annulated benzothiazepines xxiii which were obtained in a diastereomerically pure form 
via column chromatography. This concerned the first report on the detailed synthesis and 
isolation of both diastereomers of tricyclic cyclohexane- and cycloheptane-fused 
tetrahydrobenzothiazepines xxiii, and the correct structure was secured by X-ray 
crystallography. These heterocyclic structures xxiii were treated with methyl 4-
(bromomethyl)benzoate xxiv (neat) which gave esters xxv in acceptable yields. The sulfur 
atom present in the heterocyclic cap-group of sulfides xxv was selectively oxidized to a 
sulfoxide or a sulfone and yielded compounds xxvi. Finally, esters xxv-xxvi were transformed 
to hydroxamic acids iv employing an excess of hydroxylamine. 
 
Scheme 3. Synthetic pathway presented in chapter V. 
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In total, ten benzohydroxamic acids iv were efficiently synthesized and tested for their ability 
to inhibit HDAC6. All these inhibitors were shown to be highly active HDAC6 inhibitors at a 
concentration of 10 µM (96-100% inhibition). Therefore, for all ten hydroxamic acids iv the IC50 
values toward HDAC6 were determined, and all inhibitors showed nanomolar potential (6.3-
650 nM). In accordance with previous observations regarding the effect of S-oxidation, 
oxidized sulfur analogs iv (x = 1, 2) were again demonstrated to be more potent HDAC6 
inhibitors than their non-oxidized counterparts. This superior HDAC6 inhibitory activity was 
supported by a molecular dynamics simulation, which again revealed the possibility of 
additional hydrogen bonding between a sulfur-bound oxygen atom and an amino acid residue. 
Five compounds showed an IC50 value lower then 50 nM, and their selectivity toward the other 
HDAC isoforms was determined via enzyme and cellular assays. These assays revealed that 
this class of molecules can be regarded as highly potent and selective HDAC6 inhibitors 
suitable for further assessment. 
In the final chapter (chapter VI), all 42 thiaheterocyclic benzohydroxamic acids synthesized 
during this PhD thesis were evaluated as potential antiplasmodial agents. Several pan-HDAC 
inhibitors are known to exert powerful antimalarial activity, but their possible toxicity delays 
further development. A problem which might be circumvented by the deployment of isoform-
selective HDAC inhibitors, such as several of the inhibitors described in this dissertation. Six 
selective HDAC6 inhibitors were demonstrated to exhibit submicromolar antiplasmodial 
potency against both a chloroquine-sensitive and a chloroquine-resistant Plasmodium 
falciparum strain, and four of these structures xxvii-xxx also proved to have an excellent 
therapeutic window (SI > 300, Figure 2). On the other hand, hydroxamic acids which do not 
strongly inhibit hHDAC6, appear to possess only moderate antiplasmodial effects. Thus, potent 
and selective hHDAC6 inhibitory activity of thiaheterocyclic benzohydroxamic acids seems to 
be a necessary but not a sufficient condition to elicit pronounced antiplasmodial activity as well. 
 
Figure 2. Most potent antiplasmodial benzohydroxamic acids described in chapter VI. 
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In conclusion, from each class (ii, iii and iv) several lead structures were discovered 
demonstrating excellent HDAC6 inhibitory activity and selectivity (Figure 3). This clearly 
demonstrates the potential of thiaheterocyclic benzohydroxamic acids in the discovery of 
selective HDAC6 inhibitors.  
 
Figure 3. Most potent representatives from each class ii, iii and iv. 
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Het gebrek aan selectiviteit van gecommercialiseerde HDAC-inhibitoren wordt geassocieerd 
met ongewenste toxiciteit; en daarom is het onderzoek naar het ontwerp en de ontwikkeling 
van isozym-selectieve inhibitoren een ‘hot topic’ binnen de medicinale chemie. In dat verband 
is HDAC6 een interessant doelwit binnen de HDAC-familie. HDAC6 behoort tot HDAC-klasse 
IIb, en zijn activiteit wordt gerelateerd aan verschillende aandoening zoals neurodegeneratieve 
ziekten, kanker en immuunziekten. Eén van de eerst gerapporteerde selectieve HDAC6 
inhibitoren die bovendien vele karakteristieken heeft van een klassiek medicijn is Tubastatin A 
(i, Figuur 1). Deze inhibitor bestaat uit een benzohydroxamzure eenheid die gekoppeld is aan 
een γ-tetrahydrocarboline heterocyclishe structuur. Het benzohydroxamzure skelet is breder 
dan de typische alkylketen van niet-selectieve HDAC-inhibitoren, en dit geeft aanleiding tot 
een verbeterde selectiviteit voor HDAC6. Daarom werd gekozen om deze benzohydroxamzure 
functionaliteit intact te houden en werden enkel structuren ontworpen met variaties in de 
heterocyclische regio. In dat opzicht vormt de ontwikkeling van thiaheterocyclische 
benzohydroxamzuren een ononderzocht domein binnen het ontwerp van nieuwe selectieve 
HDAC6-inhibitoren en werden tijdens dit doctoraat drie nieuwe klassen thiaheterocyclische 
benzohydroxamzuren gesynthetiseerd ii, iii en iv (Figuur 1). 
 
Figuur 1. Gesynthetiseerde thiaheterocyclische benzohydroxamzuren ii, iii en iv. 
 
In het eerste hoofdstuk van dit onderzoek werd een literatuuroverzicht gegeven over de 
synthese en biologische activiteit van de meest veelbelovende benzohydroxamzuur-
gebaseerde histondeacetylase inhibitoren tot op heden gepubliceerd. Via dit overzicht werd 
ontdekt dat door optimalizatie van het deel volgend op de benzohydroxamzure eenheid 
inhibitoren kunnen worden ontworpen die HDAC6-selectief, niet selectief, HDAC8-selectief of 
HDAC6- en 8-selectief zijn. Bovendien werd het belang van de benzohydroxamzure structuur 
tijdens het ontwerpen van HDAC-inhibitoren aangetoond.  
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In het tweede en derde hoofdstuk werd de synthese en biologische evaluatie van structuren ii 
beschreven (Schema 1). De syntheseroute startte met de vorming van heterocyclische ringen 
vii via een bismuthnitraat-gekataliseerde Fisher-indoolsynthese gebruik makende van 
hydrazinen v en cyclische ketonen vi. Het zwavelatoom aanwezig in deze ringen werd selectief 
geoxideerd tot sulfoxiden viii of sulfonen ix. In één geval werd succesvol een Suzuki-Miyaura-
koppeling uitgevoerd om zo toegang te krijgen tot fenylgesubstitueerd derivaat ix (R1 = Ph, n 
= 1, 60%). Deze indoolbevattende structuren vii-ix werden N-gedeprotoneerd door 
natriumhydride en daaropvolgend gereageerd met benzylbromide x. Zo werden 21 esters xi 
geproduceerd die in een laatste stap werden omgezet tot nieuwe thiaheterocyclische 
benzohydroxamzuren ii. 
 
Schema 1. Syntheseroute beschreven in hoofdstukken II en III. 
 
Van alle 21 gesynthetiseerde HDAC6 inhibitoren ii vertoonden 11 verbindingen meer dan 70% 
inhibitie van HDAC6 bij een concentratie van 10 µM, en van deze 11 structuren bezaten negen 
inhibitoren een IC50-waarde lager dan 0.1 µM. Deze negen moleculen zijn allemaal para-
gesubstitueerd en dragen geen extra methoxygroep op de aromatische linker. Verder bezaten 
de geoxideerde zwavelanalogen (x = 1 of 2) een beter HDAC6-inhibitieprofiel, wat kan worden 
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verklaard door de mogelijkheid tot extra waterstofbrugvorming van de zuurstofatomen op het 
zwavelatoom met naburige aminozuurzijketens. De selectiviteit ten opzichte van HDAC1-11 
werd bepaald via enzym- en celtesten, waarbij werd aangetoond dat alle negen inhibitoren 
selectief blijken te zijn voor HDAC6. ADME/Tox-evaluatie van deze negen actieve HDAC6-
inhibitoren onthulde dat de geoxideerde zwavelanalogen een beter profiel vertoonden dan de 
niet-geoxideerde derivaten, waardoor de para-gesubstitueerde sulfoxiden en sulfonen kunnen 
dienen als ‘lead’-structuren voor verdere optimalisatie. 
In hoofdstuk IV werd de synthese en biologische activiteit van benzohydroxamzuren iii 
besproken (Schema 2). Vertrekkende vanuit commercieel beschikbaar benzothiofeen-3-
carbaldehyde xii werd 6-broombenzothiofeen-3-carbaldehyde xiii gevormd gebruik makende 
van vijf equiv broom. Vervolgens werden het commercieel beschikbaar 5-
broombenzothiofeen-3-carbaldehyde xiv en het aangemaakte carbaldehyde xiii onderworpen 
aan een Suzuki-Miyaura-koppeling, hetgeen aanleiding gaf tot de vorming van fenyl-
gederivatiseerde aldehyden xv en xvi. Deze precursoren xii-xvi werden verder reductief 
geamineerd m.b.v. methyl-4-aminobenzoaat xvii en natriumcyaanboorhydride. Het 
stikstofatoom aanwezig in esters xviii werd dan gederivatiseerd met benzylbromide en vormde 
tertiaire aminen xix in goede opbrengsten. Finale omzetting van de 11 beschikbare esters 
xviii-xix met hydroxylamine resulteerde in de vorming van benzohydroxamzuren iii.  
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Schema 2. Syntheseroute beschreven in hoofdstuk IV. 
 
In totaal werden 11 benzothiofeen-benzohydroxamzuren iii geëvalueerd m.b.t. hun potentieel 
om HDAC6 selectief te inhiberen. Negen van deze verbindingen vertoonden meer dan 70% 
inhibitie van HDAC6 bij een concentratie van 10 µM, en drie structuren hadden een IC50-
waarde lager dan 0.1 µM. Deze hoogactieve structuren iii (R1 = H, 5-Br, 6-Br, R2 = H, R3 = H) 
bevatten een secundair amine en zijn gesubstitueerd met een broom- of waterstofatoom op 
de ‘cap’-groep. Bovendien bezitten deze structuren een selectiviteitsprofiel vergelijkbaar met 
het profiel van Tubastatin A en werd aangetoond dat HDAC6-inhibitie ontkoppeld kan worden 
van transcriptionele inhibitie op het niveau van geactiveerd NF-κB, AP-1 en GR. 
In hoofdstuk V werd een gedetailleerd overzicht gegeven van de synthese en biologische 
evaluatie van benzohydroxamzuren iv (Schema 3). Via een aldolcondensatie werden β-
hydroxyketonen xxi gemaakt uit ketonen xx met behulp van paraformaldehyde. In de volgende 
stap werden tegelijk een tosylering, een reactie met 2-aminothiophenol xxii en een reductie 
door middel van natriumcyaanboorhydride uitgevoerd met als resultaat de vorming van zowel 
cis- en trans- benzothiazepinen xxiii die diastereomeer zuiver werden bekomen via 
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kolomchromtografie. Dit is de eerste maal dat de gedetailleerde synthese en isolatie van beide 
diastereomeren van tricyclische cyclohexaan- en cycloheptaan-gefuseerde 
tetrahydrobenzothiazepinen xxiii werd beschreven, waarbij de correcte structuur werd 
bevestigd via X-stralendiffractie. Deze heterocyclische structuren xxiii werden onder 
solventvrije reactiecondities gemengd met methyl-4-(broommethyl)benzoaat xxiv, hetgeen 
aanleiding gaf tot de vorming van esters xxv. Het zwavelatoom aanwezig in de heterocyclische 
‘cap’-groep van sulfiden xxv werd selectief geoxideerd tot sulfoxide en sulfonen xxvi. In de 
laatste stap werden esters xxv-xxvi getransformeerd tot hydroxamzuren iv door gebruik te 
maken van een overmaat hydroxylamine.  
 
Schema 3. Syntheseroute beschreven in hoofdstuk V. 
 
In totaal werden tien benzohydroxamzuren iv efficient gesynthetiseerd en getest m.b.t. hun 
vermogen om HDAC6 te inhiberen. Al deze inhibitoren vertoonden zeer krachtige HDAC6-
inhibitie bij een concentratie van 10 µM (96-100% inhibitie). Daarom werden van alle tien de 
hydroxamzuren iv de IC50-waarden voor HDAC6 bepaald en werd gevonden dat alle 
inhibitoren nanomolaire activiteit (6,3-650 nM) bezitten. In overeenstemming met vorige 
observaties omtrent het effect van S-oxidatie vertoonden de geoxideerde zwavelderivaten iv 
(x = 1, 2) wederom een lager IC50-waarde dan de niet-geoxideerde tegenhangers. Dit superieur 
HDAC6-profiel werd ondersteund door moleculair dynamische simulaties in silico, die de 
mogelijkheid tot additionele waterstofbrugvorming van het zwavelgebonden zuurstofatoom 
met een aminozuurzijketen onthulden. Vijf benzothiazepinen beschikten over een IC50-waarde 
lager dan 50 nM en hun selectiviteit ten opzichte van de andere HDAC-isozymen werd bepaald 
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via enzym- en celassays. Uit deze testen bleek dat deze klasse verbindingen kan worden 
beschouwd als zeer krachtige en selectieve HDAC6-inhibitoren geschikt voor verdere 
evaluatie. 
In het laatste hoofdstuk (hoofdstuk VI) werden alle 42 aangemaakte thiaheterocyclische 
benzohydroxamzuren geëvalueerd als potentiële antimalariamedicijnen. Verschillende ‘pan’-
HDAC-inhibitoren zijn gekend een impressionante antimalaria-activiteit te bezitten, maar hun 
mogelijke toxiciteit vertraagt de verdere ontwikkeling tot antimalariamiddel. Dit probleem kan 
mogelijk worden omzeild door de ontwikkeling van isoform-selectieve HDAC-inhibitoren, zoals 
verschillende inhibitoren beschreven in dit werk. Tijdens deze studie werden zes selectieve 
HDAC6-inhibitoren gevonden die submicromolaire antiplasmodiale activiteit vertonen tegen 
zowel een chloroquine-gevoelige als een chloroquine-resistente Plasmodium falciparum stam, 
en vier structuren xxvii-xxx vertoonden daarenboven een excellente therapeutische index (SI 
> 300, Figuur 2). Daarnaast bezaten de hydroxamzuren die hHDAC6 niet goed inhiberen, lage 
antiplasmodiale effecten. Er kan dus besloten worden dat krachtige en selectieve hHDAC6-
inhibitie een noodzakelijke maar niet voldoende voorwaarde is voor thiaheterocyclische 
benzohydroxamzuren om goede antimalaria-activiteit te vertonen. 
 
Figuur 2. Meest krachtige antiplasmodiale benzohydroxamzuren beschreven in hoofdstuk VI. 
 
Als overkoepelende conclusie kan worden gesteld dat van iedere klasse ii, iii en iv 
verschillende ‘lead’-structuren werden ontdekt die krachtige HDAC6-inhibitie en selectiviteit 
vertonen (Figuur 3). Dit toont duidelijk het potentieel aan van thiaheterocyclische 
benzohydroxamzuren voor het ontdekken van selectieve HDAC6-inhibitoren.  
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Figuur 3. Meest interessante derivaten van elke klasse ii, iii en iv. 
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